Method for predicting efficacy of drugs in a patient

ABSTRACT

The present invention concerns a method for predicting the relative efficacy of a plurality of drugs for treating a tumour in an individual comprising the molecular characterization of the tumour, and the calculation of a score for the plurality of drugs essentially based on the percentage of deregulated target genes.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No.13/382,585, filed Feb. 8, 2012, which is the U.S. national stageapplication of International Patent Application No. PCT/EP2010/059648,filed Jul. 6, 2010, which claims the benefit of U.S. Provisional PatentApplication No. 61/223,798, filed Jul. 8, 2009.

FIELD OF INVENTION

The present invention relates to the field of medicine, in particularpersonalized medicine in cancer therapy.

BACKGROUND OF THE INVENTION

The therapeutic care of the patients having cancer is primarily based onsurgery, radiotherapy and chemotherapy which have to be used accordingto standard protocols. The curative surgery consists in removal of allthe tumoral mass. However, this is not always possible to guarantee theabsence of any residual disease after the ablation of the observablepart of the tumour, even by experienced surgeons. This is why thesurgery is generally used in combination is with radiotherapy and/orchemotherapy. Chemotherapy and/or radiotherapy can be used asneoadjuvant therapy or auxiliary or adjuvant therapy, or alone when thesurgery is impossible. Neoadjuvant therapy is usually used when thetumoral mass is too important and requires a reduction before surgery.Auxiliary or adjuvant chemotherapy is used to treat the residual tumoraldiseases and to limit the local recurrences or the metastatic relapses.When a tumour is detected at an inoperable stage, then the therapeuticcare is only based on chemotherapy and/or radiotherapy. Surgery ismarginally used in this context and has palliative objectives.

In any case, the choice of chemotherapy always raises the followingquestions: Which drug or combination of drugs is adapted to this type ofcancer? What is the most adapted therapeutic strategy for this patient?What are the chances for observing a therapeutic benefit with theselected drugs?

The current medical practice consists in treating the patients accordingto the existing therapeutic protocols. In the majority of the cases, thechoice of the therapeutic protocol is based on the anatomo-pathologicaland clinical data. These protocols apply in first, second, even thirdtherapeutic line. When there is therapeutic failure, or for themetastatic stages, certain patient are included in clinical trialsgenerally using broad selection criteria defining primarily, thelocation of the primitive tumour, the extension of the disease, thesituation of the vital functions of the patient and certain specificcontraindications of the drug under trial. Whatever the therapeuticapproach (standard or clinical trial), only part of the treatedpopulation profits from the treatment whereas the remainder of thepatients do not respond and show a progressing disease even undertreatment.

To improve this situation, since many years, physicians and researchersare trying to identify markers for predicting the efficacy of thetreatments for a given patient and to be able to adapt the treatment ofeach patient. Thus the concept of personalized medicine consists inadapting the therapeutic decision according to the anatomo-pathological,clinical characteristics but especially of the biologicalcharacteristics of the tumour.

Several examples are known without representing a solution useful forany patient having a cancer.

A first approach was the so-called “test-companion” assay, used for thefirst time for the trastuzumab (Herceptin®), a monoclonal antibodytargeting the Her2/Neu receptor. In breast cancers, this drug isadministered only when an amplification/overexpression of this receptoris observed. However, this overexpression does not guarantee atherapeutic response. Some resistances to Herceptin® can be explained byan activation of the Akt pathway, for instance. The association of anmTOR inhibitor (targeting the Akt pathway) can restore the sensitivityto Herceptin. Nevertheless, for some patients, the therapeutic benefitwas observed in the absence of an amplification of the receptor.

The measurement of the expression level of the Her2 receptor is thefirst example of test companion and the majority of pharmaceuticalcompanies or researchers are trying to reproduce this model consideredas the first example of personalized medicine. The following examplesare relevant to illustrate the concept of selection of the patients whocould profit from a given drug:

-   -   Mutation or amplification of EGFR receptor and        erlotinib/gefitinib;    -   Mutations c-Kit/PDGFRa and imatinib;    -   Translocation of Bcr-Abl and imatinib;    -   Amplification of HER2 and HER2 inhibitors;    -   Amplification of TOP2A and anthracyclines;    -   Deletion of PTEN and mTOR inhibitors;    -   Amplification of FGFR1 and FGFR1 inhibitors;    -   ERCC1 negative-treatment and platinum salts;    -   RAS mutations and treatment of colon cancer    -   etc.

In the case of breast cancer, prognostic molecular signatures, such asthe tests Mamaprint® (developed by the Agendia company) or OncotypeDX®(company Genomic Health) are available. These signatures are used todetermine if an auxiliary chemotherapy is necessary or not. But,although these tests make it possible to conclude on the need from anauxiliary chemotherapy, they do not make it possible to select theoptimal therapy.

In short, the concept of personalized medicine corresponds to aselection of patients on biological criteria to increase the chances ofresponse to a given therapy. Currently, these tests companion are ratherused for the treatments by targeted therapies and make it possible toselect the patients likely to profit from a given therapy but not toselect the best therapy for a given patient. This is a major conceptualdifference which constitutes the main interest of the present inventioncompared to the other markers proposed to date.

The anomalies of strong amplitude of the gene copy number(amplifications or deletions) modify the levels of gene expression. Thismechanism of genomic deregulation is involved in the ontogenesis of manycancers. Amplifications of the EGFR gene are found in approximately 30%of lung cancers. The inhibition of EGFR in case of amplification isassociated with a significant benefit in this same pathology. Similarly,MYCN is amplified in approximately 25% of the neuroblastoma and severalstudies showed the prognostic value of this anomaly in this pathology.Other oncogenes/anti-oncogenes (tumour suppressor genes) are frequentlyamplified/deleted in other types of tumours such HER, PTEN, PUTS, andthe like.

Breast cancer presents an important frequency of chromosomalaberrations. Gene HER2 (ErbB2) is amplified in 10 to 20% of the cases.This amplification is associated with a hyper-expression of the Her2protein and is involved in the tumoral transformation. A therapeuticstrategy based on the targeting of this anomaly showed a benefit in thepatients having HER2-positive breast cancer. In addition, the genecoding for the topoisomerase II is amplified in approximately 7% ofbreast cancers. This amplification is correlated with a good sensitivityto the anthracyclines, a class of drugs targeting the topoisomerase II.Other anomalies have often been observed in breast cancer. A1B1 gene isamplified in 10% of the cases, and leads to ontogenesis via theactivation of AKT by the IGFR. FGF1R gene is amplified in 10% of case.The targeting of this protein by a tyrosine kinase inhibitor leads invitro to a reduction of the cell multiplication. Similarly,amplifications of the genes EGFR, IGF1R or the deletions of PTEN can betreated by molecules targeting EGFR, IGF1R or mTOR, respectively.

In the scientific literature, certain works, among which those of A.Potti et al., propose a prediction of the drug's efficacy, primarilycytotoxicity, based on the analysis of the expression of genes selectedfrom experiments on well-established cell lines (panel NCI60). Thesedata allow the identification of expression profiles associated with theresponse for each tested molecule and this prediction is transposed tothe human tumours. However, if this approach allows a molecule bymolecule prediction, it does not allow the comparison of the efficacy ofeach molecule for a given patient in order to select the best drug. Inaddition, the one skilled in the art knows the limitations of in vitromodel to perform in vivo predictions. These approaches tend to enrichthe patient cohort for a given chemotherapy rather than to select atargeted individual therapy for a given patient on the basis of theintrinsic tumoral characteristics.

However, the choice of the appropriate chemotherapy in cancer treatmentis a crucial issue. Indeed, most of the chemotherapies have verysignificant adverse effects and an erroneous choice (i.e., treatmentwithout any therapeutic benefit) could lead to a cancer progression.

Up today, there is no marker efficient to select the most optimaltherapeutic strategy for a given individual having a cancer.Accordingly, there is a strong need to methods of personalized medicinein the field of cancer treatment allowing the selection for a givenindividual of the most appropriate chemotherapy strategy.

SUMMARY OF THE INVENTION

The present invention concerns a method for predicting the relativeefficacy of a plurality of drugs for treating a cancer in a patientcomprising:

-   -   characterizing molecular anomalies of a tumour or metastase        sample from the patient in comparison to a normal sample from        the same patient, thereby determining the deregulated genes in        the tumour;    -   providing a database comprising the target genes for each drug        of the plurality of drugs;    -   determining a score for each drug of the plurality of drugs        essentially based on the percentage of deregulated genes among        the target genes for each drug in the tumour sample from the        patient, thereby a higher score is predictive of a higher        relative efficacy of the drug for treating the tumour in the        patient. Preferably, the normal sample is the normal histologic        counterpart to the primary tumor.

In particular, the step of characterizing molecular anomalies of atumour sample comprises determining the genes differentially expressedin the tumour in comparison to the normal sample, and/or determining thegain or loss of gene copy number and/or detecting the presence of amutation in a gene. Preferably, the step of characterizing molecularanomalies of a tumour sample comprises determining a fold change (F) forthe differentially expressed genes and/or for the gain or loss of genecopy number and, optionally, further determining the intensity of thegene transcription (Int) for the differentially expressed genes.

Preferably, the target genes for each drug are classified in thedatabase into the major target genes (CM), the minor target genes (Cm)and the resistance genes (CR).

In a first embodiment, the score (W) for a given drug is determined bythe following algorithm:

$W = {{Pz}\frac{\left( {\sum_{C}F_{c > 2}} \right)}{n_{C}F_{c > 2}}}$

wherein

W is the score for the given drug;

P is the percentage of target genes for the given drug which arederegulated in the tumour of the patient;

z is an optional multiplication coefficient associated to the presenceof a mutation in a target gene of the given drug;

Σ is sum;

Fc>2 is the fold change of each deregulated target gene for the givendrug with a Fold Change higher than 2;

nC_(Fc>2) refers to the number of target genes for the given drug with aFold Change higher than 2.

Preferably, Fc>2 is the Fold Change of each over-expressed target genefor the given drug with a Fold Change higher than 2 and nC_(Fc>2) iseither the number of target genes for the given drug with a Fold Changehigher than 2, or the number of over-expressed target genes for thegiven drug with a Fold Change higher than 2.

In a second embodiment, the score (W) for a given drug is determined bythe following algorithm:

$W = {P\left( {{\frac{\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{\left( {\sum_{Cm}F_{Cm}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}$

wherein

W is the score for the given drug;

P is the percentage of target genes for the given drug which arederegulated in the tumour of the patient;

Σ is sum;

CM refers to major target genes for the given drug;

Cm refers to minor target genes for the given drug;

CR refers to resistance genes for the given drug;

n₁CM, n₂Cm and n₃CR are respectively the number of deregulated targetgenes with a defined threshold for major target genes, minor targetgenes and resistance genes;

F_(CM), F_(Cm) and F_(CR) are the Fold change of each gene higher thanthe defined threshold for major target genes, minor target genes andresistance genes, respectively;

q₁, q₂ and q₃ are optional multiplication coefficients for major targetgenes, minor target genes and resistance genes, respectively;

z₁, z₂ and z₃ are optional multiplication coefficients associated to thepresence of a mutation in a major target gene, a minor target gene and aresistance gene, respectively.

In a third embodiment, the score (W) for a given drug is determined bythe following algorithm:

$W = {{\frac{P_{CM}\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{P_{Cm}\left( {\sum_{Cm}F_{Cm}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{P_{CR}\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}}$

wherein the meaning of W, Σ, CM, Cm, CR, F_(CM), F_(Cm), F_(CR), q₁, q₂,q₃, z₁, z₂ and z₃ are the same than the previous algorithm and P_(CM),P_(Cm) and P_(CR) are the percentage of genes for the given drug whichare deregulated in the tumour of the individual for major target genes,minor target genes and resistance genes, respectively.

In a fourth embodiment, the score (W) for a given drug is determined byone of the following algorithms:

$W = {P\left( {{\frac{\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{\left( {\sum_{Cm}{F_{Cm} \times {Int}_{Cm}}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}$or$W = {{\frac{P_{CM}\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{P_{Cm}\left( {\sum_{Cm}{F_{Cm} \times {Int}_{Cm}}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{P_{CR}\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}}$

wherein the meaning of W, Σ, CM, Cm, CR, F_(CM), F_(Cm), F_(CR), q₁, q₂,q₃, z₁, z₂ and z₃, and if present P_(CM), P_(Cm) and P_(CR), are thesame than the previous algorithm and Int_(CM), Int_(Cm) and Int_(CR) arethe intensity for major target genes, minor target genes and resistancegenes, respectively.

In a fifth embodiment, the score (W) for a given drug is determined byone of the following algorithms:

$W = {P\left( {{\frac{\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}$or$W = {{\frac{P_{CM}\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{P_{CR}\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}}$or$W = {P\left( {{\frac{\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}$or$W = {{\frac{P_{CM}\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{P_{CR}\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}}$

wherein the meaning of W, Σ, CM, CR, F_(CM), F_(CR), q₁, q₃, z₁ and z₃,and if present P_(CM), P_(CR), Int_(CM), and Int_(CR) are the same asthe previous algorithms.

Preferably, in the second to fifth embodiment, F_(CM), F_(Cm) and F_(CR)are the Fold Change of each over-expressed target gene for the givendrug with the defined threshold and n₁CM, n₂Cm and n₃CR are either thenumber of target genes for the given drug with the defined threshold, orthe number of over-expressed target genes for the given drug with thedefined threshold. More preferably, the defined threshold is a Foldchange of at least 2 or higher than 2.

In addition, in the second to fifth embodiment, multiplicationcoefficients for the target genes can be comprised between 10 and 1,000for major target genes (q₁), 0.1 and 10 for minor target genes (q₂) and10 to 1,000 for resistance genes (q₃).

Furthermore, in the second to fifth embodiment, multiplicationcoefficients associated to a mutation z₁, z₂ and z₃ are 1 when nomutation exists and, depending on the functional impact of the mutation,can be comprised between 10 and 1,000.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Thoracic scanner in October 2005 of the patient of Example 1.

FIG. 2: Thoracic scanner in November 2008 of the patient of Example 1.

FIG. 3: Thoracic scanner in April 2009 of the patient of Example 1.

FIG. 4: Thoracic scanner in July 2009 of the patient of Example 1.

FIG. 5: Thoracic scanners in January and March 2010 of the patient ofExample 3.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides a new concept for selecting the mostappropriate therapy at the individual level. The drug selection is basedon the biologic characteristics of the tumor of the individual to betreated in comparison to a normal sample from the same individual. Basedon a score essentially based on the percentage of deregulated targetgenes or microRNAs for each drug, the relative efficacy of the drugs canbe predicted for the individual in order to treat the specific tumour.

General Concept

It is at the level of the optimal therapeutic strategy choice thatapplies the object of the present invention. For selecting the mostappropriate therapeutic strategy, the method of the present invention istaking into account of, on one hand, the biological data of the tumor tobe treated as a whole and, on the other hand, a plurality of drugs,preferably all existing drugs (either registered or in development). Ascore is determined for each drug based on the biologicalcharacteristics of the specific tumour to be treated for a givensubject. This score makes it possible to order the various drugs indecreasing order for their potential efficacy. The physician can usethese scores to select the optimal drug or combination of drugs for thegiven subject. This approach, allowing the association of each drug witha score depending on the biological characteristics of the tumour,constitutes the basis of this invention. Therefore, this invention islikely to meet the present needs for personalized medicine.

The method can be used both for registered drugs and for developed drugs(e.g., temporary authorization of use or clinical trials).

This concept thus consists in considering the choice of the therapy forthe patient at the level of the individual depending on the intrinsiccharacteristics of his tumour and not on global results obtained fromlarge groups of individuals.

The present invention is based on the combination of three fundamentalpoints, detailed below, and which are combined together to optimize thechoice of the strategy for each individual having a cancer:

-   -   The first point corresponds to the analysis, as exhaustive as        possible, of the biological or gene anomalies (amplification,        deletions, mutations, gene expression, microRNAs expression and        the like) which characterize a given tumour for an individual.    -   The second point consists in the identification of genes known        to be in relation with a drug.    -   The third point corresponds to the establishment of the        connection between each drug and the anomalies detected in the        tumour to be treated in an individual. An algorithm has been        indentified for calculating a score for each drug in        consideration of the tumour characteristics and the genes known        to be in relation with a drug.

The method of the invention will allow guiding the therapeutic choicebecause the available drugs will be ordered on their score basis,reflecting their potential therapeutic efficacy for the given tumour inan individual.

One advantage of the present method is that the relative efficacy of aplurality of drugs can be predicted for an individual without exposingthe individual to drugs. By a plurality of drugs is intended at least orabout 10, 20, 30, 40, 50 or 100 different drugs. Indeed, when a panel ofdrugs is available for treatment, one cannot be envisaged to try thetreatment by each drug on the patient. The present method allows theconsideration of all potential therapeutic strategy and the selection ofthe most appropriate for the patient.

Indeed, the scores for the plurality of drugs allow the determination ofthe relative efficacy of the plurality of drugs for treating the tumourof the considered individual. Indeed, a drug having a higher score thananother drug is predicted to have a higher efficacy for treating thetumour. By treating is intended that the drug allows to stop or slowdown the growth of the tumour, and/or to decrease the size of tumoureven up to its disappearance. By treating is also intended to avoid themetastasis, the recurrence or the relapse.

Another advantage is that the method does not depend on a cancer type.The method of the invention can be used for any type of cancer includinghaematological tumour (e.g. leukemia, lymphoma) and bladder, breast,stomach, thyroid, prostate, testis, liver, pancreatic, bone, pancreatic,kidney, endometrial, melanoma, lung, gastric, colorectal, prostate, heador neck tumours, brain, neuroblastoma, and ovarian cancer.

In a preferred embodiment, the patient or individual is a human being.

Tumour Characterization

Tumour characterization corresponds to the analysis, as exhaustive aspossible, of the biological or gene anomalies (amplification, deletions,mutations, gene expression and the like) which characterize a giventumour for an individual. In particular, the anomalies are determined ina tumour from the patient in comparison with a normal tissue of the samepatient. Preferably, the tumour sample and the normal sample providesfrom the same type of tissue. For the tumour characterization, severaltechnologies are available and can be combined.

The first technology is the gene analysis. This analysis can be carriedout by CGH (Comparative Genomic Hybridization) which makes it possibleto compare the tumoral DNA with the normal DNA of the same individual todetect chromosomal aberrations, i.e. the chromosomal losses or gains.This technology is well-known by the man skilled in the art. As anillustration of this knowledge, the following reviews or reference bookscan be cited: Davies et al. (2005, Chromosome Research, 13, 237-248).This technology can also help to identify translocations. It can beeasily carried out with frozen biopsies or tumoral paraffin-includedmaterial. CGH results are expressed as the ratios of copy numbers in thetumoral material and in normal tissue. A threshold of 0.5 is beenacknowledged to describe a gain or a loss. More this ratio is high, morethe amplitude of the anomaly is important. Thus, an important anomaly islikely to have a real impact at the biological level. However, thechromosomal aberrations only represent a weak part of the origins ofgene expression deregulation. This is why other technologies arenecessary. CGH have another advantage, to certify presence of tumoralsamples in the tumoral biopsy or biospecimen, and this whenever anaberration can be detected.

The second technology allowing a functional genomic analysis correspondsto the measurement of mRNA and microRNA. The determination of theexpression level variation for these RNA is carried out by comparing theexpression levels in a tumoral tissue and in the corresponding normaltissue. For instance, in case of colon adenocarcinoma, the correspondingnormal tissue is the normal colic mucosal tissue. The gene expressionanalysis allows the study of the independent deregulations orderegulations due to chromosomal aberrations. Indeed, the regulation ofthe transformational activity of genes is complex and involves manylevels of regulation: trans/cis transcription factors, promoters,chromatin regulation, and the like. Generally, all deregulations(over-expression or under-expression) are considered with a ratiotumour/normal of at least 2. This threshold called “fold change” canthus have a positive value >2 or a negative value <−2. The same conceptapplies to the microRNAs which play an important role in thepost-transcriptional regulation of genes, therefore for the proteinsexpression. Technologies that can be used comprise northern analysis,mRNA or cDNA microarrays, RT-PCT (in particular quantitative RT-PCR) andthe like. The level of transcription can be determined at the mRNA levelor at the encoded protein level. Protein expression can be assessed byWestern blotting, immunoassay, proteomics tools or mass spectrometry.

These two types of analyses, CGH and RNA expression determination can besupplemented by an analysis of the mutational status of genes. Indeed,the presence of mutation leading to a functional gain or loss has animportant effect on biology of the tumour without being always connectedto variations of gene expression or of gene copy number. Many mutationsare known to have a direct effect on the activity of a treatment byinducing increased sensitivities or resistances. For example, themutations in the tyrosine kinase domain of EGFR are often associatedwith sensitivity to the small molecules inhibiting EGFR, the mutationsin KRAS gene are associated with resistance to the treatment bymonoclonal antibodies targeting EGFR. In addition to mutational status,some SNP can also be detected. Indeed, SNP can be also associated to afunctional gain or loss, a resistance or a toxicity for a drug. Themutational status can be determined by any method known in the art, forinstance by sequencing, microsequencing or hybridization.

In short, high throughput genomic technologies can be used tocharacterize in the most exhaustive possible way the biologicalanomalies of a given tumour from an individual to be treated. Theexperimental data for each tumour are compiled in basic files being usedfor the application of the algorithms allowing calculation of a scorefor each drug. These files comprise the copy number of genes, themutations, the fold-changes or the intensities of signals (proportionalto the number of transcripts or to the number of gene copy) for normaltissue (Intensity 1 or I1) and for tumoral tissue (intensity 2 or I2).The functional genomic analysis allows the simultaneous measurement of44,000 or more (for example 244,000) RNA sequences covering all thegenome. Preferably, a filtration can be applied to retain only theprobes having a ratio or fold-changes higher or lower than 2 and whoseaverage of the intensities I1 and I2 is higher than 100 units offluorescence (arbitrary units).

The term “molecular anomalies” refers herein to the gene expressiondifferences (either mRNA, microRNA or protein expression), to a gain orloss of gene copy number, or to a mutation presence.

In a particular embodiment of the invention, the exhaustivecharacterization of the tumour is replaced by the characterization ofthe target genes of the drug database. In this embodiment, specificarray can be prepared to determine the gene expression level of all thetarget genes of the database.

Drug Database

For the method of the invention, it is necessary to provide a databasewith a list of target genes for each drug of the database. As explainedbefore, a target gene for a drug can be, without being limited thereto,any gene documented to be involved in the drug mechanism of action, tobe involved in the drug metabolism, to have a modified gene expressionin presence of the drug, to be associated with a drug resistance, to beassociated with a drug toxicity. The database can be prepared based onthe search in the public databases (such as CTD, DrugBank, PubMed, andthe like) in order to identify the genes associated with each drug. Forinstance, the database can be built based on the CTD (The ComparativeToxicogenomics Database, See Worldwide Website: ctd.mdibl.org) data fora selection of drugs and their molecular targets (genes), restricted tothe human species (ID 9606). These data can be crossed with genes'information from LocusLink (gene symbol, RefSeq NM, gene description).Finally, each drug/gene interaction in the database can be qualifiedfrom the available publications, to determine the type of interactions:some positive interactions (target, sensitivity, drug activator, drugcarrier, toxicity reverser), some negative interactions (resistance,toxicity, drug metabolism, apoptosis, death).

The identified genes can have different roles and significances.Therefore, in a preferred embodiment, the target genes are classifiedinto three categories: the major target genes, the minor target genesand the resistance genes. The identification of these genes from thepublic data (public literatures and data banks) and their classificationin the three categories form an integral part of this invention. Themajor target genes are those which have been demonstrated to have aclear cause and effect link with the drug mechanism of action. Forexample, HER2 gene is regarded as major target gene for trastuzumab,VEGFA gene is regarded as major target gene for bevacizumab, and thelike. A given drug can have one or more major target genes. Thiscategory also includes the genes known to be involved in the drugmetabolization when drugs are known to become active only when an activemetabolite is generated. The minor target genes are those which arefound to be those whose level of regulation is modified in the presenceof the drug, without a direct link with the drug mechanism of action.The resistance genes comprise genes known to induce a direct resistanceto the drug but also genes associated with a major toxicity. Forexample, ERCC1 gene is a target gene of resistance for the use ofplatinum salts. For example, some cytochrome P450 isoforms areassociated with a major toxicity.

In a particular embodiment of the invention, the considered target genescan only belong to the two following categories: the major target genesand the resistance genes.

A first drug database has been established by the inventors and isdisclosed in Table 1. For some drugs, the target genes have beencategorized.

The drug database can be incremented over the time, by categorizingtarget genes for a drug, and/or by adding new drug, new target genesand/or by including combination data (e.g. combination of drugs withradiotherapy or combination of drugs).

More complete is the drug database, more accurate is the prediction.However, the method for predicting the relative efficacy of drugs can becarried out as soon as a preliminary database is ready.

Algorithm

An algorithm has been indentified for calculating a score for each drugin consideration of the tumour characteristics and the genes known to bein relation with a drug. This calculation can be carried out by specificsoftwares by using of the scripts developed under R for instance, andallowing the determination of the frequencies and the association linksbetween the file of target genes for the drugs and the file integratingthe data of the genomic analysis resulting from the biologicalinvestigation from the tumour of the individual.

The algorithm can take into account the following parameter:

1) the whole percentage of deregulation of target genes of a drug.Therefore, the list of target genes for a given drug is compared withthe list of deregulated genes in order to determine the percentage ofderegulated genes for this drug. For instance, if 10 target genes havebeen identified for a given drug and, for a given tumour, 4 of the 10target genes are found to be deregulated, then the percentage ofderegulated genes for this drug is 40%.

2) the deregulation extent and sense (e.g., over- or under-expression)of the target genes defined by a Fold Change (Fc) and an averageintensity (AvgInt). These parameters can be defined either as a wholefor the target genes or by each category (e.g., major target genes,minor target genes and resistance target genes).

3) the presence of mutations in target genes known to have an effect onthe given drug.

An algorithm is used to calculate a score for each drug of the databasein consideration of the tumour characterization for the subject to betreated.

A first basic algorithm that can be used in the method is the following:

$W = {{Pz}\frac{\left( {\sum_{C}F_{c > 2}} \right)}{n_{C}F_{c > 2}}}$

wherein

W is the score for a given drug;

P is the percentage of target genes for the given drug which arederegulated in the tumour of the individual;

z is an optional multiplication coefficient associated to the presenceof a mutation in a target gene;

Σ is sum;

Fc>2 is the Fold Change of each deregulated target gene for a given drugwith a Fold Change higher than 2;

nC_(Fc>2) refers to the number of target genes for the given drug with aFold Change higher than 2.

In a particular embodiment of this algorithm, Fc>2 is the Fold Change ofeach over-expressed target gene for a given drug with a Fold Changehigher than 2 and nC_(Fc>2) can refer to the number of target genes forthe given drug with a Fold Change higher than 2, or the number ofover-expressed target genes for the given drug with a Fold Change higherthan 2.

Of course, the algorithm can be more complex in order to take intoaccount the category of the target genes (e.g., major target gene, minortarget gene or resistance target gene), for instance by introducing amultiplication coefficient.

Such a more complex algorithm can be the following:

$W = {P\left( {{\frac{\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{\left( {\sum_{Cm}F_{Cm}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}$

wherein

W is the score for a given drug;

P is the percentage of target genes for the given drug which arederegulated in the tumour of the individual;

Σ is sum;

CM refers to major target gene for the given drug;

Cm refers to minor target gene for the given drug;

CR refers to resistance gene for the given drug;

-   -   n₁CM, n₂Cm and n₃CR respectively are the number of deregulated        target genes with a defined threshold for major target genes,        minor target genes and resistance genes;

F_(CM), F_(Cm) and F_(CR) are the Fold change of each gene higher thanthe defined threshold for major target genes, minor target genes andresistance genes, respectively;

q₁, q₂ and q₃ are multiplication coefficients for major target genes,minor target genes and resistance genes, respectively;

z₁, z₂ and z₃ are optional multiplication coefficients associated to thepresence of a mutation in a major target gene, a minor target gene and aresistance gene, respectively.

For instance, multiplication coefficients for the target genes can becomprised between 10 and 1,000 for major target genes, 0.1 and 10 forminor target genes and 10 to 1,000 for resistance genes. Other valuesfor multiplication coefficients are not excluded.

The multiplication coefficients associated to a mutation are 1 when nomutation exists. Depending on the functional impact of the mutation, thecoefficient z can be comprised between 10 and 1,000, for instance. Othervalues for multiplication coefficients associated to a mutation are notexcluded.

In a preferred embodiment, the defined threshold is a Fold change of atleast 2 or higher than 2. However, the consideration of a lowerthreshold is not excluded in the present method since a fold change of1.5 can be significant for some genes.

In a particular embodiment, F_(CM), F_(Cm) and F_(CR) can be the FoldChange of each over-expressed target gene for the given drug with thedefined threshold and n₁CM, n₂Cm and n₃CR can refer to the number oftarget genes for the given drug with the defined threshold, or thenumber of over-expressed target genes for the given drug with thedefined threshold.

In an alternative complex algorithm, the formulae can be the following:

$W = {{\frac{P_{CM}\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{P_{Cm}\left( {\sum_{Cm}F_{Cm}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{P_{CR}\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}}$

wherein the meaning of W, Σ, CM, Cm, CR, F_(CM), F_(Cm), F_(CR), q₁, q₂,q₃, z₁, z₂ and z₃ are the same than the previous algorithm and P_(CM),P_(Cm) and P_(CR) are the percentage of genes for the given drug whichare deregulated in the tumour of the individual for major target genes,minor target genes and resistance genes, respectively.

Similarly, in a preferred embodiment, the defined threshold is a Foldchange of at least 2 or higher than 2. However, the consideration of alower threshold is not excluded in the present method since a foldchange of 1.5 can be significant for some genes.

In a particular embodiment, F_(CM), F_(Cm) and F_(CR) can be the FoldChange of each over-expressed target gene for the given drug with thedefined threshold and n₁CM, n₂Cm and n₃CR can refer to the number oftarget genes for the given drug with the defined threshold, or thenumber of over-expressed target genes for the given drug with thedefined threshold.

In a particular embodiment, the algorithm can take into account theaverage intensity or intensity variation. This parameter is indicativeof the transcription level of genes. Indeed, it can be considered thatfor a same Fold Change of 2, a gene deregulation can have a differentweight depending on the intensity of the transcription, for instance200/100 in comparison to 200,000/100,000.

Accordingly, a still more complex algorithm can be one of thefollowings:

$W = {P\left( {{\frac{\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{\left( {\sum_{Cm}{F_{Cm} \times {Int}_{Cm}}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}$$W = {{\frac{P_{CM}\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{P_{Cm}\left( {\sum_{Cm}{F_{Cm} \times {Int}_{Cm}}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{P_{CR}\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}}$

wherein the meaning of W, Σ, CM, Cm, CR, F_(CM), F_(Cm), F_(CR), q₁, q₂,q₃, z₁, z₂ and z₃, and if present P_(CM), P_(Cm) and P_(CR), are thesame than the previous algorithm and Int_(CM), Int_(Cm) and Int_(CR) arethe intensity for major target genes, minor target genes and resistancegenes, respectively. “Int” can be the intensity of the genetranscription in the tumour sample, the difference of the genetranscription between the tumour sample and the normal sample from theindividual.

In an additional embodiment, the method can be focused on the majortarget genes and the resistance genes, without taking into account ofthe minor target genes. In this embodiment, the algorithm could be oneof the followings:

$W = {P\left( {{\frac{\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}$$W = {{\frac{P_{CM}\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{P_{CR}\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}}$$W = {P\left( {{\frac{\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}$$W = {{\frac{P_{CM}\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{P_{CR}\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}}$

wherein the meaning of W, Σ, CM, CR, F_(CM), F_(CR), q₁, q₃, z₁ and z₃,and if present P_(CM), P_(CR), Int_(CM), and Int_(CR) are the same thanthe previous algorithms.

Preferably, the selected algorithm is validated with two models: aretrospective model (e.g., tumours for which chemotherapies have beenperformed and for which the response to treatments is known); and aprospective model allowing the evaluation of the efficacy of aparticular treatment in relation with the score.

During the algorithm validation tests, some variables can be refined, inparticular the multiplication coefficients, the consideration of theaverage intensity or not, the threshold of the fold change. In addition,during this step, one can determine if it is preferable to use CGH orfunctional genomic analysis or both.

The method also considers other variants of the algorithm that could beproposed, the final objective staying to calculate a score for each drugbased on the characteristic of the tumour of the individual to betreated, in particular on the biologic and genetic anomalies of thetumour.

Further aspects and advantages of this invention will be disclosed inthe following examples, which should be regarded as illustrative and notlimiting the scope of this invention.

EXAMPLES Example 1

At diagnosis, 70% of lung cancers are in late stages. They are nonoperable with a poor clinical outcome.

The method of the present invention has been used in a patient case tohelp the practitioner to choose the most appropriate treatment.

The patient was a male Caucasian of 58 years old. He suffered of anon-small cell lung carcinoma (NSCLC), cT4, N0, M1. Nine therapeuticlines have been used, namely cisplatin-Gemzar, taxotere, navelbine,taxol-carboplatin, mediastinal radiotherapy, IRESSA, alimta, tarceva andHKI 272 (pan Her inhibitor). For HKI 272, the patient has been includedin a clinical trial.

HKI 272 began in October 2005. FIG. 1 show NMR of mediastinal lymph node(C1) and adrenal node (C2). HKI was efficient; the patient remained inthe study almost three years. However, after 37 months of HKI 272, adisease progression was observed (FIG. 2). New subclavious metastasisappeared. This is one of the biggest problems in oncology today; even ifthere is initial response, a secondary resistance to treatment oftenoccurs. Accordingly, the decision to stop HKI 272 treatment was takensince new metastasis occurred. It is important to mention thatpractitioners considered at that time that HKI 272 was the lasttherapeutic line available for this patient.

Subclavious metastasis was resected and used for complete molecularprofiling. The features of the profiling were:

-   -   1—comparison tumoral tissue versus normal lung tissue (T vs N);    -   2—Comparative genome hybridzation (CGH) (T vs N);    -   3—Gene expression (GE) comparison (T vs N);    -   4—microRNA (miRNA) profiling (T vs N);    -   5—Sequencing of genes including EGFR, p53, CTNNB1, AKT1, BRAF,        KRAS, HRAS, NRAS, PIK3CA, FBXW7, EGFR, ERBB2, KIT, NOTCH1, PTEN,        STK11, TP53, APC, MET, RB1, FGFR2, FGFR3, JAK2, TSC1, TSC2,        CDKN2A, CDKN2A, TOP1, TOP2A, PDGFRA, VHL, CDK4, JAK1, TYK.    -   6—No relevant mutations were found in any of these genes (for        example no mutation of EGFR or other genes). Therefore mutations        did not impact algorithm for this patient. Only relevant results        obtained with gene expression were used.

Then, the algorithm of the present invention was applied on these datain order to predict the drug efficacy. A score for each drug wascalculated based on the collected data. The algorithm used was thefollowing:

$W = {{Pz}\frac{\left( {\sum_{C}F_{c > 2}} \right)}{n_{C}F_{c > 2}}}$

wherein

W is the score for a given drug;

P is the percentage of target genes for the given drug which arederegulated in the tumour of the individual;

z is 1 because, in this example, no mutation was detected;

Σ is sum;

Fc>2 is the Fold Change of each deregulated target gene for a given drugwith a Fold Change higher than 2;

nC_(Fc>2) refers to the number of target genes for the given drug with aFold Change higher than 2.

Table 2 shows the calculated scores. It can be observed that the drugsused in the previous therapeutic lines were associated with low scores,namely 108 for cisplatine, 70 for gemzar, 77 for taxotere, 147 fortaxol, 82 for carboplatin, 66 for Iressa, and 73 for Alimta.

On December 2008, HKI 272 was stopped and a treatment with a combinationof Xeloda (3 600 mg/day, from Day 1 to Day 14, every 21 days) andLapatinib (1 250 mg/day) began. At the beginning of this treatment, thepatient showed a rapid disease progression and demonstrated a degradedhealth. Lapatinib, an anti-HER1 and -HER2 inhibitor, was justified, evenif no mutation was detected in EGFR, because EGF overexpressed 15 foldsin the patient and it was needed to continue HKI 272. Indeed,overexpression of EGF in the tumor induces a constant activation ofEGFR, that is why it appeared logic to assure the transition from HKI272to another anti EGFR in order to cover the same spectra. Xeloda (score555) was selected based on algorithm's score.

The disease was stable but recurrential paralysis was observed.Accordingly, in February 2009, it was decided to add Thiotepa whichshowed the highest algorithm score (score 713). After two months oftreatment with the combination Xeloda (3 600 mg/day, 5 days by week, 3weeks on 4 weeks), Lapatinib (1 250 mg/day) and Thiotepa (15-30 mg/day,Days 1 and 2, every 4 weeks), the disease was stable (FIG. 3). Thedisease was still stable for eleven months (FIG. 4), no morerecurrential paralysis occurred and the patient showed a good generalstatus.

In addition, the present method allows the determination of futuretherapeutic combinations. Indeed, during cancer treatment, resistanceoften appears. At least three others drugs showed high scores and can beused in case of resistance to the combination Xeloda, Lapatinib andThiotepa, namely fotemustine (score 627), rituximab (score 761) andtrabectidin (score 376).

By using the present method for selecting drugs, unexpected results wereobtained. Indeed, without the score predicting the potential efficacy ofa drug for a particular patient, the practitioner would not select bothXeloda and Thiotepa. Indeed, there is no indication for these drugs inlung cancer, in particular NSCLC. The present method allowed reachingfourteen months of stability with a good general status for the patient,whereas the vital prognosis was only of few weeks at the initiation ofthe treatment with the combination of Xeloda and Thiotepa.

In conclusion, the present example proves the value of the method of thepresent invention to help the practitioner to select appropriate drugsbased on the individual data.

Retrospectively, the use of the new predicting method clearlydemonstrated that all previous therapeutic lines, totally inefficient,were associated with a very low predictive score, as described. This isexactly the purpose of this innovative method, to be able to provide apredictive determination of the efficacy of drugs, and in this example,there is perfect validation of the concept, since all used inefficientdrugs are linked with low score.

Other patients experiment the new procedure, and the high added value ofthe present method is to demonstrate that each patient needs a uniquecombination of drugs. The method appears therefore extremely relevant inthe area of individualized selection of treatments.

Example 2

The patient was 64 years old. He suffered of a bronchial adenocarcinomaT4 with bones and pleural metastases. Two therapeutic lines have beenused, namely cisplatin-Alimta and Tarceva. The first therapeutic linewas associated with disease progression and the second was inefficientand led to a rapid progression.

A biopsy of normal bronchial mucosa and a tumoral biopsy were carriedout and used for mutational analysis by sequencing, CGH, microRNAsanalysis and Genome expression analysis.

CGH profile comprised numerous alteration (loss or gain), proving thetumoral status of the biopsy.

Mutational analysis including the genes as listed in Example 1 resultsin the identification of a mutation G464V in BRAF gene (B-Rafproto-oncogene serine/threonine-protein kinase, GeneID 673). Thismutation is postulated to be activating with intrinsic mitoticsignalisation. Therefore, a treatment with sorafenib could becontemplated.

Based on Genome Expression analysis, scores have been calculated asdetailed in Example 1 and are shown in the following table only for somerelevant drugs.

Avg Avg Target Found Found Targets List Abs Abs (FC) Chemical GenesTarget Genes List Targets (with fold-changes) (FC) UP-REG ScoreTIPIFARNIB 4 ABCB1 CYP3A4 CYP3A5 2 CYP3A4 (17.99) 20.73 20.73 1036(Zarnestra) UGT1A1 (2 + 0) CYP3A5 (23.46) (50.0%) BEVACIZUMAB 1 VEGFA 1VEGFA (2.30, 7.27, 4.58 4.58 457 (Avastin) (1 + 0) 4.15) (100.0%)AFLIBERCEPT 1 VEGFA 1 VEGFA (2.30, 7.27, 4.58 4.58 457 (VEGF Trap) (1 +0) 4.15) (100.0%) IFOSFAMIDE 11 BCL2, CASP9, CYP2A6, 4 CYP3A4 (17.99)14.82 20.73 376 (Cyfos, Holoxan, CYP2B6, CYP3A4, CYP3A5, (2 + 2) CYP3A5(23.46) 1000, IFEX, DNMT1, GSTM1, GSTP1, (36.4%) BCL2 (−4.42) CYP2B6(−13.41) Ifex/Mesnex Kit, GSTT1, SLC34A1 Ifosfamide/Mesna Kit,Isoendoxan, Mitoxana, Naxamide) ECTEINASCIDIN 743 4 CCNA2 CCNB1 CCNB2E2F1 3 CCNA2 (4.55) CCNB1 4.24 4.24 317 (Trabectedin, ET-743, (3 + 0)(2.95) CCNB2 (5.21) Yondelis) (75.0%) VINORELBINE 7 CASP3 CDKN2A PTGS2 3PTGS2 (17.97) 7.46 10.16 290 (Navelbine, Navelbine RALBP1 RBM17 SLC29A1(2 + 1) SLC29A1 (2.36) Base) TUBB2A (42.9%) TUBB2A (−2.05) — — — — — — —— PEMETREXED 10 DHFR FAS FPGS GART GGH 4 DHFR (2.40, 2.26) 3.91 3.91 156(Alimta) RBM17 SLC19A1 TP53 TYMP (4 + 0) GART (3.29) SLC19A1 TYMS(40.0%) (4.68) TYMS (5.32) — — — — — — — — GEFITINIB 57 ABCG2 ADORA1AKT1 AREG 18 AREG (6.94) CYP3A4 6.69 7.42 143 (Iressa, Irressat, AVENCASP3 CGRRF1 (11 + 7) (17.99) CYP3A5 (23.46) Tarceva) COL4A3BP CORO1CCYP1A2 (31.6%) DUSP3 (3.18) EPOR CYP2C19 CYP2C9 CYP2D6 (2.02, 2.11) IFI6(3.79) CYP2F1 CYP3A4 CYP3A5 NPTX2 (2.77) PHLDA2 DUSP3 DUSP9 E2F1 EGF(5.98) PLBD1 (8.04) SKI EGFR EPOR EPS15 ERBB2 (2.09) TYMS (5.32) EREGESR1 FGF6 GADD45A CYP2C9 (−2.94) CYP2F1 GADD45G GARS GCLC GNB2 (−27.19,−7.80) EGF (−2.04) GUCY2D HBEGF IFI6 IGFBP3 EGFR (−3.99) IL8 LEPR MAPK1MAPK3 MLH1 GADD45G (−3.12) GCLC NFKB1 NPTX2 NRL OSMR (−2.59) LEPR(−6.56) PARP1 PHLDA2 PLBD1 PTEN QSOX1 RBM7 RPA1 SFN SKI TGFA TNFRSF1BTYMS — — — — — — — — CISPLATIN 403 A2M ABCB1 ABCC1 ABCC2 137 ABHD2(2.30, 2.58) 5.94 5.17 80 (Abiplatin, ABCC5 ABHD11 ABHD2 ABR (63 + 71 +3) ADAM10 (2.01) BACH1 Biocisplatinum, ACSL3 ADAM10 ADFP (34.0%) (2.09)BAX (2.02) BBC3 Briplatin, Carboquone, ADORA2B AHCYL1 AKAP12 (2.35) BCAM(2.00) Cis Pt II, Cismaplat, AKR1B1 AKT1 AKT2 AKT3 ALB BIRC2 (2.06)BIRC3 Cisplatine, Cisplatyl, ANXA1 APEX1 ARF6 ARHGEF6 (4.00) BIRC5(12.70) Citoplationo, ARID5B ARMCX2 ASS1 ASTN1 CCNE1 (3.18) CDKN1ALederplatin, Neoplatin, ATP6V1G2 AXL B3GALT4 (2.33) CILP (4.39) Plastin,Platamine, BACH1 BAX BBC3 BCAM CNTNAP2 (20.81) Platiblastin, Platidiam,BCAS4 BCL2 BCL2L1 BCL2L12 CYP3A4 (17.99) DAB2 Platinex, Platinol, BIRC2BIRC3 BIRC5 BMP7 (2.33) DKK1 (51.55) Platinol-AQ, BTG2 C11ORF68 C11ORF9ETV4 (2.96) FADS1 Platinoxan, Randa) C19ORF2 C4ORF29 C7ORF16 (2.31,2.17) FANCC CA2 CALCB CASP2 CASP3 (2.05) FEN1 (2.99, 3.13) CASP8 CASP9CAT CAV1 FOS (32.01) GDF15 CCDC85B CCNE1 CCNG2 (14.33) GLRX2 (2.53)CD151 CD55 CDC40 CDH3 GSTM3 (2.04) HHEX CDKL5 CDKN1A CDKN2AIP (3.59)HPCAL1 (2.96) CELSR2 CES2 CFHR1 CFLAR IFI30 (2.79) JUN (2.41) CIAPIN1CIDEB CILP CKMT1B KLK3 (2.11) LANCL1 CLU CNTF CNTNAP2 COL11A2 (2.60)LAPTM4B (3.54, COL4A5 CORO1C CREBBP 3.75) MAP2K6 (2.32) CTAGE4 CTDSP1CTH MED21 (2.11) MEST CTNNAL1 CYCS CYP2C9 (8.01) MMP15 (3.00) CYP3A4D6S2723E DAB2 MMP16 (3.26) NCOA3 DDIT3 DDR1 DENND4A (2.54) NMI (2.13)NMU DEPDC6 DIABLO DKK1 DMBT1 (2.49) NR4A1 (3.47) DPYD DRAP1 DST EDN2NUDT1 (2.01) PDXK EDNRA EGFR ELMO2 EMP3 (3.48, 2.73, 2.41) ENPP2 EP300ERBB2 ERCC1 PMAIP1 (3.68) PRKCI ERCC2 ETV4 F8A3 FADD (2.83, 2.64) PTGS2FADS1 FAM129A FAM13A1 (17.97) PXDN (3.61, FAM46A FANCC FANCG FAS 4.00)RNASET2 (2.15) FASLG FASN FEN1 FGF7 RNF34 (2.28) SDC2 FGF9 FGFR2 FGFR3FKBP2 (3.25) SLC29A1 (2.36) FMOD FOS FOSL1 FOXC1 SP1 (2.15, 2.24) SPON1FTLL1 GADD45A GALNT7 (2.57) STEAP1 (2.90, GARS GAS1 GCLC GCLM 3.34,2.83) STYX (2.41) GCNT1 GCNT2 GDF15 GLRX2 TANK (2.02) TERT GMPPA GOLGA8AGOLGA8B (2.54) TP53I3 (3.40) GOLSYN GPAA1 GPX3 GSTM1 TPI1 (2.88) TRAM1GSTM2 GSTM3 GSTO1 GSTP1 (2.56) TRIB3 (2.05, 2.13) GSTT1 GUCY1B3 GUK1HERV- TYMS (5.32) UPK1B FRD HHEX HIF1A HLA-A HLA- (2.08) VEGFA (2.30,DPA3 HLA-G HNRNPA1 7.27, 4.15) HPCAL1 HSD17B8 HSPB1 A2M (−7.98) ABCC5(−2.30, HSPE1 HTRA2 ICAM1 ID4 IFI30 −2.38) ANXA1 (−2.14) IFITM1 IGFBP3IGFBP5 ARHGEF6 (−2.10) IL13RA1 IL1B IL1R1 IL4R IL6 ARID5B (−2.58, −2.20,−2.04) ITGA9 ITGAE ITGB4 ITPA JUN BCL2 (−4.42) BTG2 KCNA5 KCNK1 KLF2KLK1 (−2.33) CA2 (−3.62) KLK10 KLK11 KLK12 KLK15 CDH3 (−4.12) CELSR2(−2.39) KLK2 KLK3 KLK4 KLK5 KLK6 CES2 (−2.61) KLK7 KLK8 KLK9 KRT17 CIDEB(−2.19) CLU (−8.31) KRT19 KRT4 LANCL1 COL4A5 (−2.74) LAPTM4B LASS4LEPREL1 CTNNAL1 (−4.41) LIMCH1 LOH11CR2A LTBP1 CYP2C9 (−2.94) DDR1(−2.50, M6PRBP1 MACF1 MAD2L2 −2.46) DMBT1 (−31.82) MAGED2 MAL MAP2K6MCM2 DPYD (−4.02, −3.55) MED1 MED21 MEST MGMT DST (−3.08, −14.93) MLLMMP10 MMP15 MMP16 EGFR (−3.99) FAM129A MMP3 MPO MPP2 MRPS27 (−11.54,−14.34) FGF7 (−6.10, MT1A MT1F MT2A MT3 MVP −6.45, −2.30) FGF9 MYC NAB1NAIP NCOA3 (−2.12) FGFR2 (−15.60, −8.81) NDUFS8 NEAT1 NEDD9 NMI 8.81)FGFR3 (−3.11, −7.43) NMU NOTCH2 NOTCH4 NR1I2 FMOD (−2.27) NR4A1 NTHL1NUDT1 OPTN FOXC1 (−3.90, −4.46) P4HA2 PAFAH1B3 PAPPA2 GAS1 (−2.36) GCLC(−2.59) PARD6A PARP1 PAX8 PBX1 GCLM (−3.92) PCNA PDIA3 PDXK PFDN5GOLGA8A (−3.47, −2.17) PFKFB4 PFKP PGK1 PHIP GOLSYN (−3.18) GSTM2 PHLDA1PLP2 PMAIP1 PMPCA (−3.53) HLA-A (−2.18) PMS2L11 POLA1 POP4 PPIE ID4(−2.25) ITGA9 (−2.61) PPP1R1B PPP3CB PRKCI KLK10 (−5.32, −12.20) PRKDCPRNP PRODH PROS1 KLK11 (−51.60) KLK12 (−21.92) PSMB10 PTEN PTGS1 PTGS2KRT19 (−2.14) PTK2 PXDN QSOX1 RAB40B KRT4 (−11.12) LASS4 (−2.24) RAD21RALB RALBP1 RASSF1 LIMCH1 (−2.87) RB1 RBCK1 RBM9 RBP1 RELA LTBP1 (−2.35)MACF1 (−2.02) RHOC RING1 RNASET2 RNF34 MAL (−12.81) RPL21 RPL36 RPL6RPS14 MMP10 (−62.97) MT3 (−13.83, RPS18 RPS4Y2 RPS5 RRAGD −2.32) NAIP(−2.67) RUNX3 RXRB SCRN1 SDC2 PBX1 (−3.32, −3.26) SERPINB4 SERPINE2 SFNPHIP (−2.01) PHLDA1 (−3.12, SH2B3 SH3BGRL3 SLC15A1 −2.49) PPP1R1B(−3.30) SLC20A1 SLC29A1 SLC2A1 PTGS1 (−4.87) SLC31A1 SLC39A7 SLC6A12RRAGD (−2.48) RUNX3 SLC7A11 SLC7A8 SLPI (−4.02) SERPINB4 (−7.72) SNAP29SNAPC3 SNRPA SLC31A1 (−2.78, −2.75, SOCS1 SOCS2 SOD2 SOD3 −2.79) SLPI(−10.90, SP1 SP100 SP110 SPINT2 −12.82) SOD3 (−5.07) SPON1 SPTLC2 STEAP1STYX SWAP70 (−2.00) SULT1A1 SULT1A2 SWAP70 TF (−4.25, −4.55) SYNJ2 TANKTERT TF TFAP2A TNFSF10 (−3.01) TFB1M TGFA TGFB1 TLR2 TUBB2A (−2.05) UCP2(−2.53) TMSL6 TNF TNFAIP3 TNFSF10 UGT1A6 (−16.01, −24.90) TNFSF13 TP53TP53I3 TP73 VAV3 (−7.76) TPI1 TRADD TRAM1 TRAP1 WFDC2 (−14.33, −12.71)TRIB3 TRIP13 TSPAN12 XPA (−2.62) XRCC1 (−2.80) TUBA1A TUBB2A TXN BCAS4(2.21, −2.07) TXNDC13 TXNRD1 TYMP CYCS (−2.70, 2.03) TYMS UCP2 UGDHUGT1A1 PRNP (−4.40, 2.43) UGT1A3 UGT1A6 UMPS UPK1B USP14 VAPAVAV3 VEGFAVPS52 WDR46 WFDC2 WWC1 XIAP XPA XRCC1 XRCC5 XRCC6 YARS ZFP36L1 ZFP36L2ZNF192 ZNRD1

Accordingly, it can be observed that the drugs used in the twotherapeutic lines, which did not provide therapeutic efficacy areassociated with low scores, namely 80 for cisplatine, 156 for alimta and143 for Tarceva. Accordingly, the method of the invention should avoidthe choice of such treatments.

Since January 2010, Vinorelbine, associated with a score of 290, hasbeen selected for treating the patient. At the beginning, the patienthas a very worsened general status. Three months later, the disease wasstable, then progressed. In conclusion, although the drug associatedwith the best score has not been selected, the selected drug showedefficacy, conferring three months survival.

Example 3

A patient was diagnosed in May 2007 for a primary bronchialadenocarcinoma with bilateral pulmonary metastases and asymptomaticcerebral metastases. A surgical treatment has been carried out inNovember 2008 and two therapeutic lines have been used, namely thirteencycles of cisplatin-gemcitabin for the first line and Alimta for thesecond one. The first line was associated with a partial responsefollowed by a disease progression and the second line was onlyassociated with a disease progression.

A normal bronchial biopsy and a pulmonary metastasis biopsy were carriedout and used for mutational analysis by sequencing, CGH, microRNAsanalysis and Genome expression analysis.

CGH profile comprised numerous aberrations (loss and gain throughout thegenome) demonstrating the tumoral status of the biopsy.

Mutational analysis including the genes as listed in Example 1 did notlead to the identification of any mutation.

Based on Genome Expression analysis, scores have been calculated asdetailed in Example 1 and are shown in the following table only for somerelevant drugs.

Avg Abs Avg (FC) Target Found Found Targets List (with Abs UP- ChemicalGenes Target Genes List Targets fold-changes) (FC) REG Score CARBOPLATIN16 ALB BAX BCL2 BCL2L12 BIRC2 6 ALB (84.71) BAX (2.03) 16.14 29.85 559(Paraplatin, CASP3 CASP9 DCT DPYD ERBB2 FAS (3 + 3) PTGS2 (2.81)Paraplatin-AQ) PARP1 PCNA PTGS2 RBM17 TYMS (37.5%) CASP3 (−2.56) DPYD(−2.07) FAS (−2.69) BEVACIZUMAB 1 VEGFA 1 VEGFA (3.18, 3.55, 4.81, 3.843.84 384 (Avastin) (1 + 0) 3.82) (100.0%) AFLIBERCEPT 1 VEGFA 1 VEGFA(3.18, 3.55, 4.81, 3.84 3.84 384 (VEGF Trap) (1 + 0) 3.82) (100.0%)CEDIRANIB 2 FLT1 FLT4 1 FLT1 (4.36, 5.59) 4.98 4.98 248 (Recentin) (1 +0) (50.0%) AXITINIB 6 FLT1 FLT4 KDR KIT PDGFRA PDGFRB 3 FLT1 (4.36,5.59) 4.68 4.68 234 (3 + 0) PDGFRA (4.21, 3.56) (50.0%) PDGFRB (5.18)CAMPTOTHECIN 57 ABCB1 AGRN ALB ANXA4 BAX BCL2 16 AGRN (2.26, 2.29, 2.11)8.40 14.18 199 BID BIRC5 BRCA1 BRCA2 CAB39 (8 + 8) ALB (84.71) BAX(2.03) CASP2 CASP3 CCNB1 CDK2 CDKN1A (28.1%) LGALS1 (3.09) PLK3 CEACAM1CEBPZ CTSB CYCS DPYD (2.10) PPP1R1B (5.31) EI24 EP300 EPM2AIP1 FDXRGSTP1 THBS1 (10.46, 9.80) HNRNPC IL1B IL8 JUN LGALS1 VEGFA (3.18, 3.55,4.81, MAP2K3 MAP3K5 MAPK9 MAPT 3.82) MDM2 NCK2 PARP1 PLK3 PPP1R1B ABCB1(−2.74) CASP3 (−2.56) PRC1 RAD51 RB1 RBL1 RBL2 SDC1 DPYD (−2.07) FDXRTAP1 TAX1BP3 THBS1 TNFSF9 TOP1 (−4.08) GSTP1 (−2.04) TP53 TP53I3 TP53TG1TYMS VEGFA MDM2 (−2.46) TAP1 (−2.71) XIAP TP53TG1 (−2.28) VINORELBINE 7CASP3 CDKN2A PTGS2 RALBP1 4 CDKN2A (9.83, 6.61) 4.12 4.64 198(Navelbine, RBM17 SLC29A1 TUBB2A (3 + 1) PTGS2 (2.81) TUBB2A NavelbineBase) (57.1%) (2.88) CASP3 (−2.56) GEMCITABINE 158 AGPAT2 ALDH1A3ALDH6A1 ANAPC1 48 ANTXR1 (2.23, 2.64, 3.53) 6.60 6.60 129 (DDFC, DFDC,ANK3 ANKRD1 ANTXR1 ARF1 ATF3 (31 + 17) BAX (2.03) CLIC4 (2.63, GEO,Gemcin, BAIAP1 BAX BCL2 BCL2L1 BCL2L11 (30.4%) 2.54, 2.54) CTHRC1Gemcitabina, BCL6 BIRC2 BIRC3 BIRC5 BNIP3L (19.05) DLG2 (3.80) ETV1Gemcitabine, C15ORF15 C1ORF144 C4ORF18 (3.09, 3.19) GAL3ST1 HCl,Gemcitabine CASP3 CCL20 CCND1 CCNG2 CD40 (5.88) GAS1 (2.17) GPC3hydrochloride, CDA CDH1 CDKN1A CEBPB CKB (3.00) HOXB2 (2.95, 2.38)Gemcitabinum, CLIC4 CMPK COX3 CSRP2 CTHRC1 IFIT1 (2.11) IL6 (2.67)Gemtro, Gemzar) CXCL1 CXCL2 CXCL3 CYP24A1 DDIT4 JAM3 (2.13, 2.01) KLF8DHX9 DLG2 DNCH1 DPYD EDN2 (3.81) KRT8 (2.56, 2.55) EGFR EGR1 ETV1 EVI2BFBXO25 MAF (2.66, 2.91) NEDD9 FGG FOSL2 FXYD3 GAL3ST1 GAS1 (3.66) NEU1(2.80) NNMT GLRX GPC3 GTF2A1 HDAC9 HIF1A (3.15) NRP1 (2.03, 3.00,HIST1H4B HIST1H4C HOXB2 HSPA1L 2.60) PLAU (9.25) RGS2 HSPA5 IFIT1 IL6INSIG1 IQGAP1 (3.75) SCD (3.76, 3.04, IRAK2 IRF3 ITSN2 JAM3 KCTD12 KLF83.90) SLC2A3 (4.22, 7.94) KRT8 LARP5 LIFR LRRC28 LYZ MAF SPP1 (70.93)MAGEA10 MAGEC1 MAP17 MARCKS TNFRSF11B (12.11, 8.17) MARS MDM2 MGMT MXI1MYB TYRP1 (13.30) VEGFA NCBP1 NEDD9 NEU1 NFKB2 NFKBIE (3.18, 3.55, 4.81,3.82) NNMT NPEPPS NR4A3 NRG1 NRP1 WBP5 (2.13) ZNF274 P2RY5 PAQR8 PARP1PCSK9 PDPK1 (3.73) ZNF521 (2.79) PJA2 PLAU PPFIA4 PPP1R15A PSAT1 ANK3(−3.59, −3.38, −3.62) PTEN PTGS1 PTPN11 RAB8A RBM17 BIRC3 (−2.27)CASP3(−2.56) RELA RGS2 RNF149 RPL37 RRAGD CCL20 (−10.90) RRM1 SAT SCDSLC25A29 SLC29A1 CD40 (−2.36) CXCL1 (−47.43) SLC2A14 SLC2A3 SLC43A3SLITRK2 CXCL2 (−2.14, −5.83) SPP1 SYNCRIP TCOF1 TERT TGFB2 CXCL3 (−4.04)TNF TNFAIP3 TNFRSF11B TP53 CYP24A1 (−2.10) DPYD (−2.07) TP53BP1 TP53INP1TRAF1 TUBE1 FXYD3 (−2.79) TYMP TYMS TYRP1 UBE2C UGGT2 HDAC9 (−4.09) LYZ(−7.83) VEGFA VGF VLDLR WBP5 WNT5A MDM2 (−2.46) XIAP ZNF274 ZNF449ZNF521 MGMT (−2.34) MYB (−8.21) NRG1 (−2.47, −3.36) CISPLATIN 403 A2MABCB1 ABCC1 ABCC2 ABCC5 112 A2M (2.45) ABCC2 (4.03, 5.94 4.76 80(Abiplatin, ABHD11 ABHD2 ABR ACSL3 ADAM10 (68 + 43 + 1) 3.37) AKAP12(2.40) Biocisplatinum, ADFP ADORA2B AHCYL1 AKAP12 (27.8%) AKT3 (3.10)ALB (84.71) Briplatin, AKR1B1 AKT1 AKT2 AKT3 ALB ANXA1 BAX (2.03) CA2(2.50) Carboquone, Cis APEX1 ARF6 ARHGEF6 ARID5B CCNE1 (3.72) CILP(3.81) Pt II, Cismaplat, ARMCX2 ASS1 ASTN1 ATP6V1G2 AXL COL11A2 (21.07)DAB2 Cisplatine, B3GALT4 BACH1 BAX BBC3 BCAM (2.64) DKK1 (6.38)Cisplatyl, BCAS4 BCL2 BCL2L1 BCL2L12 BIRC2 EDNRA (2.53, 2.37)Citoplationo, BIRC3 BIRC5 BMP7 BTG2 C11ORF68 ENPP2 (2.36) ERCC2Lederplatin, C11ORF9 C19ORF2 C4ORF29 (2.03) FADS1 (3.44, 3.92)Neoplatin, C7ORF16 CA2 CALCB CASP2 CASP3 FANCC (2.22) FASN Plastin,CASP8 CASP9 CAT CAV1 CCDC85B (2.36) FGF7 (2.19, 3.31, Platamine, CCNE1CCNG2 CD151 CD55 CDC40 2.06, 2.66) FMOD (2.38) Platiblastin, CDH3 CDKL5CDKN1A CDKN2AIP GARS (2.10) GAS1 (2.17) Platidiam, CELSR2 CES2 CFHR1CFLAR GCNT1 (2.06) GDF15 Platinex, Platinol, CIAPIN1 CIDEB CILP CKMT1BCLU (3.10) GPX3 (2.08) Platinol-AQ, CNTF CNTNAP2 COL11A2 COL4A5 GSTM1(4.71) GSTM3 Platinoxan, CORO1C CREBBP CTAGE4 CTDSP1 (5.35, 5.57)GUCY1B3 Randa) CTH CTNNAL1 CYCS CYP2C9 (2.65) HHEX (2.27) CYP3A4D6S2723E DAB2 DDIT3 DDR1 HPCAL1 (2.54) ICAM1 DENND4A DEPDC6 DIABLO DKK1(5.72) ID4 (2.59) IGFBP3 DMBT1 DPYD DRAP1 DST EDN2 (2.97, 2.56) IGFBP5(3.91, EDNRA EGFR ELMO2 EMP3 ENPP2 2.60, 2.94) IL13RA1 (2.10, EP300ERBB2 ERCC1 ERCC2 ETV4 2.42) IL1R1 (2.41, 2.24) F8A3 FADD FADS1 FAM129AIL6 (2.67) ITGA9 (3.20, FAM13A1 FAM46A FANCC FANCG 4.54) KLK8 (4.87)LIMCH1 FAS FASLG FASN FEN1 FGF7 FGF9 (2.71, 2.26) LTBP1 (2.86) FGFR2FGFR3 FKBP2 FMOD FOS MACF1 (3.18, 3.43) MAL FOSL1 FOXC1 FTLL1 GADD45A(2.83) MEST (5.64) GALNT7 GARS GAS1 GCLC GCLM MMP15 (3.05) MMP16 GCNT1GCNT2 GDF15 GLRX2 GMPPA (3.43) NEDD9 (3.66) GOLGA8A GOLGA8B GOLSYN GPAA1PAFAH1B3 (2.04) PAX8 GPX3 GSTM1 GSTM2 GSTM3 GSTO1 (2.17) PFKFB4 (2.76)GSTP1 GSTT1 GUCY1B3 GUK1 PPP1R1B (5.31) PRKCI HERV-FRD HHEX HIF1A HLA-AHLA- (2.31, 2.39) PRODH DPA3 HLA-G HNRNPA1 HPCAL1 (3.77) PTGS2 (2.81)HSD17B8 HSPB1 HSPE1 HTRA2 PXDN (10.10, 19.71) ICAM1 ID4 IFI30 IFITM1IGFBP3 SCRN1 (2.76) SDC2 IGFBP5 IL13RA1 IL1B IL1R1 IL4R IL6 (3.16)SERPINE2 (2.63) ITGA9 ITGAE ITGB4 ITPA JUN KCNA5 SLC39A7 (3.59) SPINT2KCNK1 KLF2 KLK1 KLK10 KLK11 (2.47) SPON1 (2.80) KLK12 KLK15 KLK2 KLK3KLK4 KLK5 STYX (2.12) SWAP70 KLK6 KLK7 KLK8 KLK9 KRT17 KRT19 (2.36)TGFB1 (2.40) KRT4 LANCL1 LAPTM4B LASS4 TRIB3 (8.75) TUBB2A LEPREL1LIMCH1 LOH11CR2A LTBP1 (2.88) VEGFA (3.18, 3.55, M6PRBP1 MACF1 MAD2L2MAGED2 4.81, 3.82) WWC1 (2.43) MAL MAP2K6 MCM2 MED1 MED21 ABCB1 (−2.74)ABHD2 (−2.82, MEST MGMT MLL MMP10 MMP15 −2.33, −2.55) MMP16 MMP3 MPOMPP2 MRPS27 ADORA2B (−4.27) BIRC3 MT1A MT1F MT2A MT3 MVP MYC (−2.27)CASP3 (−2.56) NAB1 NAIP NCOA3 NDUFS8 NEAT1 CES2 (−2.08) CLU (−4.24)NEDD9 NMI NMU NOTCH2 NOTCH4 COL4A5 (−3.24) DMBT1 NR1I2 NR4A1 NTHL1 NUDT1OPTN (−34.95) DPYD (−2.07) FAS P4HA2 PAFAH1B3 PAPPA2 PARD6A (−2.69)FGFR2 (−4.25, −4.25) PARP1 PAX8 PBX1 PCNA PDIA3 FGFR3 (−2.10, −2.89)PDXK PFDN5 PFKFB4 PFKP PGK1 FOXC1 (−2.51, −3.13) PHIP PHLDA1 PLP2 PMAIP1PMPCA GCLC (−2.03) GCLM PMS2L11 POLA1 POP4 PPIE (−3.16, −2.98) GOLSYN(−3.36) PPP1R1B PPP3CB PRKCI PRKDC GSTP1 (−2.04) HLA- PRNP PRODH PROS1PSMB10 PTEN A (−2.16, −2.37) HLA-G (−2.84) PTGS1 PTGS2 PTK2 PXDN QSOX1KLK10 (−3.75, −5.35) RAB40B RAD21 RALB RALBP1 KLK11 (−10.49) KLK3(−9.01) RASSF1 RB1 RBCK1 RBM9 RBP1 KRT17 (−3.10) KRT4 RELA RHOC RING1RNASET2 RNF34 (−4.61) MGMT (−2.34) RPL21 RPL36 RPL6 RPS14 RPS18 MMP10(−12.00) MT3 (−8.76) RPS4Y2 RPS5 RRAGD RUNX3 RXRB NAB1 (−2.03) SCRN1SDC2 SERPINB4 SERPINE2 NEAT1 (−2.29, −2.02) NMU SFN SH2B3 SH3BGRL3SLC15A1 (−7.07) PMAIP1 (−3.07) SLC20A1 SLC29A1 SLC2A1 SLC31A1 PSMB10(−3.25) SLC39A7 SLC6A12 SLC7A11 SLC7A8 SERPINB4 (−71.70) SLPI SNAP29SNAPC3 SNRPA SOCS1 SLC31A1 (−2.06) SLPI (−17.09, SOCS2 SOD2 SOD3SP1SP100 −28.09) SOD2 (−2.54) SP110 SPINT2 SPON1 SPTLC2 TF (−15.98, −17.72)STEAP1 STYX SULT1A1 SULT1A2 TNFSF10 (−3.33) UGT1A6 SWAP70 SYNJ2 TANKTERT TF (−8.88, −8.56) UPK1B (−28.60) TFAP2A TFB1M TGFA TGFB1 TLR2 VAV3(−4.99, −3.12) TMSL6 TNF TNFAIP3 TNFSF10 WFDC2 (−20.20, −15.05) TNFSF13TP53 TP53I3 TP73 TPI1 DST (2.30, 2.14, 2.36, −2.86) TRADD TRAM1 TRAP1TRIB3 TRIP13 TSPAN12 TUBA1A TUBB2A TXN TXNDC13 TXNRD1 TYMP TYMS UCP2UGDH UGT1A1 UGT1A3 UGT1A6 UMPS UPK1B USP14 VAPA VAV3 VEGFA VPS52 WDR46WFDC2 WWC1 XIAP XPA XRCC1 XRCC5 XRCC6 YARS ZFP36L ZFP36L2 ZNF192 ZNRD1PEMETREXED 10 DHFR FAS FPGS GART GGH RBM17 1 FAS (−2.69) 2.69 0.00 0(Alimta) SLC19A1 TP53 TYMP TYMS (0 + 1) (10.0%)

First of all, the scores associated with the drugs used in the first andsecond therapeutic lines are low (Gemcitabin=129; cisplatine=80 andAlimta=0). Those scores are consistent with the observed clinical data.

However, based on this score table, avastin associated with a score of384 has been selected. The treatment has begun in January 2010 and amajor response has been observed after two treatment cycles, as showedwith the scanners of FIG. 5. This major response validates the presentmethod and the unquestionable benefit for the patient.

Example 4

The patient was 59 years old. He suffered of a non small cell bronchialcarcinoma with adrenal metastases. Two therapeutic lines have been used,namely three cycles of cisplatin-Alimta and three cycles oftaxotere-cisplatine-avastin. These therapeutic lines were associatedwith a first step of stabilization and then a step of diseaseprogression.

Normal and tumoral bronchial biopsies were carried out and used formutational analysis by sequencing, CGH, microRNAs analysis and Genomeexpression analysis.

CGH profile is shown in FIG. 6 and comprises chromosomal aberrations inchromosome 11.

Mutational analysis including the genes as listed in Example 1 did notlead to the identification of any mutation.

Based on Genome Expression analysis, scores have been calculated asdetailed in Example 1 and are shown in the following table only for somerelevant drugs.

Avg Ab Found Targets List Avg (FC) Target Found (with fold- Abs UP-Chemical Genes Target Genes List Targets changes) (FC) REG ScoreECTEINASCIDIN 4 CCNA2 CCNB1 CCNB2 E2F1 4 CCNA2 (7.13) 5.13 5.13 512 743(4 + 0) CCNB1 (4.52) (Trabectedin, ET- (100.0%) CCNB2 (4.00) E2F1 743,Yondelis) (4.85) GEMTUZUMAB 1 CD33 1 CD33 (2.02, 2.63) 2.33 2.33 232(Mylotarg) (1 + 0) (100.0%) HYDROXYUREA 26 BAX C13ORF34 CASP3 CCNA2CCNB1 11 CCNA2 (7.13) 4.45 4.67 179 (Biosupressin, CCND1 CCND2 CCND3CCNE1 CCNG1 (10 + 1) CCNB1 (4.52) Droxia, Hidrix, CDC25C CDCA8 CDKN1ACKS2 EDN3 FAS (42.3%) CCNE1 (2.56) Hydrea, Hydreia, KPNA2 MECOM PRC1PSRC1 RRM1 RRM2 CDCA8 (4.40) Hydura, Hydurea, RUNX1 SNCA TP53 UBE2CCDKN1A (2.35) Litaler, Litalir, KPNA2 (2.00) Onco-Carbide, PRC1 (3.28)Oxyurea, PSRC1 (2.71) Ureaphil) RRM2 (14.29, 5.77) UBE2C (7.67) BAX(−2.32) — — — — — — — — DOCETAXEL 43 ABCB1 ABCC1 ABCC2 BAX BCL2 BCL2L115 ABCC1 (2.14) 3.56 3.87 107 (Taxotere) BIRC5 BUB1B CASP3 CCNB1 CFLARCSF2 (12 + 3) ABCC2 (2.58, 3.19) CYP19A1 CYP1B1 CYP3A4 DPYD ERBB2(34.9%) BIRC5 (8.83) F2R GSTP1 HIF1A HRAS IL6 MAD2L1 BUB1B (8.66) MAPK1MAPK3 MDM2 PARP1 PGR POR CCNB1 (4.52) PTGS2 RAF1 RB1 SKP2 TNF TNFRSF10BCYP1B1 (2.39) IL6 TP53 TUBB TUBB1 TYMP TYMS UMPS (2.79) MAD2L1 VEGFAXIAP (2.68) PTGS2 (3.78, 2.77) SKP2 (2.18) TNFRSF10B (2.35) TYMS (3.72)BAX (−2.32) BCL2 (−2.35) VEGFA (−2.35) — — — — — — — — PEMETREXED 10DHFR FAS FPGS GART GGH RBM17 3 DHFR (2.02, 2.20, 2.94 2.94 88 (Alimta)SLC19A1 TP53 TYMP TYMS (3 + 0) 2.69, 3.12) (30.0%) SLC19A1 (2.59) TYMS(3.72) — — — — — — — — VINORELBINE 7 CASP3 CDKN2A PTGS2 RALBP1 RBM17 2CDKN2A (2.42, 2.87 2.87 81 (Navelbine, SLC29A1 TUBB2A (2 + 0) 2.51)PTGS2 (3.78, Navelbine Base) (28.6%) 2.77) — — — — — — — — CISPLATIN 403A2M ABCB1 ABCC1 ABCC2 ABCC5 59 ABCC1 (2.14) 4.23 5.04 48 (Abiplatin,ABHD11 ABHD2 ABR ACSL3 ADAM10 (39 + 19 + 1) ABCC2 (2.58, 3.19)Biocisplatinum, ADFP ADORA2B AHCYL1 AKAP12 AKR1B1 (14.6%) BIRC3 (4.02)BIRC5 Briplatin, AKT1 AKT2 AKT3 ALB ANXA1 APEX1 ARF6 (8.83) CA2 (2.25)Carboquone, Cis Pt ARHGEF6 ARID5B ARMCX2 ASS1 ASTN1 CCNE1 (2.56) II,Cismaplat, ATP6V1G2 AXL B3GALT4 BACH1 BAX CDH3 (2.23) Cisplatine,Cisplatyl BBC3 BCAM BCAS4 BCL2 BCL2L1 CDKN1A (2.35) Citoplationo,BCL2L12 BIRC2 BIRC3 BIRC5 BMP7 BTG2 CREBBP (2.16) Lederplatin, C11ORF68C11ORF9 C19ORF2 C4ORF29 CYP2C9 (2.09) Neoplatin, Plastin, C7ORF16 CA2CALCB CASP2 CASP3 DDIT3 (2.09) DKK1 Platamine, CASP8 CASP9 CAT CAV1CCDC85B (14.15) ETV4 (2.22) Platiblastin, CCNE1 CCNG2 CD151 CD55 CDC40CDH3 FADS1 (2.84, 3.87) Platidiam, Platinex CDKL5 CDKN1A CDKN2AIP CELSR2CES2 FEN1 (2.52, 2.70) Platinol CFHR1 CFLAR CIAPIN1 CIDEB CILP FGFR3(2.26, 3.09) Platinol-AQ, CKMT1B CLU CNTF CNTNAP2 COL11A2 ICAM1 (3.90)Platinoxan, Randa) COL4A5 CORO1C CREBBP CTAGE4 IGFBP5 (2.04) IL1B CTDSP1CTH CTNNAL1 CYCS CYP2C9 (4.60) IL6 (2.79) CYP3A4 D6S2723E DAB2 DDIT3DDR1 KRT17 (3.17) DENND4A DEPDC6 DIABLO DKK1 DMBT1 MAP2K6 (3.28) DPYDDRAP1 DST EDN2 EDNRA EGFR MCM2 (3.84) MEST ELMO2 EMP3 ENPP2 EP300 ERBB2(2.74) MMP10 ERCC1 ERCC2 ETV4 F8A3 FADD FADS1 (70.58) MYC (2.42) FAM129AFAM13A1 FAM46A FANCC PAFAH1B3 (2.10) FANCG FAS FASLG FASN FEN1 FGF7PHLDA1 (2.20) FGF9 FGFR2 FGFR3 FKBP2 FMOD FOS PTGS2 (3.78, 2.77) FOSL1FOXC1 FTLL1 GADD45A GALNT7 PXDN (2.31) GARS GAS1 GCLC GCLM GCNT1 GCNT2SERPINB4 (2.63) GDF15 GLRX2 GMPPA GOLGA8A SFN (2.66) GOLGA8B GOLSYNGPAA1 GPX3 GSTM1 SLC7A11 (2.22) GSTM2 GSTM3 GSTO1 GSTP1 GSTT1 SOD2(3.28) GUCY1B3 GUK1 HERV-FRD HHEX HIF1A SPON1 (2.86) HLA-A HLA-DPA3HLA-G HNRNPA1 TRIB3 (6.70) HPCAL1 HSD17B8 HSPB1 HSPE1 HTRA2 TXNRD1(2.49) ICAM1 ID4 IFI30 IFITM1 IGFBP3 IGFBP5 TYMS (3.72) IL13RA1 IL1BIL1R1 IL4R IL6 ITGA9 ITGAE UGT1A6 (2.26, ITGB4 ITPA JUN KCNA5 KCNK1 KLF22.11) KLK1 KLK10 KLK11 KLK12 KLK15 KLK2 BAX (−2.32) BBC3 (−2.27) KLK3KLK4 KLK5 KLK6 KLK7 KLK8 KLK9 BCAM (−2.07) KRT17 KRT19 KRT4 LANCL1LAPTM4B BCL2 (−2.35) LASS4 LEPREL1 LIMCH1 LOH11CR2A CASP8 (−3.17) LTBP1M6PRBP1 MACF1 MAD2L2 CD55 (−4.47) CILP MAGED2 MAL MAP2K6 MCM2 MED1(−2.53) FOS (−2.24) MED21 MEST MGMT MLL MMP10 MMP15 KLK3 (−2.46) KRT4MMP16 MMP3 MPO MPP2 MRPS27 MT1A (−4.87) LEPREL1 (−2.15) MT1F MT2A MT3MVP MYC NAB1 NAIP LIMCH1 (−2.07) NCOA3 NDUFS8 NEAT1 NEDD9 NMI NMU MLL(−2.34) NOTCH2 NOTCH4 NR1I2 NR4A1 NTHL1 PRNP (−2.27) NUDT1 OPTN P4HA2PAFAH1B3 PAPPA2 PTGS1 (−2.24) SLPI PARD6A PARP1 PAX8 PBX1 PCNA PDIA3(−2.68, −2.32) SOD3 PDXK PFDN5 PFKFB4 PFKP PGK1 PHIP (−2.54) SP100(−2.51, PHLDA1 PLP2 PMAIP1 PMPCA PMS2L11 −2.24) VEGFA POLA1 POP4 PPIEPPP1R1B PPP3CB (−2.35) PRKCI PRKDC PRNP PRODH PROS1 DST (−3.26, 3.55)PSMB10 PTEN PTGS1 PTGS2 PTK2 PXDN QSOX1 RAB40B RAD21 RALB RALBP1 RASSF1RB1 RBCK1 RBM9 RBP1 RELA RHOC RING1 RNASET2 RNF34 RPL21 RPL36 RPL6 RPS14RPS18 RPS4Y2 RPS5 RRAGD RUNX3 RXRB SCRN1 SDC2 SERPINB4 SERPINE2 SFNSH2B3 SH3BGRL3 SLC15A1 SLC20A1 SLC29A1 SLC2A1 SLC31A1 SLC39A7 SLC6A12SLC7A11 SLC7A8 SLPI SNAP29 SNAPC3 SNRPA SOCS1 SOCS2 SOD2 SOD3 SP1 SP100SP110 SPINT2 SPON1 SPTLC2 STEAP1 STYX SULT1A1 SULT1A2 SWAP70 SYNJ2 TANKTERT TF TFAP2A TFB1M TGFA TGFB1 TLR2 TMSL6 TNF TNFAIP3 TNFSF10 TNFSF13TP53 TP53I3 TP73 TPI1 TRADD TRAM1 TRAP1 TRIB3 TRIP13 TSPAN12 TUBA1ATUBB2A TXN TXNDC13 TXNRD1 TYMP TYMS UCP2 UGDH UGT1A1 UGT1A3 UGT1A6 UMPSUPK1B USP14 VAPA VAV3 VEGFA VPS52 WDR46 WFDC2 WWC1 XIAP XPA XRCC1 XRCC5XRCC6 YARS ZFP36L1 ZFP36L2 ZNF192 ZNRD1 — — — — — — — — BEVACIZUMAB 1VEGFA 1 VEGFA (−2.35) 2.35 0.00 0 (Avastin) (0 + 1) (100.0%)

Accordingly, the following scores are associated with the drugs of thefirst and second therapeutic lines: cisplatine (48), Alimta (88),taxotere (107) and avastin (0). Those scores are consistent with theclinical data.

However, other drugs are associated with better scores, for instanceTrabectedin (512), Gemtuzumab (232) and hydroxyuea (179).

Example 5

The patient suffered of a rhabdomyosarcoma with pulmonary metastases,proving that the present method is efficient to predict the therapeuticefficacy in any type of tumors. This is an evolutive metastatic diseasederived from a fibromixoid sarcoma of a buttock muscle.

This initial tumor has been resected by curative surgery in 2006.Subsequently, the patient developed pleural mesothelial metastases in2007. After six cycles of treatment with a combination of Alimta andcisplatine, with a really poor response, the patient was subjected to apleuralectomy. A novel pulmonary metastatic lesion was then detectedwith complex location prohibiting any surgery.

Normal muscle biopsy and pulmonary metastasis biopsy were carried outand used for mutational analysis by sequencing, CGH and Genomeexpression analysis.

CGH profile showed an important amplification of chromosome 16. Itcorresponds to an amplification of the PDGA locus.

Mutational analysis including the genes as listed in Example 1 did notlead to the identification of any mutation.

Based on Genome Expression analysis, scores have been calculated asdetailed in Example 1 and are shown in the following table only for somerelevant drugs.

Avg Target Found Found Targets List (with fold- Avg Abs (FC) ChemicalGenes Target Genes List Targets changes) Abs (FC) UP-REG ScoreVINORELBINE 6 CDKN2A PTGS2 1 CDKN2A (48.68) 48.68 48.68 811 (Navelbine,RALBP1 RBM17 (1 + 0) Navelbine SLC29A1 TUBB2A (16.7%) Base) TEGAFUR 5CDA CYP2A6 1 TYMS (16.61) 16.61 16.61 332 (UFT) DPYD TP53 TYMS (1 + 0)(20.0%) NILOTINIB 5 ABL1 BCR KIT 2 BCR (5.91) PDGFRA (11.97, 10.80, 8.108.10 324 (Ketek) PDGFRA PDGFRB (2 + 0) 8.13) (40.0%)

Remarkably, Nilotinib is associated with a high score of 324 and isknown to be active on the pathway of PDGFRA and PDGFRB. Accordingly, theinventors studied more precisely the PDGF pathway and obtained thefollowing results.

Primary seq. Fold name Sequence Description Change Intensity 1 Intensity2 Accession # PDGFD Platelet derived growth factor D 18.6 114.8 2142.4NM_025208 PDGFRA Platelet derived growth factor receptor, alpha 12.02072.6 24849.8 NM_006206 PDGFRA Platelet derived growth factor receptor,alpha 10.8 819.6 8964.0 AA559881 PDGFRA Platelet derived growth factorreceptor, alpha 8.1 21.3 182.3 BC015186 PDGFA Platelet derived growthfactor alpha 7.7 591.2 4576.5 NM_002607 PDGFRL Platelet derived growthfactor receptor like 4.7 5397.2 25269.9 NM_006207 PDGFRB Plateletderived growth factor receptor beta 3.2 3327.0 10558.3 NM_002609 PDGFCPlatelet derived growth factor C 1.1 23.1 23.7 NM_016205 PDGFC Plateletderived growth factor C −1.6 1028.7 615.7 NM_016205 PDGFB Plateletderived growth factor beta −3.7 375.2 101.8 NM_002608

A very significant activation can be observed.

CGH and Gene expression profiles corroborate to designate the PDGFpathway as an important driver of tumorogenesis for this lesion. Indeed,PDGF D is overexpressed 18 fold in tumor versus normal tissue and willactivate receptor beta-beta. It is worthwhile to mention that PDGFRB isalso overexpressed 3 fold. PDFGA is overexpressed 8 fold and receptorPDGFRA is overexpressed 10 fold.

Taken together, Nilotinib appears a good candidate of targeted therapiesbecause it inhibits both receptors.

The patient is awaiting for regulatory authorization for Nilotinibtreatment. His attending physician acknowledged this therapeutic choice.

In conclusion, the studied patients were all in therapeutic failure. Forall of them, there was no more therapeutic choice, and their generalstatus was prohibiting entering into clinical trials. Based upon writtenconsentment and upon request of oncology doctors, this method wasapplied. The present method allows the association of low scores for thedrugs used in the previous therapeutic lines, illustrating the goodcorrelation between low scores and therapeutic efficiency.Retrospectively, experts may envision that use of inefficient drugs mayhave been avoided if such strategy would have been applied, saving timefor the patient. It is important to note that the studied patientsshowed quite unique profiles, proving the potency of the concept forpersonalized medicine. Method can apply to any type of tumors as far asnormal cells and tumoral cells of same histologic type can be comparedfor a patient. Another advantage is that the method can provide asolution with potential therapeutic benefit for all patients, whereascurrent methods based on companion tests can apply only for limitednumber of patients which harbour a given abnormality.

TABLE 1 Molecule RefSeq Description Symbol PMID Interaction METHOTREXATENM_000927 ATP-binding cassette, sub-family B (MDR/TAP), ABCB1 12576456,15239124 drug efflux member 1 METHOTREXATE NM_004996; NM_019862;NM_019898; ATP-binding cassette, sub-family C (CFTR/MRP), ABCC1 15718312drug efflux NM_019899; NM_019900 member 1 METHOTREXATE NM_000392ATP-binding cassette, sub-family C (CFTR/MRP), ABCC2 11500505, 15864128drug efflux member 2 METHOTREXATE NM_001105515; NM_005845 ATP-bindingcassette, sub-family C (CFTR/MRP), ABCC4 15454390 drug efflux member 4METHOTREXATE NM_004827 ATP-binding cassette, sub-family G (WHITE),member 2 ABCG2 17032904 drug efflux METHOTREXATE NM_000477 albumin ALB —used as drug carrier METHOTREXATE NM_001631 alkaline phosphatase,intestinal ALPI 16598758 mesure drug toxicity METHOTREXATE NM_0040445-aminoimidazole-4-carboxamide ribonucleotide ATIC 17410198 targetformyltransferase/IMP cyclohydrolase METHOTREXATE NM_000616 CD4 moleculeCD4 15476228 altered by MTX METHOTREXATE NM_001040059; NM_001251 CD68molecule CD68 15476228 altered by MTX METHOTREXATE NM_001145873;NM_001768; NM_171827 CD8a molecule CD8A 15476228 altered by MTXMETHOTREXATE NM_017460 cytochrome P450, family 3, subfamily A,polypeptide 4 CYP3A4 12065438, 16837568 drug metabolism METHOTREXATENM_000791 dihydrofolate reductase DHFR 14679136 resistance METHOTREXATENM_012242 dickkopf homolog 1 (Xenopus laevis) DKK1 17320366 unrelatedMETHOTREXATE NM_000561; NM_146421 glutathione S-transferase mu 1 GSTM115713801 hepatotoxicity METHOTREXATE NM_000201 intercellular adhesionmolecule 1 ICAM1 15476228 altered by MTX METHOTREXATE NM_000584interleukin 8 IL8 15476228 altered by MTX METHOTREXATE NM_002422 matrixmetallopeptidase 3 (stromelysin 1, MMP3 15476228 altered by MTXprogelatinase) METHOTREXATE NM_005957 5,10-methylenetetrahydrofolatereductase (NADPH) MTHFR 17488658 polymorphisms METHOTREXATE NM_0002545-methyltetrahydrofolate-homocysteine MTR 16598758 polymorphismsmethyltransferase METHOTREXATE NM_000662 N-acetyltransferase 1(arylamine N-acetyltransferase) NAT1 16003948 target METHOTREXATENM_003889; NM_022002; NM_033013 nuclear receptor subfamily 1, group I,member 2 NR1I2 12065438 METHOTREXATE NM_002539 ornithine decarboxylase 1ODC1 16598758 resistance METHOTREXATE NM_001618 poly (ADP-ribose)polymerase 1 PARP1 17286800 apoptosis marker METHOTREXATE NM_003981;NM_199413; NM_199414 protein regulator of cytokinesis 1 PRC1 17374387METHOTREXATE NM_000321 retinoblastoma 1 RB1 12972956, 14534726, 14679136resistance METHOTREXATE NM_000450 selectin E SELE 15476228 altered byMTX METHOTREXATE NM_194255 solute carrier family 19 (folatetransporter), member 1 SLC19A1 14679136, 16505119, 17034785, drug uptake17410198 METHOTREXATE NM_080669 solute carrier family 46 (folatetransporter), member 1 SLC46A1 17475902 drug uptake METHOTREXATENM_001001522; NM_003186 transgelin TAGLN 17320366 unrelated METHOTREXATENM_003254 TIMP metallopeptidase inhibitor 1 TIMP1 15476228 altered byMTX METHOTREXATE NM_001071 thymidylate synthetase TYMS 15713801,17410198 resistance METHOTREXATE NM_007019; NM_181799; NM_181800;ubiquitin-conjugating enzyme E2C UBE2C 17374387 NM_181801; NM_181802;NM_181803 METHOTREXATE NM_000376; NM_001017535 vitamin D(1,25-dihydroxyvitamin D3) receptor VDR 15713801 METHOTREXATE NM_003882;NM_080838 WNT1 inducible signaling pathway protein 1 WISP1 17320366unrelated METHOTREXATE NM_003392 wingless-type MMTV integration sitefamily, member WNT5A 17320366 unrelated 5A PEMETREXED NM_000791dihydrofolate reductase DHFR — target PEMETREXED NM_001018078; NM_004957folylpolyglutamate synthase FPGS 17575230 drug activation PEMETREXEDNM_000819; NM_001136005; NM_001136006; phosphoribosylglycinamideformyltransferase, GART — target NM_175085 phosphoribosylglycinamidesynthetase, phosphoribosylaminoimidazole synthetase PEMETREXED NM_003878gamma-glutamyl hydrolase (conjugase, GGH 17575230 folylpolygammaglutamylhydrolase) PEMETREXED NM_001145547; NM_032905 RNA binding motif protein17 RBM17 16061639 resistance PEMETREXED NM_194255 solute carrier family19 (folate transporter), member 1 SLC19A1 16505119 drug uptakePEMETREXED NM_001113755; NM_001113756; NM_001953 thymidine phosphorylaseTYMP 17575230 PEMETREXED NM_001071 thymidylate synthetase TYMS —resistance FLUDARABINE NM_000022 adenosine deaminase ADA — unrelatedFLUDARABINE NM_001014431; NM_001014432; NM_005163 v-akt murine thymomaviral oncogene homolog 1 AKT1 15059916, 15213310 resistance FLUDARABINENM_001668; NM_178426; NM_178427 aryl hydrocarbon receptor nucleartranslocator ARNT 15213310 FLUDARABINE NM_001127240; NM_001127241;NM_001127242; BCL2 binding component 3 BBC3 16439685 NM_014417FLUDARABINE NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 —FLUDARABINE NM_004346; NM_032991 caspase 3, apoptosis-related cysteinepeptidase CASP3 11675354 FLUDARABINE NM_001080124; NM_001080125;NM_001228; caspase 8, apoptosis-related cysteine peptidase CASP811675354 NM_033355; NM_033356; NM_033358 FLUDARABINE NM_001237 cyclin A2CCNA2 15059916 FLUDARABINE NM_053056 cyclin D1 CCND1 15059916 altered byF- ara-A FLUDARABINE NM_001238; NM_057182 cyclin E1 CCNE1 15059916FLUDARABINE NM_000389; NM_078467 cyclin-dependent kinase inhibitor 1A(p21, Cip1) CDKN1A 16439685, 16 FLUDARABINE NM_004064 cyclin-dependentkinase inhibitor 1B (p27, Kip1) CDKN1B 15059916 altered by F- ara-AFLUDARABINE NM_018947 cytochrome c, somatic CYCS 15059916 death pathwayFLUDARABINE NM_019887; NM_138929 diablo homolog (Drosophila) DIABLO15059916 death pathway FLUDARABINE — — ERK 15059916 resistanceFLUDARABINE NM_000043; NM_152871; NM_152872; Fas (TNF receptorsuperfamily, member 6) FAS 11675354 NM_152873; NM_152874; NM_152875;NM_152876; NM_152877 FLUDARABINE NM_004864 growth differentiation factor15 GDF15 16439677 FLUDARABINE NM_001530; NM_181054 hypoxia induciblefactor 1, alpha subunit (basic helix- HIF1A 15213310 altered by F-loop-helix transcription factor) ara-A FLUDARABINE NM_003493 histonecluster 3, H3 HIST3H3 15059916 unrelated FLUDARABINE NM_175054 histonecluster 4, H4 HIST4H4 15059916 unrelated FLUDARABINE NM_002755mitogen-activated protein kinase kinase 1 MAP2K1 15059916 resistanceFLUDARABINE NM_030662 mitogen-activated protein kinase kinase 2 MAP2K215059916 FLUDARABINE NM_002745; NM_138957 mitogen-activated proteinkinase 1 MAPK1 15213310 resistance FLUDARABINE NM_001040056;NM_001109891; NM_002746 mitogen-activated protein kinase 3 MAPK315213310 resistance FLUDARABINE NM_021960; NM_182763 myeloid cellleukemia sequence 1 (BCL2-related) MCL1 15059916 resistance FLUDARABINENM_002592; NM_182649 proliferating cell nuclear antigen PCNA 16439677FLUDARABINE — — PDCD8 15059916 FLUDARABINE NM_016937 polymerase (DNAdirected), alpha 1, catalytic subunit POLA1 — target FLUDARABINENM_001033 ribonucleotide reductase M1 RRM1 — target FLUDARABINENM_007315; NM_139266 signal transducer and activator of transcription 1,STAT1 — altered by F- 91 kDa ara-A FLUDARABINE NM_003844 tumor necrosisfactor receptor superfamily, member TNFRSF10A 14614459 10a FLUDARABINENM_003842; NM_147187 tumor necrosis factor receptor superfamily, memberTNFRSF10B 14614459, 18092340 10b FLUDARABINE NM_000546; NM_001126112;NM_001126113; tumor protein p53 TP53 16439677, 17226861, 18092340NM_001126114; NM_001126115; NM_001126116; NM_001126117 FLUDARABINENM_001025366; NM_001025367; NM_001025368; vascular endothelial growthfactor A VEGFA 15213310 altered by F- NM_001025369; NM_001025370; ara-ANM_001033756; NM_003376 FLUDARABINE NM_001167 X-linked inhibitor ofapoptosis XIAP 15059916 altered by F- ara-A FLUDARABINE NM_022470;NM_152240 zinc finger, matrin type 3 ZMAT3 16439685 FLUOROURACILNM_000927 ATP-binding cassette, sub-family B (MDR/TAP), ABCB1 12576456,15239124 resistance member 1 FLUOROURACIL NM_004996; NM_019862;NM_019898; ATP-binding cassette, sub-family C (CFTR/MRP), ABCC1 12576456resistance NM_019899; NM_019900 member 1 FLUOROURACIL NM_032583;NM_033151; NM_145186 ATP-binding cassette, sub-family C (CFTR/MRP),ABCC11 18310281 member 11 FLUOROURACIL NM_001023587; NM_005688ATP-binding cassette, sub-family C (CFTR/MRP), ABCC5 19077464 resistancemember 5 FLUOROURACIL NM_004827 ATP-binding cassette, sub-family G(WHITE), member 2 ABCG2 12576456 FLUOROURACIL NM_001608 acyl-Coenzyme Adehydrogenase, long chain ACADL 15585135 FLUOROURACIL NM_001116adenylate cyclase 9 ADCY9 19219653 FLUOROURACIL NM_001126adenylosuccinate synthase ADSS 15585135 FLUOROURACIL NM_001130846;NM_001130847; NM_004208; apoptosis-inducing factor,mitochondrion-associated, 1 AIFM1 16168113 death pathway NM_145812;NM_145813 FLUOROURACIL NM_001014431; NM_001014432; NM_005163 v-aktmurine thymoma viral oncogene homolog 1 AKT1 18794807 FLUOROURACILNM_001144 autocrine motility factor receptor AMFR 16896004 FLUOROURACILNM_004037; NM_139156; NM_203404 adenosine monophosphate deaminase 2(isoform L) AMPD2 19219653 FLUOROURACIL NM_000481 aminomethyltransferaseAMT 15585135 FLUOROURACIL NM_012098 angiopoietin-like 2 ANGPTL2 17327601altered by 5FU FLUOROURACIL NM_001657 amphiregulin AREG 15067352sensitivity FLUOROURACIL NM_001024226; NM_001024227; NM_001024228;ADP-ribosylation factor 1 ARF1 18927307 NM_001658 FLUOROURACIL NM_001697ATP synthase, H+ transporting, mitochondrial F1 ATP5O 17327601sensitivity complex, O subunit FLUOROURACIL NM_000053; NM_001005918ATPase, Cu++ transporting, beta polypeptide ATP7B 18593893 FLUOROURACILNM_001188 BCL2-antagonist/killer 1 BAK1 18593893 FLUOROURACIL NM_003658BARX homeobox 2 BARX2 15585135 FLUOROURACIL NM_004324; NM_138761;NM_138763; BCL2-associated X protein BAX 11062132, 15986848, 15996812,death pathway NM_138764; NM_138765 16168113, 18834353, 19015929FLUOROURACIL NM_033028 Bardet-Biedl syndrome 4 BBS4 16896004FLUOROURACIL NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 14503796,15940066, 15996812, resistance 18949393, 19015929, 19084572 FLUOROURACILNM_001040668; NM_138639 BCL2-like 12 (proline rich) BCL2L12 19015929FLUOROURACIL NM_004051; NM_203314; NM_203315 3-hydroxybutyratedehydrogenase, type 1 BDH1 15585135 altered by 5FU FLUOROURACILNM_003766 beclin 1, autophagy related BECN1 16896004 FLUOROURACILNM_001012270; NM_001012271; NM_001168 baculoviral IAP repeat-containing5 BIRC5 15067352, 18714155 resistance FLUOROURACIL NM_016252 baculoviralIAP repeat-containing 6 BIRC6 18239605 FLUOROURACIL NM_004052BCL2/adenovirus E1B 19 kDa interacting protein 3 BNIP3 15067352sensitivity FLUOROURACIL NM_004331 BCL2/adenovirus E1B 19 kDainteracting protein 3-like BNIP3L 15067352 sensitivity FLUOROURACILNM_033030; NM_197970 bol, boule-like (Drosophila) BOLL 17327601FLUOROURACIL NM_001130914; NM_006806 BTG family, member 3 BTG3 16896004FLUOROURACIL NM_001007793; NM_004725 budding uninhibited bybenzimidazoles 3 homolog BUB3 15585135 altered by 5FU (yeast)FLUOROURACIL — — C13ORF34 17374387 FLUOROURACIL NM_001218; NM_206925carbonic anhydrase XII CA12 16896004 FLUOROURACIL NM_001024649;NM_001746 calnexin CANX 18678097 FLUOROURACIL NM_032982; NM_032983caspase 2, apoptosis-related cysteine peptidase CASP2 14757846 deathpathway FLUOROURACIL NM_004346; NM_032991 caspase 3, apoptosis-relatedcysteine peptidase CASP3 12414664, 12414664, 18830594, death pathway14503796, 15585135, 16168113, 18608205, 18772588, 19084572 FLUOROURACILNM_001227; NM_033338; NM_033339; caspase 7, apoptosis-related cysteinepeptidase CASP7 16168113 death pathway NM_033340 FLUOROURACILNM_001080124; NM_001080125; NM_001228; caspase 8, apoptosis-relatedcysteine peptidase CASP8 12414664, 18830594, 15585135, death pathwayNM_033355; NM_033356; NM_033358 16168113 FLUOROURACIL NM_001229;NM_032996 caspase 9, apoptosis-related cysteine peptidase CASP912414664, death pathway 15996812, 12414664, 18830594, 16168113, 19015929FLUOROURACIL NM_001237 cyclin A2 CCNA2 18383818 FLUOROURACIL NM_053056cyclin D1 CCND1 18930000 FLUOROURACIL NM_001136017; NM_001136125;NM_001136126; cyclin D3 CCND3 15067352, 18383818 resistance NM_001760FLUOROURACIL NM_001238; NM_057182 cyclin E1 CCNE1 18930000 resistanceFLUOROURACIL NM_057749 cyclin E2 CCNE2 15067352 FLUOROURACIL NM_001761cyclin F CCNF 15067352 resistance FLUOROURACIL NM_004354 cyclin G2 CCNG215067352, 18754885 sensitivity FLUOROURACIL NM_001790; NM_022809 celldivision cycle 25 homolog C (S. pombe) CDC25C 19074854 FLUOROURACILNM_018101 cell division cycle associated 8 CDCA8 17374387 FLUOROURACILNM_001798; NM_052827 cyclin-dependent kinase 2 CDK2 18383818FLUOROURACIL NM_000389; NM_078467 cyclin-dependent kinase inhibitor 1A(p21, Cip1) CDKN1A 15067352, 16168113, 18834353 sensitivity FLUOROURACILNM_004064 cyclin-dependent kinase inhibitor 1B (p27, Kip1) CDKN1B18930000 FLUOROURACIL NM_000076; NM_001122630; NM_001122631cyclin-dependent kinase inhibitor 1C (p57, Kip2) CDKN1C 15067352sensitivity FLUOROURACIL NM_001114121; NM_001114122; NM_001274 CHK1checkpoint homolog (S. pombe) CHEK1 18698031 FLUOROURACIL NM_020313cytokine induced apoptosis inhibitor 1 CIAPIN1 18389626 FLUOROURACILNM_014430 cell death-inducing DFFA-like effector b CIDEB 15585135altered by 5FU FLUOROURACIL NM_001827 CDC28 protein kinase regulatorysubunit 2 CKS2 17374387 FLUOROURACIL NM_004859 clathrin, heavy chain(Hc) CLTC 18927307 FLUOROURACIL NM_001083914; NM_001329; NM_022802C-terminal binding protein 2 CTBP2 18927307 FLUOROURACIL NM_001332catenin (cadherin-associated protein), delta 2 (neural CTNND2 16896004plakophilin-related arm-repeat protein) FLUOROURACIL NM_001905 CTPsynthase CTPS 19219653 FLUOROURACIL NM_005231; NM_138565 cortactin CTTN15585135 altered by 5FU FLUOROURACIL NM_000762 cytochrome P450, family2, subfamily A, polypeptide 6 CYP2A6 11376561 FLUOROURACIL NM_001554cysteine-rich, angiogenic inducer, 61 CYR61 15067352 resistanceFLUOROURACIL NM_001098424; NM_004087 discs, large homolog 1 (Drosophila)DLG1 18927307 FLUOROURACIL NM_000110 dihydropyrimidine dehydrogenaseDPYD 15239142, 15737843, 15858133, drug 15930747, 18600527, 16761622,metabolism 18383874, 18443386, 18443386, 18299612, 18986760, 19020767,15655543, 18619742, 18846242, 19093184, 19104657, 19105824, 19219653FLUOROURACIL NM_000798 dopamine receptor D5 DRD5 17327601 FLUOROURACILNM_012145 deoxythymidylate kinase (thymidylate kinase) DTYMK 15067352drug metabolism FLUOROURACIL NM_001025248; NM_001025249; NM_001948deoxyuridine triphosphatase DUT 19015155 FLUOROURACIL NM_001949 E2Ftranscription factor 3 E2F3 16896004 sensitivity FLUOROURACIL NM_005228;NM_201282; NM_201283; epidermal growth factor receptor (erythroblasticEGFR 15723263, 15737843, 15981280, resistance NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) 16098254, 18794807, 19217205FLUOROURACIL NM_001964 early growth response 1 EGR1 18757417FLUOROURACIL NM_014239 eukaryotic translation initiation factor 2B,subunit 2 EIF2B2 15585135 beta, 39 kDa FLUOROURACIL — — EIF3S3 15585135FLUOROURACIL NM_012155 echinoderm microtubule associated protein like 2EML2 17327601 FLUOROURACIL NM_001126123; NM_017512; NM_202758 enolasesuperfamily member 1 ENOSF1 18357371 FLUOROURACIL NM_001098175;NM_001776 ectonucleoside triphosphate diphosphohydrolase 1 ENTPD119219653 FLUOROURACIL NM_001005862; NM_004448 v-erb-b2 erythroblasticleukemia viral oncogene ERBB2 15737843, 15940066, 18337622 resistancehomolog 2, neuro/glioblastoma derived oncogene homolog (avian)FLUOROURACIL NM_001042599; NM_005235 v-erb-a erythroblastic leukemiaviral oncogene ERBB4 16896004 homolog 4 (avian) FLUOROURACIL NM_001983;NM_202001 excision repair cross-complementing rodent repair ERCC115737843, 17401013, resistance deficiency, complementation group 1(includes 18448328, 15213713 overlapping antisense sequence)FLUOROURACIL NM_000400; NM_001130867 excision repair cross-complementingrodent repair ERCC2 15213713, 17401013 deficiency, complementation group2 FLUOROURACIL NM_001034025; NM_006817 endoplasmic reticulum protein 29ERP29 15585135 FLUOROURACIL NM_001001998; NM_002685 exosome component 10EXOSC10 18567802 FLUOROURACIL NM_001993 coagulation factor III(thromboplastin, tissue factor) F3 15067352 resistance FLUOROURACILNM_000132; NM_019863 coagulation factor VIII, procoagulant component F817327601 marker microvessels FLUOROURACIL NM_004629 Fanconi anemia,complementation group G FANCG 15067352 resistance FLUOROURACILNM_000043; NM_152871; NM_152872; Fas (TNF receptor superfamily, member6) FAS 15034078, 15585135, 19015929 death pathway NM_152873; NM_152874;NM_152875; NM_152876; NM_152877 FLUOROURACIL NM_004111 flapstructure-specific endonuclease 1 FEN1 15067352 resistance FLUOROURACILNM_002009 fibroblast growth factor 7 (keratinocyte growth factor) FGF718575591, 18708365, 15375550 resistance FLUOROURACIL NM_000141;NM_001144913; NM_001144914; fibroblast growth factor receptor 2 FGFR218575591 NM_001144915; NM_001144916; NM_001144917; NM_001144918;NM_001144919; NM_022970 FLUOROURACIL NM_022110 FK506 binding proteinlike FKBPL 14503796 FLUOROURACIL NM_001455; NM_201559 forkhead box O3FOXO3 15067352 sensitivity FLUOROURACIL NM_001924 growth arrest andDNA-damage-inducible, alpha GADD45A 15067352, 19003803 sensitivityFLUOROURACIL NM_000156; NM_138924 guanidinoacetate N-methyltransferaseGAMT 16896004 FLUOROURACIL NM_000819; NM_001136005; NM_001136006;phosphoribosylglycinamide formyltransferase, GART 19219653 NM_175085phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazolesynthetase FLUOROURACIL NM_001145453; NM_005264; NM_145793 GDNF familyreceptor alpha 1 GFRA1 16896004 FLUOROURACIL NM_005269 GLI family zincfinger 1 GLI1 18776995 FLUOROURACIL NM_181077 golgi autoantigen, golginsubfamily a, 8A GOLGA8A 17327601 FLUOROURACIL NM_000852 glutathioneS-transferase pi 1 GSTP1 15213713, 15737843 resistance FLUOROURACILNM_000853 glutathione S-transferase theta 1 GSTT1 15585135 FLUOROURACILNM_000857 guanylate cyclase 1, soluble, beta 3 GUCY1B3 19219653FLUOROURACIL NM_005524 hairy and enhancer of split 1, (Drosophila) HES119147571 FLUOROURACIL NM_005340 histidine triad nucleotide bindingprotein 1 HINT1 15585135 FLUOROURACIL NM_005320 histone cluster 1, H1dHIST1H1D 15585135 FLUOROURACIL NM_000189 hexokinase 2 HK2 18772588FLUOROURACIL — — HNRPC 15585135 FLUOROURACIL NM_001540 heat shock 27 kDaprotein 1 HSPB1 18949417, 19088045 FLUOROURACIL NM_001541 heat shock 27kDa protein 2 HSPB2 18757417 FLUOROURACIL NM_002176 interferon, beta 1,fibroblast IFNB1 18608205, 18695887 FLUOROURACIL NM_000875 insulin-likegrowth factor 1 receptor IGF1R 15499378 FLUOROURACIL NM_001552insulin-like growth factor binding protein 4 IGFBP4 16896004FLUOROURACIL NM_000634 interleukin 8 receptor, alpha IL8RA 16098254FLUOROURACIL NM_001025242; NM_001025243; NM_001569 interleukin-1receptor-associated kinase 1 IRAK1 15067352 resistance FLUOROURACIL — —JMJD2B 16896004 death pathway FLUOROURACIL NM_002229 jun Bproto-oncogene JUNB 18678097 FLUOROURACIL NM_012289; NM_203500kelch-like ECH-associated protein 1 KEAP1 18692501 FLUOROURACILNM_015443 KIAA1267 KIAA1267 18927307 FLUOROURACIL NM_020853 KIAA1467KIAA1467 16896004 FLUOROURACIL NM_007054 kinesin family member 3A KIF3A16896004 FLUOROURACIL NM_002266 karyopherin alpha 2 (RAG cohort 1,importin alpha 1) KPNA2 17374387 FLUOROURACIL NM_004985; NM_033360v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog KRAS 15585135FLUOROURACIL NM_006499; NM_201543; NM_201544; lectin,galactoside-binding, soluble, 8 LGALS8 17327601 NM_201545 FLUOROURACILNM_005573 lamin B1 LMNB1 15067352 resistance FLUOROURACIL NM_002355mannose-6-phosphate receptor (cation dependent) M6PR 15585135FLUOROURACIL NR_002819; NR_002819; NR_002819; metastasis associated lungadenocarcinoma transcript MALAT1 18927307 NR_002819; NR_002819;NR_002819 1 (non-protein coding) FLUOROURACIL NM_006785; NM_173844mucosa associated lymphoid tissue lymphoma MALT1 15067352 resistancetranslocation gene 1 FLUOROURACIL NM_002754 mitogen-activated proteinkinase 13 MAPK13 15585135 FLUOROURACIL NM_001123066; NM_001123067;NM_005910; microtubule-associated protein tau MAPT 16896004 NM_016834;NM_016835; NM_016841 FLUOROURACIL NM_022132 methylcrotonoyl-Coenzyme Acarboxylase 2 (beta) MCCC2 18927307 FLUOROURACIL NM_002393 Mdm4 p53binding protein homolog (mouse) MDM4 18678097 FLUOROURACIL NM_015335mediator complex subunit 13-like MED13L 16896004 FLUOROURACIL NM_014791maternal embryonic leucine zipper kinase MELK 16896004 FLUOROURACILNM_024042 meteorin, glial cell differentiation regulator METRN 16896004FLUOROURACIL NM_002417 antigen identified by monoclonal antibody Ki-67MKI67 15940066 sensitivity FLUOROURACIL NM_000249 mutL homolog 1, coloncancer, nonpolyposis MLH1 18497967, 18949393 type 2 (E. coli)FLUOROURACIL NM_001127891; NM_004530 matrix metallopeptidase 2(gelatinase A, 72 kDa MMP2 18678097 gelatinase, 72 kDa type IVcollagenase) FLUOROURACIL NM_001142418; NM_001142419; NM_001142420;mortality factor 4 like 2 MORF4L2 18593893 NM_001142421; NM_001142422;NM_001142423; NM_001142424; NM_001142425; NM_001142426; NM_001142427;NM_001142428; NM_001142429; NM_001142430; NM_001142431; NM_001142432;NM_012286 FLUOROURACIL NM_000251 mutS homolog 2, colon cancer,nonpolyposis type 1 MSH2 18949393 (E. coli) FLUOROURACIL NM_0059575,10-methylenetetrahydrofolate reductase (NADPH) MTHFR 18633250,19203896 FLUOROURACIL NM_002467 v-myc myelocytomatosis viral oncogenehomolog MYC 15585135, 18802399 resistance (avian) FLUOROURACIL NM_006311nuclear receptor co-repressor 1 NCOR1 18927307 FLUOROURACIL NM_004544NADH dehydrogenase (ubiquinone) 1 alpha NDUFA10 15585135 subcomplex, 10,42 kDa FLUOROURACIL NM_001145412; NM_001145413; NM_006164 nuclear factor(erythroid-derived 2)-like 2 NFE2L2 18692501 FLUOROURACIL NM_024522Na+/K+ transporting ATPase interacting 1 NKAIN1 16896004 FLUOROURACILNM_020201 5′,3′-nucleotidase, mitochondrial NT5M 19219653 FLUOROURACILNM_022731 nuclear casein kinase and cyclin-dependent kinase NUCKS115585135 substrate 1 FLUOROURACIL NM_001079524; NM_001079525; NM_006452phosphoribosylaminoimidazole carboxylase, PAICS 19219653phosphoribosylaminoimidazole succinocarboxamide synthetase FLUOROURACILNM_001618 poly (ADP-ribose) polymerase 1 PARP1 15996812, 16525653,19084572 apoptosis marker FLUOROURACIL NM_018908; NM_031501protocadherin alpha 5 PCDHA5 15585135 FLUOROURACIL NM_014891 PDGFAassociated protein 1 PDAP1 15585135 FLUOROURACIL NM_000926 progesteronereceptor PGR 15940066 FLUOROURACIL NM_000944; NM_001130691; NM_001130692protein phosphatase 3 (formerly 2B), catalytic subunit, PPP3CA 15585135,18927307 alpha isoform FLUOROURACIL NM_003981; NM_199413; NM_199414protein regulator of cytokinesis 1 PRC1 17374387 altered by 5FUFLUOROURACIL NM_001081640; NM_006904 protein kinase, DNA-activated,catalytic polypeptide PRKDC 18546291 FLUOROURACIL NM_000311;NM_001080121; NM_001080122; prion protein PRNP 15386405 unrelatedNM_001080123; NM_183079 FLUOROURACIL — — PSCD3 15585135 FLUOROURACILNM_002784 pregnancy specific beta-1-glycoprotein 9 PSG9 17327601FLUOROURACIL NM_001005290; NM_001032290; NM_001032291;proline/serine-rich coiled-coil 1 PSRC1 17374387 unrelated NM_032636FLUOROURACIL NM_000264; NM_001083602; NM_001083603; patched homolog 1(Drosophila) PTCH1 18776995 NM_001083604; NM_001083605; NM_001083606;NM_001083607 FLUOROURACIL NM_012212 prostaglandin reductase 1 PTGR115585135 FLUOROURACIL NM_000963 prostaglandin-endoperoxide synthase 2(prostaglandin PTGS2 12414664, 18695918 G/H synthase and cyclooxygenase)FLUOROURACIL NM_002874 RAD23 homolog B (S. cerevisiae) RAD23B 15067352resistance FLUOROURACIL NM_005855 receptor (G protein-coupled) activitymodifying protein 1 RAMP1 16896004 FLUOROURACIL NM_000321 retinoblastoma1 RB1 18383818, 18678097 FLUOROURACIL NM_001135255; NM_001135256;NM_005610 retinoblastoma binding protein 4 RBBP4 18678097 FLUOROURACILNM_001145138; NM_021975 v-rel reticuloendotheliosis viral oncogenehomolog A RELA 19003803 (avian) FLUOROURACIL NM_001128617; NM_031922RALBP1 associated Eps domain containing 1 REPS1 18927307 FLUOROURACILNM_025126; NM_194271 ring finger protein 34 RNF34 16270526 resistanceFLUOROURACIL NM_000967; NM_001033853 ribosomal protein L3 RPL3 15585135FLUOROURACIL NM_001034 ribonucleotide reductase M2 polypeptide RRM216896004 target FLUOROURACIL NM_001015055; NM_001015056; NM_033046rhotekin RTKN 15480428 resistance FLUOROURACIL NM_005980 S100 calciumbinding protein P S100P 18636193 FLUOROURACIL NM_020974 signal peptide,CUB domain, EGF-like 2 SCUBE2 16896004 FLUOROURACIL NM_001136528;NM_001136529; NM_001136530; serpin peptidase inhibitor, clade E (nexin,plasminogen SERPINE2 17327601 unrelated NM_006216 activator inhibitortype 1), member 2 FLUOROURACIL NM_006142 stratifin SFN 15999354FLUOROURACIL NM_000193 sonic hedgehog homolog (Drosophila) SHH 18776995FLUOROURACIL NM_001078174; NM_001078175; NM_001078176; solute carrierfamily 29 (nucleoside transporters), SLC29A1 18383843, 18992248NM_001078177; NM_004955 member 1 FLUOROURACIL NM_005631 smoothenedhomolog (Drosophila) SMO 18776995 FLUOROURACIL NM_003082 small nuclearRNA activating complex, polypeptide 1, SNAPC1 15585135 43 kDaFLUOROURACIL NM_003090 small nuclear ribonucleoprotein polypeptide A′SNRPA1 18927307 FLUOROURACIL NM_003109; NM_138473 Sp1 transcriptionfactor SP1 18927307 FLUOROURACIL NM_005417; NM_198291 v-src sarcoma(Schmidt-Ruppin A-2) viral oncogene SRC 18794807 homolog (avian)FLUOROURACIL NM_003130; NM_198901 sorcin SRI 18423116 FLUOROURACILNM_006282 serine/threonine kinase 4 STK4 18927307 FLUOROURACIL NM_016169suppressor of fused homolog (Drosophila) SUFU 18776995 FLUOROURACILNM_030756 transcription factor 7-like 2 (T-cell specific, HMG-box)TCF7L2 18678097 FLUOROURACIL NM_005652 telomeric repeat binding factor 2TERF2 15585135 FLUOROURACIL NM_198253; NM_198255 telomerase reversetranscriptase TERT 18396642 FLUOROURACIL NM_003246 thrombospondin 1THBS1 18757417 FLUOROURACIL NM_018271 threonine synthase-like 2 (S.cerevisiae) THNSL2 16896004 FLUOROURACIL NM_004614 thymidine kinase 2,mitochondrial TK2 19219653 FLUOROURACIL NM_003265 toll-like receptor 3TLR3 18779317 FLUOROURACIL NM_021109 thymosin beta 4, X-linked TMSB4X16364925 FLUOROURACIL — — TMSL8 15067352 FLUOROURACIL NM_003842;NM_147187 tumor necrosis factor receptor superfamily, member TNFRSF10B17922852 death pathway 10b FLUOROURACIL NM_003810 tumor necrosis factor(ligand) superfamily, member 10 TNFSF10 19106633 FLUOROURACIL NM_003808;NM_172087; NM_172088 tumor necrosis factor (ligand) superfamily, member13 TNFSF13 18423122 FLUOROURACIL NM_003286 topoisomerase (DNA) I TOP118509181 FLUOROURACIL NM_001067 topoisomerase (DNA) II alpha 170 kDaTOP2A 18465341 FLUOROURACIL NM_000546; NM_001126112; NM_001126113; tumorprotein p53 TP53 15940066, 15999354, 16077963, death pathwayNM_001126114; NM_001126115; 16168113, 18498133, 18600534, NM_001126116;NM_001126117 18698031, 18779317, 18930000, 19015155, 12082016, 19106633FLUOROURACIL NM_001126240; NM_001126241; NM_001126242; tumor protein p73TP73 18714155 NM_005427 FLUOROURACIL NM_000365; NM_001159287triosephosphate isomerase 1 TPI1 18309519 FLUOROURACIL NM_000367thiopurine S-methyltransferase TPMT 18927307 FLUOROURACIL NM_006472thioredoxin interacting protein TXNIP 18930000 FLUOROURACILNM_001093771; NM_003330; NM_182729; thioredoxin reductase 1 TXNRD119219653 NM_182742; NM_182743 FLUOROURACIL NM_001113755; NM_001113756;NM_001953 thymidine phosphorylase TYMP 15655543, 17454858 sensitivityFLUOROURACIL NM_001071 thymidylate synthetase TYMS 15067352, 15213713,15239142, resistance 15737843, (following) (following) 15788669,18794807, 19020767, 15655543, 18633250, 18505590, 10482907, 18607850,16168113, 17454858, 18425338, 18448328, 18490900, 18593893, 18383874,18490900, 19105824, 18505590, 18600534, 18676755, 18722050, 19082493,18661526, 18794807, 18986760, 18507058, 19074750, 19084572, 19219653,19084572 FLUOROURACIL NM_007019; NM_181799; NM_181800;ubiquitin-conjugating enzyme E2C UBE2C 17374387 NM_181801; NM_181802;NM_181803 FLUOROURACIL NM_000463 UDP glucuronosyltransferase 1 family,polypeptide A1 UGT1A1 18797458 FLUOROURACIL NM_000373 uridinemonophosphate synthetase UMPS 19020767, 19020740, 19082440, 19084572FLUOROURACIL NM_003362; NM_080911 uracil-DNA glycosylase UNG 18714155FLUOROURACIL NM_003364; NM_181597 uridine phosphorylase 1 UPP1 15067352sensitivity FLUOROURACIL NM_145052 uracil phosphoribosyltransferase(FUR1) homolog UPRT 18575323 sensitivity (S. cerevisiae) FLUOROURACILNM_004182; NM_153477 ubiquitously-expressed transcript UXT 15585135FLUOROURACIL NM_001025366; NM_001025367; NM_001025368; vascularendothelial growth factor A VEGFA 18494554 NM_001025369; NM_001025370;NM_001033756; NM_003376 FLUOROURACIL — — WBSCR1 15585135 FLUOROURACILNM_017523; NM_199139 XIAP associated factor 1 XAF1 15843754 sensitivityFLUOROURACIL NM_021141 X-ray repair complementing defective repair inChinese XRCC5 18546291 hamster cells 5 (double-strand-break rejoining)FLUOROURACIL NM_001469 X-ray repair complementing defective repair inChinese XRCC6 18546291 hamster cells 6 FLUOROURACIL NM_024493 zincfinger with KRAB and SCAN domains 3 ZKSCAN3 18519692 FLUOROURACILNM_001005368; NM_006973 zinc finger protein 32 ZNF32 17327601FLUOROURACIL NM_024762 zinc finger protein 552 ZNF552 16896004FLUOROURACIL NM_144690 zinc finger protein 582 ZNF582 17327601FLUOROURACIL NM_005089 zinc finger (CCCH type), RNA-binding motif andZRSR2 17327601 serine/arginine rich 2 CAPECITABINE NM_001024649;NM_001746 calnexin CANX 18678097 drug activation CAPECITABINENM_001025194; NM_001025195; NM_001266 carboxylesterase 1(monocyte/macrophage serine CES1 15687373 drug activation esterase 1)CAPECITABINE NM_003869; NM_198061 carboxylesterase 2 (intestine, liver)CES2 15687373, 18473752 drug activation CAPECITABINE NM_024922carboxylesterase 3 CES3 15687373 reverse toxicity CAPECITABINE NM_000110dihydropyrimidine dehydrogenase DPYD 18846242 CAPECITABINE NM_002229 junB proto-oncogene JUNB 18678097 CAPECITABINE NM_002393 Mdm4 p53 bindingprotein homolog (mouse) MDM4 18678097 CAPECITABINE NM_001127891;NM_004530 matrix metallopeptidase 2 (gelatinase A, 72 kDa MMP2 18678097gelatinase, 72 kDa type IV collagenase) CAPECITABINE NM_000321retinoblastoma 1 RB1 18678097 CAPECITABINE NM_001135255; NM_001135256;NM_005610 retinoblastoma binding protein 4 RBBP4 18678097 CAPECITABINENM_030756 transcription factor 7-like 2 (T-cell specific, HMG-box)TCF7L2 18678097 CAPECITABINE NM_001071 thymidylate synthetase TYMS —resistance GEMCITABINE NM_004324; NM_138761; NM_138763; BCL2-associatedX protein BAX 15770523 death pathway NM_138764; NM_138765 GEMCITABINENM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 15770523 resistanceGEMCITABINE NM_004346; NM_032991 caspase 3, apoptosis-related cysteinepeptidase CASP3 15770523 death pathway GEMCITABINE NM_001785 cytidinedeaminase CDA 18728667 GEMCITABINE NM_000389; NM_078467 cyclin-dependentkinase inhibitor 1A (p21, Cip1) CDKN1A 15770523 sensitivity GEMCITABINE— — CMPK — sensitivity GEMCITABINE — cytochrome c oxidase III COX317428446 GEMCITABINE NM_001618 poly (ADP-ribose) polymerase 1 PARP115770523 altered by DFDC GEMCITABINE NM_002613; NM_0312683-phosphoinositide dependent protein kinase-1 PDPK1 16782806 resistanceGEMCITABINE NM_001145547; NM_032905 RNA binding motif protein 17 RBM1716061639 resistance GEMCITABINE NM_001033 ribonucleotide reductase M1RRM1 — resistance GEMCITABINE NM_001078174; NM_001078175; NM_001078176;solute carrier family 29 (nucleoside transporters), SLC29A1 18383843,18490900, drug uptake NM_001078177; NM_004955 member 1 18728667,18452103, 18992248, 18992248, 18383843 GEMCITABINE NM_000546;NM_001126112; NM_001126113; tumor protein p53 TP53 12082016 unrelatedNM_001126114; NM_001126115; NM_001126116; NM_001126117 GEMCITABINENM_001113755; NM_001113756; NM_001953 thymidine phosphorylase TYMP18728667 GEMCITABINE NM_001071 thymidylate synthetase TYMS — resistanceCYCLOPHOSPHAMIDE NM_000927 ATP-binding cassette, sub-family B (MDR/TAP),ABCB1 12576456 resistance member 1 CYCLOPHOSPHAMIDE NM_004996;NM_019862; NM_019898; ATP-binding cassette, sub-family C (CFTR/MRP),ABCC1 12576456 resistance NM_019899; NM_019900 member 1 CYCLOPHOSPHAMIDENM_004827 ATP-binding cassette, sub-family G (WHITE), member 2 ABCG212576456 resistance CYCLOPHOSPHAMIDE NM_001101 actin, beta ACTB 12167460CYCLOPHOSPHAMIDE NM_000689 aldehyde dehydrogenase 1 family, member A1ALDH1A1 12513786, 17403535, 17502835, 18496131 CYCLOPHOSPHAMIDENM_000690 aldehyde dehydrogenase 2 family (mitochondrial) ALDH2 17403535CYCLOPHOSPHAMIDE NM_000691; NM_001135167; NM_001135168 aldehydedehydrogenase 3 family, memberA1 ALDH3A1 18496131 CYCLOPHOSPHAMIDENM_001629 arachidonate 5-lipoxygenase-activating protein ALOX5AP17403535 CYCLOPHOSPHAMIDE NM_001144 autocrine motility factor receptorAMFR 16896004 CYCLOPHOSPHAMIDE NM_001146 angiopoietin 1 ANGPT1 17403535CYCLOPHOSPHAMIDE NM_012068 activating transcription factor 5 ATF517403535 CYCLOPHOSPHAMIDE NM_004323 BCL2-associated athanogene BAG116322899 sensitivity CYCLOPHOSPHAMIDE NM_033028 Bardet-Biedl syndrome 4BBS4 16896004 CYCLOPHOSPHAMIDE NM_000633; NM_000657 B-cell CLL/lymphoma2 BCL2 11723234, 14503796, 15940066, sensitivity 16322899CYCLOPHOSPHAMIDE NM_003766 beclin 1, autophagy related BECN1 16896004CYCLOPHOSPHAMIDE NM_001197 BCL2-interacting killer (apoptosis-inducing)BIK 17403535 CYCLOPHOSPHAMIDE NM_001725bactericidal/permeability-increasing protein BPI 17403535CYCLOPHOSPHAMIDE NM_001130914; NM_006806 BTG family, member 3 BTG316896004 CYCLOPHOSPHAMIDE NM_001007793; NM_004725 budding uninhibited bybenzimidazoles 3 homolog BUB3 16322899 sensitivity (yeast)CYCLOPHOSPHAMIDE — — C13ORF27 17403535 CYCLOPHOSPHAMIDE NM_001218;NM_206925 carbonic anhydrase XII CA12 16896004 CYCLOPHOSPHAMIDENM_000067 carbonic anhydrase II CA2 17403535 CYCLOPHOSPHAMIDE NM_001223;NM_033292; NM_033293; caspase 1, apoptosis-related cysteine peptidaseCASP1 17403535 NM_033294; NM_033295 (interleukin 1, beta, convertase)CYCLOPHOSPHAMIDE NM_004346; NM_032991 caspase 3, apoptosis-relatedcysteine peptidase CASP3 11723234, 14503796, 16675587 death pathwayCYCLOPHOSPHAMIDE NM_001229; NM_032996 caspase 9, apoptosis-relatedcysteine peptidase CASP9 11723234 death pathway CYCLOPHOSPHAMIDENM_005893 calicin CCIN 17475930 CYCLOPHOSPHAMIDE NM_005201 chemokine(C-C motif) receptor 8 CCR8 17403535 CYCLOPHOSPHAMIDE NM_004064cyclin-dependent kinase inhibitor 1B (p27, Kip1) CDKN1B 16322899sensitivity CYCLOPHOSPHAMIDE NM_001865 cytochrome c oxidase subunit VIIapolypeptide 2 (liver) COX7A2 17403535 CYCLOPHOSPHAMIDE NM_003650cystatin F (leukocystatin) CST7 17403535 CYCLOPHOSPHAMIDE NM_001012329;NM_020248 catenin, beta interacting protein 1 CTNNBIP1 16322899resistance CYCLOPHOSPHAMIDE NM_001332 catenin (cadherin-associatedprotein), delta 2 (neural CTNND2 16896004 plakophilin-related arm-repeatprotein) CYCLOPHOSPHAMIDE NM_004390; NM_148979 cathepsin H CTSH 17403535CYCLOPHOSPHAMIDE — — CTSL 17403535 CYCLOPHOSPHAMIDE NM_000104 cytochromeP450, family 1, subfamily B, polypeptide 1 CYP1B1 12167460CYCLOPHOSPHAMIDE — — CYP2B1 11933215, 16 CYCLOPHOSPHAMIDE NM_000767cytochrome P450, family 2, subfamily B, polypeptide 6 CYP2B6 10919648,12498089, 11389073, drug activation 12872138, 15248218, 15769884,18633247, 18212249, 16322899, 17502835, 17502835, 16183265, 12872138,18496131 CYCLOPHOSPHAMIDE NM_000769 cytochrome P450, family 2, subfamilyC, polypeptide CYP2C19 15248218, 16116487, 17502835, 19 18496131CYCLOPHOSPHAMIDE NM_000771 cytochrome P450, family 2, subfamily C,polypeptide 9 CYP2C9 10991840, 18496131 CYCLOPHOSPHAMIDE NM_017460cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A4 17502835,18496131 CYCLOPHOSPHAMIDE NM_000777 cytochrome P450, family 3, subfamilyA, polypeptide 5 CYP3A5 17502835, 18496131 CYCLOPHOSPHAMIDE NM_006094;NM_024767; NM_182643 deleted in liver cancer 1 DLC1 17403535CYCLOPHOSPHAMIDE NM_005494; NM_058246 DnaJ (Hsp40) homolog, subfamily B,member 6 DNAJB6 17475930 CYCLOPHOSPHAMIDE NM_014934; NM_198968 DAZinteracting protein 1 DZIP1 17403535 CYCLOPHOSPHAMIDE NM_001949 E2Ftranscription factor 3 E2F3 16896004 CYCLOPHOSPHAMIDE NM_005228;NM_201282; NM_201283; epidermal growth factor receptor (erythroblasticEGFR 15981280 resistance NM_201284 leukemia viral (v-erb-b) oncogenehomolog, avian) CYCLOPHOSPHAMIDE NM_001412 eukaryotic translationinitiation factor 1A, X-linked EIF1AX 16322899 resistanceCYCLOPHOSPHAMIDE NM_004095 eukaryotic translation initiation factor 4Ebinding EIF4EBP1 16322899 resistance protein 1 CYCLOPHOSPHAMIDENM_001135554; NM_001135555; NM_001431 erythrocyte membrane protein band4.1-like 2 EPB41L2 17403535 CYCLOPHOSPHAMIDE NM_001005862; NM_004448v-erb-b2 erythroblastic leukemia viral oncogene ERBB2 15834928,15940066, 17010609 resistance homolog 2, neuro/glioblastoma derivedoncogene homolog (avian) CYCLOPHOSPHAMIDE NM_001042599; NM_005235v-erb-a erythroblastic leukemia viral oncogene ERBB4 16896004 homolog 4(avian) CYCLOPHOSPHAMIDE NM_001136154; NM_001136155; NM_004449; v-etserythroblastosis virus E26 oncogene homolog ERG 17403535 NM_182918(avian) CYCLOPHOSPHAMIDE NM_000125; NM_001122740; NM_001122741; estrogenreceptor 1 ESR1 16322899 NM_001122742 CYCLOPHOSPHAMIDE NM_001040275;NM_001040276; NM_001437 estrogen receptor 2 (ER beta) ESR2 16322899CYCLOPHOSPHAMIDE NM_001993 coagulation factor III (thromboplastin,tissue factor) F3 17403535 CYCLOPHOSPHAMIDE NM_022110 FK506 bindingprotein like FKBPL 14503796 CYCLOPHOSPHAMIDE NM_003088 fascin homolog 1,actin-bundling protein FSCN1 17403535 (Strongylocentrotus purpuratus)CYCLOPHOSPHAMIDE NM_002037; NM_153047; NM_153048 FYN oncogene related toSRC, FGR, YES FYN 17403535 CYCLOPHOSPHAMIDE NM_000156; NM_138924guanidinoacetate N-methyltransferase GAMT 16896004 CYCLOPHOSPHAMIDENM_001143830; NM_005256; NM_177553 growth arrest-specific 2 GAS217475930 CYCLOPHOSPHAMIDE NM_001145453; NM_005264; NM_145793 GDNF familyreceptor alpha 1 GFRA1 16896004 CYCLOPHOSPHAMIDE NM_000824 glycinereceptor, beta GLRB 17403535 CYCLOPHOSPHAMIDE NM_018841 guaninenucleotide binding protein (G protein), gamma GNG12 17403535 12CYCLOPHOSPHAMIDE NM_001039847; NM_001039848; NM_002085 glutathioneperoxidase 4 (phospholipid GPX4 17475930 hydroperoxidase)CYCLOPHOSPHAMIDE NM_145740 glutathione S-transferase alpha 1 GSTA112516103, 18496131 polymorphisms CYCLOPHOSPHAMIDE NM_000852 glutathioneS-transferase pi 1 GSTP1 18496131 CYCLOPHOSPHAMIDE NM_001520 generaltranscription factor IIIC, polypeptide 1, alpha GTF3C1 16322899resistance 220 kDa CYCLOPHOSPHAMIDE NM_002140; NM_031262; NM_031263heterogeneous nuclear ribonucleoprotein K HNRNPK 17475930CYCLOPHOSPHAMIDE NM_002162 intercellular adhesion molecule 3 ICAM317403535 CYCLOPHOSPHAMIDE NM_001552 insulin-like growth factor bindingprotein 4 IGFBP4 16896004 CYCLOPHOSPHAMIDE NM_000575 interleukin 1,alpha IL1A 16636934 CYCLOPHOSPHAMIDE NM_001137673; NM_004516; NM_012218;interleukin enhancer binding factor 3, 90 kDa ILF3 16322899 resistanceNM_017620; NM_153464 CYCLOPHOSPHAMIDE NM_005544 insulin receptorsubstrate 1 IRS1 16322899 sensitivity CYCLOPHOSPHAMIDE — — JMJD2B16896004 CYCLOPHOSPHAMIDE NM_014867 kelch repeat and BTB (POZ) domaincontaining 11 KBTBD11 17403535 CYCLOPHOSPHAMIDE NM_020853 KIAA1467KIAA1467 16896004 CYCLOPHOSPHAMIDE NM_007054 kinesin family member 3AKIF3A 16896004 CYCLOPHOSPHAMIDE NM_002305 lectin, galactoside-binding,soluble, 1 LGALS1 17403535 CYCLOPHOSPHAMIDE NM_000240 monoamine oxidaseA MAOA 17403535 CYCLOPHOSPHAMIDE NM_001315; NM_139012; NM_139013;mitogen-activated protein kinase 14 MAPK14 16322899 sensitivityNM_139014 CYCLOPHOSPHAMIDE NM_001123066; NM_001123067; NM_005910;microtubule-associated protein tau MAPT 16896004 unrelated NM_016834;NM_016835; NM_016841 CYCLOPHOSPHAMIDE NM_002356 myristoylatedalanine-rich protein kinase C substrate MARCKS 17403535 CYCLOPHOSPHAMIDENM_199072 MyoD family inhibitor domain containing MDFIC 17403535CYCLOPHOSPHAMIDE NM_015335 mediator complex subunit 13-like MED13L16896004 CYCLOPHOSPHAMIDE NM_014791 maternal embryonic leucine zipperkinase MELK 16896004 CYCLOPHOSPHAMIDE NM_024042 meteorin, glial celldifferentiation regulator METRN 16896004 CYCLOPHOSPHAMIDE NM_002412O-6-methylguanine-DNA methyltransferase MGMT 15741301, 17403535resistance CYCLOPHOSPHAMIDE NM_002417 antigen identified by monoclonalantibody Ki-67 MKI67 15940066 CYCLOPHOSPHAMIDE NM_001031666;NM_001031809; NM_006138 membrane-spanning 4-domains, subfamily A, memberMS4A3 17403535 3 (hematopoietic cell-specific) CYCLOPHOSPHAMIDENM_002463 myxovirus (influenza virus) resistance 2 (mouse) MX2 17403535CYCLOPHOSPHAMIDE NM_004536; NM_022892 NLR family, apoptosis inhibitoryprotein NAIP 16322899 BIRC1— sensitivity CYCLOPHOSPHAMIDE — — NK417403535 CYCLOPHOSPHAMIDE NM_024522 Na+/K+ transporting ATPaseinteracting 1 NKAIN1 16896004 CYCLOPHOSPHAMIDE NM_002564; NM_176071;NM_176072 purinergic receptor P2Y, G-protein coupled, 2 P2RY2 17403535CYCLOPHOSPHAMIDE NM_007203; NM_147150 PALM2-AKAP2 readthrough transcriptPALM2- 17403535 AKAP2 CYCLOPHOSPHAMIDE NM_000926 progesterone receptorPGR 15940066 CYCLOPHOSPHAMIDE NM_003311 pleckstrin homology-like domain,family A, member 2 PHLDA2 17403535 CYCLOPHOSPHAMIDE NM_000302procollagen-lysine 1,2-oxoglutarate 5-dioxygenase 1 PLOD1 16322899resistance CYCLOPHOSPHAMIDE NM_001084 procollagen-lysine, 2-oxoglutarate5-dioxygenase 3 PLOD3 16322899 resistance CYCLOPHOSPHAMIDE NM_000941P450 (cytochrome) oxidoreductase POR 10919648 CYCLOPHOSPHAMIDE NM_002777proteinase 3 PRTN3 17403535 CYCLOPHOSPHAMIDE NM_002790 proteasome(prosome, macropain) subunit, alpha type, 5 PSMA5 17475930CYCLOPHOSPHAMIDE NM_005855 receptor (G protein-coupled) activitymodifying protein 1 RAMP1 16896004, 17403535 CYCLOPHOSPHAMIDENM_001008710; NM_001008711; NM_001008712; RNA binding protein withmultiple splicing RBPMS 17403535 NM_006867 CYCLOPHOSPHAMIDE NM_002934ribonuclease, RNase A family, 2 (liver, eosinophil- RNASE2 17403535derived neurotoxin) CYCLOPHOSPHAMIDE NM_006570 Ras-related GTP binding ARRAGA 17403535 CYCLOPHOSPHAMIDE NM_001102669; NM_012250 related RASviral (r-ras) oncogene homolog 2 RRAS2 17403535 CYCLOPHOSPHAMIDENM_001034 ribonucleotide reductase M2 polypeptide RRM2 16896004resistance CYCLOPHOSPHAMIDE NM_016434; NM_032957 regulator of telomereelongation helicase 1 RTEL1 17475930 CYCLOPHOSPHAMIDE NM_005980 S100calcium binding protein P S100P 17403535 CYCLOPHOSPHAMIDE NM_020974signal peptide, CUB domain, EGF-like 2 SCUBE2 16896004 CYCLOPHOSPHAMIDENM_003118 secreted protein, acidic, cysteine-rich (osteonectin) SPARC17403535 CYCLOPHOSPHAMIDE NM_003132 spermidine synthase SRM 16322899resistance CYCLOPHOSPHAMIDE NM_021978 suppression of tumorigenicity 14(colon carcinoma) ST14 16322899 resistance CYCLOPHOSPHAMIDE NM_013233serine threonine kinase 39 (STE20/SPS1 homolog, STK39 16322899sensitivity yeast) CYCLOPHOSPHAMIDE NM_018271 threonine synthase-like 2(S. cerevisiae) THNSL2 16896004 CYCLOPHOSPHAMIDE NM_014220 transmembrane4 L six family member 1 TM4SF1 17403535 CYCLOPHOSPHAMIDE NM_001067topoisomerase (DNA) II alpha 170 kDa TOP2A 18465341 CYCLOPHOSPHAMIDENM_000546; NM_001126112; NM_001126113; tumor protein p53 TP53 15940066death pathway NM_001126114; NM_001126115; NM_001126116; NM_001126117CYCLOPHOSPHAMIDE NM_024762 zinc finger protein 552 ZNF552 16896004IFOSFAMIDE NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 11723234IFOSFAMIDE NM_001229; NM_032996 caspase 9, apoptosis-related cysteinepeptidase CASP9 11723234 death pathway IFOSFAMIDE NM_000762 cytochromeP450, family 2, subfamily A, polypeptide 6 CYP2A6 12136253 drugactivation IFOSFAMIDE NM_000767 cytochrome P450, family 2, subfamily B,polypeptide 6 CYP2B6 15875221 drug activation IFOSFAMIDE NM_017460cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A4 12136253,15821045, 15875221 drug activation IFOSFAMIDE NM_000777 cytochrome P450,family 3, subfamily A, polypeptide 5 CYP3A5 15821045, 15875221 drugactivation IFOSFAMIDE NM_001130823; NM_001379 DNA(cytosine-5-)-methyltransferase 1 DNMT1 — IFOSFAMIDE NM_000561;NM_146421 glutathione S-transferase mu 1 GSTM1 12868187 polymorphism/toxicity IFOSFAMIDE NM_000852 glutathione S-transferase pi 1 GSTP112868187 polymorphism/ toxicity IFOSFAMIDE NM_000853 glutathioneS-transferase theta 1 GSTT1 12868187 polymorphism/ toxicity MELPHALANNM_004996; NM_019862; NM_019898; ATP-binding cassette, sub-family C(CFTR/MRP), ABCC1 11115505 resistance NM_019899; NM_019900 member 1MELPHALAN NM_001012270; NM_001012271; NM_001168 baculoviral IAPrepeat-containing 5 BIRC5 16373717 MELPHALAN NM_032982; NM_032983caspase 2, apoptosis-related cysteine peptidase CASP2 14757846 deathpathway MELPHALAN NM_004346; NM_032991 caspase 3, apoptosis-relatedcysteine peptidase CASP3 16951922 death pathway MELPHALAN NM_001785cytidine deaminase CDA 10830723 resistance MELPHALAN NM_000136 Fanconianemia, complementation group C FANCC 16243825 MELPHALAN NM_004629Fanconi anemia, complementation group G FANCG 16243825 MELPHALANNM_145740 glutathione S-transferase alpha 1 GSTA1 15779864 unrelatedMELPHALAN NM_000852 glutathione S-transferase pi 1 GSTP1 15779864, 27unrelated MELPHALAN NM_000201 intercellular adhesion molecule 1 ICAM116025434 MELPHALAN NM_002745; NM_138957 mitogen-activated protein kinase1 MAPK1 16025434 MELPHALAN NM_001040056; NM_001109891; NM_002746mitogen-activated protein kinase 3 MAPK3 16025434 MELPHALAN NM_002412O-6-methylguanine-DNA methyltransferase MGMT 16039682 unrelatedMELPHALAN NM_002413 microsomal glutathione S-transferase 2 MGST215779864 resistance MELPHALAN NM_006788 ralA binding protein 1 RALBP1 —resistance MELPHALAN NM_000594 tumor necrosis factor (TNF superfamily,member 2) TNF 16025434 MELPHALAN NM_001071 thymidylate synthetase TYMS10482907 CARMUSTINE NM_000927 ATP-binding cassette, sub-family B(MDR/TAP), ABCB1 15239124 resistance member 1 CARMUSTINE NM_004996;NM_019862; NM_019898; ATP-binding cassette, sub-family C (CFTR/MRP),ABCC1 12653207 resistance NM_019899; NM_019900 member 1 CARMUSTINENM_005159 actin, alpha, cardiac muscle 1 ACTC1 15980968 CARMUSTINENM_001615 actin, gamma 2, smooth muscle, enteric ACTG2 15980968CARMUSTINE NM_001102; NM_001130004; NM_001130005 actinin, alpha 1 ACTN115980968 CARMUSTINE NM_003815; NM_207191; NM_207194; ADAMmetallopeptidase domain 15 ADAM15 15980968 NM_207195; NM_207196;NM_207197 CARMUSTINE NM_005099 ADAM metallopeptidase with thrombospondintype 1 ADAMTS4 15980968 motif, 4 CARMUSTINE NM_001099733; NM_001117adenylate cyclase activating polypeptide 1 (pituitary) ADCYAP1 15980968CARMUSTINE NM_000679 adrenergic, alpha-1B-, receptor ADRA1B 15980968CARMUSTINE NM_000029 angiotensinogen (serpin peptidase inhibitor, cladeA, AGT 11034089 member 8) CARMUSTINE — — AGTRL1 15980968 CARMUSTINENM_001626 v-akt murine thymoma viral oncogene homolog 2 AKT2 15980968CARMUSTINE NM_000031 aminolevulinate, delta-, dehydratase ALAD 15980968CARMUSTINE NM_001039130; NM_001039131; NM_001141 arachidonate15-lipoxygenase, type B ALOX15B 15980968 CARMUSTINE NM_000479anti-Mullerian hormone AMH 15980968 CARMUSTINE NM_005883 adenomatosispolyposis coli 2 APC2 15980968 CARMUSTINE NM_001169 aquaporin 8 AQP815980968 CARMUSTINE — — ARGBP2 15980968 CARMUSTINE NM_005731; NM_152862actin related protein 2/3 complex, subunit 2, 34 kDa ARPC2 15980968CARMUSTINE NM_001136215; NM_003976; NM_057090; artemin ARTN 15980968NM_057091; NM_057160 CARMUSTINE NM_004192 acetylserotoninO-methyltransferase-like ASMTL 15980968 CARMUSTINE NM_152296 ATPase,Na+/K+ transporting, alpha 3 polypeptide ATP1A3 15980968 CARMUSTINENM_000705 ATPase, H+/K+ exchanging, beta polypeptide ATP4B 15980968CARMUSTINE NM_001001975; NM_001687 ATP synthase, H+ transporting,mitochondrial F1 ATP5D 15980968 complex, delta subunit CARMUSTINENM_001694 ATPase, H+ transporting, lysosomal 16 kDa, ATP6V0C 15980968 V0subunit c CARMUSTINE NM_007245; NM_145714; NM_148414; ataxin 2-likeATXN2L 15980968 NM_148415; NM_148416 CARMUSTINE NM_000706 argininevasopressin receptor 1A AVPR1A 15980968 CARMUSTINE NM_004776UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, B4GALT5 15980968polypeptide 5 CARMUSTINE NM_001144888; NM_006340; NM_017450;BAI1-associated protein 2 BAIAP2 15980968 NM_017451 CARMUSTINE NM_003933BAI1-associated protein 3 BAIAP3 15980968 CARMUSTINE NM_003921 B-cellCLL/lymphoma 10 BCL10 15980968 CARMUSTINE NM_000633; NM_000657 B-cellCLL/lymphoma 2 BCL2 16187019 resistance CARMUSTINE NM_001191; NM_138578BCL2-like 1 BCL2L1 16187019 CARMUSTINE NM_003766 beclin 1, autophagyrelated BECN1 15980968 CARMUSTINE NM_001003398; NM_001714 bicaudal Dhomolog 1 (Drosophila) BICD1 15980968 CARMUSTINE NM_001715 B lymphoidtyrosine kinase BLK 15980968 CARMUSTINE NM_001719 bone morphogeneticprotein 7 BMP7 15980968 CARMUSTINE NM_001519; NM_145685 BRF1 homolog,subunit of RNA polymerase III BRF1 15980968 transcription initiationfactor IIIB (S. cerevisiae) CARMUSTINE NM_001215 carbonic anhydrase VICA6 15980968 CARMUSTINE NM_001740; NM_007087; NM_007088 calbindin 2CALB2 15980968 CARMUSTINE NM_002982 chemokine (C-C motif) ligand 2 CCL215980968 CARMUSTINE NM_001039490; NM_004357; NM_139029; CD151 molecule(Raph blood group) CD151 15980968 NM_139030 CARMUSTINE NM_001040059;NM_001251 CD68 molecule CD68 15980968 CARMUSTINE NM_001783; NM_021601CD79a molecule, immunoglobulin-associated alpha CD79A 15980968CARMUSTINE NM_005191 CD80 molecule CD80 15980968 CARMUSTINE NM_001790;NM_022809 cell division cycle 25 homolog C (S. pombe) CDC25C 15735757CARMUSTINE NM_001260 cyclin-dependent kinase 8 CDK8 15980968 CARMUSTINENM_000389; NM_078467 cyclin-dependent kinase inhibitor 1A (p21, Cip1)CDKN1A 15735757 resistance CARMUSTINE NM_005193 caudal type homeobox 4CDX4 15980968 CARMUSTINE NM_001815 carcinoembryonic antigen-related celladhesion CEACAM3 15980968 molecule 3 CARMUSTINE NM_005194 CCAAT/enhancerbinding protein (C/EBP), beta CEBPB 15980968 CARMUSTINE NM_001114121;NM_001114122; NM_001274 CHK1 checkpoint homolog (S. pombe) CHEK115735757 CARMUSTINE NM_000741 cholinergic receptor, muscarinic 4 CHRM415980968 CARMUSTINE NM_000749 cholinergic receptor, nicotinic, beta 3CHRNB3 15980968 CARMUSTINE NM_005199 cholinergic receptor, nicotinic,gamma CHRNG 15980968 CARMUSTINE NM_001824 creatine kinase, muscle CKM15980968 altered by CNU CARMUSTINE NM_001835; NM_007098 clathrin, heavychain-like 1 CLTCL1 15980968 CARMUSTINE NM_003632 contactin associatedprotein 1 CNTNAP1 15980968 CARMUSTINE NM_001851; NM_078485 collagen,type IX, alpha 1 COL9A1 15980968 CARMUSTINE NM_005205 cytochrome coxidase subunit VIa polypeptide 2 COX6A2 15980968 CARMUSTINE NM_004378cellular retinoic acid binding protein 1 CRABP1 15980968 CARMUSTINENM_000755; NM_004003 carnitine acetyltransferase CRAT 15980968CARMUSTINE NM_001887 crystallin, beta B1 CRYBB1 15980968 CARMUSTINENM_001900 cystatin D CST5 15980968 CARMUSTINE NM_001142544; NM_001330cardiotrophin 1 CTF1 15980968 CARMUSTINE NM_003798 catenin(cadherin-associated protein), alpha-like 1 CTNNAL1 15980968 CARMUSTINENM_000103; NM_031226 cytochrome P450, family 19, subfamily A,polypeptide 1 CYP19A1 15980968 CARMUSTINE NM_004762; NM_017456 cytohesin1 CYTH1 15980968 CARMUSTINE NM_003587 DEAH (Asp-Glu-Ala-His) boxpolypeptide 16 DHX16 15980968 CARMUSTINE NM_001374 deoxyribonucleaseI-like 2 DNASE1L2 15980968 CARMUSTINE NM_004421 dishevelled, dsh homolog1 (Drosophila) DVL1 15980968 CARMUSTINE NM_001393 extracellular matrixprotein 2, female organ and ECM2 15980968 adipocyte specific CARMUSTINENM_001404 eukaryotic translation elongation factor 1 gamma EEF1G15980968 CARMUSTINE NM_001414 eukaryotic translation initiation factor2B, subunit 1 EIF2B1 15980968 alpha, 26 kDa CARMUSTINE NM_002212;NM_181466; NM_181468 eukaryotic translation initiation factor 6 EIF615980968 CARMUSTINE NM_000120; NM_001136018 epoxide hydrolase 1,microsomal (xenobiotic) EPHX1 15980968 resistance ? CARMUSTINE NM_004451estrogen-related receptor alpha ESRRA 15980968 CARMUSTINE NM_004456;NM_152998 enhancer of zeste homolog 2 (Drosophila) EZH2 15980968CARMUSTINE NM_000138 fibrillin 1 FBN1 15980968 CARMUSTINE NM_000801;NM_054014 FK506 binding protein 1A, 12 kDa FKBP1A 15980968 CARMUSTINENM_001018676; NM_001018677; NM_002027 farnesyltransferase, CAAX box,alpha FNTA 15980968 CARMUSTINE NM_001454 forkhead box J1 FOXJ1 15980968CARMUSTINE NM_002032 ferritin, heavy polypeptide 1 FTH1 15980968CARMUSTINE NM_000146 ferritin, light polypeptide FTL 15980968 CARMUSTINENM_002037; NM_153047; NM_153048 FYN oncogene related to SRC, FGR, YESFYN 15980968 CARMUSTINE NM_000807; NM_001114175 gamma-aminobutyric acid(GABA) A receptor, alpha 2 GABRA2 15980968 CARMUSTINE NM_000811gamma-aminobutyric acid (GABA) A receptor, alpha 6 GABRA6 15980968CARMUSTINE NM_000156; NM_138924 guanidinoacetate N-methyltransferaseGAMT 15980968 CARMUSTINE NM_000805 gastrin GAST 15980968 CARMUSTINENM_003643 glial cells missing homolog 1 (Drosophila) GCM1 15980968CARMUSTINE NM_001493 GDP dissociation inhibitor 1 GDI1 15980968CARMUSTINE NM_001115156; NM_001494 GDP dissociation inhibitor 2 GDI215980968 CARMUSTINE NM_001131019; NM_002055 glial fibrillary acidicprotein GFAP 15980968 CARMUSTINE NM_004122; NM_198407 growth hormonesecretagogue receptor GHSR 15980968 CARMUSTINE NM_000406; NM_001012763gonadotropin-releasing hormone receptor GNRHR 15980968 CARMUSTINENM_004486 golgi autoantigen, golgin subfamily a, 2 GOLGA2 15980968CARMUSTINE NM_002078 golgi autoantigen, golgin subfamily a, 4 GOLGA415980968 CARMUSTINE NM_000407 glycoprotein Ib (platelet), betapolypeptide GP1BB 15980968 CARMUSTINE NM_005298 G protein-coupledreceptor 25 GPR25 15980968 CARMUSTINE NM_001506 G protein-coupledreceptor 32 GPR32 15980968 CARMUSTINE NM_005302 G protein-coupledreceptor 37 (endothelin receptor GPR37 15980968 type B-like) CARMUSTINENM_003608 G protein-coupled receptor 65 GPR65 15980968 CARMUSTINENM_001030002; NM_005310 growth factor receptor-bound protein 7 GRB715980968 CARMUSTINE NM_002087 granulin GRN 15980968 CARMUSTINE NM_000637glutathione reductase GSR — target CARMUSTINE NM_145740 glutathioneS-transferase alpha 1 GSTA1 8395980 unrelated CARMUSTINE NM_000561;NM_146421 glutathione S-transferase mu 1 GSTM1 8395980 unrelatedCARMUSTINE NM_000849 glutathione S-transferase mu 3 (brain) GSTM315247628, 8395980 resistance CARMUSTINE NM_000852 glutathioneS-transferase pi 1 GSTP1 16899598, 8395980 unrelated CARMUSTINENM_002096 general transcription factor IIF, polypeptide 1, 74 kDa GTF2F115980968 CARMUSTINE NM_002105 H2A histone family, member X H2AFX15980968 CARMUSTINE — — HADHSC 15980968 CARMUSTINE NM_001040427;NM_005326 hydroxyacylglutathione hydrolase HAGH 15980968 CARMUSTINENM_005334 host cell factor C1 (VP16-accessory protein) HCFC1 15980968CARMUSTINE NM_005517 high-mobility group nucleosomal binding domain 2HMGN2 15980968 CARMUSTINE NM_000545 HNF1 homeobox A HNF1A 15980968CARMUSTINE NM_002141 homeobox A4 HOXA4 15980968 CARMUSTINE NM_003259intercellular adhesion molecule 5, telencephalin ICAM5 15980968CARMUSTINE NM_000202; NM_006123 iduronate 2-sulfatase IDS 15980968CARMUSTINE NM_003897 immediate early response 3 IER3 15980968 CARMUSTINENM_001099856; NM_001099857; NM_001145255; inhibitor of kappa lightpolypeptide gene enhancer in B- IKBKG 15980968 NM_003639 cells, kinasegamma CARMUSTINE NM_001567 inositol polyphosphate phosphatase-like 1INPPL1 15980968 CARMUSTINE NM_005542; NM_198336; NM_198337 insulininduced gene 1 INSIG1 15980968 CARMUSTINE NM_005543 insulin-like 3(Leydig cell) INSL3 15980968 CARMUSTINE NM_005544 insulin receptorsubstrate 1 IRS1 15980968 CARMUSTINE NM_005545; NM_201526 immunoglobulinsuperfamily containing leucine-rich ISLR 15980968 repeat CARMUSTINENM_002204; NM_005501 integrin, alpha 3 (antigen CD49C, alpha 3 subunitof ITGA3 15980968 VLA-3 receptor) CARMUSTINE NM_002215 inter-alpha(globulin) inhibitor H1 ITIH1 15980968 CARMUSTINE NM_000238; NM_172056;NM_172057 potassium voltage-gated channel, subfamily H (eag- KCNH215980968 related), member 2 CARMUSTINE NM_004984 kinesin family member5A KIF5A 15980968 CARMUSTINE NM_000422 keratin 17 KRT17 15980968CARMUSTINE NM_002277 keratin 31 KRT31 15980968 CARMUSTINE NM_005558ladinin 1 LAD1 15980968 CARMUSTINE NM_002287; NM_021706leukocyte-associated immunoglobulin-like receptor 1 LAIR1 15980968CARMUSTINE NM_000228; NM_001017402; NM_001127641 laminin, beta 3 LAMB315980968 CARMUSTINE NM_002316 LIM homeobox transcription factor 1, betaLMX1B 15980968 CARMUSTINE NM_005576 lysyl oxidase-like 1 LOXL1 15980968CARMUSTINE NM_002319 leucine-rich repeats and calponin homology (CH)LRCH4 15980968 domain containing 4 CARMUSTINE NM_006152lymphoid-restricted membrane protein LRMP 15980968 CARMUSTINENM_001013836; NM_001013837; NM_003550 MAD1 mitotic arrest deficient-like1 (yeast) MAD1L1 15980968 CARMUSTINE NM_004579 mitogen-activated proteinkinase kinase kinase kinase 2 MAP4K2 15980968 CARMUSTINE NM_002753;NM_138980; NM_138981; mitogen-activated protein kinase 10 MAPK1015980968 NM_138982 CARMUSTINE NM_000429 methionine adenosyltransferaseI, alpha MAT1A 15980968 CARMUSTINE NM_001012333; NM_001012334; NM_002391midkine (neurite growth-promoting factor 2) MDK 15980968 CARMUSTINENM_004774 mediator complex subunit 1 MED1 15980968 CARMUSTINENM_001098270; NM_002409 mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-MGAT3 15980968 acetylglucosaminyltransferase CARMUSTINE NM_002412O-6-methylguanine-DNA methyltransferase MGMT 15319033, resistance15833865, 16039682, 15814657, 16899598, 16033832 CARMUSTINE NM_002445;NM_138715; NM_138716 macrophage scavenger receptor 1 MSR1 15980968CARMUSTINE NM_002457 mucin 2, oligomeric mucus/gel-forming MUC2 15980968CARMUSTINE NM_002461 mevalonate (diphospho) decarboxylase MVD 15980968CARMUSTINE NM_004997 myosin binding protein H MYBPH 15980968 CARMUSTINENM_002468 myeloid differentiation primary response gene (88) MYD8815980968 CARMUSTINE NM_002478 myogenic differentiation 1 MYOD1 15980968CARMUSTINE NM_002479 myogenin (myogenic factor 4) MYOG 15980968CARMUSTINE NM_002494 NADH dehydrogenase (ubiquinone) 1, subcomplexNDUFC1 15980968 unknown, 1, 6 kDa CARMUSTINE NM_002509 NK2 homeobox 2NKX2-2 15980968 CARMUSTINE NM_002517 neuronal PAS domain protein 1 NPAS115980968 CARMUSTINE NM_005286 neuropeptides B/W receptor 2 NPBWR215980968 CARMUSTINE NM_004558 neurturin NRTN 15980968 CARMUSTINENM_002542; NM_016819; NM_016820; 8-oxoguanine DNA glycosylase OGG111181913 NM_016821; NM_016826; NM_016827; NM_016828; NM_016829CARMUSTINE NM_006189 olfactory marker protein OMP 15980968 CARMUSTINENM_001018049; NM_002571 progestagen-associated endometrial protein PAEP15980968 CARMUSTINE NM_003466; NM_013951; NM_013952; paired box 8 PAX815980968 NM_013953; NM_013992 CARMUSTINE NM_002586 pre-B-cell leukemiahomeobox 2 PBX2 15980968 CARMUSTINE NM_000281 pterin-4alpha-carbinolamine dehydratase/dimerization PCBD1 15980968 cofactor ofhepatocyte nuclear factor 1 alpha CARMUSTINE NM_002588; NM_032402;NM_032403 protocadherin gamma subfamily C, 3 PCDHGC3 15980968 CARMUSTINENM_002593 procollagen C-endopeptidase enhancer PCOLCE 15980968CARMUSTINE NM_005017 phosphate cytidylyltransferase 1, choline, alphaPCYT1A 15980968 CARMUSTINE NM_001018053; NM_0062126-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 PFKFB2 15980968CARMUSTINE NM_000289 phosphofructokinase, muscle PFKM 15980968CARMUSTINE NM_005022 profilin 1 PFN1 15980968 CARMUSTINE NM_001114172;NM_003629 phosphoinositide-3-kinase, regulatory subunit 3 PIK3R315980968 (gamma) CARMUSTINE NR_023383; NR_023383; NR_023383; postmeioticsegregation increased 2-like 11 PMS2L11 15980968 NR_023383; NR_023383;NR_023383; pseudogene NR_023383; NR_023383; NR_023383 CARMUSTINENM_002695 polymerase (RNA) II (DNA directed) polypeptide E, POLR2E15980968 25 kDa CARMUSTINE NM_002707; NM_177983 protein phosphatase 1G(formerly 2C), magnesium- PPM1G 15980968 dependent, gamma isoformCARMUSTINE NM_003981; NM_199413; NM_199414 protein regulator ofcytokinesis 1 PRC1 17374387 CARMUSTINE NM_000948 prolactin PRL 15980968CARMUSTINE NM_002762 protamine 2 PRM2 15980968 CARMUSTINE NM_001145368;NM_001145369; NM_001145370; protein tyrosine phosphatase, non-receptortype 3 PTPN3 15980968 NM_001145371; NM_001145372; NM_002829 CARMUSTINENM_002864 pregnancy-zone protein PZP 15980968 CARMUSTINE NM_005053 RAD23homolog A (S. cerevisiae) RAD23A 15980968 CARMUSTINE NM_002875;NM_133487 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) RAD5115980968 CARMUSTINE — — RAD9 15980968 CARMUSTINE NM_002901reticulocalbin 1, EF-hand calcium binding domain RCN1 15980968CARMUSTINE NM_001012720; NM_001012722; NM_002921 retinal G proteincoupled receptor RGR 15980968 CARMUSTINE NM_002930 Ras-like without CAAX2 RIT2 15980968 CARMUSTINE NM_002937; NM_194431 ribonuclease, RNase Afamily, 4 RNASE4 15980968 CARMUSTINE NM_002688 septin 5 sept-05 15980968CARMUSTINE NM_005066 splicing factor proline/glutamine-rich(polypyrimidine SFPQ 15980968 tract binding protein associated)CARMUSTINE NM_000023; NM_001135697 sarcoglycan, alpha (50 kDadystrophin-associated SGCA 15980968 glycoprotein) CARMUSTINE NM_005412serine hydroxymethyltransferase 2 (mitochondrial) SHMT2 15980968CARMUSTINE NM_000451; NM_006883 short stature homeobox SHOX 15980968CARMUSTINE — — SIAT1 15980968 CARMUSTINE NM_003049 solute carrier family10 (sodium/bile acid cotransporter SLC10A1 15980968 family), member 1CARMUSTINE NM_006517 solute carrier family 16, member 2 (monocarboxylicSLC16A2 15980968 acid transporter 8) CARMUSTINE NM_003459 solute carrierfamily 30 (zinc transporter), member 3 SLC30A3 15980968 CARMUSTINENM_001043 solute carrier family 6 (neurotransmitter transporter, SLC6A215980968 noradrenalin), member 2 CARMUSTINE NM_021094; NM_134431 solutecarrier organic anion transporter family, member SLCO1A2 15980968 1A2CARMUSTINE NM_003076; NM_139071 SWI/SNF related, matrix associated,actin dependent SMARCD1 15980968 regulator of chromatin, subfamily d,member 1 CARMUSTINE NM_003080 sphingomyelin phosphodiesterase 2, neutralSMPD2 15980968 membrane (neutral sphingomyelinase) CARMUSTINE NM_003082small nuclear RNA activating complex, polypeptide 1, SNAPC1 15980968 43kDa CARMUSTINE NM_001039697 small nuclear RNA activating complex,polypeptide 3, SNAPC3 15980968 50 kDa CARMUSTINE NM_003087 synuclein,gamma (breast cancer-specific protein 1) SNCG 15980968 CARMUSTINENM_003092; NM_198220 small nuclear ribonucleoprotein polypeptide B″SNRPB2 15980968 CARMUSTINE NM_003745 suppressor of cytokine signaling 1SOCS1 17374387 CARMUSTINE NM_005876 SPEG complex locus SPEG 15980968CARMUSTINE NM_001017418 small proline-rich protein 2B SPRR2B 15980968CARMUSTINE NM_003134 signal recognition particle 14 kDa (homologous AluSRP14 15980968 RNA binding protein) CARMUSTINE NM_003140 sex determiningregion Y SRY 15980968 CARMUSTINE NM_003034 ST8alpha-N-acetyl-neuraminide alpha-2,8- ST8SIA1 15980968 sialyltransferase1 CARMUSTINE NM_003473 signal transducing adaptor molecule (SH3 domainand STAM 15980968 ITAM motif) 1 CARMUSTINE NM_000351 steroid sulfatase(microsomal), isozyme S STS 15980968 CARMUSTINE NM_052874 syntaxin 1BSTX1B 15980968 CARMUSTINE NM_001127396; NM_006949 syntaxin bindingprotein 2 STXBP2 15980968 CARMUSTINE NM_003182; NM_013996; NM_013997;tachykinin, precursor 1 TAC1 15980968 NM_013998 CARMUSTINE NM_003206;NM_198392 transcription factor 21 TCF21 15980968 CARMUSTINE — — TEGT15980968 CARMUSTINE NM_198253; NM_198255 telomerase reversetranscriptase TERT 18021753 CARMUSTINE NM_001105192; NM_005078;NM_020908 transducin-like enhancer of split 3 (E(sp1) homolog, TLE315980968 Drosophila) CARMUSTINE NM_002546 tumor necrosis factor receptorsuperfamily, member TNFRSF11B 15980968 11b CARMUSTINE NM_000546;NM_001126112; NM_001126113; tumor protein p53 TP53 15735757 resistanceNM_001126114; NM_001126115; NM_001126116; NM_001126117 CARMUSTINENM_005658 TNF receptor-associated factor 1 TRAF1 15980968 CARMUSTINENM_001025234; NM_001025235; NM_001025236; tetraspanin 4 TSPAN4 15980968NM_001025237; NM_001025238; NM_001025239; NM_003271 CARMUSTINE NM_178014tubulin, beta TUBB 15980968 CARMUSTINE NM_001070 tubulin, gamma 1 TUBG115980968 CARMUSTINE NM_001128174; NM_003360 UDP glycosyltransferase 8UGT8 15980968 CARMUSTINE NM_002911 UPF1 regulator of nonsensetranscripts homolog UPF1 15980968 (yeast) CARMUSTINE NM_003378 VGF nervegrowth factor inducible VGF 15980968 CARMUSTINE NM_001077269; NM_003387WAS/WASL interacting protein family, member 1 WIPF1 15980968 CARMUSTINENM_003405 tyrosine 3-monooxygenase/tryptophan 5- YWHAH 15980968monooxygenase activation protein, eta polypeptide CARMUSTINE NM_003443zinc finger and BTB domain containing 17 ZBTB17 15980968 CARMUSTINENM_001010972; NM_003461 zyxin ZYX 15980968 FOTEMUSTINE NM_002412O-6-methylguanine-DNA methyltransferase MGMT 12970393, 16039682,12970393 resistance FOTEMUSTINE NM_001093771; NM_003330; NM_182729;thioredoxin reductase 1 TXNRD1 — target NM_182742; NM_182743 CARBOPLATINNM_000477 albumin ALB — unrelated CARBOPLATIN NM_004324; NM_138761;NM_138763; BCL2-associated X protein BAX 15576332, 15996812 deathpathway NM_138764; NM_138765 CARBOPLATIN NM_000633; NM_000657 B-cellCLL/lymphoma 2 BCL2 15996812, resistance 15996812, 17404015, 15576332CARBOPLATIN NM_001040668; NM_138639 BCL2-like 12 (proline rich) BCL2L1215576332 CARBOPLATIN NM_001166 baculoviral IAP repeat-containing 2 BIRC210815900 CARBOPLATIN NM_004346; NM_032991 caspase 3, apoptosis-relatedcysteine peptidase CASP3 15576332 death pathway CARBOPLATIN NM_001229;NM_032996 caspase 9, apoptosis-related cysteine peptidase CASP915996812, 17404015, 15576332 death pathway CARBOPLATIN NM_001129889;NM_001922 dopachrome tautomerase (dopachrome delta- DCT 15897911resistance isomerase, tyrosine-related protein 2) CARBOPLATIN NM_000043;NM_152871; NM_152872; Fas (TNF receptor superfamily, member 6) FAS15576332 death pathway NM_152873; NM_152874; NM_152875; NM_152876;NM_152877 CARBOPLATIN NM_001618 poly (ADP-ribose) polymerase 1 PARP115996812 altered by platin CARBOPLATIN NM_000963prostaglandin-endoperoxide synthase 2 (prostaglandin PTGS2 18089846 G/Hsynthase and cyclooxygenase) CARBOPLATIN NM_001145547; NM_032905 RNAbinding motif protein 17 RBM17 16061639 resistance CISPLATIN NM_000014alpha-2-macroglobulin A2M 16773208 CISPLATIN NM_000927 ATP-bindingcassette, sub-family B (MDR/TAP), ABCB1 15650019, 15756446, 15802814,resistance member 1 15990222, 15990222, 15650019, 15239124 CISPLATINNM_004996; NM_019862; NM_019898; ATP-binding cassette, sub-family C(CFTR/MRP), ABCC1 15448748, 15756446, 15802814, resistance NM_019899;NM_019900 member 1 18695918 CISPLATIN NM_000392 ATP-binding cassette,sub-family C (CFTR/MRP), ABCC2 15688364, 8797578, 15756446, resistancemember 2 15985617, 18695918 CISPLATIN NM_001023587; NM_005688ATP-binding cassette, sub-family C (CFTR/MRP), ABCC5 15882455 resistancemember 5 CISPLATIN NM_001014431; NM_001014432; NM_005163 v-akt murinethymoma viral oncogene homolog 1 AKT1 15981204, 18071906 resistanceCISPLATIN NM_001626 v-akt murine thymoma viral oncogene homolog 2 AKT218071906 resistance CISPLATIN NM_005465; NM_181690 v-akt murine thymomaviral oncogene homolog 3 AKT3 18071906 resistance (protein kinase B,gamma) CISPLATIN NM_000477 albumin ALB 16773208 drug carrier CISPLATINNM_001641; NM_080648; NM_080649 APEX nuclease (multifunctional DNArepair enzyme) 1 APEX1 16373707 resistance CISPLATIN NM_001699;NM_021913 AXL receptor tyrosine kinase AXL 16061661 resistance CISPLATINNM_004324; NM_138761; NM_138763; BCL2-associated X protein BAX 14512787,14601052, 16009487 death pathway NM_138764; NM_138765 CISPLATINNM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 14512787, 15917659,resistance 15981204, 14601052, 16009487, 17404015 CISPLATIN NM_001191;NM_138578 BCL2-like 1 BCL2L1 15917659, 15981204, 14601052, resistance16020667 CISPLATIN NM_001040668; NM_138639 BCL2-like 12 (proline rich)BCL2L12 17404015 sensitivity CISPLATIN NM_001166 baculoviral IAPrepeat-containing 2 BIRC2 14601052, resistance 14654915, 16142363,10815900 CISPLATIN NM_001165; NM_182962 baculoviral IAPrepeat-containing 3 BIRC3 14654915, 16391810 resistance CISPLATINNM_001012270; NM_001012271; NM_001168 baculoviral IAP repeat-containing5 BIRC5 14601052, 15917659, 16382892, resistance 15970709, 11911975,15981204, 15981204, 16142363, 14654915, 11911975 CISPLATIN NM_032982;NM_032983 caspase 2, apoptosis-related cysteine peptidase CASP2 14757846death pathway CISPLATIN NM_004346; NM_032991 caspase 3,apoptosis-related cysteine peptidase CASP3 16009487, 15863139, 14512787,death pathway 18071906 CISPLATIN NM_001080124; NM_001080125; NM_001228;caspase 8, apoptosis-related cysteine peptidase CASP8 16009487, 18071906death pathway NM_033355; NM_033356; NM_033358 CISPLATIN NM_001229;NM_032996 caspase 9, apoptosis-related cysteine peptidase CASP916009487, 17404015 death pathway CISPLATIN NM_001752 catalase CAT10754530, 15930895 altered by platin CISPLATIN NM_000389; NM_078467cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 11099651,12807743, 14601052 resistance CISPLATIN NM_001127183; NM_001127184;NM_003879 CASP8 and FADD-like apoptosis regulator CFLAR 14601052resistance CISPLATIN NM_020313 cytokine induced apoptosis inhibitor 1CIAPIN1 18389626 CISPLATIN NM_001831; NM_203339 clusterin CLU 15955107resistance CISPLATIN NM_000614 ciliary neurotrophic factor CNTF 16898872CISPLATIN NM_001079846; NM_004380 CREB binding protein CREBBP 17498666CISPLATIN NM_018947 cytochrome c, somatic CYCS 16009487 death pathwayCISPLATIN NM_017460 cytochrome P450, family 3, subfamily A, polypeptide4 CYP3A4 15650019 unrelated CISPLATIN NM_019887; NM_138929 diablohomolog (Drosophila) DIABLO 16391810 death pathway CISPLATIN NM_000110dihydropyrimidine dehydrogenase DPYD 15737843 resistance CISPLATINNM_001956 endothelin 2 EDN2 16898872 CISPLATIN NM_005228; NM_201282;NM_201283; epidermal growth factor receptor (erythroblastic EGFR15723263, 15737843, 18337622 resistance NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) CISPLATIN NM_001429 E1A bindingprotein p300 EP300 17498666 CISPLATIN NM_001005862; NM_004448 v-erb-b2erythroblastic leukemia viral oncogene ERBB2 15737843, 18337622resistance homolog 2, neuro/glioblastoma derived oncogene homolog(avian) CISPLATIN NM_001983; NM_202001 excision repaircross-complementing rodent repair ERCC1 15737843 resistance deficiency,complementation group 1 (includes overlapping antisense sequence)CISPLATIN NM_000400; NM_001130867 excision repair cross-complementingrodent repair ERCC2 15882455 resistance deficiency, complementationgroup 2 CISPLATIN NM_001079675; NM_001986 ets variant 4 ETV4 16061661resistance CISPLATIN NM_003824 Fas (TNFRSF6)-associated via death domainFADD 16009487 death pathway CISPLATIN NM_000136 Fanconi anemia,complementation group C FANCC 16243825 CISPLATIN NM_004629 Fanconianemia, complementation group G FANCG 16061661, 16243825 resistanceCISPLATIN NM_000043; NM_152871; NM_152872; Fas (TNF receptorsuperfamily, member 6) FAS 16009487, 17305640 death pathway NM_152873;NM_152874; NM_152875; NM_152876; NM_152877 CISPLATIN NM_000639 Fasligand (TNF superfamily, member 6) FASLG 16009487 death pathwayCISPLATIN NM_002009 fibroblast growth factor 7 (keratinocyte growthfactor) FGF7 18708365 CISPLATIN NM_000142; NM_022965 fibroblast growthfactor receptor 3 FGFR3 12066199 CISPLATIN NM_005438 FOS-like antigen 1FOSL1 15756446, 16061661 sensitivity CISPLATIN NM_001924 growth arrestand DNA-damage-inducible, alpha GADD45A 19003803 CISPLATIN NM_004864growth differentiation factor 15 GDF15 16898872 CISPLATIN NM_000561;NM_146421 glutathione S-transferase mu 1 GSTM1 12851839 polymorphismsCISPLATIN NM_000849 glutathione S-transferase mu 3 (brain) GSTM311081456 polymorphisms CISPLATIN NM_000852 glutathione S-transferase pi1 GSTP1 14678959, 15239142, 15279901, resistance 15737843, 2747627CISPLATIN NM_000853 glutathione S-transferase theta 1 GSTT1 12851839polymorphisms CISPLATIN NM_000858; NM_001159390; NM_001159391 guanylatekinase 1 GUK1 16898872 CISPLATIN NM_001530; NM_181054 hypoxia induciblefactor 1, alpha subunit (basic helix- HIF1A 16532342, 17498666resistance loop-helix transcription factor) CISPLATIN NM_001540 heatshock 27 kDa protein 1 HSPB1 19088045 CISPLATIN NM_002157 heat shock 10kDa protein 1 (chaperonin 10) HSPE1 16394183 resistance CISPLATINNM_013247; NM_145074 HtrA serine peptidase 2 HTRA2 15863139 deathpathway CISPLATIN NM_003641 interferon induced transmembrane protein 1(9-27) IFITM1 16898872 sensitivity CISPLATIN NM_000598; NM_001013398insulin-like growth factor binding protein 3 IGFBP3 16061661 sensitivityCISPLATIN NM_000418; NM_001008699 interleukin 4 receptor IL4R 14678968CISPLATIN NM_002207 integrin, alpha 9 ITGA9 12066199 CISPLATINNM_000213; NM_001005619; NM_001005731 integrin, beta 4 ITGB4 12066199altered by platin CISPLATIN NM_002228 jun oncogene JUN 16898872 alteredby platin CISPLATIN NM_002276 keratin 19 KRT19 16061661 sensitivityCISPLATIN NM_002272 keratin 4 KRT4 16061661 sensitivity CISPLATINNM_024552 LAG1 homolog, ceramide synthase 4 LASS4 15756446 unrelatedCISPLATIN NM_004526 minichromosome maintenance complex component 2 MCM216061661 resistance CISPLATIN NM_004774 mediator complex subunit 1 MED115650019 sensitivity CISPLATIN NM_002412 O-6-methylguanine-DNAmethyltransferase MGMT 15015788, 2766459, 7562019, resistance 15809756,16043385, 16039682, 16043385 CISPLATIN NM_002425 matrix metallopeptidase10 (stromelysin 2) MMP10 12066199 altered by platin CISPLATIN NM_002428matrix metallopeptidase 15 (membrane-inserted) MMP15 12066199 altered byplatin CISPLATIN NM_005941; NM_022564 matrix metallopeptidase 16(membrane-inserted) MMP16 12066199 altered by platin CISPLATIN NM_015084mitochondrial ribosomal protein S27 MRPS27 15756446 sensitivityCISPLATIN NM_005946 metallothionein 1A MT1A 12680227 resistanceCISPLATIN NM_005953 metallothionein 2A MT2A 12680227, 16394183resistance CISPLATIN NM_005954 metallothionein 3 MT3 16061661, 16898872resistance CISPLATIN NM_005115; NM_017458 major vault protein MVP15802814 resistance CISPLATIN NM_004536; NM_022892 NLR family, apoptosisinhibitory protein NAIP 11911975, 11911975, 14654915 CISPLATINNM_006534; NM_181659 nuclear receptor coactivator 3 NCOA3 15650019CISPLATIN NM_004557 Notch homolog 4 (Drosophila) NOTCH4 16898872CISPLATIN NM_003889; NM_022002; NM_033013 nuclear receptor subfamily 1,group I, member 2 NR1I2 15650019 resistance CISPLATIN NM_002528 nthendonuclease III-like 1 (E. coli) NTHL1 16898872 resistance CISPLATINNM_001618 poly (ADP-ribose) polymerase 1 PARP1 16009487, 18 altered byplatin CISPLATIN NM_002592; NM_182649 proliferating cell nuclear antigenPCNA 11099651 CISPLATIN NM_005313 protein disulfide isomerase family A,member 3 PDIA3 15756446 CISPLATIN NM_002624; NM_145897 prefoldin subunit5 PFDN5 16898872 CISPLATIN NM_000291 phosphoglycerate kinase 1 PGK115756446 sensitivity CISPLATIN NM_021127phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 17216584CISPLATIN NM_001081640; NM_006904 protein kinase, DNA-activated,catalytic polypeptide PRKDC 18546291 CISPLATIN NM_000311; NM_001080121;NM_001080122; prion protein PRNP 15386405 NM_001080123; NM_183079CISPLATIN NM_000314 phosphatase and tensin homolog PTEN 11707646sensitivity CISPLATIN NM_000963 prostaglandin-endoperoxide synthase 2(prostaglandin PTGS2 15517878, 18695918 resistance G/H synthase andcyclooxygenase) CISPLATIN NM_005607; NM_153831 PTK2 protein tyrosinekinase 2 PTK2 16391810 resistance CISPLATIN NM_006788 ralA bindingprotein 1 RALBP1 — resistance CISPLATIN NM_000321 retinoblastoma 1 RB114704340 CISPLATIN NM_001145138; NM_021975 v-rel reticuloendotheliosisviral oncogene homolog A RELA 19003803 (avian) CISPLATIN NM_001042678;NM_001042679; NM_175744 ras homolog gene family, member C RHOC 16898872CISPLATIN NM_015414; NM_033643 ribosomal protein L36 RPL36 16394183resistance CISPLATIN NM_001009 ribosomal protein S5 RPS5 16898872CISPLATIN NM_001031680; NM_004350 runt-related transcription factor 3RUNX3 15756676 CISPLATIN NM_006142 stratifin SFN 15999354 CISPLATINNM_001078174; NM_001078175; NM_001078176; solute carrier family 29(nucleoside transporters), SLC29A1 18728667 drug import NM_001078177;NM_004955 member 1 CISPLATIN NM_001859 solute carrier family 31 (coppertransporters), member 1 SLC31A1 15985617 CISPLATIN NM_003745 suppressorof cytokine signaling 1 SOCS1 17374387 unrelated CISPLATIN NM_021102serine peptidase inhibitor, Kunitz type, 2 SPINT2 15756446 CISPLATINNM_198253; NM_198255 telomerase reverse transcriptase TERT 18021753CISPLATIN NM_001063 transferrin TF 16773208 CISPLATIN NM_003808;NM_172087; NM_172088 tumor necrosis factor (ligand) superfamily, member13 TNFSF13 18423122 CISPLATIN NM_000546; NM_001126112; NM_001126113;tumor protein p53 TP53 12807743, 14562046, 15578696, sensitivityNM_001126114; NM_001126115; 15990222, 12082016, 17555331, NM_001126116;NM_001126117 15990222, 16020667, 15999354, 16077963, 16211088, 17216584,17498666, 17555331 CISPLATIN NM_001126240; NM_001126241; NM_001126242;tumor protein p73 TP73 14678968, 17076661 sensitivity NM_005427CISPLATIN NM_000365; NM_001159287 triosephosphate isomerase 1 TPI118309519 CISPLATIN NM_014294 translocation associated membrane protein 1TRAM1 16061661 sensitivity CISPLATIN NM_016292 TNF receptor-associatedprotein 1 TRAP1 16061661 resistance CISPLATIN NM_006009 tubulin, alpha1a TUBA1A 16898872 resistance CISPLATIN NM_003329 thioredoxin TXN10754530 resistance CISPLATIN NM_001071 thymidylate synthetase TYMS10482907, 15737843 resistance CISPLATIN NM_001025366; NM_001025367;NM_001025368; vascular endothelial growth factor A VEGFA 17498666NM_001025369; NM_001025370; NM_001033756; NM_003376 CISPLATIN NM_001167X-linked inhibitor of apoptosis XIAP 11911975, 16142363, 15863139,resistance 14654915, 15981204, 14601052, 16391810, 16391810, 15863139,18071906 CISPLATIN NM_000380 xeroderma pigmentosum, complementationgroup A XPA 15882455 CISPLATIN NM_006297 X-ray repair complementingdefective repair in Chinese XRCC1 15882455 hamster cells 1 CISPLATINNM_021141 X-ray repair complementing defective repair in Chinese XRCC512384553, 18546291 hamster cells 5 (double-strand-break rejoining)CISPLATIN NM_001469 X-ray repair complementing defective repair inChinese XRCC6 18546291 polymorphisms hamster cells 6 CISPLATIN NM_004926zinc finger protein 36, C3H type-like 1 ZFP36L1 15880358 altered byplatin OXALIPLATIN NM_001014431; NM_001014432; NM_005163 v-akt murinethymoma viral oncogene homolog 1 AKT1 18790786, 19147571 OXALIPLATINNM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 16024531 resistanceOXALIPLATIN NM_001191; NM_138578 BCL2-like 1 BCL2L1 16024531 resistanceOXALIPLATIN NM_001012270; NM_001012271; NM_001168 baculoviral IAPrepeat-containing 5 BIRC5 16004971, 16004971, 16024531, altered by19147571 oxaliplatin OXALIPLATIN NM_001237 cyclin A2 CCNA2 15204521altered by oxaliplatin OXALIPLATIN NM_031966 cyclin B1 CCNB1 15204521altered by oxaliplatin OXALIPLATIN NM_053056 cyclin D1 CCND1 19147571OXALIPLATIN NM_001238; NM_057182 cyclin E1 CCNE1 15204521 altered byoxaliplatin OXALIPLATIN NM_001785 cytidine deaminase CDA 18728667OXALIPLATIN NM_001130829; NM_001786; NM_033379 cell division cycle 2, G1to S and G2 to M CDC2 15204521, 16024531 altered by oxaliplatinOXALIPLATIN NM_001798; NM_052827 cyclin-dependent kinase 2 CDK2 15204521altered by oxaliplatin OXALIPLATIN NM_004064 cyclin-dependent kinaseinhibitor 1B (p27, Kip1) CDKN1B 15204521 altered by oxaliplatinOXALIPLATIN NM_001025248; NM_001025249; NM_001948 deoxyuridinetriphosphatase DUT 19015155 OXALIPLATIN NM_005228; NM_201282; NM_201283;epidermal growth factor receptor (erythroblastic EGFR 16098254polymorphism NM_201284 leukemia viral (v-erb-b) oncogene homolog, avian)OXALIPLATIN NM_001983; NM_202001 excision repair cross-complementingrodent repair ERCC1 15655543, 17401013, resistance deficiency,complementation group 1 (includes 18448328, 15213713 overlappingantisense sequence) OXALIPLATIN NM_000400; NM_001130867 excision repaircross-complementing rodent repair ERCC2 15213713, 15655543, 17401013deficiency, complementation group 2 OXALIPLATIN NM_001160030;NM_001160031; NM_002019 fms-related tyrosine kinase 1 (vascularendothelial FLT1 18790786 growth factor/vascular permeability factorreceptor) OXALIPLATIN — — FRAP1 19147571 OXALIPLATIN NM_000852glutathione S-transferase pi 1 GSTP1 15213713, 15655543, 17401013resistance OXALIPLATIN NM_005524 hairy and enhancer of split 1,(Drosophila) HES1 19147571 OXALIPLATIN NM_000634 interleukin 8 receptor,alpha IL8RA 16098254 OXALIPLATIN NM_002745; NM_138957 mitogen-activatedprotein kinase 1 MAPK1 18790786 OXALIPLATIN NM_001040056; NM_001109891;NM_002746 mitogen-activated protein kinase 3 MAPK3 18790786 OXALIPLATINNM_002467 v-myc myelocytomatosis viral oncogene homolog MYC 15204521sensitivity (avian) OXALIPLATIN NM_015331 nicastrin NCSTN 19147571OXALIPLATIN NM_017617 Notch homolog 1, translocation-associated NOTCH119147571 (Drosophila) OXALIPLATIN NM_001024628; NM_001024629; NM_003873neuropilin 1 NRP1 18790786 OXALIPLATIN NM_002632 placental growth factorPGF 18790786 OXALIPLATIN NM_000021; NM_007318 presenilin 1 PSEN119147571 OXALIPLATIN NM_000321 retinoblastoma 1 RB1 15204521 altered byoxaliplatin OXALIPLATIN NM_005980 S100 calcium binding protein P S100P18636193 OXALIPLATIN NM_003109; NM_138473 Sp1 transcription factor SP119015155 OXALIPLATIN NM_005417; NM_198291 v-src sarcoma (Schmidt-RuppinA-2) viral oncogene SRC 18790786 homolog (avian) OXALIPLATIN NM_003286topoisomerase (DNA) I TOP1 18509181 OXALIPLATIN NM_000546; NM_001126112;NM_001126113; tumor protein p53 TP53 19015155 NM_001126114;NM_001126115; NM_001126116; NM_001126117 OXALIPLATIN NM_001113755;NM_001113756; NM_001953 thymidine phosphorylase TYMP 18728667OXALIPLATIN NM_001071 thymidylate synthetase TYMS 15213713, 18448328,19074750 resistance OXALIPLATIN NM_001025366; NM_001025367;NM_001025368; vascular endothelial growth factor A VEGFA 18790786NM_001025369; NM_001025370; NM_001033756; NM_003376 OXALIPLATINNM_005429 vascular endothelial growth factor C VEGFC 18790786 BUSULFANNM_145740 glutathione S-transferase alpha 1 GSTA1 10437668, 10570028,8886613, drug 12429583, 15779864 metabolism BUSULFAN NM_000561;NM_146421 glutathione S-transferase mu 1 GSTM1 15142875, 8886613unrelated BUSULFAN NM_000852 glutathione S-transferase pi 1 GSTP115779864, 8886613 unrelated BUSULFAN NM_002412 O-6-methylguanine-DNAmethyltransferase MGMT 16039682 unrelated BUSULFAN NM_002413 microsomalglutathione S-transferase 2 MGST2 15779864 resistance PROCARBAZINENM_002412 O-6-methylguanine-DNA methyltransferase MGMT 16033832DACARBAZINE NM_001641; NM_080648; NM_080649 APEX nuclease(multifunctional DNA repair enzyme) 1 APEX1 16373707 resistanceDACARBAZINE NM_001012270; NM_001012271; NM_001168 baculoviral IAPrepeat-containing 5 BIRC5 15577328 DACARBAZINE NM_004346; NM_032991caspase 3, apoptosis-related cysteine peptidase CASP3 17410615 deathpathway DACARBAZINE NM_001080124; NM_001080125; NM_001228; caspase 8,apoptosis-related cysteine peptidase CASP8 17410615 NM_033355;NM_033356; NM_033358 DACARBAZINE NM_001775 CD38 molecule CD38 11583285,14669796, 16078447 unrelated DACARBAZINE NM_001781 CD69 molecule CD6914669796, 17973783 unrelated DACARBAZINE NM_000499 cytochrome P450,family 1, subfamily A, polypeptide 1 CYP1A1 11751525 drug activationDACARBAZINE NM_000761 cytochrome P450, family 1, subfamily A,polypeptide 2 CYP1A2 11751525 drug activation DACARBAZINE NM_000799erythropoietin EPO 15743794 resistance DACARBAZINE NM_024013 interferon,alpha 1 IFNA1 11583285, 16078447 therapy DACARBAZINE NM_000605interferon, alpha 2 IFNA2 14669796, 17973783 therapy DACARBAZINENM_000584 interleukin 8 IL8 12939465, 15123733, altered by 15026559,12939465, DTIC 15026559, 15123733, 12939465 DACARBAZINE NM_002198interferon regulatory factor 1 IRF1 17973783 unrelated DACARBAZINENM_005921 mitogen-activated protein kinase kinase kinase 1 MAP3K115123733 DACARBAZINE NM_002745; NM_138957 mitogen-activated proteinkinase 1 MAPK1 15123733 DACARBAZINE NM_001040056; NM_001109891;NM_002746 mitogen-activated protein kinase 3 MAPK3 15123733 DACARBAZINENM_021960; NM_182763 myeloid cell leukemia sequence 1 (BCL2-related)MCL1 12787138 DACARBAZINE NM_002412 O-6-methylguanine-DNAmethyltransferase MGMT 10751609, 12170182, 15870882, resistance 14562026DACARBAZINE NM_002689 polymerase (DNA directed), alpha 2 (70 kD subunit)POLA2 — DACARBAZINE NM_006516 solute carrier family 2 (facilitatedglucose transporter), SLC2A1 17520257 resistance member 1 DACARBAZINENM_003810 tumor necrosis factor (ligand) superfamily, member 10 TNFSF1017410615 therapy DACARBAZINE NM_001025366; NM_001025367; NM_001025368;vascular endothelial growth factor A VEGFA 12939465, 15123733, 15026559,NM_001025369; NM_001025370; 12939465, 15026559, 12939465, NM_001033756;NM_003376 15123733, 15026559, 15123733, 12939465 TEMOZOLOMIDE NM_000029angiotensinogen (serpin peptidase inhibitor, clade A, AGT 11034089resistance member 8) TEMOZOLOMIDE — — AKT — resistance TEMOZOLOMIDENM_004052 BCL2/adenovirus E1B 19 kDa interacting protein 3 BNIP3 —resistance TEMOZOLOMIDE NM_001129889; NM_001922 dopachrome tautomerase(dopachrome delta- DCT 15897911 isomerase, tyrosine-related protein 2)TEMOZOLOMIDE NM_002006 fibroblast growth factor 2 (basic) FGF2 —resistance TEMOZOLOMIDE NM_001145336; NM_001145337; NM_001145339; Mdm2p53 binding protein homolog (mouse) MDM2 — sensitivity NM_001145340;NM_002392; NM_006878; NM_006879; NM_006881; NM_006882 TEMOZOLOMIDENM_002412 O-6-methylguanine-DNA methyltransferase MGMT 15319033,15486188, resistance 15758010, 15814657, 15833865, 16039682, 15865885,16075413 TEMOZOLOMIDE NM_001015052; NM_001015054; NM_002434N-methylpurine-DNA glycosylase MPG 15299078, 15299078, 16024643sensitivity TEMOZOLOMIDE NM_020529 nuclear factor of kappa lightpolypeptide gene NFKBIA 17638900 enhancer in B-cells inhibitor, alphaTEMOZOLOMIDE NM_001618 poly (ADP-ribose) polymerase 1 PARP1 15867241resistance TEMOZOLOMIDE NM_021127phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 17216584unrelated TEMOZOLOMIDE NM_002690 polymerase (DNA directed), beta POLB16024643 resistance TEMOZOLOMIDE NM_007195 polymerase (DNA directed)iota POLI 16024643 unrelated TEMOZOLOMIDE NM_013274 polymerase (DNAdirected), lambda POLL 16024643 unrelated TEMOZOLOMIDE NM_000963prostaglandin-endoperoxide synthase 2 (prostaglandin PTGS2 17638900 G/Hsynthase and cyclooxygenase) TEMOZOLOMIDE NM_001145138; NM_021975 v-relreticuloendotheliosis viral oncogene homolog A RELA 17638900 (avian)TEMOZOLOMIDE NM_000636; NM_001024465; NM_001024466 superoxide dismutase2, mitochondrial SOD2 17638900 TEMOZOLOMIDE NM_198253; NM_198255telomerase reverse transcriptase TERT 18021753 TEMOZOLOMIDE NM_000594tumor necrosis factor (TNF superfamily, member 2) TNF 17638900TEMOZOLOMIDE NM_000546; NM_001126112; NM_001126113; tumor protein p53TP53 17216584 resistance NM_001126114; NM_001126115; NM_001126116;NM_001126117 TEMOZOLOMIDE NM_001167 X-linked inhibitor of apoptosis XIAP17638900 THIOTEPA NM_004322; NM_032989 BCL2-associated agonist of celldeath BAD 10822281 THIOTEPA NM_001188 BCL2-antagonist/killer 1 BAK110822281 THIOTEPA NM_004324; NM_138761; NM_138763; BCL2-associated Xprotein BAX 10822281 NM_138764; NM_138765 THIOTEPA NM_000633; NM_000657B-cell CLL/lymphoma 2 BCL2 10822281 THIOTEPA NM_001191; NM_138578BCL2-like 1 BCL2L1 10822281 THIOTEPA NM_000767 cytochrome P450, family2, subfamily B, polypeptide 6 CYP2B6 15769884 THIOTEPA NM_145740glutathione S-transferase alpha 1 GSTA1 7712478 polymorphism THIOTEPANM_000846 glutathione S-transferase alpha 2 GSTA2 7712478 polymorphismTHIOTEPA NM_000561; NM_146421 glutathione S-transferase mu 1 GSTM17712478 polymorphism THIOTEPA NM_000852 glutathione S-transferase pi 1GSTP1 10334868, 7712478 polymorphism THIOTEPA NM_002412O-6-methylguanine-DNA methyltransferase MGMT 16039682 unrelated THIOTEPANM_002542; NM_016819; NM_016820; 8-oxoguanine DNA glycosylase OGG111431349, 11 NM_016821; NM_016826; NM_016827; NM_016828; NM_016829ECTEINASCIDIN NM_001237 cyclin A2 CCNA2 — 743 ECTEINASCIDIN NM_031966cyclin B1 CCNB1 — 743 ECTEINASCIDIN NM_004701 cyclin B2 CCNB2 — 743ECTEINASCIDIN NM_005225 E2F transcription factor 1 E2F1 — 743 DOCETAXELNM_000927 ATP-binding cassette, sub-family B (MDR/TAP), ABCB1 15239124,15239142 resistance member 1 DOCETAXEL NM_004996; NM_019862; NM_019898;ATP-binding cassette, sub-family C (CFTR/MRP), ABCC1 15239124 resistanceNM_019899; NM_019900 member 1 DOCETAXEL NM_000392 ATP-binding cassette,sub-family C (CFTR/MRP), ABCC2 15849751 resistance member 2 DOCETAXELNM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 — resistance DOCETAXELNM_001191; NM_138578 BCL2-like 1 BCL2L1 16080463 resistance DOCETAXELNM_001012270; NM_001012271; NM_001168 baculoviral IAP repeat-containing5 BIRC5 16224667, 19 resistance DOCETAXEL NM_001211 budding uninhibitedby benzimidazoles 1 homolog beta BUB1B 18691855 (yeast) DOCETAXELNM_004346; NM_032991 caspase 3, apoptosis-related cysteine peptidaseCASP3 15970518 death pathway DOCETAXEL NM_031966 cyclin B1 CCNB1 —DOCETAXEL NM_001127183; NM_001127184; NM_003879 CASP8 and FADD-likeapoptosis regulator CFLAR 16080463 unrelated DOCETAXEL NM_000103;NM_031226 cytochrome P450, family 19, subfamily A, polypeptide 1 CYP19A115623590 DOCETAXEL NM_000104 cytochrome P450, family 1, subfamily B,polypeptide 1 CYP1B1 18187806 drug metabolism DOCETAXEL NM_017460cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A4 15239142drug metabolism DOCETAXEL NM_001005862; NM_004448 v-erb-b2erythroblastic leukemia viral oncogene ERBB2 15567936, 15834928,17010609 unrelated homolog 2, neuro/glioblastoma derived oncogenehomolog (avian) DOCETAXEL NM_000852 glutathione S-transferase pi 1 GSTP115239142 resistance DOCETAXEL NM_001530; NM_181054 hypoxia induciblefactor 1, alpha subunit (basic helix- HIF1A 17498666 altered byloop-helix transcription factor) docetaxel DOCETAXEL NM_001130442;NM_005343; NM_176795 v-Ha-ras Harvey rat sarcoma viral oncogene homologHRAS 15970518 resistance DOCETAXEL NM_000600 interleukin 6 (interferon,beta 2) IL6 15623590 altered by docetaxel DOCETAXEL NM_002358 MAD2mitotic arrest deficient-like 1 (yeast) MAD2L1 18691855 DOCETAXELNM_002745; NM_138957 mitogen-activated protein kinase 1 MAPK1 15970518resistance DOCETAXEL NM_001040056; NM_001109891; NM_002746mitogen-activated protein kinase 3 MAPK3 15970518 resistance DOCETAXELNM_001145336; NM_001145337; NM_001145339; Mdm2 p53 binding proteinhomolog (mouse) MDM2 16080190 NM_001145340; NM_002392; NM_006878;NM_006879; NM_006881; NM_006882 DOCETAXEL NR_022009; NR_022009;NR_022009; Prader-Willi/Angelman region-1 PAR1 16052512 NR_022009;NR_022009; NR_022009; NR_022009 DOCETAXEL NM_001618 poly (ADP-ribose)polymerase 1 PARP1 15970518 altered by docetaxel DOCETAXEL NM_000926progesterone receptor PGR 15623590 DOCETAXEL NM_000941 P450 (cytochrome)oxidoreductase POR 15239142 unrelated DOCETAXEL NM_000963prostaglandin-endoperoxide synthase 2 (prostaglandin PTGS2 15623590resistance G/H synthase and cyclooxygenase) DOCETAXEL NM_002880 v-raf-1murine leukemia viral oncogene homolog 1 RAF1 15970518 unrelatedDOCETAXEL NM_000321 retinoblastoma 1 RB1 15297405 DOCETAXEL NM_005983;NM_032637 S-phase kinase-associated protein 2 (p45) SKP2 18644126unrelated DOCETAXEL NM_000594 tumor necrosis factor (TNF superfamily,member 2) TNF 15623590 DOCETAXEL NM_003842; NM_147187 tumor necrosisfactor receptor superfamily, member TNFRSF10B 17922852 10b DOCETAXELNM_000546; NM_001126112; NM_001126113; tumor protein p53 TP53 15297405,15970518, 15970518, NM_001126114; NM_001126115; 16080190, 16080190,17369602 NM_001126116; NM_001126117 DOCETAXEL NM_178014 tubulin, betaTUBB 15239142, 16080190 target/resistance DOCETAXEL NM_030773 tubulin,beta 1 TUBB1 — target/resistance DOCETAXEL NM_001071 thymidylatesynthetase TYMS 19074750 DOCETAXEL NM_001025366; NM_001025367;NM_001025368; vascular endothelial growth factor A VEGFA 17498666altered by NM_001025369; NM_001025370; docetaxel NM_001033756; NM_003376DOCETAXEL NM_001167 X-linked inhibitor of apoptosis XIAP 19102932PACLITAXEL NM_000927 ATP-binding cassette, sub-family B (MDR/TAP), ABCB110617675, 15239142, 15650019, resistance member 1 15901749, 15990222,15252144, 15990222, 15650019, 16322897, 18433974 PACLITAXEL NM_004996;NM_019862; NM_019898; ATP-binding cassette, sub-family C (CFTR/MRP),ABCC1 15548710 resistance NM_019899; NM_019900 member 1 PACLITAXELNM_000392 ATP-binding cassette, sub-family C (CFTR/MRP), ABCC2 15645438,15849751 resistance member 2 PACLITAXEL NM_001130846; NM_001130847;NM_004208; apoptosis-inducing factor, mitochondrion-associated, 1 AIFM116168113 death pathway NM_145812; NM_145813 PACLITAXEL NM_001354;NM_205845 aldo-keto reductase family 1, member C2 (dihydrodiol AKR1C216322897 unrelated dehydrogenase 2; bile acid binding protein; 3-alphahydroxysteroid dehydrogenase, type III) PACLITAXEL NM_001014431;NM_001014432; NM_005163 v-akt murine thymoma viral oncogene homolog 1AKT1 16211241, 16782806, 18071906 resistance PACLITAXEL NM_001626 v-aktmurine thymoma viral oncogene homolog 2 AKT2 18071906 resistancePACLITAXEL NM_005465; NM_181690 v-akt murine thymoma viral oncogenehomolog 3 AKT3 18071906 resistance (protein kinase B, gamma) PACLITAXELNM_001144 autocrine motility factor receptor AMFR 16896004 PACLITAXELNM_001160; NM_013229; NM_181861; apoptotic peptidase activating factor 1APAF1 14749477 death pathway NM_181868; NM_181869 PACLITAXEL NM_004312arrestin 3, retinal (X-arrestin) ARR3 16322897 PACLITAXEL NM_018136 asp(abnormal spindle) homolog, microcephaly ASPM 17374387 associated(Drosophila) PACLITAXEL NM_003600; NM_198433; NM_198434; aurora kinase AAURKA 17374387 resistance NM_198435; NM_198436; NM_198437 PACLITAXELNM_004322; NM_032989 BCL2-associated agonist of cell death BAD 10822281,16413505 death pathway PACLITAXEL NM_001188 BCL2-antagonist/killer 1BAK1 10822281 PACLITAXEL NM_004324; NM_138761; NM_138763;BCL2-associated X protein BAX 10822281, 16051289, 16168113 death pathwayNM_138764; NM_138765 PACLITAXEL NM_033028 Bardet-Biedl syndrome 4 BBS416896004 PACLITAXEL NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL210822281, 12086014, 16168113, resistance 16243823, 16275990, 16322897PACLITAXEL NM_001191; NM_138578 BCL2-like 1 BCL2L1 10822281, 14749477,16051289, resistance 16243823, 16275990, 11468182, 16080463 PACLITAXELNM_003766 beclin 1, autophagy related BECN1 16896004 PACLITAXELNM_001196; NM_197966; NM_197967 BH3 interacting domain death agonist BID14749477 unrelated PACLITAXEL NM_001166 baculoviral IAPrepeat-containing 2 BIRC2 14749477, 16243823 unrelated PACLITAXELNM_001165; NM_182962 baculoviral IAP repeat-containing 3 BIRC3 14749477,16243823 resistance PACLITAXEL NM_001012270; NM_001012271; NM_001168baculoviral IAP repeat-containing 5 BIRC5 14749477, 15970709, 16170024,resistance 16202317, 16211241, 16373717 PACLITAXEL NM_001719 bonemorphogenetic protein 7 BMP7 16322897 PACLITAXEL NM_001130914; NM_006806BTG family, member 3 BTG3 16896004 PACLITAXEL NM_001211 buddinguninhibited by benzimidazoles 1 homolog beta BUB1B 18691855 resistance(yeast) PACLITAXEL — — C7ORF23 15556294 PACLITAXEL NM_001218; NM_206925carbonic anhydrase XII CA12 16896004 unrelated PACLITAXEL NM_001033952;NM_001033953; NM_001741 calcitonin-related polypeptide alpha CALCA16222118 PACLITAXEL NM_004346; NM_032991 caspase 3, apoptosis-relatedcysteine peptidase CASP3 10822281, 12086014, 16051289, death pathway16168113, 16170024, 16413505, 18071906 PACLITAXEL NM_001227; NM_033338;NM_033339; caspase 7, apoptosis-related cysteine peptidase CASP714749477, 16168113 death pathway NM_033340 PACLITAXEL NM_001080124;NM_001080125; NM_001228; caspase 8, apoptosis-related cysteine peptidaseCASP8 14749477, 16051289, 16168113, death pathway NM_033355; NM_033356;NM_033358 18071906 PACLITAXEL NM_001229; NM_032996 caspase 9,apoptosis-related cysteine peptidase CASP9 14749477, 16168113, 16170024death pathway PACLITAXEL NM_001753 caveolin 1, caveolae protein, 22 kDaCAV1 16322897 altered by paclitaxel PACLITAXEL NM_031966 cyclin B1 CCNB116356831 sensitivity/ resistance PACLITAXEL NM_053056 cyclin D1 CCND116243823 sensitivity/ unrelated PACLITAXEL NM_002389; NM_153826;NM_172350; CD46 molecule, complement regulatory protein CD46 16322897NM_172351; NM_172352; NM_172353; NM_172354; NM_172355; NM_172356;NM_172357; NM_172358; NM_172359; NM_172360; NM_172361 PACLITAXELNM_001025079; NM_001777; NM_198793 CD47 molecule CD47 16322897PACLITAXEL NM_001785 cytidine deaminase CDA 18728667 PACLITAXELNM_000389; NM_078467 cyclin-dependent kinase inhibitor 1A (p21, Cip1)CDKN1A 16168113, 16413505 sensitivity PACLITAXEL NM_001127183;NM_001127184; NM_003879 CASP8 and FADD-like apoptosis regulator CFLAR16080463 resistance PACLITAXEL NM_001831; NM_203339 clusterin CLU16308731, 16 resistance PACLITAXEL NM_006565 CCCTC-binding factor (zincfinger protein) CTCF 16322897 PACLITAXEL NM_001332 catenin(cadherin-associated protein), delta 2 (neural CTNND2 16896004plakophilin-related arm-repeat protein) PACLITAXEL NM_001912; NM_145918cathepsin L1 CTSL1 16322897 PACLITAXEL NM_001008540; NM_003467 chemokine(C—X—C motif) receptor 4 CXCR4 16322897 PACLITAXEL NM_006564 chemokine(C—X—C motif) receptor 6 CXCR6 16322897 PACLITAXEL NM_020311 chemokine(C—X—C motif) receptor 7 CXCR7 16322897 PACLITAXEL NM_018947 cytochromec, somatic CYCS 14749477, 16051289, 16413505 death pathway PACLITAXELNM_000103; NM_031226 cytochrome P450, family 19, subfamily A,polypeptide 1 CYP19A1 14691014 PACLITAXEL NM_000767 cytochrome P450,family 2, subfamily B, polypeptide 6 CYP2B6 14977870 PACLITAXELNM_000770 cytochrome P450, family 2, subfamily C, polypeptide 8 CYP2C812464242, 12401345, 16124035, drug 15239142, 15933212, 15901749metabolism PACLITAXEL NM_017460 cytochrome P450, family 3, subfamily A,polypeptide 4 CYP3A4 12065438, 15650019, 15901749 drug metabolismPACLITAXEL NM_019887; NM_138929 diablo homolog (Drosophila) DIABLO14749477 sensitivity PACLITAXEL NM_000110 dihydropyrimidinedehydrogenase DPYD 18506536, 18630517 PACLITAXEL NM_001949 E2Ftranscription factor 3 E2F3 16896004 PACLITAXEL NM_005228; NM_201282;NM_201283; epidermal growth factor receptor (erythroblastic EGFR15723263, 16211241, 16413505 resistance NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) PACLITAXEL NM_001042599; NM_005235v-erb-a erythroblastic leukemia viral oncogene ERBB4 16896004 homolog 4(avian) PACLITAXEL NM_000043; NM_152871; NM_152872; Fas (TNF receptorsuperfamily, member 6) FAS 16051289 sensitivity NM_152873; NM_152874;NM_152875; NM_152876; NM_152877 PACLITAXEL NM_000639 Fas ligand (TNFsuperfamily, member 6) FASLG 16051289 sensitivity PACLITAXELNM_001135821; NM_001135822; NM_002004 farnesyl diphosphate synthase(farnesyl FDPS 16322897 pyrophosphate synthetase,dimethylallyltranstransferase, geranyltranstransferase) PACLITAXELNM_002032 ferritin, heavy polypeptide 1 FTH1 16322897 PACLITAXELNM_000146 ferritin, light polypeptide FTL 16322897 PACLITAXEL NM_002569furin (paired basic amino acid cleaving enzyme) FURIN 16322897PACLITAXEL NM_001136007; NM_001136008; NM_001136009; FXYD domaincontaining ion transport regulator 3 FXYD3 16322897 NM_001136010;NM_001136011; NM_001136012; NM_005971; NM_021910 PACLITAXEL NM_001924growth arrest and DNA-damage-inducible, alpha GADD45A 16322897sensitivity PACLITAXEL NM_000156; NM_138924 guanidinoacetateN-methyltransferase GAMT 16896004 PACLITAXEL NM_001145453; NM_005264;NM_145793 GDNF family receptor alpha 1 GFRA1 16896004 PACLITAXELNM_000561; NM_146421 glutathione S-transferase mu 1 GSTM1 12851839resistance PACLITAXEL NM_000851 glutathione S-transferase mu 5 GSTM516322897 resistance PACLITAXEL NM_000852 glutathione S-transferase pi 1GSTP1 15239142 resistance PACLITAXEL NM_000853 glutathione S-transferasetheta 1 GSTT1 12851839 resistance PACLITAXEL NM_001530; NM_181054hypoxia inducible factor 1, alpha subunit (basic helix- HIF1A 17498666loop-helix transcription factor) PACLITAXEL NM_000201 intercellularadhesion molecule 1 ICAM1 16243823 altered by paclitaxel PACLITAXELNM_006332 interferon, gamma-inducible protein 30 IFI30 16322897PACLITAXEL NM_000875 insulin-like growth factor 1 receptor IGF1R15499378 PACLITAXEL NM_001552 insulin-like growth factor binding protein4 IGFBP4 16896004 PACLITAXEL NM_002213 integrin, beta 5 ITGB5 16322897PACLITAXEL — — JMJD2B 16896004 PACLITAXEL NM_002228 jun oncogene JUN15585644 altered by paclitaxel PACLITAXEL NM_020853 KIAA1467 KIAA146716896004 PACLITAXEL NM_007054 kinesin family member 3A KIF3A 16896004PACLITAXEL NM_002274; NM_153490 keratin 13 KRT13 16322897 PACLITAXELNM_002358 MAD2 mitotic arrest deficient-like 1 (yeast) MAD2L1 18691855PACLITAXEL NM_002745; NM_138957 mitogen-activated protein kinase 1 MAPK116051289, 16211241, 16413505 PACLITAXEL NM_001315; NM_139012; NM_139013;mitogen-activated protein kinase 14 MAPK14 16051289 death pathwayNM_139014 PACLITAXEL NM_001040056; NM_001109891; NM_002746mitogen-activated protein kinase 3 MAPK3 16051289, 16211241, 16413505PACLITAXEL NM_002750; NM_139046; NM_139047; mitogen-activated proteinkinase 8 MAPK8 16051289 death pathway NM_139049 PACLITAXEL NM_001135044;NM_002752; NM_139068; mitogen-activated protein kinase 9 MAPK9 16051289death pathway NM_139069; NM_139070 PACLITAXEL NM_001123066;NM_001123067; NM_005910; microtubule-associated protein tau MAPT16896004 resistance NM_016834; NM_016835; NM_016841 PACLITAXELNM_021960; NM_182763 myeloid cell leukemia sequence 1 (BCL2-related)MCL1 14749477 resistance PACLITAXEL NM_001145336; NM_001145337;NM_001145339; Mdm2 p53 binding protein homolog (mouse) MDM2 13130078resistance NM_001145340; NM_002392; NM_006878; NM_006879; NM_006881;NM_006882 PACLITAXEL NM_004774 mediator complex subunit 1 MED1 15650019PACLITAXEL NM_015335 mediator complex subunit 13-like MED13L 16896004PACLITAXEL NM_014791 maternal embryonic leucine zipper kinase MELK16896004 PACLITAXEL NM_024042 meteorin, glial cell differentiationregulator METRN 16896004 PACLITAXEL NM_004994 matrix metallopeptidase 9(gelatinase B, 92 kDa MMP9 16243823 gelatinase, 92 kDa type IVcollagenase) PACLITAXEL NM_175617 metallothionein 1E MT1E 16322897unrelated PACLITAXEL NM_005953 metallothionein 2A MT2A 16322897unrelated PACLITAXEL NM_002467 v-myc myelocytomatosis viral oncogenehomolog MYC 16243823, 18802399 death pathway (avian) PACLITAXELNM_000662 N-acetyltransferase 1 (arylamine N-acetyltransferase) NAT115015580, 17564303 altered by paclitaxel PACLITAXEL NM_006534; NM_181659nuclear receptor coactivator 3 NCOA3 15650019 PACLITAXEL NM_003998nuclear factor of kappa light polypeptide gene NFKB1 16243823 altered byenhancer in B-cells 1 paclitaxel PACLITAXEL NM_020529 nuclear factor ofkappa light polypeptide gene NFKBIA 16243823 sensitivity enhancer inB-cells inhibitor, alpha PACLITAXEL NM_024522 Na+/K+ transporting ATPaseinteracting 1 NKAIN1 16896004 PACLITAXEL NM_003889; NM_022002; NM_033013nuclear receptor subfamily 1, group I, member 2 NR1I2 14977870,15864135, 15650019, resistance 15650019, 12065438, 15864135 PACLITAXELNM_001618 poly (ADP-ribose) polymerase 1 PARP1 14749477, 15585644,altered by 18071906, 15585644 paclitaxel PACLITAXEL NM_002613; NM_0312683-phosphoinositide dependent protein kinase-1 PDPK1 16782806 resistancePACLITAXEL NM_000304; NM_153321; NM_153322 peripheral myelin protein 22PMP22 16322897 PACLITAXEL NM_000941 P450 (cytochrome) oxidoreductase POR15239142 unrelated PACLITAXEL NM_003981; NM_199413; NM_199414 proteinregulator of cytokinesis 1 PRC1 17374387 PACLITAXEL NM_000314phosphatase and tensin homolog PTEN 11707646, 15548710 resistance/mutation PACLITAXEL NM_000963 prostaglandin-endoperoxide synthase 2(prostaglandin PTGS2 16127422, 16243823, 16831230 sensitivity/ G/Hsynthase and cyclooxygenase) resistance PACLITAXEL NM_005855 receptor (Gprotein-coupled) activity modifying protein 1 RAMP1 16896004 PACLITAXELNM_000321 retinoblastoma 1 RB1 15138593 altered by paclitaxel PACLITAXELNM_005611 retinoblastoma-like 2 (p130) RBL2 15585644 unrelatedPACLITAXEL NM_001145138; NM_021975 v-rel reticuloendotheliosis viraloncogene homolog A RELA 15291876, 16243823 resistance (avian) PACLITAXELNM_000449; NM_001025603 regulatory factor X, 5 (influences HLA class IIRFX5 16322897 expression) PACLITAXEL NM_000984 ribosomal protein L23aRPL23A 16322897 PACLITAXEL NM_001003; NM_213725 ribosomal protein,large, P1 RPLP1 16322897 PACLITAXEL NM_001034 ribonucleotide reductaseM2 polypeptide RRM2 16896004 PACLITAXEL NM_001015055; NM_001015056;NM_033046 rhotekin RTKN 15480428 PACLITAXEL NM_005980 S100 calciumbinding protein P S100P 16322897, 18636193 sensitivity PACLITAXELNM_020974 signal peptide, CUB domain, EGF-like 2 SCUBE2 16896004PACLITAXEL NM_003130; NM_198901 sorcin SRI 18423116 PACLITAXELNM_198253; NM_198255 telomerase reverse transcriptase TERT 18021753PACLITAXEL NM_003225 trefoil factor 1 TFF1 16322897 PACLITAXEL NM_018271threonine synthase-like 2 (S. cerevisiae) THNSL2 16896004 PACLITAXELNM_003842; NM_147187 tumor necrosis factor receptor superfamily, memberTNFRSF10B 17922852 altered by 10b paclitaxel PACLITAXEL NM_001067topoisomerase (DNA) II alpha 170 kDa TOP2A 16322897 altered bypaclitaxel PACLITAXEL NM_000546; NM_001126112; NM_001126113; tumorprotein p53 TP53 15990222, 15990222, 12082016, unrelated NM_001126114;NM_001126115; 16168113, 16413505 NM_001126116; NM_001126117 PACLITAXELNM_178014 tubulin, beta TUBB 15239142 target/resistance PACLITAXELNM_030773 tubulin, beta 1 TUBB1 — target ? PACLITAXEL NM_001113755;NM_001113756; NM_001953 thymidine phosphorylase TYMP 18506536, 18630517PACLITAXEL NM_001071 thymidylate synthetase TYMS 10482907, 16168113,18630517 unrelated PACLITAXEL NM_001025366; NM_001025367; NM_001025368;vascular endothelial growth factor A VEGFA 16243823, 17498666NM_001025369; NM_001025370; NM_001033756; NM_003376 PACLITAXEL NM_001167X-linked inhibitor of apoptosis XIAP 16243823, 16356831, 18071906resistance PACLITAXEL NM_024762 zinc finger protein 552 ZNF552 16896004VINBLASTINE NM_000927 ATP-binding cassette, sub-family B (MDR/TAP),ABCB1 11355955, 8917702, 15725475, resistance member 1 15466210,15640379, 15824923, 16221533 VINBLASTINE NM_004996; NM_019862;NM_019898; ATP-binding cassette, sub-family C (CFTR/MRP), ABCC1 16156793resistance NM_019899; NM_019900 member 1 VINBLASTINE NM_000392ATP-binding cassette, sub-family C (CFTR/MRP), ABCC2 15849751, 9525973,15849751 resistance member 2 VINBLASTINE NM_032982; NM_032983 caspase 2,apoptosis-related cysteine peptidase CASP2 14757846 VINBLASTINENM_001556 inhibitor of kappa light polypeptide gene enhancer in B- IKBKB17029595 altered by VB cells, kinase beta VINBLASTINE NM_002228 junoncogene JUN 12221076 resistance VINBLASTINE NM_002750; NM_139046;NM_139047; mitogen-activated protein kinase 8 MAPK8 12221076 deathpathway NM_139049 VINBLASTINE NM_001135044; NM_002752; NM_139068;mitogen-activated protein kinase 9 MAPK9 12221076 death pathwayNM_139069; NM_139070 VINBLASTINE NM_002467 v-myc myelocytomatosis viraloncogene homolog MYC 18802399 (avian) VINBLASTINE NM_001136022;NM_004554 nuclear factor of activated T-cells, cytoplasmic, NFATC417044076 calcineurin-dependent 4 VINBLASTINE NM_020529 nuclear factor ofkappa light polypeptide gene NFKBIA 17029595 enhancer in B-cellsinhibitor, alpha VINBLASTINE NM_006788 ralA binding protein 1 RALBP1 —resistance VINBLASTINE NM_003842; NM_147187 tumor necrosis factorreceptor superfamily, member TNFRSF10B 17922852 10b VINBLASTINENM_000546; NM_001126112; NM_001126113; tumor protein p53 TP53 12221076NM_001126114; NM_001126115; NM_001126116; NM_001126117 VINBLASTINENM_001069 tubulin, beta 2A TUBB2A — unrelated VINCRISTINE NM_000927ATP-binding cassette, sub-family B (MDR/TAP), ABCB1 10617675, 11934808,resistance member 1 15239124, 16038730, 15645438, 16925584 VINCRISTINENM_004996; NM_019862; NM_019898; ATP-binding cassette, sub-family C(CFTR/MRP), ABCC1 10900222, 15581632, 15896345, resistance NM_019899;NM_019900 member 1 16042792, 15896345, 10900222, 15044619, 12067707VINCRISTINE NM_000392 ATP-binding cassette, sub-family C (CFTR/MRP),ABCC2 15896345 resistance member 2 VINCRISTINE NM_001014431;NM_001014432; NM_005163 v-akt murine thymoma viral oncogene homolog 1AKT1 16740780 resistance VINCRISTINE NM_001160; NM_013229; NM_181861;apoptotic peptidase activating factor 1 APAF1 16001973 death pathwayNM_181868; NM_181869 VINCRISTINE NM_000039 apolipoprotein A-I APOA116001973 VINCRISTINE NM_018136 asp (abnormal spindle) homolog,microcephaly ASPM 17374387 associated (Drosophila) VINCRISTINENM_003600; NM_198433; NM_198434; aurora kinase A AURKA 17374387resistance NM_198435; NM_198436; NM_198437 VINCRISTINE NM_004322;NM_032989 BCL2-associated agonist of cell death BAD 16001973 deathpathway VINCRISTINE NM_004324; NM_138761; NM_138763; BCL2-associated Xprotein BAX 16001973 death pathway NM_138764; NM_138765 VINCRISTINENM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 16001973 resistanceVINCRISTINE NM_001223; NM_033292; NM_033293; caspase 1,apoptosis-related cysteine peptidase CASP1 16001973 NM_033294; NM_033295(interleukin 1, beta, convertase) VINCRISTINE NM_001230; NM_032974;NM_032977 caspase 10, apoptosis-related cysteine peptidase CASP1016001973 VINCRISTINE NM_032982; NM_032983 caspase 2, apoptosis-relatedcysteine peptidase CASP2 16001973 death pathway VINCRISTINE NM_004346;NM_032991 caspase 3, apoptosis-related cysteine peptidase CASP3 16001973death pathway VINCRISTINE NM_001225; NM_033306 caspase 4,apoptosis-related cysteine peptidase CASP4 16001973 VINCRISTINENM_001136109; NM_001136110; NM_001136111; caspase 5, apoptosis-relatedcysteine peptidase CASP5 16001973 NM_001136112; NM_004347 VINCRISTINENM_001226; NM_032992 caspase 6, apoptosis-related cysteine peptidaseCASP6 16001973 death pathway VINCRISTINE NM_001227; NM_033338;NM_033339; caspase 7, apoptosis-related cysteine peptidase CASP716001973 death pathway NM_033340 VINCRISTINE NM_001080124; NM_001080125;NM_001228; caspase 8, apoptosis-related cysteine peptidase CASP816001973 death pathway NM_033355; NM_033356; NM_033358 VINCRISTINENM_001229; NM_032996 caspase 9, apoptosis-related cysteine peptidaseCASP9 16001973 death pathway VINCRISTINE NM_001752 catalase CAT 11178967VINCRISTINE NM_005194 CCAAT/enhancer binding protein (C/EBP), beta CEBPB16001973 VINCRISTINE NM_001025194; NM_001025195; NM_001266carboxylesterase 1 (monocyte/macrophage serine CES1 16001973 esterase 1)VINCRISTINE NM_000492 cystic fibrosis transmembrane conductanceregulator CFTR 16038730 (ATP-binding cassette sub-family C, member 7)VINCRISTINE NM_020313 cytokine induced apoptosis inhibitor 1 CIAPIN118389626 VINCRISTINE NM_001916 cytochrome c-1 CYC1 16001973 deathpathway VINCRISTINE NM_005225 E2F transcription factor 1 E2F1 16001973VINCRISTINE NM_005228; NM_201282; NM_201283; epidermal growth factorreceptor (erythroblastic EGFR 16001973 NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) VINCRISTINE NM_003824 Fas(TNFRSF6)-associated via death domain FADD 16001973 VINCRISTINENM_012306 Fas apoptotic inhibitory molecule 2 FAIM2 16001973 VINCRISTINENM_002046 glyceraldehyde-3-phosphate dehydrogenase GAPDH 16001973VINCRISTINE NM_001498 glutamate-cysteine ligase, catalytic subunit GCLC10900222 VINCRISTINE NM_002061 glutamate-cysteine ligase, modifiersubunit GCLM 10900222 VINCRISTINE NM_000561; NM_146421 glutathioneS-transferase mu 1 GSTM1 15044619, 15713801 resistance VINCRISTINENM_000852 glutathione S-transferase pi 1 GSTP1 10900222 VINCRISTINENM_016315 GULP, engulfment adaptor PTB domain containing 1 GULP116001973 VINCRISTINE NM_001130442; NM_005343; NM_176795 v-Ha-ras Harveyrat sarcoma viral oncogene homolog HRAS 16001973 resistance VINCRISTINENM_000415 islet amyloid polypeptide IAPP 16001973 VINCRISTINE NM_000618;NM_001111283; NM_001111284; insulin-like growth factor 1 (somatomedin C)IGF1 16740780 NM_001111285 VINCRISTINE NM_000875 insulin-like growthfactor 1 receptor IGF1R 16001973 resistance VINCRISTINE NM_000600interleukin 6 (interferon, beta 2) IL6 16001973 unrelated VINCRISTINENM_005572; NM_170707; NM_170708 lamin A/C LMNA 16001973 VINCRISTINENM_005573 lamin B1 LMNB1 16001973 resistance VINCRISTINE NM_003010mitogen-activated protein kinase kinase 4 MAP2K4 16001973 altered byvincristine VINCRISTINE NM_003188; NM_145331; NM_145332;mitogen-activated protein kinase kinase kinase 7 MAP3K7 16001973NM_145333 VINCRISTINE NM_002745; NM_138957 mitogen-activated proteinkinase 1 MAPK1 16001973 VINCRISTINE NM_001145336; NM_001145337;NM_001145339; Mdm2 p53 binding protein homolog (mouse) MDM2 16001973NM_001145340; NM_002392; NM_006878; NM_006879; NM_006881; NM_006882VINCRISTINE NM_001130926; NM_001130927; NM_001130928; myocyte enhancerfactor 2A MEF2A 16001973 NM_005587 VINCRISTINE NM_002412O-6-methylguanine-DNA methyltransferase MGMT 16033832 VINCRISTINENM_002467 v-myc myelocytomatosis viral oncogene homolog MYC 16001973(avian) VINCRISTINE NM_003998 nuclear factor of kappa light polypeptidegene NFKB1 15744361, 16001973 resistance enhancer in B-cells 1VINCRISTINE NM_006025 26 serine protease P11 16001973 VINCRISTINE — —PCAF 16001973 VINCRISTINE NM_003981; NM_199413; NM_199414 proteinregulator of cytokinesis 1 PRC1 17374387 VINCRISTINE NM_000311;NM_001080121; NM_001080122; prion protein PRNP 15386405 NM_001080123;NM_183079 VINCRISTINE NM_000963 prostaglandin-endoperoxide synthase 2(prostaglandin PTGS2 18695918 G/H synthase and cyclooxygenase)VINCRISTINE NM_004103; NM_173174; NM_173175; PTK2B protein tyrosinekinase 2 beta PTK2B 11478917 NM_173176 VINCRISTINE NM_006264; NM_080683;NM_080684; protein tyrosine phosphatase, non-receptor type 13 PTPN1316001973 NM_080685 (APO-1/CD95 (Fas)-associated phosphatase) VINCRISTINENM_006788 ralA binding protein 1 RALBP1 — VINCRISTINE NM_000965;NM_016152 retinoic acid receptor, beta RARB 17608728 VINCRISTINENM_001145547; NM_032905 RNA binding motif protein 17 RBM17 16061639resistance VINCRISTINE NM_001145138; NM_021975 v-relreticuloendotheliosis viral oncogene homolog A RELA 15744361 resistance(avian) VINCRISTINE NM_002944 c-ros oncogene 1, receptor tyrosine kinaseROS1 16001973 VINCRISTINE NM_001031680; NM_004350 runt-relatedtranscription factor 3 RUNX3 15756676 VINCRISTINE NM_006516 solutecarrier family 2 (facilitated glucose transporter), SLC2A1 17520257member 1 VINCRISTINE NM_005633 son of sevenless homolog 1 (Drosophila)SOS1 16001973 VINCRISTINE NM_003130; NM_198901 sorcin SRI 18423116VINCRISTINE NM_007315; NM_139266 signal transducer and activator oftranscription 1, STAT1 16001973 91 kDa VINCRISTINE NM_005419 signaltransducer and activator of transcription 2, STAT2 16001973 113 kDaVINCRISTINE NM_003150; NM_139276; NM_213662 signal transducer andactivator of transcription 3 STAT3 16001973 (acute-phase responsefactor) VINCRISTINE NM_000594 tumor necrosis factor (TNF superfamily,member 2) TNF 16001973 synergistic effects VINCRISTINE NM_000546;NM_001126112; NM_001126113; tumor protein p53 TP53 12082016, 16001973,17555331 NM_001126114; NM_001126115; NM_001126116; NM_001126117VINCRISTINE NM_000365; NM_001159287 triosephosphate isomerase 1 TPI118309519 VINCRISTINE NM_001069 tubulin, beta 2A TUBB2A — target?VINCRISTINE NM_001071 thymidylate synthetase TYMS 15713801 VINCRISTINENM_000376; NM_001017535 vitamin D (1,25-dihydroxyvitamin D3) receptorVDR 15713801 VINCRISTINE NM_001079539; NM_005080 X-box binding protein 1XBP1 17353921 VINFLUNINE NM_030773 tubulin, beta 1 TUBB1 — targetVINDESINE NM_030773 tubulin, beta 1 TUBB1 — target VINORELBINE NM_006788ralA binding protein 1 RALBP1 — resistance VINORELBINE NM_001145547;NM_032905 RNA binding motif protein 17 RBM17 16061639 resistanceVINORELBINE NM_001078174; NM_001078175; NM_001078176; solute carrierfamily 29 (nucleoside transporters), SLC29A1 18452103 resistanceNM_001078177; NM_004955 member 1 VINORELBINE NM_001069 tubulin, beta 2ATUBB2A — target EPOTHILONES NM_004324; NM_138761; NM_138763;BCL2-associated X protein BAX 12517783 death pathway NM_138764;NM_138765 EPOTHILONES NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL212517783 resistance EPOTHILONES NM_001191; NM_138578 BCL2-like 1 BCL2L112517783 EPOTHILONES NM_001165; NM_182962 baculoviral IAPrepeat-containing 3 BIRC3 12517783 altered by epothilone EPOTHILONESNM_021960; NM_182763 myeloid cell leukemia sequence 1 (BCL2-related)MCL1 12517783 altered by epothilone EPOTHILONES — — TUBA1 — EPOTHILONES— — TUBA2 — EPOTHILONES — — TUBA3 — EPOTHILONES — — TUBA6 — EPOTHILONESNM_018943 tubulin, alpha 8 TUBA8 — EPOTHILONES NM_030773 tubulin, beta 1TUBB1 — target? EPOTHILONES NM_001069 tubulin, beta 2A TUBB2A — target?EPOTHILONES NM_006088 tubulin, beta 2C TUBB2C — target? EPOTHILONESNM_006086 tubulin, beta 3 TUBB3 — target? EPOTHILONES NM_006087 tubulin,beta 4 TUBB4 — target? EPOTHILONES NM_020040 tubulin, beta polypeptide4, member Q TUBB4Q — target? EPOTHILONES NM_001167 X-linked inhibitor ofapoptosis XIAP 12517783 altered by epothilone DOXORUBICIN NM_000927ATP-binding cassette, sub-family B (MDR/TAP), ABCB1 11355955, 15765123,11313874, resistance member 1 17947497, (following) (following) 8917702,15725475, 15861398, 15239142, 15501994, 15501994, 16579640, 15501994,17526808, 15736412, 15861398, 15946544, 15967469, 16223781, 16322897,16044152, 15765123, 16356834, 16499877, 16544145, 16544145, 18510171,18560228, 17852453, 16579640, 17085340, 17483874, 8917702, 17526808,17947497, 17947497, 17526808, 18461970, 8917702 DOXORUBICIN — — ABCB1A15695394 resistance DOXORUBICIN NM_000443; NM_018849; NM_018850ATP-binding cassette, sub-family B (MDR/TAP), ABCB4 11313874, 12926078,16579640 resistance member 4 DOXORUBICIN NM_178559 ATP-binding cassette,sub-family B (MDR/TAP), ABCB5 15899824 resistance member 5 DOXORUBICINNM_004996; NM_019862; NM_019898; ATP-binding cassette, sub-family C(CFTR/MRP), ABCC1 11560771, 12504668, 15473893, resistance NM_019899;NM_019900 member 1 15473893, 12067707, 11560771, 10900222, 12657726,17940500, 15548710, 15581632, 15880572, 15946544, 16331495, 17352253,17852453, 18560228, 17940500 DOXORUBICIN NM_001144070; NM_003786ATP-binding cassette, sub-family C (CFTR/MRP), ABCC3 15695394, 15884115,15901850, resistance member 3 18463201 DOXORUBICIN NM_004827 ATP-bindingcassette, sub-family G (WHITE), member 2 ABCG2 17273774, 17938326,18382425 resistance DOXORUBICIN NM_023038; NM_033274 ADAMmetallopeptidase domain 19 (meltrin beta) ADAM19 18510171 DOXORUBICINNM_007038 ADAM metallopeptidase with thrombospondin type 1 ADAMTS516404146 motif, 5 DOXORUBICIN NM_000687; NM_001161766adenosylhomocysteinase AHCY 18510171 DOXORUBICIN NM_001130846;NM_001130847; NM_004208; apoptosis-inducing factor,mitochondrion-associated, 1 AIFM1 16168113 NM_145812; NM_145813DOXORUBICIN NM_006066; NM_153326 aldo-keto reductase family 1, member A1(aldehyde AKR1A1 18322072 drug reductase) metabolism DOXORUBICINNM_001354; NM_205845 aldo-keto reductase family 1, member C2(dihydrodiol AKR1C2 18322072 dehydrogenase 2; bile acid binding protein;3-alpha hydroxysteroid dehydrogenase, type III) DOXORUBICIN NM_003739aldo-keto reductase family 1, member C3 (3-alpha AKR1C3 18635746 drughydroxysteroid dehydrogenase, type II) metabolism DOXORUBICINNM_001014431; NM_001014432; NM_005163 v-akt murine thymoma viraloncogene homolog 1 AKT1 15494689, 16168102, 17359293, resistance16059641, 16168102, 16438844, 16740780, 16782806, 17339365, 17359293,17935137, 17935137, 16168102, 18071906 DOXORUBICIN NM_001626 v-aktmurine thymoma viral oncogene homolog 2 AKT2 18071906 resistanceDOXORUBICIN NM_005465; NM_181690 v-akt murine thymoma viral oncogenehomolog 3 AKT3 18071906 resistance (protein kinase B, gamma) DOXORUBICINNM_000477 albumin ALB 17378599, 17378599, 16211657 used as drug carrierDOXORUBICIN NM_001144 autocrine motility factor receptor AMFR 16896004DOXORUBICIN NM_001146 angiopoietin 1 ANGPT1 15763944 resistanceDOXORUBICIN NM_007347 adaptor-related protein complex 4, epsilon 1subunit AP4E1 16044152 DOXORUBICIN NM_001160; NM_013229; NM_181861;apoptotic peptidase activating factor 1 APAF1 15939500, 16001973,15939500 death pathway NM_181868; NM_181869 DOXORUBICIN NM_001142930;NM_001142931; NM_006595 apoptosis inhibitor 5 API5 16322897 DOXORUBICINNM_000039 apolipoprotein A-I APOA1 16001973 DOXORUBICIN NM_000484;NM_001136016; NM_001136129; amyloid beta (A4) precursor protein APP17608641 resistance NM_001136130; NM_001136131; NM_201413; NM_201414DOXORUBICIN NM_004706; NM_198977; NM_199002 Rho guanine nucleotideexchange factor (GEF) 1 ARHGEF1 16404146 DOXORUBICIN NM_014786 Rhoguanine nucleotide exchange factor (GEF) 17 ARHGEF17 16404146DOXORUBICIN NM_006407 ADP-ribosylation-like factor 6 interacting protein5 ARL6IP5 16430862 DOXORUBICIN NM_001675; NM_182810 activatingtranscription factor 4 (tax-responsive ATF4 16298333 enhancer elementB67) DOXORUBICIN NM_000051; NM_138292 ataxia telangiectasia mutated ATM15489221 DOXORUBICIN NM_003945 ATPase, H+ transporting, lysosomal 9 kDa,V0 subunit ATP6V0E1 16579640 e1 DOXORUBICIN NM_001185alpha-2-glycoprotein 1, zinc-binding AZGP1 16404146 DOXORUBICINNM_001497 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, B4GALT116404146 polypeptide 1 DOXORUBICIN NM_001011545; NM_001186; NM_206866BTB and CNC homology 1, basic leucine zipper BACH1 16322897transcription factor 1 DOXORUBICIN NM_004322; NM_032989 BCL2-associatedagonist of cell death BAD 16001973, 16438844, 16705698, 16843435,17359293 DOXORUBICIN NM_004323 BCL2-associated athanogene BAG1 16322899DOXORUBICIN NM_001188 BCL2-antagonist/killer 1 BAK1 11313874, 15917298DOXORUBICIN NM_004324; NM_138761; NM_138763; BCL2-associated X proteinBAX 14601052, 15456408, 15492826, NM_138764; NM_138765 15576332,15939500, 15985719, 16001973, 17404015, 16168113, 16322301, 16705698,17542780, 17959036, 17959036, 17339365, 17542780, 17922852 DOXORUBICINNM_001127240; NM_001127241; NM_001127242; BCL2 binding component 3 BBC316439685 NM_014417 DOXORUBICIN NM_152618 Bardet-Biedl syndrome 12 BBS1216044152 DOXORUBICIN NM_033028 Bardet-Biedl syndrome 4 BBS4 16896004DOXORUBICIN NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 14601052,15897917, 15571967, 15576332, (following) 15939500, 15985719, 16001973,17404015, 18560228, 16168113, 16322301, 17541305, 16450387, 16322899,16705698, 16890185, 17542780, 17959036, 17959036, 17542780, 16890185,18325115 DOXORUBICIN NM_001114735; NM_004049 BCL2-related protein A1BCL2A1 16572199 DOXORUBICIN NM_001191; NM_138578 BCL2-like 1 BCL2L114601052, 15781649, 11468182, 15911101, 15939500, 15939500, 18560228,16843435, 17912235, 17922852, 16843435, 17923112 DOXORUBICIN NM_006538;NM_138621; NM_207002 BCL2-like 11 (apoptosis facilitator) BCL2L1117339365 DOXORUBICIN NM_001040668; NM_138639 BCL2-like 12 (proline rich)BCL2L12 15576332, 17404015 DOXORUBICIN NM_003766 beclin 1, autophagyrelated BECN1 16718815, 16896004 DOXORUBICIN NM_001196; NM_197966;NM_197967 BH3 interacting domain death agonist BID 15812552, 15870702,16705698, 16868541 DOXORUBICIN NM_001197 BCL2-interacting killer(apoptosis-inducing) BIK 16007125, 16705698 DOXORUBICIN NM_001166baculoviral IAP repeat-containing 2 BIRC2 14601052, 14666661, 15359644,15571967, 15571967, 14666661, 17521628 DOXORUBICIN NM_001165; NM_182962baculoviral IAP repeat-containing 3 BIRC3 12926068, 12948851, 15899819,15911101, 16705698, 17521628 DOXORUBICIN NM_001012270; NM_001012271;NM_001168 baculoviral IAP repeat-containing 5 BIRC5 11911975, 16086872,16364925, 16108013, 11911975, 17124180, 16108013, 14601052, 16086872,16086872, 17521628, 16108013, 17124180 DOXORUBICIN NM_016252 baculoviralIAP repeat-containing 6 BIRC6 17521628 DOXORUBICIN NM_022161; NM_139317baculoviral IAP repeat-containing 7 BIRC7 17521628 DOXORUBICIN NM_033341baculoviral IAP repeat-containing 8 BIRC8 17521628 DOXORUBICINNM_007294; NM_007295; NM_007296; breast cancer 1, early onset BRCA110344722 NM_007297; NM_007298; NM_007299; NM_007300; NM_007302;NM_007303; NM_007304; NM_007305 DOXORUBICIN NM_000059 breast cancer 2,early onset BRCA2 10344722 DOXORUBICIN NM_001731 B-cell translocationgene 1, anti-proliferative BTG1 16705698 DOXORUBICIN NM_006763 BTGfamily, member 2 BTG2 16705698 DOXORUBICIN NM_001130914; NM_006806 BTGfamily, member 3 BTG3 16896004 DOXORUBICIN NM_001211 budding uninhibitedby benzimidazoles 1 homolog beta BUB1B 15870702 (yeast) DOXORUBICINNM_001007793; NM_004725 budding uninhibited by benzimidazoles 3 homologBUB3 16322899 (yeast) DOXORUBICIN — — C21ORF87 16044152 DOXORUBICIN — —C5ORF13 16044152 DOXORUBICIN — — C7ORF23 15556294, 15556294, 18510171DOXORUBICIN NM_001218; NM_206925 carbonic anhydrase XII CA12 16896004DOXORUBICIN NM_020247 chaperone, ABC1 activity of bc1 complex CABC116404146 homolog (S. pombe) DOXORUBICIN NM_004342; NM_033138; NM_033139;caldesmon 1 CALD1 16044152 NM_033140; NM_033157 DOXORUBICIN NM_014289calpain 6 CAPN6 16404146 DOXORUBICIN NM_001223; NM_033292; NM_033293;caspase 1, apoptosis-related cysteine peptidase CASP1 16001973NM_033294; NM_033295 (interleukin 1, beta, convertase) DOXORUBICINNM_001230; NM_032974; NM_032977 caspase 10, apoptosis-related cysteinepeptidase CASP10 16001973 DOXORUBICIN NM_032982; NM_032983 caspase 2,apoptosis-related cysteine peptidase CASP2 14757846, 15917298, 16001973,17013758 DOXORUBICIN NM_004346; NM_032991 caspase 3, apoptosis-relatedcysteine peptidase CASP3 15456408, 15557793, 15571967, 15578696,(following) 15812552, 15870702, 15939500, 15981920, 15985719, 15985719,16962673, 17437844, 15456408, 16364925, 17085670, 17088416, 16909308,15680309, 15981920, 19106633, 15571967, 15578696, 16823846, 16843435,15868924, 18508926, 16001973, 15576332, 16705698, 15939500, 16168113,16364925, 16823846, 16843435, 16868541, 16890185, 16909308, 16962673,17013758, 17085670, 17088416, 17285121, 17437844, 17542780, 17935137,17935137, 17542780, 16024631, 18246814, 15897917, 17285121, 16890185,17651020, 17959036, 17959036, 15557793, 18071906, 15555623, 17653088,18246814, 18278454, 18508926, 19106633 DOXORUBICIN NM_001225; NM_033306caspase 4, apoptosis-related cysteine peptidase CASP4 16001973DOXORUBICIN NM_001136109; NM_001136110; NM_001136111; caspase 5,apoptosis-related cysteine peptidase CASP5 16001973 NM_001136112;NM_004347 DOXORUBICIN NM_001226; NM_032992 caspase 6, apoptosis-relatedcysteine peptidase CASP6 15870702, 16001973, 17437844, 17922852,17437844 DOXORUBICIN NM_001227; NM_033338; NM_033339; caspase 7,apoptosis-related cysteine peptidase CASP7 15870702, 16001973, 16705698,NM_033340 16024631, 16168113, 16298333, 17653088, 19106633 DOXORUBICINNM_001080124; NM_001080125; NM_001228; caspase 8, apoptosis-relatedcysteine peptidase CASP8 15812552, 15870702, 15897917, NM_033355;NM_033356; NM_033358 16024631, 15981920, 16001973, 16168113, 16705698,16868541, 17013758, 17437844, 17437844, 18508926, 15868924, 17970047,18071906, 18508926 DOXORUBICIN NM_001229; NM_032996 caspase 9,apoptosis-related cysteine peptidase CASP9 15812552, 15870702, 15939500,15981920, (following) 15981920, 15868924, 18508926, 17437844, 16001973,15576332, 15939500, 16168113, 16311509, 16311509, 15557793, 17935137,17653088, 15555623, 16364925, 16705698, 17013758, 17285121, 17339365,17404015, 17437844, 17651020, 17651020, 17285121, 16024631, 16364925,17935137, 18508926 DOXORUBICIN NM_001757 carbonyl reductase 1 CBR118635746 drug metabolism DOXORUBICIN NM_002982 chemokine (C-C motif)ligand 2 CCL2 12908082 DOXORUBICIN NM_001237 cyclin A2 CCNA2 16036217,16284694, 16537896, 17390037 DOXORUBICIN NM_031966 cyclin B1 CCNB115141020, 16537896, 16928833, 17320279, 17893511 DOXORUBICIN NM_053056cyclin D1 CCND1 16036217 DOXORUBICIN NM_001759 cyclin D2 CCND2 16928833DOXORUBICIN NM_001238; NM_057182 cyclin E1 CCNE1 16036217 DOXORUBICINNM_000610; NM_001001389; NM_001001390; CD44 molecule (Indian bloodgroup) CD44 16705698 NM_001001391; NM_001001392 DOXORUBICINNM_001130829; NM_001786; NM_033379 cell division cycle 2, G1 to S and G2to M CDC2 15870702, 16036217, 16537896, 17320279, 17320279, 15141020DOXORUBICIN NM_001790; NM_022809 cell division cycle 25 homolog C (S.pombe) CDC25C 17320279, 19074854 sensitivity DOXORUBICIN NM_001098533;NM_001160367; NM_052987; cyclin-dependent kinase 10 CDK10 16404146NM_052988 DOXORUBICIN NM_001798; NM_052827 cyclin-dependent kinase 2CDK2 15823547, 16036217 DOXORUBICIN NM_000389; NM_078467cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 14601052,15141020, 15492826, 15601469, (following) 15781256, 15823547, 16168113,16537896, 17974990, 15601469, 15555623, 19074854, 17682292, 17653088,15781256, 16909308, 17079232, 17653088, 16705698, 16439685, 17682292,17893511, 17974990, 18269916, 19074854 DOXORUBICIN NM_004064cyclin-dependent kinase inhibitor 1B (p27, Kip1) CDKN1B 16322899,16705698, 17893511, 16036217, 17935137 DOXORUBICIN NM_000077; NM_058195;NM_058197 cyclin-dependent kinase inhibitor 2A (melanoma, p16, CDKN2A16705698 inhibits CDK4) DOXORUBICIN NM_005194 CCAAT/enhancer bindingprotein (C/EBP), beta CEBPB 16001973 DOXORUBICIN NM_001042426; NM_001809centromere protein A CENPA 15870702 DOXORUBICIN NM_001025194;NM_001025195; NM_001266 carboxylesterase 1 (monocyte/macrophage serineCES1 16001973 esterase 1) DOXORUBICIN NM_001127183; NM_001127184;NM_003879 CASP8 and FADD-like apoptosis regulator CFLAR 14601052, 16DOXORUBICIN NM_000492 cystic fibrosis transmembrane conductanceregulator CFTR 17762173 (ATP-binding cassette sub-family C, member 7)DOXORUBICIN NM_001114121; NM_001114122; NM_001274 CHK1 checkpointhomolog (S. pombe) CHEK1 15489221, 15870702, 16036217, 17085670,17088865, 17088865, 17085670, 17320279, 18698031 DOXORUBICINNM_001005735; NM_007194; NM_145862 CHK2 checkpoint homolog (S. pombe)CHEK2 15489221, 17085670, 17320279 DOXORUBICIN NM_001278 conservedhelix-loop-helix ubiquitous kinase CHUK 18463201 DOXORUBICIN NM_020313cytokine induced apoptosis inhibitor 1 CIAPIN1 18389626 DOXORUBICINNM_013324; NM_145071 cytokine inducible SH2-containing protein CISH16044152 DOXORUBICIN NM_021101 claudin 1 CLDN1 16404146 DOXORUBICINNM_002956; NM_198240 CAP-GLY domain containing linker protein 1 CLIP116404146 DOXORUBICIN NM_001294 cleft lip and palate associatedtransmembrane protein 1 CLPTM1 16243817 DOXORUBICIN NM_001831; NM_203339clusterin CLU 16322897 DOXORUBICIN NM_030582; NM_130444; NM_130445collagen, type XVIII, alpha 1 COL18A1 17627616 DOXORUBICIN — cytochromec oxidase II COX2 16278810 DOXORUBICIN NM_001031847; NM_001876 carnitinepalmitoyltransferase 1A (liver) CPT1A 16283381 DOXORUBICIN NM_001079846;NM_004380 CREB binding protein CREBBP 17498666 DOXORUBICIN NM_001142407;NM_001142408; NM_001142417; cysteine-rich secretory protein 2 CRISP216404146 NM_001142435; NM_003296 DOXORUBICIN NM_000394 crystallin, alphaA CRYAA 16322897 DOXORUBICIN NM_001885 crystallin, alpha B CRYAB16322897 DOXORUBICIN NM_001897 chondroitin sulfate proteoglycan 4 CSPG416404146 DOXORUBICIN NM_001901 connective tissue growth factor CTGF16579640 DOXORUBICIN NM_001012329; NM_020248 catenin, beta interactingprotein 1 CTNNBIP1 16322899 DOXORUBICIN NM_001332 catenin(cadherin-associated protein), delta 2 (neural CTNND2 16896004plakophilin-related arm-repeat protein) DOXORUBICIN NM_001908;NM_147780; NM_147781; cathepsin B CTSB 16705698, 17378599 NM_147782;NM_147783 DOXORUBICIN NM_001909 cathepsin D CTSD 18566016 DOXORUBICINNM_001911 cathepsin G CTSG 16458935 DOXORUBICIN NM_002993 chemokine(C—X—C motif) ligand 6 (granulocyte CXCL6 16404146 chemotactic protein2) DOXORUBICIN NM_001916 cytochrome c-1 CYC1 16001973 DOXORUBICINNM_018947 cytochrome c, somatic CYCS 16001973, 16705698, 16331251,16749863, 16868541 DOXORUBICIN NM_000499 cytochrome P450, family 1,subfamily A, polypeptide 1 CYP1A1 15377855 DOXORUBICIN NM_000785cytochrome P450, family 27, subfamily B, polypeptide 1 CYP27B1 17716971DOXORUBICIN NM_000767 cytochrome P450, family 2, subfamily B,polypeptide 6 CYP2B6 16322899 DOXORUBICIN NM_001141969; NM_001141970;NM_001350 death-domain associated protein DAXX 12948851 DOXORUBICIN — —DDEF1 16404146 DOXORUBICIN NM_004083 DNA-damage-inducible transcript 3DDIT3 16298333, 17912235 DOXORUBICIN NM_001134709; NM_003472 DEKoncogene DEK 16579640 DOXORUBICIN NM_004717 diacylglycerol kinase, iotaDGKI 16404146 DOXORUBICIN NM_001930; NM_013406; NM_013407 deoxyhypusinesynthase DHPS 16404146 DOXORUBICIN NM_019887; NM_138929 diablo homolog(Drosophila) DIABLO 12948851, 17521628 DOXORUBICIN NM_014421 dickkopfhomolog 2 (Xenopus laevis) DKK2 16404146 DOXORUBICIN NM_001539 DnaJ(Hsp40) homolog, subfamily A, member 1 DNAJA1 16579640 DOXORUBICINNM_001130823; NM_001379 DNA (cytosine-5-)-methyltransferase 1 DNMT117124180 DOXORUBICIN NM_001935 dipeptidyl-peptidase 4 DPP4 15753397DOXORUBICIN NM_014208 dentin sialophosphoprotein DSPP 16404146DOXORUBICIN NM_012145 deoxythymidylate kinase (thymidylate kinase) DTYMK18413751 DOXORUBICIN NM_005225 E2F transcription factor 1 E2F1 16001973DOXORUBICIN NM_001949 E2F transcription factor 3 E2F3 16896004DOXORUBICIN NM_004092 enoyl Coenzyme A hydratase, short chain, 1, ECHS115492826 mitochondrial DOXORUBICIN NM_030796 EGFR-coamplified andoverexpressed protein ECOP 18510171 DOXORUBICIN NM_001955 endothelin 1EDN1 17974986 DOXORUBICIN NM_001406 ephrin-B3 EFNB3 16322897 DOXORUBICINNM_001963 epidermal growth factor (beta-urogastrone) EGF 16969495DOXORUBICIN NM_005228; NM_201282; NM_201283; epidermal growth factorreceptor (erythroblastic EGFR 15981280, 16001973, 17938326, NM_201284leukemia viral (v-erb-b) oncogene homolog, avian) 17974986 DOXORUBICINNM_001964 early growth response 1 EGR1 17330857 DOXORUBICIN NM_006709;NM_025256 euchromatic histone-lysine N-methyltransferase 2 EHMT217124180 DOXORUBICIN NM_001412 eukaryotic translation initiation factor1A, X-linked EIF1AX 16322899 DOXORUBICIN NM_032025 eukaryotictranslation initiation factor 2A, 65 kDa EIF2A 16298333 DOXORUBICINNM_004095 eukaryotic translation initiation factor 4E binding EIF4EBP116322899 protein 1 DOXORUBICIN NM_001429 E1A binding protein p300 EP30010344722, 17498666, 10344722 DOXORUBICIN NM_004431 EPH receptor A2 EPHA216900372 DOXORUBICIN NM_001040458; NM_016442 endoplasmic reticulumaminopeptidase 1 ERAP1 16404146 DOXORUBICIN NM_001005862; NM_004448v-erb-b2 erythroblastic leukemia viral oncogene ERBB2 15486187,15834928, 16168102, homolog 2, neuro/glioblastoma derived oncogene17010609 homolog (avian) DOXORUBICIN NM_001005915; NM_001982 v-erb-b2erythroblastic leukemia viral oncogene ERBB3 16168102 homolog 3 (avian)DOXORUBICIN NM_001042599; NM_005235 v-erb-a erythroblastic leukemiaviral oncogene ERBB4 16896004 homolog 4 (avian) DOXORUBICIN NM_000125;NM_001122740; NM_001122741; estrogen receptor 1 ESR1 16322899NM_001122742 DOXORUBICIN NM_001040275; NM_001040276; NM_001437 estrogenreceptor 2 (ER beta) ESR2 16322899, 16900372 DOXORUBICIN NM_001987 etsvariant 6 ETV6 15217836 DOXORUBICIN NM_001993 coagulation factor III(thromboplastin, tissue factor) F3 18246814, 18278454, 18325115DOXORUBICIN NM_000131; NM_019616 coagulation factor VII (serumprothrombin conversion F7 18325115 accelerator) DOXORUBICIN NM_003824Fas (TNFRSF6)-associated via death domain FADD 16001973, 16705698,17970047 DOXORUBICIN NM_012306 Fas apoptotic inhibitory molecule 2 FAIM216001973 DOXORUBICIN NM_000043; NM_152871; NM_152872; Fas (TNF receptorsuperfamily, member 6) FAS 15763944, NM_152873; NM_152874; NM_152875;15763944, 15576332, 17088865, NM_152876; NM_152877 16705698, 15981920,17088865, 17404015, 17970047 DOXORUBICIN NM_000639 Fas ligand (TNFsuperfamily, member 6) FASLG 15763944, 15763944, 17088865, 15981920,17088865 DOXORUBICIN NM_000569; NM_001127592; NM_001127593; Fc fragmentof IgG, low affinity IIIa, receptor (CD16a) FCGR3A 17852453NM_001127595; NM_001127596 DOXORUBICIN NM_004462 farnesyl-diphosphatefarnesyltransferase 1 FDFT1 16322897 DOXORUBICIN NM_001039492;NM_001450; NM_201555; four and a half LIM domains 2 FHL2 17682292NM_201557 DOXORUBICIN NM_001145775; NM_001145776; NM_001145777; FK506binding protein 5 FKBP5 15571967 NM_004117 DOXORUBICIN NM_012181 FK506binding protein 8, 38 kDa FKBP8 16404146 DOXORUBICIN NM_002026;NM_054034; NM_212474; fibronectin 1 FN1 17703109 NM_212475; NM_212476;NM_212478; NM_212482 DOXORUBICIN NM_000802; NM_016724; NM_016725; folatereceptor 1 (adult) FOLR1 15634643, 16404146 NM_016729; NM_016730;NM_016731 DOXORUBICIN NM_005252 v-fos FBJ murine osteosarcoma viraloncogene FOS 16900372 homolog DOXORUBICIN NM_001454 forkhead box J1FOXJ1 16044152 DOXORUBICIN NM_002015 forkhead box O1 FOXO1 17935137DOXORUBICIN NM_001455; NM_201559 forkhead box O3 FOXO3 17935137DOXORUBICIN NM_000510; NM_001018080 follicle stimulating hormone, betapolypeptide FSHB 17028438 DOXORUBICIN NM_000146 ferritin, lightpolypeptide FTL 12644586 DOXORUBICIN NM_177478 ferritin mitochondrialFTMT 12644586 DOXORUBICIN NM_002033 fucosyltransferase 4 (alpha (1,3)fucosyltransferase, FUT4 17852453 myeloid-specific) DOXORUBICINNM_000402; NM_001042351 glucose-6-phosphate dehydrogenase G6PD 16404146DOXORUBICIN NM_006705 growth arrest and DNA-damage-inducible, gammaGADD45G 16404146 DOXORUBICIN NM_000156; NM_138924 guanidinoacetateN-methyltransferase GAMT 16896004 DOXORUBICIN NM_002046glyceraldehyde-3-phosphate dehydrogenase GAPDH 16001973 DOXORUBICINNM_002049 GATA binding protein 1 (globin transcription factor 1) GATA114623254, 17097070 DOXORUBICIN NM_001498 glutamate-cysteine ligase,catalytic subunit GCLC 10900222, 11560771 DOXORUBICIN NM_002061glutamate-cysteine ligase, modifier subunit GCLM 10900222 DOXORUBICINNM_004864 growth differentiation factor 15 GDF15 16705698 DOXORUBICINNM_001135031; NM_004188 growth factor independent 1B transcriptionrepressor GFI1B 16322897 DOXORUBICIN NM_001145453; NM_005264; NM_145793GDNF family receptor alpha 1 GFRA1 16896004 DOXORUBICIN NM_006708glyoxalase I GLO1 16085563 DOXORUBICIN NM_000406; NM_001012763gonadotropin-releasing hormone receptor GNRHR 17943530 DOXORUBICINNM_000174 glycoprotein IX (platelet) GP9 16404146 DOXORUBICIN NM_000581;NM_201397 glutathione peroxidase 1 GPX1 15473893 DOXORUBICIN NM_002093glycogen synthase kinase 3 beta GSK3B 17339365 DOXORUBICIN NM_145740glutathione S-transferase alpha 1 GSTA1 16890185 DOXORUBICIN NM_001512glutathione S-transferase alpha 4 GSTA4 18225754 DOXORUBICIN NM_000852glutathione S-transferase pi 1 GSTP1 10900222, 14623254, 15448748,resistance 15946544, 16356834, 16579640, 15533597, 14623254, 18225754DOXORUBICIN NM_001520 general transcription factor IIIC, polypeptide 1,alpha GTF3C1 16322899 220 kDa DOXORUBICIN NM_016315 GULP, engulfmentadaptor PTB domain containing 1 GULP1 16001973 DOXORUBICIN NM_002105 H2Ahistone family, member X H2AFX 15489221, 15489221, 16432175 DOXORUBICINNM_000184 hemoglobin, gamma G HBG2 17097070 DOXORUBICIN NM_001525hypocretin (orexin) receptor 1 HCRTR1 16404146 DOXORUBICIN NM_004964histone deacetylase 1 HDAC1 17124180 DOXORUBICIN NM_000410; NM_139003;NM_139004; hemochromatosis HFE 16823846 NM_139006; NM_139007; NM_139008;NM_139009; NM_139010; NM_139011 DOXORUBICIN NM_000601; NM_001010931;NM_001010932; hepatocyte growth factor (hepapoietin A; scatter factor)HGF 15688034, 16 NM_001010933; NM_001010934 DOXORUBICIN NM_001530;NM_181054 hypoxia inducible factor 1, alpha subunit (basic helix- HIF1A16532342, 17498666, 17912235 loop-helix transcription factor)DOXORUBICIN NM_003526 histone cluster 1, H2bc HIST1H2BC 16322897DOXORUBICIN NM_002123 major histocompatibility complex, class II, DQbeta 1 HLA- 16322897, 16404146 DQB1 DOXORUBICIN NM_021983 majorhistocompatibility complex, class II, DR beta 4 HLA- 16322897 DRB4DOXORUBICIN NM_015980 HMP19 protein HMP19 16044152 DOXORUBICINNM_005968; NM_031203 heterogeneous nuclear ribonucleoprotein M HNRNPM16928833 DOXORUBICIN NM_001130442; NM_005343; NM_176795 v-Ha-ras Harveyrat sarcoma viral oncogene homolog HRAS 16001973 DOXORUBICIN NM_005114heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1 16044152DOXORUBICIN NM_001017963; NM_005348 heat shock protein 90 kDa alpha(cytosolic), class A HSP90AA1 17680992 member 1 DOXORUBICIN NM_002154heat shock 70 kDa protein 4 HSPA4 16311509 DOXORUBICIN NM_005347 heatshock 70 kDa protein 5 (glucose-regulated protein, HSPA5 16298333,17680992 78 kDa) DOXORUBICIN NM_006597; NM_153201 heat shock 70 kDaprotein 8 HSPA8 16579640, 16579640, 17680992 DOXORUBICIN NM_004134 heatshock 70 kDa protein 9 (mortalin) HSPA9 17680992 DOXORUBICIN NM_001540heat shock 27 kDa protein 1 HSPB1 17680992 DOXORUBICIN NM_002156;NM_199440 heat shock 60 kDa protein 1 (chaperonin) HSPD1 17680992DOXORUBICIN NM_002775 HtrA serine peptidase 1 HTRA1 16243817 DOXORUBICINNM_031407 HECT, UBA and WWE domain containing 1 HUWE1 16404146DOXORUBICIN NM_000415 islet amyloid polypeptide IAPP 16001973DOXORUBICIN NM_024013 interferon, alpha 1 IFNA1 17959036 DOXORUBICINNM_000618; NM_001111283; NM_001111284; insulin-like growth factor 1(somatomedin C) IGF1 16740780 NM_001111285 DOXORUBICIN NM_000875insulin-like growth factor 1 receptor IGF1R 16001973 DOXORUBICINNM_001552 insulin-like growth factor binding protein 4 IGFBP4 16896004DOXORUBICIN NM_001556 inhibitor of kappa light polypeptide gene enhancerin B- IKBKB 15899819, 18463201 cells, kinase beta DOXORUBICINNM_001099856; NM_001099857; NM_001145255; inhibitor of kappa lightpolypeptide gene enhancer in B- IKBKG 17890907 NM_003639 cells, kinasegamma DOXORUBICIN NM_000600 interleukin 6 (interferon, beta 2) IL616001973 DOXORUBICIN NM_000584 interleukin 8 IL8 12908082, 15899819,18510171 DOXORUBICIN NM_001137673; NM_004516; NM_012218; interleukinenhancer binding factor 3, 90 kDa ILF3 16322899 NM_017620; NM_153464DOXORUBICIN NM_005544 insulin receptor substrate 1 IRS1 16322899DOXORUBICIN NM_002226; NM_145159 jagged 2 JAG2 16404146 DOXORUBICIN — —JMJD2B 16896004 DOXORUBICIN NM_002228 jun oncogene JUN 15585644,15880572, 18645001 DOXORUBICIN NM_000238; NM_172056; NM_172057 potassiumvoltage-gated channel, subfamily H (eag- KCNH2 16086867 related), member2 DOXORUBICIN NM_002242 potassium inwardly-rectifying channel, subfamilyJ, KCNJ13 16404146 member 13 DOXORUBICIN NM_018658; NM_170741; NM_170742potassium inwardly-rectifying channel, subfamily J, KCNJ16 16404146member 16 DOXORUBICIN NM_002035 3-ketodihydrosphingosine reductase KDSR16322897 DOXORUBICIN NM_003685 KH-type splicing regulatory protein KHSRP16404146 DOXORUBICIN NM_020853 KIAA1467 KIAA1467 16896004 DOXORUBICINNM_007054 kinesin family member 3A KIF3A 16896004 DOXORUBICIN NM_016270Kruppel-like factor 2 (lung) KLF2 18510171 DOXORUBICIN NM_000224;NM_199187 keratin 18 KRT18 16928833 DOXORUBICIN NM_002306 lectin,galactoside-binding, soluble, 3 LGALS3 16322897 DOXORUBICINNM_001098268; NM_002312; NM_206937 ligase IV, DNA, ATP-dependent LIG418508926 DOXORUBICIN NM_001113546; NM_001113547; NM_016357 LIM domainand actin binding 1 LIMA1 16044152 DOXORUBICIN NM_005572; NM_170707;NM_170708 lamin A/C LMNA 16001973 DOXORUBICIN NM_005573 lamin B1 LMNB116001973 DOXORUBICIN NM_002349 lymphocyte antigen 75 LY75 16404146DOXORUBICIN NM_002358 MAD2 mitotic arrest deficient-like 1 (yeast)MAD2L1 15870702 DOXORUBICIN NM_002755 mitogen-activated protein kinasekinase 1 MAP2K1 17974986 DOXORUBICIN NM_030662 mitogen-activated proteinkinase kinase 2 MAP2K2 17974986 DOXORUBICIN NM_002756; NM_145109mitogen-activated protein kinase kinase 3 MAP2K3 15870702 DOXORUBICINNM_003010 mitogen-activated protein kinase kinase 4 MAP2K4 15870702,16001973 DOXORUBICIN NM_002758 mitogen-activated protein kinase kinase 6MAP2K6 15870702 DOXORUBICIN NM_003188; NM_145331; NM_145332;mitogen-activated protein kinase kinase kinase 7 MAP3K7 16001973NM_145333 DOXORUBICIN NM_005204 mitogen-activated protein kinase kinasekinase 8 MAP3K8 16322897 DOXORUBICIN NM_002745; NM_138957mitogen-activated protein kinase 1 MAPK1 15557793, 16001973, 17526808,17974986, 15557793, 18468633, 18468633, 18468633, 15557793 DOXORUBICINNM_001315; NM_139012; NM_139013; mitogen-activated protein kinase 14MAPK14 15494689, 16843435, 15557793, NM_139014 15870702, 16322899,16843435 DOXORUBICIN NM_001040056; NM_001109891; NM_002746mitogen-activated protein kinase 3 MAPK3 15557793, 16059641, 16928833,17526808, 17974986, 18468633, 15557793, 18468633, 18468633, 15557793DOXORUBICIN NM_002750; NM_139046; NM_139047; mitogen-activated proteinkinase 8 MAPK8 15494689, 15870702, 15880572, NM_139049 15917298,15917298, 16890185, 16868541, 16890185 DOXORUBICIN NM_001135044;NM_002752; NM_139068; mitogen-activated protein kinase 9 MAPK9 15494689,15557793, 15557793, NM_139069; NM_139070 15585644, 15585644 DOXORUBICINNM_001123066; NM_001123067; NM_005910; microtubule-associated proteintau MAPT 16896004 NM_016834; NM_016835; NM_016841 DOXORUBICIN NM_021960;NM_182763 myeloid cell leukemia sequence 1 (BCL2-related) MCL1 17935137DOXORUBICIN NM_005918 malate dehydrogenase 2, NAD (mitochondrial) MDH216322897 DOXORUBICIN NM_001012333; NM_001012334; NM_002391 midkine(neurite growth-promoting factor 2) MDK 16322897 DOXORUBICINNM_001145336; NM_001145337; NM_001145339; Mdm2 p53 binding proteinhomolog (mouse) MDM2 16001973, 17935137, 17959036, NM_001145340;NM_002392; 17959036, 19074854, 17653088 NM_006878; NM_006879; NM_006881;NM_006882 DOXORUBICIN NM_015335 mediator complex subunit 13-like MED13L16896004 DOXORUBICIN NM_001130926; NM_001130927; NM_001130928; myocyteenhancer factor 2A MEF2A 16001973 NM_005587 DOXORUBICIN NM_014791maternal embryonic leucine zipper kinase MELK 16896004 DOXORUBICINNM_006838 methionyl aminopeptidase 2 METAP2 16404146 DOXORUBICINNM_024042 meteorin, glial cell differentiation regulator METRN 16896004DOXORUBICIN NM_001114614; NM_005928 milk fat globule-EGF factor 8protein MFGE8 16404146 DOXORUBICIN NM_002412 O-6-methylguanine-DNAmethyltransferase MGMT 16356834 DOXORUBICIN NM_005933 myeloid/lymphoidor mixed-lineage leukemia (trithorax MLL 16322897 homolog, Drosophila)DOXORUBICIN NM_004529 myeloid/lymphoid or mixed-lineage leukemia(trithorax MLLT3 16404146 homolog, Drosophila); translocated to, 3DOXORUBICIN NM_000902; NM_007287; NM_007288; membranemetallo-endopeptidase MME 16997790 NM_007289 DOXORUBICIN NM_002421matrix metallopeptidase 1 (interstitial collagenase) MMP1 11313874DOXORUBICIN NM_001127891; NM_004530 matrix metallopeptidase 2(gelatinase A, 72 kDa MMP2 16458935 gelatinase, 72 kDa type IVcollagenase) DOXORUBICIN NM_018135 mitochondrial ribosomal protein S18AMRPS18A 16404146 DOXORUBICIN NM_000179 mutS homolog 6 (E. coli) MSH616404146 DOXORUBICIN NM_005950 metallothionein 1G MT1G 16579640DOXORUBICIN NR_001447; NR_001447; NR_001447; metallothionein 1L(gene/pseudogene) MT1L 16579640 NR_001447; NR_001447; NR_001447DOXORUBICIN NM_005953 metallothionein 2A MT2A 16579640 DOXORUBICINNM_000254 5-methyltetrahydrofolate-homocysteine MTR 16322897methyltransferase DOXORUBICIN NM_014751 metastasis suppressor 1 MTSS116243817 DOXORUBICIN NM_005115; NM_017458 major vault protein MVP17575109 DOXORUBICIN NM_002467 v-myc myelocytomatosis viral oncogenehomolog MYC 15911101, 16001973, 11585056, (avian) 18606404, 18802399DOXORUBICIN NM_004536; NM_022892 NLR family, apoptosis inhibitoryprotein NAIP 11911975, 15911101, 16322899, DOXORUBICIN NM_002485 nibrinNBN 17521628 15489221 DOXORUBICIN NM_004146 NADH dehydrogenase(ubiquinone) 1 beta NDUFB7 16404146 subcomplex, 7, 18 kDa DOXORUBICINNM_003998 nuclear factor of kappa light polypeptide gene NFKB1 15555623,15571967, 15870702, enhancer in B-cells 1 15905586, 16001973, 16322301,17912235, 18463201 DOXORUBICIN NM_001077493; NM_001077494; NM_002502nuclear factor of kappa light polypeptide gene NFKB2 17890907 enhancerin B-cells 2 (p49/p100) DOXORUBICIN NM_020529 nuclear factor of kappalight polypeptide gene NFKBIA 15571967, 15870702, 15899819, enhancer inB-cells inhibitor, alpha 17542780, 17935137, 17935137, 15899819,17542780, 18463201 DOXORUBICIN NM_002508 nidogen 1 NID1 17703109DOXORUBICIN NM_024522 Na+/K+ transporting ATPase interacting 1 NKAIN116896004 DOXORUBICIN NM_002511 neuromedin B receptor NMBR 16404146DOXORUBICIN NM_004741 nucleolar and coiled-body phosphoprotein 1 NOLC117129415 DOXORUBICIN NM_000625 nitric oxide synthase 2, inducible NOS215695394, 15695394, 18463201, 18463201 DOXORUBICIN NM_002135; NM_173157nuclear receptor subfamily 4, group A, member 1 NR4A1 16322897DOXORUBICIN NM_013936 olfactory receptor, family 12, subfamily D, member2 OR12D2 16404146 DOXORUBICIN NM_012369 olfactory receptor, family 2,subfamily F, member 1 OR2F1 16404146 DOXORUBICIN NM_000916 oxytocinreceptor OXTR 11313874 DOXORUBICIN NM_006025 26 serine protease P1116001973 DOXORUBICIN NM_012226; NM_016318; NM_170682; purinergicreceptor P2X, ligand-gated ion channel, 2 P2RX2 16404146 NM_170683;NM_174872; NM_174873 DOXORUBICIN NM_004154; NM_176796; NM_176797;pyrimidinergic receptor P2Y, G-protein coupled, 6 P2RY6 16044152NM_176798 DOXORUBICIN NM_001618 poly (ADP-ribose) polymerase 1 PARP115456408, 15557793, 15585644, 15753397, (following) 15870702, 15981920,16311509, 16311509, 17651020, 16890185, 15557793, 18071906, 15585644,16843435, 16962673, 15555623, 17285121, 17935137, 17959036, 16843435,16890185, 16962673, 17285121, 17339365, 17418594, 17651020, 17935137,17959036 DOXORUBICIN NM_002583 PRKC, apoptosis, WT1, regulator PAWR12948851 DOXORUBICIN NM_000280; NM_001127612; NM_001604 paired box 6PAX6 16404146 DOXORUBICIN — — PCAF 16001973 DOXORUBICIN NM_002592;NM_182649 proliferating cell nuclear antigen PCNA 16322897, 16537896DOXORUBICIN NM_004708 programmed cell death 5 PDCD5 16579640 DOXORUBICINNM_002613; NM_031268 3-phosphoinositide dependent protein kinase-1 PDPK116782806 DOXORUBICIN NM_002653 paired-like homeodomain 1 PITX1 16404146DOXORUBICIN NM_001145031; NM_002658 plasminogen activator, urokinasePLAU 12908082, 15557793, 16356834 DOXORUBICIN NM_000302procollagen-lysine 1,2-oxoglutarate 5-dioxygenase 1 PLOD1 16322899DOXORUBICIN NM_001084 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3PLOD3 16322899 DOXORUBICIN NM_021127phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 17653088DOXORUBICIN NM_021173 polymerase (DNA-directed), delta 4 POLD4 16404146DOXORUBICIN NM_013382 protein-O-mannosyltransferase 2 POMT2 16404146DOXORUBICIN NM_000941 P450 (cytochrome) oxidoreductase POR 15942634,16322897 DOXORUBICIN NM_006238; NM_177435 peroxisomeproliferator-activated receptor delta PPARD 16404146 DOXORUBICINNM_005155; NM_138717 palmitoyl-protein thioesterase 2 PPT2 16404146DOXORUBICIN NM_002730; NM_207518 protein kinase, cAMP-dependent,catalytic, alpha PRKACA 16404146 DOXORUBICIN NM_002737 protein kinase C,alpha PRKCA 16087181, 16579994 DOXORUBICIN NM_006254; NM_212539 proteinkinase C, delta PRKCD 15917298 DOXORUBICIN NM_001081640; NM_006904protein kinase, DNA-activated, catalytic polypeptide PRKDC 18508926DOXORUBICIN NM_000948 prolactin PRL 18681966 DOXORUBICIN NM_000311;NM_001080121; NM_001080122; prion protein PRNP 15386405 NM_001080123;NM_183079 DOXORUBICIN NM_000312 protein C (inactivator of coagulationfactors Va and PROC 17172434 VIIIa) DOXORUBICIN NM_006404 protein Creceptor, endothelial (EPCR) PROCR 17172434 DOXORUBICIN NM_001143937;NM_002786; NM_148976 proteasome (prosome, macropain) subunit, alphatype, 1 PSMA1 17346995 DOXORUBICIN NM_002787 proteasome (prosome,macropain) subunit, alpha type, 2 PSMA2 17346995 DOXORUBICIN NM_002788;NM_152132 proteasome (prosome, macropain) subunit, alpha type, 3 PSMA317346995 DOXORUBICIN NM_001102667; NM_001102668; NM_002789 proteasome(prosome, macropain) subunit, alpha type, 4 PSMA4 17346995 DOXORUBICINNM_002790 proteasome (prosome, macropain) subunit, alpha type, 5 PSMA517346995 DOXORUBICIN NM_002791 proteasome (prosome, macropain) subunit,alpha type, 6 PSMA6 17346995 DOXORUBICIN NM_002792 proteasome (prosome,macropain) subunit, alpha type, 7 PSMA7 17346995 DOXORUBICIN NM_002794proteasome (prosome, macropain) subunit, beta type, 2 PSMB2 17346995DOXORUBICIN NM_002795 proteasome (prosome, macropain) subunit, betatype, 3 PSMB3 17346995 DOXORUBICIN NM_002799 proteasome (prosome,macropain) subunit, beta type, 7 PSMB7 17346995 DOXORUBICIN NM_000314phosphatase and tensin homolog PTEN 11707646, 15548710, 16438844,17330857, 17359293, 17935137, 17935137, 16438844, 17359293 DOXORUBICINNM_000963 prostaglandin-endoperoxide synthase 2 (prostaglandin PTGS215501994, 16127422, 18498876 G/H synthase and cyclooxygenase)DOXORUBICIN NM_005607; NM_153831 PTK2 protein tyrosine kinase 2 PTK215870702, 16168102 DOXORUBICIN NM_004103; NM_173174; NM_173175; PTK2Bprotein tyrosine kinase 2 beta PTK2B 16168102 NM_173176 DOXORUBICINNM_006264; NM_080683; NM_080684; protein tyrosine phosphatase,non-receptor type 13 PTPN13 16001973 NM_080685 (APO-1/CD95(Fas)-associated phosphatase) DOXORUBICIN NM_001161440; NM_002842protein tyrosine phosphatase, receptor type, H PTPRH 16044152DOXORUBICIN NM_002875; NM_133487 RAD51 homolog (RecA homolog, E. coli)(S. cerevisiae) RAD51 10344722, 17351394 DOXORUBICIN NM_006788 ralAbinding protein 1 RALBP1 15386349, 15950949, 16087181, resistance16579994, 17273774 DOXORUBICIN NM_005855 receptor (G protein-coupled)activity modifying protein 1 RAMP1 16896004 DOXORUBICIN NM_000965;NM_016152 retinoic acid receptor, beta RARB 17608728 DOXORUBICINNM_000321 retinoblastoma 1 RB1 15141020, 16537896 DOXORUBICIN NM_002895;NM_183404 retinoblastoma-like 1 (p107) RBL1 16537896 DOXORUBICINNM_005611 retinoblastoma-like 2 (p130) RBL2 15585644, 16537896DOXORUBICIN NM_001145547; NM_032905 RNA binding motif protein 17 RBM1716061639 resistance DOXORUBICIN NM_001008710; NM_001008711;NM_001008712; RNA binding protein with multiple splicing RBPMS 16404146NM_006867 DOXORUBICIN NM_002908 v-rel reticuloendotheliosis viraloncogene homolog REL 15870702, 16404146, 17890907 (avian) DOXORUBICINNM_001145138; NM_021975 v-rel reticuloendotheliosis viral oncogenehomolog A RELA 15555623, 15571967, 15823547, (avian) 15899819,(following) 15905586, 15911101, 16322301, 17097285, 17097285, 15870702,17542780, 17890907, 18269916, 18463201, 18463201, 17542780 DOXORUBICINNM_006509 v-rel reticuloendotheliosis viral oncogene homolog B RELB17890907 DOXORUBICIN NM_002927; NM_144766 regulator of G-proteinsignaling 13 RGS13 16404146 DOXORUBICIN NM_016321 Rh family, Cglycoprotein RHCG 16404146 DOXORUBICIN NM_002944 c-ros oncogene 1,receptor tyrosine kinase ROS1 16001973 DOXORUBICIN NM_001034ribonucleotide reductase M2 polypeptide RRM2 16896004 DOXORUBICINNM_001001890; NM_001122607; NM_001754 runt-related transcription factor1 RUNX1 15217836 DOXORUBICIN NM_001031680; NM_004350 runt-relatedtranscription factor 3 RUNX3 15756676 DOXORUBICIN NM_002970spermidine/spermine N1-acetyltransferase 1 SAT1 16322897 DOXORUBICINNM_001039 sodium channel, nonvoltage-gated 1, gamma SCNN1G 15564131DOXORUBICIN NM_020974 signal peptide, CUB domain, EGF-like 2 SCUBE216896004 DOXORUBICIN NM_004892 SEC22 vesicle trafficking protein homologSEC22B 16404146 B (S. cerevisiae) DOXORUBICIN NM_000602 serpin peptidaseinhibitor, clade E (nexin, plasminogen SERPINE1 15870702, 16705698activator inhibitor type 1), member 1 DOXORUBICIN NM_001235 serpinpeptidase inhibitor, clade H (heat shock protein SERPINH1 17680992 47),member 1, (collagen binding protein 1) DOXORUBICIN NM_005983; NM_032637S-phase kinase-associated protein 2 (p45) SKP2 17893511 DOXORUBICINNM_033125 solute carrier family 22 (organic cation/carnitine SLC22A1615963465 transporter), member 16 DOXORUBICIN NM_003060 solute carrierfamily 22 (organic cation/carnitine SLC22A5 16283381 transporter),member 5 DOXORUBICIN NM_001078174; NM_001078175; NM_001078176; solutecarrier family 29 (nucleoside transporters), SLC29A1 18452103NM_001078177; NM_004955 member 1 DOXORUBICIN NM_018976 solute carrierfamily 38, member 2 SLC38A2 16044152 DOXORUBICIN NM_000453 solutecarrier family 5 (sodium iodide symporter), SLC5A5 15671536 member 5DOXORUBICIN NM_003047 solute carrier family 9 (sodium/hydrogenexchanger), SLC9A1 15729714 member 1 DOXORUBICIN NM_003062 slit homolog3 (Drosophila) SLIT3 16404146 DOXORUBICIN NM_001003652; NM_001135937;NM_005901 SMAD family member 2 SMAD2 18606404 DOXORUBICIN NM_001145102;NM_001145103; NM_001145104; SMAD family member 3 SMAD3 18606404NM_005902 DOXORUBICIN NM_005359 SMAD family member 4 SMAD4 18606404DOXORUBICIN NM_005904 SMAD family member 7 SMAD7 18606404 DOXORUBICINNM_006306 structural maintenance of chromosomes 1A SMC1A 15489221DOXORUBICIN NM_000454 superoxide dismutase 1, soluble SOD1 16579640DOXORUBICIN NM_000636; NM_001024465; NM_001024466 superoxide dismutase2, mitochondrial SOD2 14660625, 10969820, 18384434 DOXORUBICIN NM_005633son of sevenless homolog 1 (Drosophila) SOS1 16001973 DOXORUBICINNM_003109; NM_138473 Sp1 transcription factor SP1 17108358, 17124180DOXORUBICIN NM_003118 secreted protein, acidic, cysteine-rich(osteonectin) SPARC 15870702 DOXORUBICIN NM_020126 sphingosine kinase 2SPHK2 17974990 DOXORUBICIN NM_003130; NM_198901 sorcin SRI 18423116DOXORUBICIN NM_003132 spermidine synthase SRM 16322899 DOXORUBICINNM_017857 slingshot homolog 3 (Drosophila) SSH3 16404146 DOXORUBICINNM_021978 suppression of tumorigenicity 14 (colon carcinoma) ST1416322899 DOXORUBICIN NM_007315; NM_139266 signal transducer andactivator of transcription 1, STAT1 16001973, 17072862 91 kDaDOXORUBICIN NM_005419 signal transducer and activator of transcription2, STAT2 16001973 113 kDa DOXORUBICIN NM_003150; NM_139276; NM_213662signal transducer and activator of transcription 3 STAT3 16001973,17920763 (acute-phase response factor) DOXORUBICIN NM_013233 serinethreonine kinase 39 (STE20/SPS1 homolog, STK39 16322899 yeast)DOXORUBICIN NM_001145454; NM_005563; NM_203399; stathmin 1 STMN116458935 NM_203401 DOXORUBICIN NM_004177 syntaxin 3 STX3 16322897DOXORUBICIN NM_001001522; NM_003186 transgelin TAGLN 15870702DOXORUBICIN NM_001136139; NM_003200 transcription factor 3 (E2Aimmunoglobulin enhancer TCF3 16886622 binding factors E12/E47)DOXORUBICIN NM_198253; NM_198255 telomerase reverse transcriptase TERT16077987, 18396642, 18560228 DOXORUBICIN NM_003225 trefoil factor 1 TFF116579640 DOXORUBICIN NM_000660 transforming growth factor, beta 1 TGFB117418594, 18606404 DOXORUBICIN NM_004613; NM_198951 transglutaminase 2(C polypeptide, protein-glutamine- TGM2 15870702, 17073438gamma-glutamyltransferase) DOXORUBICIN NM_000361 thrombomodulin THBD17172434 DOXORUBICIN NM_003246 thrombospondin 1 THBS1 16962673DOXORUBICIN NM_018271 threonine synthase-like 2 (S. cerevisiae) THNSL216896004 DOXORUBICIN NM_022037; NM_022173 TIA1 cytotoxicgranule-associated RNA binding protein TIA1 16404146 DOXORUBICINNM_021025 T-cell leukemia homeobox 3 TLX3 16404146 DOXORUBICIN NM_021109thymosin beta 4, X-linked TMSB4X 16364925 DOXORUBICIN NM_000594 tumornecrosis factor (TNF superfamily, member 2) TNF 12908082, 15823547,15899819, 16001973, 17651020 DOXORUBICIN NM_003844 tumor necrosis factorreceptor superfamily, member TNFRSF10A 16098063, 17437844, 16364925, 10a17437844, 17437844, 15897917 DOXORUBICIN NM_003842; NM_147187 tumornecrosis factor receptor superfamily, member TNFRSF10B 16364925,17922852, 15897917, 10b 17922852, 16098063, 17922852, 16705698DOXORUBICIN NM_001065 tumor necrosis factor receptor superfamily, member1A TNFRSF1A 17651020 DOXORUBICIN NM_001066 tumor necrosis factorreceptor superfamily, member 1B TNFRSF1B 17651020 DOXORUBICINNM_001039664; NM_003790; NM_148965; tumor necrosis factor receptorsuperfamily, member 25 TNFRSF25 16705698 NM_148966; NM_148967; NM_148970DOXORUBICIN NM_003810 tumor necrosis factor (ligand) superfamily, member10 TNFSF10 16364925, 19106633 DOXORUBICIN NM_014765 translocase of outermitochondrial membrane 20 TOMM20 16322897 homolog (yeast) DOXORUBICINNM_001067 topoisomerase (DNA) II alpha 170 kDa TOP2A 11470519, 15239142,15486187, 15753397, 15765123, 16969495, 17351394 DOXORUBICIN NM_001068topoisomerase (DNA) II beta 180 kDa TOP2B 16239602, 16957942 DOXORUBICINNM_000546; NM_001126112; NM_001126113; tumor protein p53 TP53 15141020,17124180, 15489221, NM_001126114; NM_001126115; 15578696, NM_001126116;NM_001126117 (following) 15671536, 19106633, 15763944, 15781256,15823547, 15823547, 15601469, 16211088, 15939500, 16001973, 16404146,15939500, 17959036, 16168113, 16432175, 16537896, 15781256, 17959036,17339365, 17912235, 16108013, 10969820, 12082016, 15555623, 15601469,17285121, 19074854, 17088865, 15763944, 15671536, 16826403, 17079232,17085670, 17088865, 17124180, 17285121, 17369602, 15578696, 17555331,17608641, 17653088, 17682292, 17893511, 17912235, 17959036, 18269916,18510171, 18698031, 19074854, 19106633 DOXORUBICIN NM_001126240;NM_001126241; NM_001126242; tumor protein p73 TP73 17716971 NM_005427DOXORUBICIN NM_000365; NM_001159287 triosephosphate isomerase 1 TPI118309519 DOXORUBICIN NM_016292 TNF receptor-associated protein 1 TRAP117680992 DOXORUBICIN NM_001656; NM_033227; NM_033228 tripartitemotif-containing 23 TRIM23 16404146 DOXORUBICIN NM_005762 tripartitemotif-containing 28 TRIM28 17079232 DOXORUBICIN NM_001003827; NM_021616;NM_130389; tripartite motif-containing 34 TRIM34 16404146 NM_130390DOXORUBICIN — — TRP53 16013437 DOXORUBICIN NM_000370 tocopherol (alpha)transfer protein TTPA 16404146 DOXORUBICIN NM_006000 tubulin, alpha 4aTUBA4A 16322897 DOXORUBICIN NM_178014 tubulin, beta TUBB 16579640DOXORUBICIN NM_006087 tubulin, beta 4 TUBB4 16322897 DOXORUBICINNM_001071 thymidylate synthetase TYMS 10482907, 16168113 DOXORUBICINNM_003358 UDP-glucose ceramide glucosyltransferase UGCG 16404146,18245173 DOXORUBICIN NM_021139 UDP glucuronosyltransferase 2 family,polypeptide B4 UGT2B4 16404146 DOXORUBICIN NM_003364; NM_181597 uridinephosphorylase 1 UPP1 18510171 DOXORUBICIN NM_006004 ubiquinol-cytochromec reductase hinge protein UQCRH 18510171 DOXORUBICIN NM_000376;NM_001017535 vitamin D (1,25-dihydroxyvitamin D3) receptor VDR 17716971DOXORUBICIN NM_001025366; NM_001025367; NM_001025368; vascularendothelial growth factor A VEGFA 16900372, 17431384, 17498666,NM_001025369; NM_001025370; 17627616, 17627616, 17498666, NM_001033756;NM_003376 17912235, 18494554 DOXORUBICIN NM_001167 X-linked inhibitor ofapoptosis XIAP 11911975, 11911975, 16211302, 12948851, 14601052,15897917, 15359644, 15911101, 17521628, 18071906 DOXORUBICIN NM_006887zinc finger protein 36, C3H type-like 2 ZFP36L2 16322897 DOXORUBICINNM_022470; NM_152240 zinc finger, matrin type 3 ZMAT3 16439685DOXORUBICIN NM_003453; NM_197968 zinc finger, MYM-type 2 ZMYM2 16579640DOXORUBICIN NM_006963 zinc finger protein 22 (KOX 15) ZNF22 16404146DOXORUBICIN NM_024762 zinc finger protein 552 ZNF552 16896004 EPIRUBICINNM_000927 ATP-binding cassette, sub-family B (MDR/TAP), ABCB1 12576456resistance member 1 EPIRUBICIN NM_004996; NM_019862; NM_019898;ATP-binding cassette, sub-family C (CFTR/MRP), ABCC1 12576456, 12657726resistance NM_019899; NM_019900 member 1 EPIRUBICIN NM_004827ATP-binding cassette, sub-family G (WHITE), member 2 ABCG2 12576456resistance EPIRUBICIN NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL214503796 EPIRUBICIN NM_001012270; NM_001012271; NM_001168 baculoviralIAP repeat-containing 5 BIRC5 16188142 resistance EPIRUBICIN NM_004346;NM_032991 caspase 3, apoptosis-related cysteine peptidase CASP314503796, 15996160 death pathway EPIRUBICIN NM_001270 chromodomainhelicase DNA binding protein 1 CHD1 — EPIRUBICIN NM_005228; NM_201282;NM_201283; epidermal growth factor receptor (erythroblastic EGFR18768436 NM_201284 leukemia viral (v-erb-b) oncogene homolog, avian)EPIRUBICIN NM_001005862; NM_004448 v-erb-b2 erythroblastic leukemiaviral oncogene ERBB2 18768436 homolog 2, neuro/glioblastoma derivedoncogene homolog (avian) EPIRUBICIN NM_001005915; NM_001982 v-erb-b2erythroblastic leukemia viral oncogene ERBB3 18768436 homolog 3 (avian)EPIRUBICIN NM_022110 FK506 binding protein like FKBPL 14503796EPIRUBICIN NM_005980 S100 calcium binding protein P S100P 18636193EPIRUBICIN NM_000636; NM_001024465; NM_001024466 superoxide dismutase 2,mitochondrial SOD2 9569045 EPIRUBICIN NM_001067 topoisomerase (DNA) IIalpha 170 kDa TOP2A 18465341 target MITOXANTRONE NM_000927 ATP-bindingcassette, sub-family B (MDR/TAP), ABCB1 15239124 resistance member 1MITOXANTRONE NM_004827 ATP-binding cassette, sub-family G (WHITE),member 2 ABCG2 15239124, 15640379, 15695404, resistance 15703302,15875186, 17032904, 16636798, 17032904 MITOXANTRONE NM_130847 angiomotinlike 1 AMOTL1 16044152 MITOXANTRONE NM_001166 baculoviral IAPrepeat-containing 2 BIRC2 15359644 MITOXANTRONE NM_001165; NM_182962baculoviral IAP repeat-containing 3 BIRC3 12948851 MITOXANTRONE — —C4ORF28 16044152 MITOXANTRONE NM_007359 cancer susceptibility candidate3 CASC3 16044152 MITOXANTRONE NM_032982; NM_032983 caspase 2,apoptosis-related cysteine peptidase CASP2 14757846 MITOXANTRONENM_004346; NM_032991 caspase 3, apoptosis-related cysteine peptidaseCASP3 12948851 MITOXANTRONE NM_001226; NM_032992 caspase 6,apoptosis-related cysteine peptidase CASP6 12948851 MITOXANTRONENM_001227; NM_033338; NM_033339; caspase 7, apoptosis-related cysteinepeptidase CASP7 12948851 NM_033340 MITOXANTRONE NM_001080124;NM_001080125; NM_001228; caspase 8, apoptosis-related cysteine peptidaseCASP8 12948851 NM_033355; NM_033356; NM_033358 MITOXANTRONE NM_001229;NM_032996 caspase 9, apoptosis-related cysteine peptidase CASP9 12948851MITOXANTRONE NM_030809 cysteine-serine-rich nuclear protein 2 CSRNP216044152 MITOXANTRONE NM_001141969; NM_001141970; NM_001350 death-domainassociated protein DAXX 12948851 MITOXANTRONE NM_019887; NM_138929diablo homolog (Drosophila) DIABLO 12948851 MITOXANTRONE NM_001144774;NM_001144775; NM_001144776; ELAV (embryonic lethal, abnormal vision,Drosophila)- ELAVL4 16044152 NM_001144777; NM_021952 like 4 (Hu antigenD) MITOXANTRONE NM_021814 ELOVL family member 5, elongation of longchain fatty ELOVL5 16044152 acids (FEN1/Elo2, SUR4/Elo3-like, yeast)MITOXANTRONE NM_001135554; NM_001135555; NM_001431 erythrocyte membraneprotein band 4.1-like 2 EPB41L2 16044152 MITOXANTRONE NM_000875insulin-like growth factor 1 receptor IGF1R 15499378 MITOXANTRONENM_024337 iroquois homeobox 1 IRX1 16044152 MITOXANTRONE NM_000426;NM_001079823 laminin, alpha 2 LAMA2 16044152 MITOXANTRONE NM_001143944;NM_181336 LEM domain containing 2 LEMD2 16044152 MITOXANTRONENM_001161572; NM_001161573; NM_001161574; v-maf musculoaponeuroticfibrosarcoma oncogene MAFF 16044152 NM_012323; NM_152878 homolog F(avian) MITOXANTRONE NM_001145336; NM_001145337; NM_001145339; Mdm2 p53binding protein homolog (mouse) MDM2 17575151 variant allelic/NM_001145340; NM_002392; resistance NM_006878; NM_006879; NM_006881;NM_006882 MITOXANTRONE NM_002583 PRKC, apoptosis, WT1, regulator PAWR12948851 MITOXANTRONE NM_000965; NM_016152 retinoic acid receptor, betaRARB 17608728 altered by mitox MITOXANTRONE NM_002890; NM_022650 RAS p21protein activator (GTPase activating protein) 1 RASA1 16044152MITOXANTRONE NM_001145547; NM_032905 RNA binding motif protein 17 RBM1716061639 resistance MITOXANTRONE NM_021244 Ras-related GTP binding DRRAGD 16044152 MITOXANTRONE NM_003014 secreted frizzled-related protein4 SFRP4 16044152 MITOXANTRONE NM_032379; NM_032943; NM_206927;synaptotagmin-like 2 SYTL2 16044152 NM_206928; NM_206929; NM_206930MITOXANTRONE NM_145274 transmembrane protein 99 TMEM99 16044152MITOXANTRONE NM_001067 topoisomerase (DNA) II alpha 170 kDa TOP2A —target MITOXANTRONE NM_001167 X-linked inhibitor of apoptosis XIAP12948851, 15359644 BLEOMYCIN NM_001166 baculoviral IAP repeat-containing2 BIRC2 10815900 BLEOMYCIN NM_000386 bleomycin hydrolase BLMH 12082022resistance BLEOMYCIN NM_001752 catalase CAT 10751631 unrelated BLEOMYCINNM_000234 ligase I, DNA, ATP-dependent LIG1 — unrelated BLEOMYCINNM_002311; NM_013975 ligase III, DNA, ATP-dependent LIG3 — resistanceBLEOMYCIN NM_000963 prostaglandin-endoperoxide synthase 2 (prostaglandinPTGS2 18695918 G/H synthase and cyclooxygenase) BLEOMYCIN NM_003745suppressor of cytokine signaling 1 SOCS1 17374387 resistance BLEOMYCINNM_006297 X-ray repair complementing defective repair in Chinese XRCC112082022 resistance hamster cells 1 BLEOMYCIN NM_021141 X-ray repaircomplementing defective repair in Chinese XRCC5 12384553 hamster cells 5(double-strand-break rejoining) MITOMYCIN NM_000691; NM_001135167;NM_001135168 aldehyde dehydrogenase 3 family, memberA1 ALDH3A1 15905174resistance MITOMYCIN NM_000484; NM_001136016; NM_001136129; amyloid beta(A4) precursor protein APP 12760830 NM_001136130; NM_001136131;NM_201413; NM_201414 MITOMYCIN NM_001675; NM_182810 activatingtranscription factor 4 (tax-responsive ATF4 12760830 enhancer elementB67) MITOMYCIN NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 15793875MITOMYCIN NM_001202; NM_130850; NM_130851 bone morphogenetic protein 4BMP4 12760830 MITOMYCIN NM_031966 cyclin B1 CCNB1 12760830 MITOMYCINNM_000611; NM_001127223; NM_001127225; CD59 molecule, complementregulatory protein CD59 17045307 NM_001127226; NM_001127227; NM_203329;NM_203330; NM_203331 MITOMYCIN NM_001785 cytidine deaminase CDA 18728667MITOMYCIN NM_001964 early growth response 1 EGR1 12760830 MITOMYCINNM_004431 EPH receptor A2 EPHA2 12760830 MITOMYCIN — — GRP58 —sensitivity MITOMYCIN NM_000852 glutathione S-transferase pi 1 GSTP115239142 resistance MITOMYCIN NM_002117 major histocompatibilitycomplex, class I, C HLA-C 12760830 MITOMYCIN NM_000234 ligase I, DNA,ATP-dependent LIG1 12760830 MITOMYCIN NM_012325 microtubule-associatedprotein, RP/EB family, member 1 MAPRE1 12760830 MITOMYCIN NM_002412O-6-methylguanine-DNA methyltransferase MGMT 16039682 sensitivityMITOMYCIN NM_004995 matrix metallopeptidase 14 (membrane-inserted) MMP1412760830 MITOMYCIN NM_002505; NM_021705 nuclear transcription factor Y,alpha NFYA 12760830 MITOMYCIN NM_000903; NM_001025433; NM_001025434NAD(P)H dehydrogenase, quinone 1 NQO1 15239142 drug activation MITOMYCINNM_000941 P450 (cytochrome) oxidoreductase POR 15239142 drug activationMITOMYCIN NM_000311; NM_001080121; NM_001080122; prion protein PRNP12760830 NM_001080123; NM_183079 MITOMYCIN NM_000963prostaglandin-endoperoxide synthase 2 (prostaglandin PTGS2 15793875 G/Hsynthase and cyclooxygenase) MITOMYCIN NM_000321 retinoblastoma 1 RB115617745 MITOMYCIN NM_002893 retinoblastoma binding protein 7 RBBP712760830 MITOMYCIN NM_002916; NM_181573 replication factor C(activator 1) 4, 37 kDa RFC4 12760830 MITOMYCIN NM_001006 ribosomalprotein S3A RPS3A 12760830 MITOMYCIN NM_001031680; NM_004350runt-related transcription factor 3 RUNX3 15756676 MITOMYCIN NM_006713SUB1 homolog (S. cerevisiae) SUB1 12760830 MITOMYCIN NM_198253;NM_198255 telomerase reverse transcriptase TERT — resistance MITOMYCINNM_000546; NM_001126112; NM_001126113; tumor protein p53 TP53 12082016sensitivity NM_001126114; NM_001126115; NM_001126116; NM_001126117MITOMYCIN NM_001113755; NM_001113756; NM_001953 thymidine phosphorylaseTYMP 18728667 HYDROXYUREA NM_004324; NM_138761; NM_138763;BCL2-associated X protein BAX 16005713 death pathway NM_138764;NM_138765 HYDROXYUREA — — C13ORF34 17374387 HYDROXYUREA NM_004346;NM_032991 caspase 3, apoptosis-related cysteine peptidase CASP3 16005713death pathway HYDROXYUREA NM_001237 cyclin A2 CCNA2 11468187 HYDROXYUREANM_031966 cyclin B1 CCNB1 11468187 HYDROXYUREA NM_053056 cyclin D1 CCND111468187 altered by HU HYDROXYUREA NM_001759 cyclin D2 CCND2 11468187altered by HU HYDROXYUREA NM_001136017; NM_001136125; NM_001136126;cyclin D3 CCND3 11468187 altered by HU NM_001760 HYDROXYUREA NM_001238;NM_057182 cyclin E1 CCNE1 11468187 HYDROXYUREA NM_004060; NM_199246cyclin G1 CCNG1 16005713 altered by HU HYDROXYUREA NM_001790; NM_022809cell division cycle 25 homolog C (S. pombe) CDC25C 19074854 HYDROXYUREANM_018101 cell division cycle associated 8 CDCA8 17374387 HYDROXYUREANM_000389; NM_078467 cyclin-dependent kinase inhibitor 1A (p21, Cip1)CDKN1A 16005713 resistance HYDROXYUREA NM_001827 CDC28 protein kinaseregulatory subunit 2 CKS2 17374387 HYDROXYUREA NM_000114; NM_207032;NM_207033; endothelin 3 EDN3 15020278 altered by HU NM_207034HYDROXYUREA NM_000043; NM_152871; NM_152872; Fas (TNF receptorsuperfamily, member 6) FAS 16005713 altered by HU NM_152873; NM_152874;NM_152875; NM_152876; NM_152877 HYDROXYUREA NM_002266 karyopherin alpha2 (RAG cohort 1, importin alpha 1) KPNA2 17374387 HYDROXYUREA NM_003981;NM_199413; NM_199414 protein regulator of cytokinesis 1 PRC1 17374387HYDROXYUREA NM_001005290; NM_001032290; NM_001032291;proline/serine-rich coiled-coil 1 PSRC1 17374387 NM_032636 HYDROXYUREANM_001033 ribonucleotide reductase M1 RRM1 — unrelated HYDROXYUREANM_001034 ribonucleotide reductase M2 polypeptide RRM2 — resistanceHYDROXYUREA NM_000546; NM_001126112; NM_001126113; tumor protein p53TP53 16005713 death pathway NM_001126114; NM_001126115; NM_001126116;NM_001126117 HYDROXYUREA NM_007019; NM_181799; NM_181800;ubiquitin-conjugating enzyme E2C UBE2C 17374387 NM_181801; NM_181802;NM_181803 CAMPTOTHECIN NM_000927 ATP-binding cassette, sub-family B(MDR/TAP), ABCB1 10692111 resistance member 1 CAMPTOTHECIN NM_198576agrin AGRN 17374387 CAMPTOTHECIN NM_000477 albumin ALB 10803926,17378599 used as a drug carrier CAMPTOTHECIN NM_001153 annexin A4 ANXA417374387 CAMPTOTHECIN NM_004324; NM_138761; NM_138763; BCL2-associated Xprotein BAX 15665116, 17555331 NM_138764; NM_138765 CAMPTOTHECINNM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 10692111 CAMPTOTHECINNM_001012270; NM_001012271; NM_001168 baculoviral IAP repeat-containing5 BIRC5 16061681 CAMPTOTHECIN NM_007294; NM_007295; NM_007296; breastcancer 1, early onset BRCA1 10344722 NM_007297; NM_007298; NM_007299;NM_007300; NM_007302; NM_007303; NM_007304; NM_007305 CAMPTOTHECINNM_000059 breast cancer 2, early onset BRCA2 10344722 CAMPTOTHECINNM_001130849; NM_001130850; NM_016289 calcium binding protein 39 CAB3917374387 CAMPTOTHECIN NM_032982; NM_032983 caspase 2, apoptosis-relatedcysteine peptidase CASP2 14757846 CAMPTOTHECIN NM_004346; NM_032991caspase 3, apoptosis-related cysteine peptidase CASP3 16273314,16962673, 16962673 CAMPTOTHECIN NM_031966 cyclin B1 CCNB1 16061681CAMPTOTHECIN NM_001798; NM_052827 cyclin-dependent kinase 2 CDK215141020 CAMPTOTHECIN NM_000389; NM_078467 cyclin-dependent kinaseinhibitor 1A (p21, Cip1) CDKN1A 11741290, 9673414, 17555331 CAMPTOTHECINNM_001024912; NM_001712 carcinoembryonic antigen-related cell adhesionCEACAM1 17374387 molecule 1 (biliary glycoprotein) CAMPTOTHECINNM_005760 CCAAT/enhancer binding protein (C/EBP), zeta CEBPZ 17374387CAMPTOTHECIN NM_001908; NM_147780; NM_147781; cathepsin B CTSB 17378599NM_147782; NM_147783 CAMPTOTHECIN NM_001007277; NM_004879 etoposideinduced 2.4 mRNA EI24 17374387 CAMPTOTHECIN NM_001429 E1A bindingprotein p300 EP300 10344722 CAMPTOTHECIN NM_014805 EPM2A (laforin)interacting protein 1 EPM2AIP1 17374387 CAMPTOTHECIN NM_004110;NM_024417 ferredoxin reductase FDXR 17374387 CAMPTOTHECIN NM_000852glutathione S-transferase pi 1 GSTP1 15500952, 15500952, 14732228CAMPTOTHECIN NM_001077442; NM_001077443; NM_004500; heterogeneousnuclear ribonucleoprotein C (C1/C2) HNRNPC 16960656 NM_031314CAMPTOTHECIN NM_000576 interleukin 1, beta IL1B 16356833 CAMPTOTHECINNM_000584 interleukin 8 IL8 16356833 CAMPTOTHECIN NM_002228 jun oncogeneJUN 15585644 CAMPTOTHECIN NM_002756; NM_145109 mitogen-activated proteinkinase kinase 3 MAP2K3 17374387 CAMPTOTHECIN NM_005923 mitogen-activatedprotein kinase kinase kinase 5 MAP3K5 17374387 CAMPTOTHECINNM_001135044; NM_002752; NM_139068; mitogen-activated protein kinase 9MAPK9 15585644 NM_139069; NM_139070 CAMPTOTHECIN NM_001145336;NM_001145337; NM_001145339; Mdm2 p53 binding protein homolog (mouse)MDM2 17555331 NM_001145340; NM_002392; NM_006878; NM_006879; NM_006881;NM_006882 CAMPTOTHECIN NM_001004720; NM_001004722; NM_003581 NCK adaptorprotein 2 NCK2 17374387 CAMPTOTHECIN NM_001618 poly (ADP-ribose)polymerase 1 PARP1 11741290, 15585644, 16962673, 15585644, 16962673CAMPTOTHECIN NM_004073 polo-like kinase 3 (Drosophila) PLK3 17374387CAMPTOTHECIN NM_032192; NM_181505 protein phosphatase 1, regulatory(inhibitor) subunit 1B PPP1R1B 16061638 CAMPTOTHECIN NM_003981;NM_199413; NM_199414 protein regulator of cytokinesis 1 PRC1 17374387CAMPTOTHECIN NM_002875; NM_133487 RAD51 homolog (RecA homolog, E. coli)(S. cerevisiae) RAD51 10344722 CAMPTOTHECIN NM_000321 retinoblastoma 1RB1 14704340, 15585644 CAMPTOTHECIN NM_002895; NM_183404retinoblastoma-like 1 (p107) RBL1 15585644 CAMPTOTHECIN NM_005611retinoblastoma-like 2 (p130) RBL2 15585644 CAMPTOTHECIN NM_001006946;NM_002997 syndecan 1 SDC1 17374387 CAMPTOTHECIN NM_000593 transporter 1,ATP-binding cassette, sub-family B TAP1 17374387 (MDR/TAP) CAMPTOTHECINNM_014604 Tax1 (human T-cell leukemia virus type I) binding TAX1BP317374387 protein 3 CAMPTOTHECIN NM_003246 thrombospondin 1 THBS116962673 CAMPTOTHECIN NM_003811 tumor necrosis factor (ligand)superfamily, member 9 TNFSF9 17374387 CAMPTOTHECIN NM_003286topoisomerase (DNA) I TOP1 — CAMPTOTHECIN NM_000546; NM_001126112;NM_001126113; tumor protein p53 TP53 10692111, 11741290, 17555331,NM_001126114; NM_001126115; 9673414, 9673414, 17555331, NM_001126116;NM_001126117 12082016 CAMPTOTHECIN NM_004881; NM_147184 tumor proteinp53 inducible protein 3 TP53I3 17374387 CAMPTOTHECIN NR_015381;NR_015381; NR_015381; TP53 target 1 (non-protein coding) TP53TG117374387 NR_015381; NR_015381; NR_015381; NR_015381; NR_015381CAMPTOTHECIN NM_001025366; NM_001025367; NM_001025368; vascularendothelial growth factor A VEGFA 16356833 NM_001025369; NM_001025370;NM_001033756; NM_003376 CAMPTOTHECIN NM_001167 X-linked inhibitor ofapoptosis XIAP 16061681, 16211302 TOPOTECAN NM_004827 ATP-bindingcassette, sub-family G (WHITE), member 2 ABCG2 15695404, 15875186,17032904, resistance 17032904 TOPOTECAN NM_001668; NM_178426; NM_178427aryl hydrocarbon receptor nuclear translocator ARNT 15930297 TOPOTECANNM_002105 H2A histone family, member X H2AFX 16432175 TOPOTECANNM_001530; NM_181054 hypoxia inducible factor 1, alpha subunit (basichelix- HIF1A 15930297 target loop-helix transcription factor) TOPOTECANNM_003286 topoisomerase (DNA) I TOP1 — target TOPOTECAN NM_052963topoisomerase (DNA) I, mitochondrial TOP1MT — target TOPOTECANNM_001025366; NM_001025367; NM_001025368; vascular endothelial growthfactor A VEGFA 15930297 target NM_001025369; NM_001025370; NM_001033756;NM_003376 IRINOTECAN NM_000927 ATP-binding cassette, sub-family B(MDR/TAP), ABCB1 12960109, 15655543, 15801936, resistance member 116815871 IRINOTECAN NM_004996; NM_019862; NM_019898; ATP-bindingcassette, sub-family C (CFTR/MRP), ABCC1 15897249, 16815871, 18927307resistance NM_019899; NM_019900 member 1 IRINOTECAN NM_000392ATP-binding cassette, sub-family C (CFTR/MRP), ABCC2 16815871, 18981587resistance member 2 IRINOTECAN NM_001105515; NM_005845 ATP-bindingcassette, sub-family C (CFTR/MRP), ABCC4 15827327 resistance member 4IRINOTECAN NM_004827 ATP-binding cassette, sub-family G (WHITE), member2 ABCG2 15239142, 15695404, 15655543, resistance 15801936 IRINOTECANNM_032859 abhydrolase domain containing 13 ABHD13 18927307 IRINOTECANNM_198834; NM_198836; NM_198837; acetyl-Coenzyme A carboxylase alphaACACA 18927307 NM_198838; NM_198839 IRINOTECAN NM_023038; NM_033274 ADAMmetallopeptidase domain 19 (meltrin beta) ADAM19 18927307 IRINOTECANNM_001121; NM_016824; NM_019903 adducin 3 (gamma) ADD3 15956246IRINOTECAN NM_018269 acireductone dioxygenase 1 ADI1 18927307 IRINOTECANNM_000029 angiotensinogen (serpin peptidase inhibitor, clade A, AGT18927307 member 8) IRINOTECAN NM_007202 A kinase (PRKA) anchor protein10 AKAP10 15956246 IRINOTECAN NM_000032; NM_001037967; NM_001037968aminolevulinate, delta-, synthase 2 ALAS2 15956246 IRINOTECAN NM_000477albumin ALB 18927307 IRINOTECAN NM_000689 aldehyde dehydrogenase 1family, member A1 ALDH1A1 15956246 IRINOTECAN NM_001143668; NM_181847adhesion molecule with Ig-like domain 2 AMIGO2 18927307 IRINOTECANNM_012098 angiopoietin-like 2 ANGPTL2 17327601 IRINOTECAN NM_032217;NM_198889 ankyrin repeat domain 17 ANKRD17 18927307 IRINOTECAN NM_015199ankyrin repeat domain 28 ANKRD28 18927307 IRINOTECAN NM_001003954;NM_004306 annexin A13 ANXA13 18927307 IRINOTECAN NM_001155; NM_004033annexin A6 ANXA6 15956246 IRINOTECAN NM_001030006; NM_001282adaptor-related protein complex 2, beta 1 subunit AP2B1 18927307IRINOTECAN NM_000038; NM_001127510; NM_001127511 adenomatous polyposiscoli APC 15956246 IRINOTECAN NM_001654 v-raf murine sarcoma 3611 viraloncogene homolog ARAF 15956246 IRINOTECAN NM_001657 amphiregulin AREG15723263 IRINOTECAN NM_001024226; NM_001024227; NM_001024228;ADP-ribosylation factor 1 ARF1 18927307 NM_001658 IRINOTECANNM_001030055; NM_001173 Rho GTPase activating protein 5 ARHGAP5 15956246IRINOTECAN NM_015313 Rho guanine nucleotide exchange factor (GEF) 12ARHGEF12 18927307 IRINOTECAN NM_152641 AT rich interactive domain 2(ARID, RFX-like) ARID2 18927307 IRINOTECAN NM_002892; NM_023000;NM_023001 AT rich interactive domain 4A (RBP1-like) ARID4A 15956246IRINOTECAN — — ARL6IP2 18927307 IRINOTECAN — — ARL7 18927307 IRINOTECANNM_014154; NM_015396; NM_213654 armadillo repeat containing 8 ARMC818927307 IRINOTECAN NM_000046; NM_198709 arylsulfatase B ARSB 18927307IRINOTECAN NM_001030287; NM_001040619; NM_001674; activatingtranscription factor 3 ATF3 15956246 NM_004024 IRINOTECAN NM_001131028;NM_031482 ATG10 autophagy related 10 homolog (S. cerevisiae) ATG1015956246 IRINOTECAN NM_001697 ATP synthase, H+ transporting,mitochondrial F1 ATP5O 17327601 complex, O subunit IRINOTECANNM_001003803; NM_001003805; NM_015684 ATP synthase, H+ transporting,mitochondrial F0 ATP5S 18927307 complex, subunit s (factor B) IRINOTECANNM_001141972; NM_080650 ATP binding domain 4 ATPBD4 18927307 IRINOTECANNM_000489; NM_138270 alpha thalassemia/mental retardation syndrome X-ATRX 18927307 linked (RAD54 homolog, S. cerevisiae) IRINOTECAN NM_004217aurora kinase B AURKB 15956246 IRINOTECAN NM_012342 BMP and activinmembrane-bound inhibitor homolog BAMBI 18927307 (Xenopus laevis)IRINOTECAN NM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 18949393IRINOTECAN NM_001024808; NM_020993 B-cell CLL/lymphoma 7A BCL7A 15956246IRINOTECAN NM_004326 B-cell CLL/lymphoma 9 BCL9 15956246 IRINOTECANNM_004327; NM_021574 breakpoint cluster region BCR 18927307 IRINOTECANNM_001012270; NM_001012271; NM_001168 baculoviral IAP repeat-containing5 BIRC5 15956246, 16373703 IRINOTECAN — — BM1_06115 18927307 IRINOTECANNM_181809 bone morphogenetic protein 8a BMP8A 15956246 IRINOTECANNM_033030; NM_197970 bol, boule-like (Drosophila) BOLL 17327601IRINOTECAN NM_014962; NM_181443 BTB (POZ) domain containing 3 BTBD318927307 IRINOTECAN NM_004336 budding uninhibited by benzimidazoles 1homolog BUB1 15956246 (yeast) IRINOTECAN — — C11ORF80 18927307IRINOTECAN — — C14ORF118 18927307 IRINOTECAN — — C15ORF5 18927307IRINOTECAN — — C16ORF87 18927307 IRINOTECAN — — C1ORF43 18927307IRINOTECAN — — C5ORF28 18927307 IRINOTECAN — — C7ORF44 18927307IRINOTECAN — — C9ORF100 18927307 IRINOTECAN — — C9ORF126 18927307IRINOTECAN — — C9ORF25 18927307 IRINOTECAN NM_012295 calcineurin bindingprotein 1 CABIN1 18927307 IRINOTECAN NM_001003406; NM_021096 calciumchannel, voltage-dependent, T type, alpha 1I CACNA1I 18927307 subunitIRINOTECAN NM_001225; NM_033306 caspase 4, apoptosis-related cysteinepeptidase CASP4 15956246 IRINOTECAN NM_019083 coiled-coil domaincontaining 76 CCDC76 18927307 IRINOTECAN NM_001237 cyclin A2 CCNA215956246 IRINOTECAN NM_004701 cyclin B2 CCNB2 15956246 IRINOTECANNM_001761 cyclin F CCNF 15956246 IRINOTECAN NM_004354 cyclin G2 CCNG218927307 IRINOTECAN NM_001295 chemokine (C-C motif) receptor 1 CCR115956246 IRINOTECAN NM_004367; NM_031409 chemokine (C-C motif) receptor6 CCR6 15956246 IRINOTECAN NM_001009186; NM_001762 chaperonin containingTCP1, subunit 6A (zeta 1) CCT6A 18927307 IRINOTECAN NM_001025079;NM_001777; NM_198793 CD47 molecule CD47 18927307 IRINOTECAN NM_001252CD70 molecule CD70 15956246 IRINOTECAN NM_005191 CD80 molecule CD8015956246 IRINOTECAN NM_001130829; NM_001786; NM_033379 cell divisioncycle 2, G1 to S and G2 to M CDC2 15956246 IRINOTECAN NM_004358;NM_021872; NM_021873 cell division cycle 25 homolog B (S. pombe) CDC25B15956246 IRINOTECAN NM_003718; NM_031267 cell division cycle 2-like 5(cholinesterase-related cell CDC2L5 15956246 division controller)IRINOTECAN NM_003607; NM_014826 CDC42 binding protein kinase alpha(DMPK-like) CDC42BPA 18927307 IRINOTECAN NM_001794 cadherin 4, type 1,R-cadherin (retinal) CDH4 18927307 IRINOTECAN NM_003936 cyclin-dependentkinase 5, regulatory subunit 2 (p39) CDK5R2 15956246 IRINOTECANNM_001145306; NM_001259 cyclin-dependent kinase 6 CDK6 18927307IRINOTECAN NM_000389; NM_078467 cyclin-dependent kinase inhibitor 1A(p21, Cip1) CDKN1A 15132777 IRINOTECAN NM_001130851; NM_005192cyclin-dependent kinase inhibitor 3 CDKN3 15956246 IRINOTECAN NM_016952Cdon homolog (mouse) CDON 18927307 IRINOTECAN NM_001813 centromereprotein E, 312 kDa CENPE 15956246, 18927307 IRINOTECAN NM_016343centromere protein F, 350/400ka (mitosin) CENPF 15956246 IRINOTECAN — —CENTG2 18927307 IRINOTECAN NM_032142 centrosomal protein 192 kDa CEP19218927307 IRINOTECAN NM_025114 centrosomal protein 290 kDa CEP29018927307 IRINOTECAN NM_001025194; NM_001025195; NM_001266carboxylesterase 1 (monocyte/macrophage serine CES1 15100172, 15239142esterase 1) IRINOTECAN NM_003869; NM_198061 carboxylesterase 2(intestine, liver) CES2 10728672, 12171891, 11716702, 12171903,(following) 12171891, 15592324, 16203781, 11716702, 15475733, 14581373,15100172, 15592324, 15655543, 16033949, 16203781 IRINOTECAN NM_024922carboxylesterase 3 CES3 15100172 IRINOTECAN NM_001270 chromodomainhelicase DNA binding protein 1 CHD1 15956246 IRINOTECAN NM_001130675;NM_004362 calmegin CLGN 18927307 IRINOTECAN NM_004859 clathrin, heavychain (Hc) CLTC 18927307 IRINOTECAN NM_017649; NM_199076; NM_199077cyclin M2 CNNM2 18927307 IRINOTECAN NM_001130103; NM_005203; NM_080798;collagen, type XIII, alpha 1 COL13A1 18927307 NM_080799; NM_080800;NM_080801; NM_080802; NM_080803; NM_080804; NM_080805; NM_080806;NM_080807; NM_080808; NM_080809; NM_080810; NM_080811; NM_080812;NM_080813; NM_080814; NM_080815 IRINOTECAN NM_000092 collagen, type IV,alpha 4 COL4A4 18927307 IRINOTECAN NM_001848 collagen, type VI, alpha 1COL6A1 15956246 IRINOTECAN NM_203495; NM_203497 COMM domain containing 6COMMD6 15956246 IRINOTECAN NM_001098398; NM_004371 coatomer proteincomplex, subunit alpha COPA 18927307 IRINOTECAN NM_001873carboxypeptidase E CPE 18927307 IRINOTECAN NM_001079846; NM_004380 CREBbinding protein CREBBP 15956246, 18927307 IRINOTECAN NM_016441 cysteinerich transmembrane BMP regulator 1 CRIM1 18927307 (chordin-like)IRINOTECAN NM_020991; NM_022644; NM_022645 chorionic somatomammotropinhormone 2 CSH2 18927307 IRINOTECAN NM_001083914; NM_001329; NM_022802C-terminal binding protein 2 CTBP2 18927307 IRINOTECAN NM_001902;NM_153742 cystathionase (cystathionine gamma-lyase) CTH 18927307IRINOTECAN NM_001008895; NM_003589 cullin 4A CUL4A 18927307 IRINOTECANNM_000609; NM_001033886; NM_199168 chemokine (C—X—C motif) ligand 12(stromal cell- CXCL12 18927307 derived factor 1) IRINOTECAN NM_000761cytochrome P450, family 1, subfamily A, polypeptide 2 CYP1A2 11901092unrelated IRINOTECAN NM_000762 cytochrome P450, family 2, subfamily A,polypeptide 6 CYP2A6 11901092 IRINOTECAN NM_000767 cytochrome P450,family 2, subfamily B, polypeptide 6 CYP2B6 11901092 IRINOTECANNM_000769 cytochrome P450, family 2, subfamily C, polypeptide CYP2C1911901092 19 IRINOTECAN NM_000770 cytochrome P450, family 2, subfamily C,polypeptide 8 CYP2C8 11901092 unrelated IRINOTECAN NM_000771 cytochromeP450, family 2, subfamily C, polypeptide 9 CYP2C9 11901092 unrelatedIRINOTECAN NM_000106; NM_001025161 cytochrome P450, family 2, subfamilyD, polypeptide 6 CYP2D6 11901092 IRINOTECAN NM_000773 cytochrome P450,family 2, subfamily E, polypeptide 1 CYP2E1 11901092 IRINOTECANNM_017460 cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A411901092, 15100172, 15239142, drug 15523087, 15655543 metabolismIRINOTECAN NM_000777 cytochrome P450, family 3, subfamily A, polypeptide5 CYP3A5 15897249 drug metabolism IRINOTECAN NM_001142936; NM_139179diacylglycerol lipase, beta DAGLB 18927307 IRINOTECAN NM_014881 DNAcross-link repair 1A (PSO2 homolog, S. cerevisiae) DCLRE1A 15956246IRINOTECAN NM_006400 dynactin 2 (p50) DCTN2 18927307 IRINOTECANNM_000107 damage-specific DNA binding protein 2, 48 kDa DDB2 15956246IRINOTECAN NM_030637 DDHD domain containing 1 DDHD1 18927307 IRINOTECANNM_001039711; NM_001039712; NM_032998 death effector domain containingDEDD 18927307 IRINOTECAN NM_004084 defensin, alpha 1 DEFA1 15956246IRINOTECAN NM_001144823; NM_005848 DENN/MADD domain containing 4ADENND4A 15956246 IRINOTECAN NM_003677 density-regulated protein DENR18927307 IRINOTECAN NM_001145208; NM_018369 DEP domain containing 1BDEPDC1B 18927307 IRINOTECAN NM_022720 DiGeorge syndrome critical regiongene 8 DGCR8 18927307 IRINOTECAN NM_176815 dihydrofolate reductase-like1 DHFRL1 18927307 IRINOTECAN NM_001146114; NM_001146115; NM_015151; DIP2disco-interacting protein 2 homolog A DIP2A 18927307 NM_206889;NM_206890; NM_206891 (Drosophila) IRINOTECAN NM_006094; NM_024767;NM_182643 deleted in liver cancer 1 DLC1 18927307 IRINOTECANNM_001098424; NM_004087 discs, large homolog 1 (Drosophila) DLG118927307 IRINOTECAN NM_001934; NM_138281 distal-less homeobox 4 DLX418927307 IRINOTECAN NM_004943 dystrophia myotonica, WD repeat containingDMWD 15956246 IRINOTECAN — — DNMT2 15956246 IRINOTECAN NM_001039589;NM_001384 DPH2 homolog (S. cerevisiae) DPH2 18927307 IRINOTECANNM_000110 dihydropyrimidine dehydrogenase DPYD 15956246 IRINOTECANNM_000798 dopamine receptor D5 DRD5 17327601 IRINOTECAN NM_004147developmentally regulated GTP binding protein 1 DRG1 15897249 IRINOTECANNM_001144769; NM_001144770; NM_001144771; dystonin DST 18927307NM_001723; NM_015548; NM_020388; NM_183380 IRINOTECAN NM_004418 dualspecificity phosphatase 2 DUSP2 15956246 IRINOTECAN NM_001396;NM_101395; NM_130436; dual-specificity tyrosine-(Y)-phosphorylationregulated DYRK1A 15956246 NM_130437; NM_130438 kinase 1A IRINOTECANNM_003583; NM_006482 dual-specificity tyrosine-(Y)-phosphorylationregulated DYRK2 15956246 kinase 2 IRINOTECAN — — EBI2 15956246IRINOTECAN NM_005228; NM_201282; NM_201283; epidermal growth factorreceptor (erythroblastic EGFR 15723263 NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) IRINOTECAN NM_001964 early growthresponse 1 EGR1 15956246 IRINOTECAN NM_001013703 eukaryotic translationinitiation factor 2 alpha kinase 4 EIF2AK4 18927307 IRINOTECAN NM_012155echinoderm microtubule associated protein like 2 EML2 17327601IRINOTECAN NM_001428 enolase 1, (alpha) ENO1 18927307 IRINOTECANNM_001429 E1A binding protein p300 EP300 15956246 IRINOTECAN NM_031308epiplakin 1 EPPK1 18927307 IRINOTECAN NM_001042599; NM_005235 v-erb-aerythroblastic leukemia viral oncogene ERBB4 15956246 homolog 4 (avian)IRINOTECAN NM_015064; NM_178037; NM_178038; ELKS/RAB6-interacting/CASTfamily member 1 ERC1 18927307 NM_178039; NM_178040 IRINOTECAN NM_001432epiregulin EREG 18927307 IRINOTECAN NM_005239 v-ets erythroblastosisvirus E26 oncogene homolog 2 ETS2 15956246 (avian) IRINOTECAN NM_001987ets variant 6 ETV6 15956246 IRINOTECAN NM_001037126; NM_021807 exocystcomplex component 4 EXOC4 18927307 IRINOTECAN NM_000132; NM_019863coagulation factor VIII, procoagulant component F8 17327601 IRINOTECANNM_001040442; NM_001130958; NM_001445 fatty acid binding protein 6,ileal FABP6 18927307 IRINOTECAN — — FAM152A 18927307 IRINOTECANNM_001040020; NM_014888 family with sequence similarity 3, member CFAM3C 18927307 IRINOTECAN — — FAM44A 18927307 IRINOTECAN NM_004629Fanconi anemia, complementation group G FANCG 15956246 IRINOTECANNM_005687 phenylalanyl-tRNA synthetase, beta subunit FARSB 18927307IRINOTECAN NM_000639 Fas ligand (TNF superfamily, member 6) FASLG15897249 IRINOTECAN NM_015962 FCF1 small subunit (SSU) processomecomponent FCF1 18927307 homolog (S. cerevisiae) IRINOTECAN NM_002006fibroblast growth factor 2 (basic) FGF2 15956246 IRINOTECAN NM_002010fibroblast growth factor 9 (glia-activating factor) FGF9 18927307IRINOTECAN NM_002026; NM_054034; NM_212474; fibronectin 1 FN1 15956246,18927307 NM_212475; NM_212476; NM_212478; NM_212482 IRINOTECAN NM_005252v-fos FBJ murine osteosarcoma viral oncogene FOS 15956246 homologIRINOTECAN NM_001114171; NM_006732 FBJ murine osteosarcoma viraloncogene homolog B FOSB 15956246 IRINOTECAN NM_032892 FERM domaincontaining 5 FRMD5 18927307 IRINOTECAN NM_001080432 fat mass and obesityassociated FTO 18927307 IRINOTECAN NM_001465; NM_199335 FYN bindingprotein (FYB-120/130) FYB 18927307 IRINOTECAN — — G1P3 18927307IRINOTECAN NM_001002295; NM_002051 GATA binding protein 3 GATA3 15956246IRINOTECAN NM_004864 growth differentiation factor 15 GDF15 15956246IRINOTECAN NM_001032364; NM_001032365; NM_005265;gamma-glutamyltransferase 1 GGT1 18927307 NM_013430 IRINOTECAN NM_000165gap junction protein, alpha 1, 43 kDa GJA1 18927307 IRINOTECANNM_000167; NM_001128127; NM_203391 glycerol kinase GK 18927307IRINOTECAN NM_006541 glutaredoxin 3 GLRX3 18927307 IRINOTECAN NM_006572guanine nucleotide binding protein (G protein), alpha GNA13 18927307 13IRINOTECAN NM_181077 golgi autoantigen, golgin subfamily a, 8A GOLGA8A17327601 IRINOTECAN NM_015590; NM_182679 G patch domain containing 4GPATCH4 18927307 IRINOTECAN NM_002084 glutathione peroxidase 3 (plasma)GPX3 15956246 IRINOTECAN NM_002105 H2A histone family, member X H2AFX15956246 IRINOTECAN NM_001945 heparin-binding EGF-like growth factorHBEGF 15723263 IRINOTECAN NM_000559 hemoglobin, gamma A HBG1 18927307IRINOTECAN NM_005334 host cell factor C1 (VP16-accessory protein) HCFC118927307 IRINOTECAN NM_173497; NM_182765 HECT domain containing 2 HECTD218927307 IRINOTECAN NM_018063 helicase, lymphoid-specific HELLS 18927307IRINOTECAN NM_005524 hairy and enhancer of split 1, (Drosophila) HES119147571 IRINOTECAN NM_003512 histone cluster 1, H2ac HIST1H2AC 15956246IRINOTECAN NM_003542 histone cluster 1, H4c HIST1H4C 18927307 IRINOTECANNM_005514 major histocompatibility complex, class I, B HLA-B 18927307IRINOTECAN NM_002124 major histocompatibility complex, class II, DR beta1 HLA- 18927307 DRB1 IRINOTECAN NM_021983 major histocompatibilitycomplex, class II, DR beta 4 HLA- 18927307 DRB4 IRINOTECAN NM_001142556;NM_001142557; NM_012484; hyaluronan-mediated motility receptor (RHAMM)HMMR 15956246 NM_012485 IRINOTECAN NM_001002032; NM_001002033; NM_016185hematological and neurological expressed 1 HN1 18927307 IRINOTECAN — —HNRPA1 18927307 IRINOTECAN — — HNRPD 18927307 IRINOTECAN NM_031372heterogeneous nuclear ribonucleoprotein D-like HNRPDL 18927307IRINOTECAN NM_000412 histidine-rich glycoprotein HRG 15956246 IRINOTECANNM_006041 heparan sulfate (glucosamine) 3-O-sulfotransferase HS3ST3B118927307 3B1 IRINOTECAN NM_014278 heat shock 70 kDa protein 4-likeHSPA4L 15956246 IRINOTECAN — — HYPK 18927307 IRINOTECAN NM_002166inhibitor of DNA binding 2, dominant negative helix- ID2 15956246loop-helix protein IRINOTECAN NM_003641 interferon induced transmembraneprotein 1 (9-27) IFITM1 18927307 IRINOTECAN NM_000618; NM_001111283;NM_001111284; insulin-like growth factor 1 (somatomedin C) IGF1 15956246NM_001111285 IRINOTECAN — immunoglobulin heavy constant gamma 1 (G1mIGHG1 18927307 marker) IRINOTECAN NM_000576 interleukin 1, beta IL1B15956246 IRINOTECAN NM_000584 interleukin 8 IL8 15723263 IRINOTECANNM_032549 IMP2 inner mitochondrial membrane IMMP2L 18927307peptidase-like (S. cerevisiae) IRINOTECAN NM_001100169; NM_001100170;NM_006839 inner membrane protein, mitochondrial (mitofilin) IMMT18927307 IRINOTECAN NM_019071; NM_198267 inhibitor of growth family,member 3 ING3 18927307 IRINOTECAN NM_005542; NM_198336; NM_198337insulin induced gene 1 INSIG1 18927307 IRINOTECAN NM_002203 integrin,alpha 2 (CD49B, alpha 2 subunit of VLA-2 ITGA2 18927307 receptor)IRINOTECAN NM_001144999; NM_001145000; NM_002210 integrin, alpha V(vitronectin receptor, alpha ITGAV 15956246 polypeptide, antigen CD51)IRINOTECAN NM_000887 integrin, alpha X (complement component 3 receptor4 ITGAX 15956246 subunit) IRINOTECAN NM_014288 integrin beta 3 bindingprotein (beta3-endonexin) ITGB3BP 15956246 IRINOTECAN NM_002228 junoncogene JUN 15956246 IRINOTECAN NM_006559 KH domain containing, RNAbinding, signal KHDRBS1 18927307 transduction associated 1 IRINOTECANNM_001162893; NM_001162894; NM_001162895; KIAA0040 KIAA0040 18927307NM_014656 IRINOTECAN NM_015443 KIAA1267 KIAA1267 18927307 IRINOTECAN — —KIAA1333 18927307 IRINOTECAN NM_033395 KIAA1731 KIAA1731 18927307IRINOTECAN NM_014875 kinesin family member 14 KIF14 18927307 IRINOTECANNM_004235 Kruppel-like factor 4 (gut) KLF4 18927307 IRINOTECAN NM_001206Kruppel-like factor 9 KLF9 15956246 IRINOTECAN NM_017644 kelch-like 24(Drosophila) KLHL24 18927307 IRINOTECAN NM_001013406; NM_004912;NM_194454; KRIT1, ankyrin repeat containing KRIT1 18927307 NM_194455;NM_194456 IRINOTECAN NM_000424 keratin 5 KRT5 15956246 IRINOTECANNM_030915 limb bud and heart development homolog (mouse) LBH 18927307IRINOTECAN NM_006499; NM_201543; NM_201544; lectin, galactoside-binding,soluble, 8 LGALS8 17327601 NM_201545 IRINOTECAN — — LIM 18927307IRINOTECAN NM_032603 lysyl oxidase-like 3 LOXL3 18927307 IRINOTECANNM_024830 lysophosphatidylcholine acyltransferase 1 LPCAT1 18927307IRINOTECAN NM_032773 leucine-rich repeats and calponin homology (CH)LRCH3 18927307 domain containing 3 IRINOTECAN NM_002343 lactotransferrinLTF 15956246 IRINOTECAN NM_032860 LTV1 homolog (S. cerevisiae) LTV118927307 IRINOTECAN NM_002358 MAD2 mitotic arrest deficient-like 1(yeast) MAD2L1 15956246 IRINOTECAN NM_002371; NM_022438; NM_022439; mal,T-cell differentiation protein MAL 15956246 NM_022440 IRINOTECANNR_002819; NR_002819; NR_002819; metastasis associated lungadenocarcinoma transcript MALAT1 18927307 NR_002819; NR_002819;NR_002819 1 (non-protein coding) IRINOTECAN NM_005434 mal, T-celldifferentiation protein-like MALL 15956246 IRINOTECAN NM_005923mitogen-activated protein kinase kinase kinase 5 MAP3K5 15956246IRINOTECAN NM_003618 mitogen-activated protein kinase kinase kinasekinase 3 MAP4K3 18927307 IRINOTECAN NM_005885 membrane-associated ringfinger (C3HC4) 6 MARCH6 18927307 IRINOTECAN NM_002380; NM_030583matrilin 2 MATN2 18927307 IRINOTECAN NM_018834; NM_199189 matrin 3 MATR318927307 IRINOTECAN NM_021038; NM_207292; NM_207293; muscleblind-like(Drosophila) MBNL1 18927307 NM_207294; NM_207295; NM_207296; NM_207297IRINOTECAN NM_001025081; NM_001025090; NM_001025092; myelin basicprotein MBP 18927307 NM_001025100; NM_001025101; NM_002385 IRINOTECANNM_022132 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) MCCC2 18927307IRINOTECAN NM_001112732; NM_024979 MCF.2 cell line derived transformingsequence-like MCF2L 15956246 IRINOTECAN NM_005914; NM_182746minichromosome maintenance complex component 4 MCM4 15956246 IRINOTECANNM_001145336; NM_001145337; NM_001145339; Mdm2 p53 binding proteinhomolog (mouse) MDM2 15956246 NM_001145340; NM_002392; NM_006878;NM_006879; NM_006881; NM_006882 IRINOTECAN NM_014611 MDN1, midasinhomolog (yeast) MDN1 18927307 IRINOTECAN NM_005121 mediator complexsubunit 13 MED13 18927307 IRINOTECAN NM_001145785 myocyte enhancerfactor 2B MEF2B 15956246 IRINOTECAN NM_002412 O-6-methylguanine-DNAmethyltransferase MGMT 15239142 IRINOTECAN NM_012064 major intrinsicprotein of lens fiber MIP 18927307 IRINOTECAN NR_027350; XR_079513;XR_079513; microRNA host gene 1 (non-protein coding) MIRHG1 18927307XR_079539; XR_079539; XR_079554; XR_079554 IRINOTECAN NM_173576 mohawkhomeobox MKX 18927307 IRINOTECAN NM_000249 mutL homolog 1, colon cancer,MLH1 18949393 nonpolyposis type 2 (E. coli) IRINOTECAN NM_004994 matrixmetallopeptidase 9 (gelatinase B, 92 kDa MMP9 15956246 gelatinase, 92kDa type IV collagenase) IRINOTECAN NM_000250 myeloperoxidase MPO15956246 IRINOTECAN NM_173496 membrane protein, palmitoylated 7 (MAGUKp55 MPP7 18927307 subfamily member 7) IRINOTECAN NM_016640 mitochondrialribosomal protein S30 MRPS30 18927307 IRINOTECAN NM_000251 mutS homolog2, colon cancer, nonpolyposis type 1 MSH2 15956246, 18949393 (E. coli)IRINOTECAN NM_015440 methylenetetrahydrofolate dehydrogenase (NADP+MTHFD1L 18927307 dependent) 1-like IRINOTECAN NM_0064415,10-methenyltetrahydrofolate synthetase (5- MTHFS 15956246formyltetrahydrofolate cyclo-ligase) IRINOTECAN NM_002463 myxovirus(influenza virus) resistance 2 (mouse) MX2 15956246 IRINOTECAN NM_005964myosin, heavy chain 10, non-muscle MYH10 18927307 IRINOTECANNM_001085487 Myb-like, SWIRM and MPN domains 1 MYSM1 18927307 IRINOTECANNM_153029 NEDD4 binding protein 1 N4BP1 18927307 IRINOTECAN NM_017940neuroblastoma breakpoint family, member 1 NBPF1 18927307 IRINOTECANNM_006153 NCK adaptor protein 1 NCK1 15956246 IRINOTECAN NM_003743;NM_147223; NM_147233 nuclear receptor coactivator 1 NCOA1 15956246IRINOTECAN NM_006311 nuclear receptor co-repressor 1 NCOR1 18927307IRINOTECAN NM_015331 nicastrin NCSTN 19147571 IRINOTECAN NM_002497 NIMA(never in mitosis gene a)-related kinase 2 NEK2 15956246 IRINOTECANNM_006018 niacin receptor 2 NIACR2 15956246 IRINOTECAN NM_002508 nidogen1 NID1 15956246 IRINOTECAN NM_000903; NM_001025433; NM_001025434 NAD(P)Hdehydrogenase, quinone 1 NQO1 18927307 IRINOTECAN NM_006178N-ethylmaleimide-sensitive factor NSF 18927307 IRINOTECAN NM_005124nucleoporin 153 kDa NUP153 18927307 IRINOTECAN NM_001129897; NM_016359;NM_018454 nucleolar and spindle associated protein 1 NUSAP1 18927307IRINOTECAN NM_002547 oligophrenin 1 OPHN1 18927307 IRINOTECAN NM_003999oncostatin M receptor OSMR 15956246 IRINOTECAN NM_018440 phosphoproteinassociated with glycosphingolipid PAG1 18927307 microdomains 1IRINOTECAN NM_000919; NM_138766; NM_138821; peptidylglycinealpha-amidating monooxygenase PAM 18927307 NM_138822 IRINOTECANNM_175854 PAN3 poly(A) specific ribonuclease subunit homolog PAN318927307 (S. cerevisiae) IRINOTECAN NM_016734 paired box 5 PAX5 18927307IRINOTECAN NM_001135254; NM_002584; NM_013945 paired box 7 PAX7 18927307IRINOTECAN — — PCAF 18927307 IRINOTECAN NM_032151 pterin-4alpha-carbinolamine dehydratase/dimerization PCBD2 18927307 cofactor ofhepatocyte nuclear factor 1 alpha (TCF1) 2 IRINOTECAN NM_002588;NM_032402; NM_032403 protocadherin gamma subfamily C, 3 PCDHGC3 15956246IRINOTECAN NM_001037339; NM_001037340; NM_001037341; phosphodiesterase4B, cAMP-specific PDE4B 15956246 NM_002600 (phosphodiesterase E4 duncehomolog, Drosophila) IRINOTECAN NM_173582 phosphoglucomutase 2-like 1PGM2L1 18927307 IRINOTECAN NM_007350 pleckstrin homology-like domain,family A, member 1 PHLDA1 18927307 IRINOTECAN NR_003700; NR_003700;NR_003700; phosphatidylinositol 4-kinase, catalytic, alpha PI4KAP215956246 NR_003700 pseudogene 2 IRINOTECAN NM_178517phosphatidylinositol glycan anchor biosynthesis, class W PIGW 18927307IRINOTECAN NM_000930; NM_033011 plasminogen activator, tissue PLAT18927307 IRINOTECAN NM_001134478; NM_153268phosphatidylinositol-specific phospholipase C, X PLCXD2 18927307 domaincontaining 2 IRINOTECAN NM_001143821; NM_019012 pleckstrin homologydomain containing, family A PLEKHA5 18927307 member 5 IRINOTECANNM_024927 pleckstrin homology domain containing, family H (with PLEKHH315956246 MyTH4 domain) member 3 IRINOTECAN NM_005030 polo-like kinase 1(Drosophila) PLK1 15956246 IRINOTECAN NM_006622 polo-like kinase 2(Drosophila) PLK2 15956246 IRINOTECAN NM_004073 polo-like kinase 3(Drosophila) PLK3 15956246 IRINOTECAN NM_021127phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 15956246IRINOTECAN NM_006813 proline-rich nuclear receptor coactivator 1 PNRC118927307 IRINOTECAN NM_015100; NM_145796; NM_207171 pogo transposableelement with ZNF domain POGZ 18927307 IRINOTECAN NM_016218 polymerase(DNA directed) kappa POLK 18927307 IRINOTECAN NM_000941 P450(cytochrome) oxidoreductase POR 15239142 IRINOTECAN NM_003620 proteinphosphatase 1D magnesium-dependent, delta PPM1D 18927307 isoformIRINOTECAN NM_000944; NM_001130691; NM_001130692 protein phosphatase 3(formerly 2B), catalytic subunit, PPP3CA 18927307 alpha isoformIRINOTECAN NM_001142353; NM_001142354; NM_021132 protein phosphatase 3(formerly 2B), catalytic subunit, PPP3CB 15956246 beta isoformIRINOTECAN NM_006251; NM_206907 protein kinase, AMP-activated, alpha 1catalytic PRKAA1 18927307 subunit IRINOTECAN NM_002737 protein kinase C,alpha PRKCA 15723263 IRINOTECAN NM_002738; NM_212535 protein kinase C,beta PRKCB 15723263 IRINOTECAN NM_006254; NM_212539 protein kinase C,delta PRKCD 15723263 IRINOTECAN NM_002740 protein kinase C, iota PRKCI15723263 IRINOTECAN NM_001145848; NM_001145849; NM_001145850; prominin 1PROM1 15956246 NM_001145851; NM_001145852; NM_006017 IRINOTECANNM_002784 pregnancy specific beta-1-glycoprotein 9 PSG9 17327601IRINOTECAN NM_004878 prostaglandin E synthase PTGES 15956246 IRINOTECANNM_005607; NM_153831 PTK2 protein tyrosine kinase 2 PTK2 18927307IRINOTECAN NM_003463 protein tyrosine phosphatase type IVA, member 1PTP4A1 18927307 IRINOTECAN NM_006264; NM_080683; NM_080684; proteintyrosine phosphatase, non-receptor type 13 PTPN13 15956246 NM_080685(APO-1/CD95 (Fas)-associated phosphatase) IRINOTECAN NM_012411;NM_015967 protein tyrosine phosphatase, non-receptor type 22 PTPN2215956246 (lymphoid) IRINOTECAN NM_001040712; NM_002839; NM_130391;protein tyrosine phosphatase, receptor type, D PTPRD 15956246 NM_130392;NM_130393 IRINOTECAN NM_002841 protein tyrosine phosphatase, receptortype, G PTPRG 18927307 IRINOTECAN NM_002846 protein tyrosinephosphatase, receptor type, N PTPRN 15956246 IRINOTECAN NM_005052ras-related C3 botulinum toxin substrate 3 (rho family, RAC3 15956246small GTP binding protein Rac3) IRINOTECAN NM_002874 RAD23 homolog B (S.cerevisiae) RAD23B 15956246 IRINOTECAN NM_002877; NM_133509; NM_133510RAD51-like 1 (S. cerevisiae) RAD51L1 18927307 IRINOTECAN NM_002890;NM_022650 RAS p21 protein activator (GTPase activating protein) 1 RASA118927307 IRINOTECAN NM_000321 retinoblastoma 1 RB1 15132777 IRINOTECANNM_005057 retinoblastoma binding protein 5 RBBP5 15956246 IRINOTECANNM_002895; NM_183404 retinoblastoma-like 1 (p107) RBL1 15956246IRINOTECAN NM_001143941; NM_001143942; NM_153020 RNA binding motifprotein 24 RBM24 18927307 IRINOTECAN — — RBPSUH 18927307 IRINOTECANNM_021111 reversion-inducing-cysteine-rich protein with kazal RECK18927307 motifs IRINOTECAN NM_001145138; NM_021975 v-relreticuloendotheliosis viral oncogene homolog A RELA 15161687, 16685529(avian) IRINOTECAN NM_001128617; NM_031922 RALBP1 associated Eps domaincontaining 1 REPS1 18927307 IRINOTECAN NM_002915; NM_181558 replicationfactor C (activator 1) 3, 38 kDa RFC3 15956246 IRINOTECAN NM_002922regulator of G-protein signaling 1 RGS1 15956246 IRINOTECAN NM_015668regulator of G-protein signaling 22 RGS22 18927307 IRINOTECAN NM_021205ras homolog gene family, member U RHOU 18927307 IRINOTECAN — — RNF1218927307 IRINOTECAN NM_000968 ribosomal protein L4 RPL4 18927307IRINOTECAN NM_001001890; NM_001122607; NM_001754 runt-relatedtranscription factor 1 RUNX1 15956246 IRINOTECAN NM_017654 sterile alphamotif domain containing 9 SAMD9 18927307 IRINOTECAN NM_015474 SAM domainand HD domain 1 SAMHD1 18927307 IRINOTECAN — — SCD4 18927307 IRINOTECANNM_002999 syndecan 4 SDC4 15956246 IRINOTECAN NM_001077206;NM_001077207; NM_001077208; SEC31 homolog A (S. cerevisiae) SEC31A18927307 NM_014933; NM_016211 IRINOTECAN NM_006379 sema domain,immunoglobulin domain (Ig), short basic SEMA3C 18927307 domain,secreted, (semaphorin) 3C IRINOTECAN NM_001100409; NM_015571SUMO1/sentrin specific peptidase 6 SENP6 18927307 IRINOTECANNM_001136528; NM_001136529; NM_001136530; serpin peptidase inhibitor,clade E (nexin, plasminogen SERPINE2 17327601 NM_006216 activatorinhibitor type 1), member 2 IRINOTECAN NM_031459 sestrin 2 SESN215956246 IRINOTECAN NM_015048 SET domain containing 1B SETD1B 18927307IRINOTECAN NM_001080517 SET domain containing 5 SETD5 18927307IRINOTECAN NM_006142 stratifin SFN 16373703 IRINOTECAN NM_001145444;NM_001145445; NM_020706 splicing factor, arginine/serine-rich 15 SFRS1518927307 IRINOTECAN — — SGK 15956246, 18927307 IRINOTECAN NM_152524shugoshin-like 2 (S. pombe) SGOL2 18927307 IRINOTECAN NM_004696 solutecarrier family 16, member 4 (monocarboxylic SLC16A4 15956246 acidtransporter 5) IRINOTECAN NM_194255 solute carrier family 19 (folatetransporter), member 1 SLC19A1 18927307 IRINOTECAN NM_030631 solutecarrier family 25 (mitochondrial oxodicarboxylate SLC25A21 18927307carrier), member 21 IRINOTECAN NM_021194 solute carrier family 30 (zinctransporter), member 1 SLC30A1 18927307 IRINOTECAN NM_001130012;NM_004785 solute carrier family 9 (sodium/hydrogen exchanger), SLC9A3R215956246 member 3 regulator 2 IRINOTECAN NM_001145102; NM_001145103;NM_001145104; SMAD family member 3 SMAD3 18927307 NM_005902 IRINOTECANNM_015295 structural maintenance of chromosomes flexible hinge SMCHD118927307 domain containing 1 IRINOTECAN NM_001122964; NM_020463 SMEKhomolog 2, suppressor of mek1 (Dictyostelium) SMEK2 18927307 IRINOTECANNM_018225 smu-1 suppressor of mec-8 and unc-52 SMU1 18927307 homolog (C.elegans) IRINOTECAN NM_020429; NM_181349 SMAD specific E3 ubiquitinprotein ligase 1 SMURF1 18927307 IRINOTECAN — — SNAG1 15956246IRINOTECAN NM_003090 small nuclear ribonucleoprotein polypeptide A′SNRPA1 18927307 IRINOTECAN NM_003109; NM_138473 Sp1 transcription factorSP1 18927307 IRINOTECAN NM_003121 Spi-B transcription factor (Spi-1/PU.1related) SPIB 15956246 IRINOTECAN NM_007271 serine/threonine kinase 38STK38 15956246 IRINOTECAN NM_006282 serine/threonine kinase 4 STK415956246, 18927307 IRINOTECAN NM_001017389; NM_001017390sulfotransferase family, cytosolic, 1A, phenol- SULT1A4 15956246preferring, member 4 IRINOTECAN NM_032184 synapse defective 1, RhoGTPase, SYDE2 18927307 homolog 2 (C. elegans) IRINOTECAN NM_001135805;NM_001135806; NM_005639 synaptotagmin I SYT1 18927307 IRINOTECANNM_003184 TAF2 RNA polymerase II, TATA box binding protein TAF2 15956246(TBP)-associated factor, 150 kDa IRINOTECAN NM_003192 tubulin foldingcofactor C TBCC 15956246 IRINOTECAN NM_003205; NM_207036; NM_207037;transcription factor 12 TCF12 18927307 NM_207038; NM_207040 IRINOTECANNM_030756 transcription factor 7-like 2 (T-cell specific, HMG-box)TCF7L2 18927307 IRINOTECAN NM_005653 transcription factor CP2 TFCP218927307 IRINOTECAN NM_001032281; NM_006287 tissue factor pathwayinhibitor (lipoprotein-associated TFPI 18927307 coagulation inhibitor)IRINOTECAN NM_001128148; NM_003234 transferrin receptor (p90, CD71) TFRC18927307 IRINOTECAN NM_001099691; NM_003236 transforming growth factor,alpha TGFA 15723263 IRINOTECAN NM_000358 transforming growth factor,beta-induced, 68 kDa TGFBI 18927307 IRINOTECAN NM_053055 thioesterasesuperfamily member 4 THEM4 18927307 IRINOTECAN NM_024838 threoninesynthase-like 1 (S. cerevisiae) THNSL1 18927307 IRINOTECAN NM_005119thyroid hormone receptor associated protein 3 THRAP3 18927307 IRINOTECANNM_006288 Thy-1 cell surface antigen THY1 15956246 IRINOTECAN NM_052932transmembrane protein 123 TMEM123 18927307 IRINOTECAN NM_015012transmembrane protein 41B TMEM41B 15956246 IRINOTECAN NM_021109 thymosinbeta 4, X-linked TMSB4X 16364925 IRINOTECAN NM_007115 tumor necrosisfactor, alpha-induced protein 6 TNFAIP6 15956246 IRINOTECAN NM_005749transducer of ERBB2, 1 TOB1 15956246 IRINOTECAN NM_016272 transducer ofERBB2, 2 TOB2 15956246 IRINOTECAN NM_003286 topoisomerase (DNA) I TOP111914913, 15655543, 18509181 IRINOTECAN NM_052963 topoisomerase (DNA) I,mitochondrial TOP1MT — IRINOTECAN NM_001067 topoisomerase (DNA) II alpha170 kDa TOP2A 15239142, 15956246 IRINOTECAN NM_005802 topoisomerase Ibinding, arginine/serine-rich TOPORS 15956246 IRINOTECAN NM_000546;NM_001126112; NM_001126113; tumor protein p53 TP53 16373703NM_001126114; NM_001126115; NM_001126116; NM_001126117 IRINOTECANNM_001135733; NM_033285 tumor protein p53 inducible nuclear protein 1TP53INP1 18927307 IRINOTECAN NM_000367 thiopurine S-methyltransferaseTPMT 18927307 IRINOTECAN NM_007030 tubulin polymerization promotingprotein TPPP 18927307 IRINOTECAN NM_012112 TPX2, microtubule-associated,homolog (Xenopus TPX2 15956246 laevis) IRINOTECAN NM_003789TNFRSF1A-associated via death domain TRADD 15956246 IRINOTECAN NM_005658TNF receptor-associated factor 1 TRAF1 15956246 IRINOTECAN NM_025195tribbles homolog 1 (Drosophila) TRIB1 18927307 IRINOTECAN NM_021643tribbles homolog 2 (Drosophila) TRIB2 18927307 IRINOTECAN NM_033017;NM_033091 tripartite motif-containing 4 TRIM4 18927307 IRINOTECANNM_015163; NM_052978 tripartite motif-containing 9 TRIM9 18927307IRINOTECAN NM_003318 TTK protein kinase TTK 15956246 IRINOTECANNM_001113755; NM_001113756; NM_001953 thymidine phosphorylase TYMP17454858 IRINOTECAN NM_001071 thymidylate synthetase TYMS 10482907,17454858 IRINOTECAN NM_007019; NM_181799; NM_181800;ubiquitin-conjugating enzyme E2C UBE2C 15956246 NM_181801; NM_181802;NM_181803 IRINOTECAN NM_006357; NM_182678 ubiquitin-conjugating enzymeE2E 3 (UBC4/5 UBE2E3 18927307 homolog, yeast) IRINOTECAN NM_058167;NM_194315; NM_194457; ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog,UBE2J2 18927307 NM_194458 yeast) IRINOTECAN NM_015984 ubiquitincarboxyl-terminal hydrolase L5 UCHL5 15956246 IRINOTECAN NM_020121UDP-glucose ceramide glucosyltransferase-like 2 UGCGL2 18927307IRINOTECAN NM_000463 UDP glucuronosyltransferase 1 family, polypeptideA1 UGT1A1 12960109, 15517893, 15523087, 15833930, 17898154, 15716465,15655543, 15858133, 17898154, 18478930, 18300238, 18797458 IRINOTECANNM_019075 UDP glucuronosyltransferase 1 family, polypeptide UGT1A1015517893, 17898154, 15716465 A10 IRINOTECAN NM_001072; NM_205862 UDPglucuronosyltransferase 1 family, polypeptide A6 UGT1A6 15716465IRINOTECAN NM_019077 UDP glucuronosyltransferase 1 family, polypeptideA7 UGT1A7 15833930, 15716465, 17898154 IRINOTECAN NM_019076 UDPglucuronosyltransferase 1 family, polypeptide A8 UGT1A8 15833930, 18IRINOTECAN NM_021027 UDP glucuronosyltransferase 1 family, polypeptideA9 UGT1A9 15833930, 18 IRINOTECAN NM_025217 UL16 binding protein 2 ULBP218927307 IRINOTECAN NM_017886 unc-51-like kinase 4 (C. elegans) ULK418927307 IRINOTECAN NM_015306 ubiquitin specific peptidase 24 USP2418927307 IRINOTECAN — — VDP 18927307 IRINOTECAN NM_013245 vacuolarprotein sorting 4 homolog A (S. cerevisiae) VPS4A 18927307 IRINOTECANNM_145206 vesicle transport through interaction with t-SNAREs VTI1A18927307 homolog 1A (yeast) IRINOTECAN NM_015045 wings apart-likehomolog (Drosophila) WAPAL 18927307 IRINOTECAN NM_003941 Wiskott-Aldrichsyndrome-like WASL 18927307 IRINOTECAN NM_015726 WD repeat domain 42AWDR42A 18927307 IRINOTECAN NM_016087; NM_057168 wingless-type MMTVintegration site family, member WNT16 18927307 16 IRINOTECAN NM_015626;NM_134265 WD repeat and SOCS box-containing 1 WSB1 18927307 IRINOTECANNM_001100161; NM_001100162; NM_015024 exportin 7 XPO7 18927307IRINOTECAN NM_003401; NM_022406; NM_022550 X-ray repair complementingdefective repair in Chinese XRCC4 15956246 hamster cells 4 IRINOTECANNM_021141 X-ray repair complementing defective repair in Chinese XRCC518927307 hamster cells 5 (double-strand-break rejoining) IRINOTECANNM_005748 YY1 associated factor 2 YAF2 18927307 IRINOTECAN NM_005433v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 YES1 15956246IRINOTECAN NM_015642 zinc finger and BTB domain containing 20 ZBTB2018927307 IRINOTECAN NM_020119; NM_024625 zinc finger CCCH-type,antiviral 1 ZC3HAV1 18927307 IRINOTECAN NM_173798 zinc finger, CCHCdomain containing 12 ZCCHC12 18927307 IRINOTECAN NM_178566 zinc finger,DHHC-type containing 21 ZDHHC21 18927307 IRINOTECAN NM_001143823;NM_003409 zinc finger protein 161 homolog (mouse) ZFP161 18927307IRINOTECAN NM_006887 zinc finger protein 36, C3H type-like 2 ZFP36L215956246 IRINOTECAN NM_003410 zinc finger protein, X-linked ZFX 15956246IRINOTECAN NM_001032293; NM_001098507; NM_003457 zinc finger protein 207ZNF207 18927307 IRINOTECAN NM_001005368; NM_006973 zinc finger protein32 ZNF32 17327601 IRINOTECAN NM_001135215; NM_001135216; NM_030899; zincfinger protein 323 ZNF323 18927307 NM_145909 IRINOTECAN NM_022752 zincfinger protein 574 ZNF574 18927307 IRINOTECAN NM_144690 zinc fingerprotein 582 ZNF582 17327601 IRINOTECAN NM_024706 zinc finger protein 668ZNF668 18927307 IRINOTECAN NM_032268 zinc and ring finger 1 ZNRF118927307 IRINOTECAN NM_005089 zinc finger (CCCH type), RNA-binding motifand ZRSR2 17327601 serine/arginine rich 2 ETOPOSIDE NM_000927ATP-binding cassette, sub-family B (MDR/TAP), ABCB1 12969965, 15239124resistance member 1 ETOPOSIDE NM_004996; NM_019862; NM_019898;ATP-binding cassette, sub-family C (CFTR/MRP), ABCC1 10900222, 12067707,15460906, resistance NM_019899; NM_019900 member 1 15617835, 15999103,16156793, 10900222, 16156793 ETOPOSIDE NM_000392 ATP-binding cassette,sub-family C (CFTR/MRP), ABCC2 15751272, 15849751, 15849751 resistancemember 2 ETOPOSIDE NM_001144070; NM_003786 ATP-binding cassette,sub-family C (CFTR/MRP), ABCC3 15884115 resistance member 3 ETOPOSIDENM_198576 agrin AGRN 17374387 ETOPOSIDE NM_001014431; NM_001014432;NM_005163 v-akt murine thymoma viral oncogene homolog 1 AKT1 17935137ETOPOSIDE NM_000691; NM_001135167; NM_001135168 aldehyde dehydrogenase 3family, memberA1 ALDH3A1 15905174 ETOPOSIDE NM_001153 annexin A4 ANXA417374387 ETOPOSIDE NM_001657 amphiregulin AREG 15228094 ETOPOSIDENM_001675; NM_182810 activating transcription factor 4 (tax-responsiveATF4 16298333 enhancer element B67) ETOPOSIDE NM_001188BCL2-antagonist/killer 1 BAK1 15215046 ETOPOSIDE NM_000633; NM_000657B-cell CLL/lymphoma 2 BCL2 15917659 ETOPOSIDE NM_001191; NM_138578BCL2-like 1 BCL2L1 11468182, 15215046, 15917659 ETOPOSIDE NM_004050BCL2-like 2 BCL2L2 14973057 ETOPOSIDE NM_001197 BCL2-interacting killer(apoptosis-inducing) BIK 16007125 ETOPOSIDE NM_001166 baculoviral IAPrepeat-containing 2 BIRC2 10815900, 15050749, 14970392 ETOPOSIDENM_001165; NM_182962 baculoviral IAP repeat-containing 3 BIRC3 14666661,15050749 ETOPOSIDE NM_001012270; NM_001012271; NM_001168 baculoviral IAPrepeat-containing 5 BIRC5 15917659, 16382892, 16322251, 16364925ETOPOSIDE NM_007294; NM_007295; NM_007296; breast cancer 1, early onsetBRCA1 16417649 NM_007297; NM_007298; NM_007299; NM_007300; NM_007302;NM_007303; NM_007304; NM_007305 ETOPOSIDE NM_001729 betacellulin BTC15228094 ETOPOSIDE NM_001130849; NM_001130850; NM_016289 calcium bindingprotein 39 CAB39 17374387 ETOPOSIDE NM_001033952; NM_001033953;NM_001741 calcitonin-related polypeptide alpha CALCA 16222118 ETOPOSIDENM_032982; NM_032983 caspase 2, apoptosis-related cysteine peptidaseCASP2 14757846 ETOPOSIDE NM_004346; NM_032991 caspase 3,apoptosis-related cysteine peptidase CASP3 15215046, 16364925, 16844113,16951922, 17935137, 18056177, 18056177, 16364925, 16844113, 16951922ETOPOSIDE NM_001227; NM_033338; NM_033339; caspase 7, apoptosis-relatedcysteine peptidase CASP7 16298333, 18056177 NM_033340 ETOPOSIDENM_001229; NM_032996 caspase 9, apoptosis-related cysteine peptidaseCASP9 15215046, 16364925, 17935137, 18056177 ETOPOSIDE NM_001237 cyclinA2 CCNA2 17390037 ETOPOSIDE NM_004354 cyclin G2 CCNG2 18754885 ETOPOSIDENM_000610; NM_001001389; NM_001001390; CD44 molecule (Indian bloodgroup) CD44 15215046 NM_001001391; NM_001001392 ETOPOSIDE NM_001798;NM_052827 cyclin-dependent kinase 2 CDK2 16417649 ETOPOSIDE NM_000389;NM_078467 cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A14601052 ETOPOSIDE NM_004064 cyclin-dependent kinase inhibitor 1B (p27,Kip1) CDKN1B 17935137 ETOPOSIDE NM_001024912; NM_001712 carcinoembryonicantigen-related cell adhesion CEACAM1 17374387 molecule 1 (biliaryglycoprotein) ETOPOSIDE NM_005760 CCAAT/enhancer binding protein(C/EBP), zeta CEBPZ 17374387 ETOPOSIDE NM_001127183; NM_001127184;NM_003879 CASP8 and FADD-like apoptosis regulator CFLAR 14601052ETOPOSIDE NM_001114121; NM_001114122; NM_001274 CHK1 checkpoint homolog(S. pombe) CHEK1 18698031 ETOPOSIDE NM_020313 cytokine induced apoptosisinhibitor 1 CIAPIN1 18389626 ETOPOSIDE NM_000785 cytochrome P450, family27, subfamily B, polypeptide 1 CYP27B1 17716971 ETOPOSIDE NM_000762cytochrome P450, family 2, subfamily A, polypeptide 6 CYP2A6 8114683unrelated ETOPOSIDE NM_000767 cytochrome P450, family 2, subfamily B,polypeptide 6 CYP2B6 8114683 unrelated ETOPOSIDE NM_000770 cytochromeP450, family 2, subfamily C, polypeptide 8 CYP2C8 8114683 unrelatedETOPOSIDE NM_000771 cytochrome P450, family 2, subfamily C, polypeptide9 CYP2C9 8114683 unrelated ETOPOSIDE NM_017460 cytochrome P450, family3, subfamily A, polypeptide 4 CYP3A4 12969965, 17279585, 8114683 drugmetabolism ETOPOSIDE NM_000777 cytochrome P450, family 3, subfamily A,polypeptide 5 CYP3A5 12969965, 8114683 drug metabolism ETOPOSIDENM_004083 DNA-damage-inducible transcript 3 DDIT3 16298333 ETOPOSIDENM_001963 epidermal growth factor (beta-urogastrone) EGF 15228094,16969495 ETOPOSIDE NM_005228; NM_201282; NM_201283; epidermal growthfactor receptor (erythroblastic EGFR 15228094 NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) ETOPOSIDE NM_001007277; NM_004879etoposide induced 2.4 mRNA EI24 17374387 ETOPOSIDE NM_014805 EPM2A(laforin) interacting protein 1 EPM2AIP1 17374387 ETOPOSIDENM_001005862; NM_004448 v-erb-b2 erythroblastic leukemia viral oncogeneERBB2 15228094 homolog 2, neuro/glioblastoma derived oncogene homolog(avian) ETOPOSIDE NM_001005915; NM_001982 v-erb-b2 erythroblasticleukemia viral oncogene ERBB3 15228094 homolog 3 (avian) ETOPOSIDENM_001042599; NM_005235 v-erb-a erythroblastic leukemia viral oncogeneERBB4 15228094 homolog 4 (avian) ETOPOSIDE NM_001432 epiregulin EREG15228094 ETOPOSIDE NM_001987 ets variant 6 ETV6 15217836 ETOPOSIDENM_004110; NM_024417 ferredoxin reductase FDXR 17374387 ETOPOSIDENM_002015 forkhead box O1 FOXO1 17935137 ETOPOSIDE NM_001455; NM_201559forkhead box O3 FOXO3 17935137 ETOPOSIDE NM_001924 growth arrest andDNA-damage-inducible, alpha GADD45A 19003803 ETOPOSIDE NM_001498glutamate-cysteine ligase, catalytic subunit GCLC 10900222 ETOPOSIDENM_002061 glutamate-cysteine ligase, modifier subunit GCLM 10900222ETOPOSIDE NM_000561; NM_146421 glutathione S-transferase mu 1 GSTM115713801 ETOPOSIDE NM_000852 glutathione S-transferase pi 1 GSTP110900222, 12969965, 15999103, 15999103, 10900222 ETOPOSIDE NM_001945heparin-binding EGF-like growth factor HBEGF 15228094 ETOPOSIDENM_005347 heat shock 70 kDa protein 5 (glucose-regulated protein, HSPA516298333 78 kDa) ETOPOSIDE NM_000875 insulin-like growth factor 1receptor IGF1R 15499378 ETOPOSIDE NM_002756; NM_145109 mitogen-activatedprotein kinase kinase 3 MAP2K3 17374387 ETOPOSIDE NM_145185mitogen-activated protein kinase kinase 7 MAP2K7 — ETOPOSIDE NM_005923mitogen-activated protein kinase kinase kinase 5 MAP3K5 17374387ETOPOSIDE NM_021960; NM_182763 myeloid cell leukemia sequence 1(BCL2-related) MCL1 17935137 ETOPOSIDE NM_001145336; NM_001145337;NM_001145339; Mdm2 p53 binding protein homolog (mouse) MDM2 17575151,17935137 resistance NM_001145340; NM_002392; NM_006878; NM_006879;NM_006881; NM_006882 ETOPOSIDE NM_001004720; NM_001004722; NM_003581 NCKadaptor protein 2 NCK2 17374387 ETOPOSIDE NM_020529 nuclear factor ofkappa light polypeptide gene NFKBIA 17935137 enhancer in B-cellsinhibitor, alpha ETOPOSIDE NM_003889; NM_022002; NM_033013 nuclearreceptor subfamily 1, group I, member 2 NR1I2 17279585 ETOPOSIDENM_001618 poly (ADP-ribose) polymerase 1 PARP1 17935137, 17935137,16844113 ETOPOSIDE NM_004073 polo-like kinase 3 (Drosophila) PLK317374387 ETOPOSIDE NM_003981; NM_199413; NM_199414 protein regulator ofcytokinesis 1 PRC1 17374387 ETOPOSIDE NM_000311; NM_001080121;NM_001080122; prion protein PRNP 15386405 NM_001080123; NM_183079ETOPOSIDE NM_000314 phosphatase and tensin homolog PTEN 17935137ETOPOSIDE NM_134424 RAD52 homolog (S. cerevisiae) RAD52 16417649ETOPOSIDE NM_001142548; NM_003579 RAD54-like (S. cerevisiae) RAD54L16417649 ETOPOSIDE NM_001145547; NM_032905 RNA binding motif protein 17RBM17 16061639 resistance ETOPOSIDE NM_001001890; NM_001122607;NM_001754 runt-related transcription factor 1 RUNX1 15217836 ETOPOSIDENM_001031680; NM_004350 runt-related transcription factor 3 RUNX315756676 ETOPOSIDE NM_005980 S100 calcium binding protein P S100P18636193 ETOPOSIDE NM_001006946; NM_002997 syndecan 1 SDC1 17374387ETOPOSIDE NM_000593 transporter 1, ATP-binding cassette, sub-family BTAP1 17374387 (MDR/TAP) ETOPOSIDE NM_014604 Tax1 (human T-cell leukemiavirus type I) binding TAX1BP3 17374387 protein 3 ETOPOSIDE NM_001099691;NM_003236 transforming growth factor, alpha TGFA 15228094 ETOPOSIDENM_021109 thymosin beta 4, X-linked TMSB4X 16364925 ETOPOSIDE NM_003844tumor necrosis factor receptor superfamily, member TNFRSF10A 1636492510a ETOPOSIDE NM_003842; NM_147187 tumor necrosis factor receptorsuperfamily, member TNFRSF10B 15964798, 16364925 10b ETOPOSIDE NM_003810tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 16364925ETOPOSIDE NM_003811 tumor necrosis factor (ligand) superfamily, member 9TNFSF9 17374387 ETOPOSIDE NM_001067 topoisomerase (DNA) II alpha 170 kDaTOP2A 11470519, 11531262, 11676865, 12569090, 16969495, 17575151ETOPOSIDE NM_001068 topoisomerase (DNA) II beta 180 kDa TOP2B 15322234,16239602 ETOPOSIDE NM_000546; NM_001126112; NM_001126113; tumor proteinp53 TP53 12082016, 15964798, 18698031 NM_001126114; NM_001126115;NM_001126116; NM_001126117 ETOPOSIDE NM_004881; NM_147184 tumor proteinp53 inducible protein 3 TP53I3 17374387 ETOPOSIDE NR_015381; NR_015381;NR_015381; TP53 target 1 (non-protein coding) TP53TG1 17374387NR_015381; NR_015381; NR_015381; NR_015381; NR_015381 ETOPOSIDENM_001126240; NM_001126241; NM_001126242; tumor protein p73 TP7317716971 NM_005427 ETOPOSIDE NM_001071 thymidylate synthetase TYMS15713801 ETOPOSIDE NM_007019; NM_181799; NM_181800;ubiquitin-conjugating enzyme E2C UBE2C 17374387 NM_181801; NM_181802;NM_181803 ETOPOSIDE NM_000463 UDP glucuronosyltransferase 1 family,polypeptide A1 UGT1A1 12969965, 17151191 ETOPOSIDE NM_019093 UDPglucuronosyltransferase 1 family, polypeptide A3 UGT1A3 17151191ETOPOSIDE NM_019076 UDP glucuronosyltransferase 1 family, polypeptide A8UGT1A8 17151191 ETOPOSIDE NM_000376; NM_001017535 vitamin D(1,25-dihydroxyvitamin D3) receptor VDR 12969965, 15713801, 17716971ETOPOSIDE NM_001025366; NM_001025367; NM_001025368; vascular endothelialgrowth factor A VEGFA 18494554 NM_001025369; NM_001025370; NM_001033756;NM_003376 ETOPOSIDE NM_000553 Werner syndrome, RecQ helicase-like WRN10725663 ETOPOSIDE NM_017523; NM_199139 XIAP associated factor 1 XAF115843754 ETOPOSIDE NM_001167 X-linked inhibitor of apoptosis XIAP14666661 ETOPOSIDE NM_005431 X-ray repair complementing defective repairin Chinese XRCC2 16417649 hamster cells 2 ETOPOSIDE NM_001100118;NM_001100119; NM_005432 X-ray repair complementing defective repair inChinese XRCC3 16417649 hamster cells 3 ETOPOSIDE NM_003401; NM_022406;NM_022550 X-ray repair complementing defective repair in Chinese XRCC416417649 hamster cells 4 ETOPOSIDE NM_021141 X-ray repair complementingdefective repair in Chinese XRCC5 12384553 hamster cells 5(double-strand-break rejoining) BEXAROTENE NM_001121; NM_016824;NM_019903 adducin 3 (gamma) ADD3 17178900 BEXAROTENE NM_000024adrenergic, beta-2-, receptor, surface ADRB2 17178900 BEXAROTENENM_001353 aldo-keto reductase family 1, member C1 (dihydrodiol AKR1C117178900 dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroiddehydrogenase) BEXAROTENE NM_003739 aldo-keto reductase family 1, memberC3 (3-alpha AKR1C3 17178900 hydroxysteroid dehydrogenase, type II)BEXAROTENE NM_016201 angiomotin like 2 AMOTL2 17178900 BEXAROTENENM_006407 ADP-ribosylation-like factor 6 interacting protein 5 ARL6IP517178900 BEXAROTENE NM_001673; NM_133436; NM_183356 asparaginesynthetase ASNS 17178900 BEXAROTENE NM_004330 BCL2/adenovirus E1B 19 kDainteracting protein 2 BNIP2 17178900 BEXAROTENE — — C10ORF10 17178900BEXAROTENE — — C10ORF116 17178900 BEXAROTENE NM_001806 CCAAT/enhancerbinding protein (C/EBP), gamma CEBPG 17178900 BEXAROTENE — cytochrome coxidase II COX2 17178900 BEXAROTENE NM_001902; NM_153742 cystathionase(cystathionine gamma-lyase) CTH 17178900 BEXAROTENE NM_004390; NM_148979cathepsin H CTSH 17178900 BEXAROTENE NM_018947 cytochrome c, somaticCYCS 17178900 BEXAROTENE NM_000783; NM_057157 cytochrome P450, family26, subfamily A, polypeptide 1 CYP26A1 17178900 BEXAROTENE NM_001554cysteine-rich, angiogenic inducer, 61 CYR61 17178900 BEXAROTENENM_019058 DNA-damage-inducible transcript 4 DDIT4 17178900 BEXAROTENENM_004753 dehydrogenase/reductase (SDR family) member 3 DHRS3 17178900BEXAROTENE NM_012242 dickkopf homolog 1 (Xenopus laevis) DKK1 17178900BEXAROTENE NM_004417 dual specificity phosphatase 1 DUSP1 17178900BEXAROTENE NM_004419 dual specificity phosphatase 5 DUSP5 17178900BEXAROTENE NM_004430 early growth response 3 EGR3 17178900 BEXAROTENENM_005801 eukaryotic translation initiation factor 1 EIF1 17178900BEXAROTENE NM_004431 EPH receptor A2 EPHA2 17178900 BEXAROTENE NM_002047glycyl-tRNA synthetase GARS 17178900 BEXAROTENE NM_001001994;NM_001001995; NM_001001996; glycoprotein M6B GPM6B 17178900 NM_005278BEXAROTENE NM_001010989; NM_001010990; NM_014685 homocysteine-inducible,endoplasmic reticulum stress- HERPUD1 17178900 inducible, ubiquitin-likedomain member 1 BEXAROTENE NM_002165; NM_181353 inhibitor of DNA binding1, dominant negative helix- ID1 17178900 loop-helix protein BEXAROTENENM_004907 immediate early response 2 IER2 17178900 BEXAROTENE NM_002178insulin-like growth factor binding protein 6 IGFBP6 17178900 BEXAROTENENM_000585; NM_172174 interleukin 15 IL15 17178900 BEXAROTENE NM_000888integrin, beta 6 ITGB6 17178900 BEXAROTENE NM_004867 integral membraneprotein 2A ITM2A 17178900 BEXAROTENE NM_001099952; NM_002222 inositol1,4,5-triphosphate receptor, type 1 ITPR1 17178900 BEXAROTENENM_001032282; NM_005655 Kruppel-like factor 10 KLF10 17178900 BEXAROTENENM_002275 keratin 15 KRT15 17178900 BEXAROTENE NM_000422 keratin 17KRT17 17178900 BEXAROTENE NM_002318 lysyl oxidase-like 2 LOXL2 17178900BEXAROTENE NM_001031804; NM_005360 v-maf musculoaponeurotic fibrosarcomaoncogene MAF 17178900 homolog (avian) BEXAROTENE NM_001161572;NM_001161573; NM_001161574; v-maf musculoaponeurotic fibrosarcomaoncogene MAFF 17178900 NM_012323; NM_152878 homolog F (avian) BEXAROTENENM_006818 myeloid/lymphoid or mixed-lineage leukemia (trithorax MLLT1117178900 homolog, Drosophila); translocated to, 11 BEXAROTENE NM_002421matrix metallopeptidase 1 (interstitial collagenase) MMP1 17178900BEXAROTENE NM_006636 methylenetetrahydrofolate dehydrogenase (NADP+MTHFD2 17178900 dependent) 2, methenyltetrahydrofolate cyclohydrolaseBEXAROTENE NM_002539 ornithine decarboxylase 1 ODC1 17178900 BEXAROTENENM_022817 period homolog 2 (Drosophila) PER2 17178900 BEXAROTENENM_000930; NM_033011 plasminogen activator, tissue PLAT 17178900BEXAROTENE NM_001005376; NM_001005377; NM_002659 plasminogen activator,urokinase receptor PLAUR 17178900 BEXAROTENE NM_000935; NM_182943procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 PLOD2 17178900BEXAROTENE NM_020143 partner of NOB1 homolog (S. cerevisiae) PNO117178900 BEXAROTENE NM_006813 proline-rich nuclear receptor coactivator1 PNRC1 17178900 BEXAROTENE NM_000965; NM_016152 retinoic acid receptor,beta RARB 17178900 BEXAROTENE NM_000321 retinoblastoma 1 RB1 16273314BEXAROTENE NM_021976 retinoid X receptor, beta RXRB — BEXAROTENENM_002965 S100 calcium binding protein A9 S100A9 17178900 BEXAROTENENM_005063 stearoyl-CoA desaturase (delta-9-desaturase) SCD 17178900BEXAROTENE NM_003016 splicing factor, arginine/serine-rich 2 SFRS217178900 BEXAROTENE NM_005067 seven in absentia homolog 2 (Drosophila)SIAH2 17178900 BEXAROTENE NM_003045 solute carrier family 7 (cationicamino acid transporter, SLC7A1 17178900 y+ system), member 1 BEXAROTENENM_003486 solute carrier family 7 (cationic amino acid transporter,SLC7A5 17178900 y+ system), member 5 BEXAROTENE NM_001001419;NM_001001420; NM_005903 SMAD family member 5 SMAD5 17178900 BEXAROTENENM_003118 secreted protein, acidic, cysteine-rich (osteonectin) SPARC17178900 BEXAROTENE NM_004613; NM_198951 transglutaminase 2 (Cpolypeptide, protein-glutamine- TGM2 17178900 gamma-glutamyltransferase)BEXAROTENE NM_014220 transmembrane 4 L six family member 1 TM4SF117178900 BEXAROTENE NM_001015881; NM_004089; NM_198057 TSC22 domainfamily, member 3 TSC22D3 17178900 BEXAROTENE NM_003115UDP-N-acteylglucosamine pyrophosphorylase 1 UAP1 17178900 BEXAROTENENM_003761 vesicle-associated membrane protein 8 (endobrevin) VAMP817178900 BEXAROTENE NM_001079539; NM_005080 X-box binding protein 1 XBP117178900 CETUXIMAB NM_001963 epidermal growth factor (beta-urogastrone)EGF — CETUXIMAB NM_005228; NM_201282; NM_201283; epidermal growth factorreceptor (erythroblastic EGFR — target NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) CETUXIMAB NM_001432 epiregulin EREG —TRASTUZUMAB NM_001963 epidermal growth factor (beta-urogastrone) EGF —TRASTUZUMAB NM_005228; NM_201282; NM_201283; epidermal growth factorreceptor (erythroblastic EGFR — resistance NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) TRASTUZUMAB NM_001005862; NM_004448v-erb-b2 erythroblastic leukemia viral oncogene ERBB2 — target homolog2, neuro/glioblastoma derived oncogene homolog (avian) TRASTUZUMABNM_001432 epiregulin EREG — RITUXIMAB NM_021950; NM_152866membrane-spanning 4-domains, subfamily A, member 1 MS4A1 — targetTOSITUMOMAB NM_021950; NM_152866 membrane-spanning 4-domains, subfamilyA, member 1 MS4A1 — target ALEMTUZUMAB NM_001803 CD52 molecule CD52 —target BEVACIZUMAB NM_001025366; NM_001025367; NM_001025368; vascularendothelial growth factor A VEGFA — target NM_001025369; NM_001025370;NM_001033756; NM_003376 EDRECOLOMAB — — TACSTD1 — target GEMTUZUMABNM_001082618; NM_001772 CD33 molecule CD33 — target AXITINIBNM_001160030; NM_001160031; NM_002019 fms-related tyrosine kinase 1(vascular endothelial FLT1 — target growth factor/vascular permeabilityfactor receptor) AXITINIB NM_002020; NM_182925 fms-related tyrosinekinase 4 FLT4 — target AXITINIB NM_002253 kinase insert domain receptor(a type III receptor KDR — target tyrosine kinase) AXITINIB NM_000222;NM_001093772 v-kit Hardy-Zuckerman 4 feline sarcoma viral KIT — targetoncogene homolog AXITINIB NM_006206 platelet-derived growth factorreceptor, alpha PDGFRA — target polypeptide AXITINIB NM_002609platelet-derived growth factor receptor, beta PDGFRB — targetpolypeptide BOSUTINIB — — ABL 17114238 BOSUTINIB NM_005157; NM_007313c-abl oncogene 1, receptor tyrosine kinase ABL1 — target BOSUTINIBNM_004327; NM_021574 breakpoint cluster region BCR — BOSUTINIB NM_053056cyclin D1 CCND1 16489032 BOSUTINIB NM_004360 cadherin 1, type 1,E-cadherin (epithelial) CDH1 16489032 BOSUTINIB NM_001098209;NM_001098210; NM_001904 catenin (cadherin-associated protein), beta 1,88 kDa CTNNB1 16489032 BOSUTINIB NM_005417; NM_198291 v-src sarcoma(Schmidt-Ruppin A-2) viral oncogene SRC 16489032 target homolog (avian)BOSUTINIB NM_001083962; NM_003199 transcription factor 4 TCF4 16489032CEDIRANIB NM_001160030; NM_001160031; NM_002019 fms-related tyrosinekinase 1 (vascular endothelial FLT1 — target growth factor/vascularpermeability factor receptor) CEDIRANIB NM_002020; NM_182925 fms-relatedtyrosine kinase 4 FLT4 — target DASATINIB NM_005157; NM_007313 c-abloncogene 1, receptor tyrosine kinase ABL1 — target DASATINIBNM_001100108; NM_001136000; NM_001136001; v-abl Abelson murine leukemiaviral oncogene ABL2 — target ? NM_005158; NM_007314 homolog 2 (arg,Abelson-related gene) DASATINIB NM_004327; NM_021574 breakpoint clusterregion BCR — DASATINIB NM_004431 EPH receptor A2 EPHA2 — targetDASATINIB NM_002037; NM_153047; NM_153048 FYN oncogene related to SRC,FGR, YES FYN — DASATINIB NM_000222; NM_001093772 v-kit Hardy-Zuckerman 4feline sarcoma viral KIT — target oncogene homolog DASATINIBNM_001042771; NM_005356 lymphocyte-specific protein tyrosine kinase LCK— target DASATINIB NM_002609 platelet-derived growth factor receptor,beta PDGFRB — target polypeptide DASATINIB NM_005417; NM_198291 v-srcsarcoma (Schmidt-Ruppin A-2) viral oncogene SRC — target homolog (avian)DASATINIB NM_012448 signal transducer and activator of transcription 5BSTAT5B — DASATINIB NM_005433 v-yes-1 Yamaguchi sarcoma viral oncogenehomolog 1 YES1 — ERLOTINIB NM_001963 epidermal growth factor(beta-urogastrone) EGF — ERLOTINIB NM_005228; NM_201282; NM_201283;epidermal growth factor receptor (erythroblastic EGFR 12907618 targetNM_201284 leukemia viral (v-erb-b) oncogene homolog, avian) ERLOTINIBNM_001432 epiregulin EREG — GEFITINIB NM_004827 ATP-binding cassette,sub-family G (WHITE), member 2 ABCG2 17938326 resistance GEFITINIBNM_000674; NM_001048230 adenosine A1 receptor ADORA1 16685379 GEFITINIBNM_001014431; NM_001014432; NM_005163 v-akt murine thymoma viraloncogene homolog 1 AKT1 17805209 GEFITINIB NM_001657 amphiregulin AREG15496427, 16230376, 15723263 sensitivity/ resistance GEFITINIB NM_020371apoptosis, caspase activation inhibitor AVEN 15496427 GEFITINIBNM_006568 cell growth regulator with ring finger domain 1 CGRRF116685379 GEFITINIB NM_001130105; NM_005713; NM_031361 collagen, type IV,alpha 3 (Goodpasture antigen) COL4A3BP 15496427 binding proteinGEFITINIB NM_014325 coronin, actin binding protein, 1C CORO1C 15496427GEFITINIB NM_000761 cytochrome P450, family 1, subfamily A, polypeptide2 CYP1A2 15788367 unrelated GEFITINIB NM_000769 cytochrome P450, family2, subfamily C, polypeptide CYP2C19 15788367 unrelated 19 GEFITINIBNM_000771 cytochrome P450, family 2, subfamily C, polypeptide 9 CYP2C915788367 unrelated GEFITINIB NM_000106; NM_001025161 cytochrome P450,family 2, subfamily D, polypeptide 6 CYP2D6 15788367 drug metabolismGEFITINIB NM_000774 cytochrome P450, family 2, subfamily F, polypeptide1 CYP2F1 16685379 GEFITINIB NM_017460 cytochrome P450, family 3,subfamily A, polypeptide 4 CYP3A4 15788367 drug metabolism GEFITINIBNM_000777 cytochrome P450, family 3, subfamily A, polypeptide 5 CYP3A515788367 drug metabolism GEFITINIB NM_004090 dual specificityphosphatase 3 DUSP3 15496427 GEFITINIB NM_001395 dual specificityphosphatase 9 DUSP9 16685379 GEFITINIB NM_005225 E2F transcriptionfactor 1 E2F1 18347146 GEFITINIB NM_001963 epidermal growth factor(beta-urogastrone) EGF 17805209, 17898861 GEFITINIB NM_005228;NM_201282; NM_201283; epidermal growth factor receptor (erythroblasticEGFR 15723263, 15976335, 16361624, target NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) 17290066, 17898861, 17938326GEFITINIB NM_000121 erythropoietin receptor EPOR 16685379 GEFITINIBNM_001159969; NM_001981 epidermal growth factor receptor pathwaysubstrate 15 EPS15 16685379 GEFITINIB NM_001005862; NM_004448 v-erb-b2erythroblastic leukemia viral oncogene ERBB2 17898861 sensitivityhomolog 2, neuro/glioblastoma derived oncogene homolog (avian) GEFITINIBNM_001432 epiregulin EREG — GEFITINIB NM_000125; NM_001122740;NM_001122741; estrogen receptor 1 ESR1 16261397 NM_001122742 GEFITINIBNM_020996 fibroblast growth factor 6 FGF6 16685379 GEFITINIB NM_001924growth arrest and DNA-damage-inducible, alpha GADD45A 16685379 GEFITINIBNM_006705 growth arrest and DNA-damage-inducible, gamma GADD45G 16685379GEFITINIB NM_002047 glycyl-tRNA synthetase GARS 16685379 GEFITINIBNM_001498 glutamate-cysteine ligase, catalytic subunit GCLC 15496427GEFITINIB NM_005273 guanine nucleotide binding protein (G protein), betaGNB2 16685379 polypeptide 2 GEFITINIB NM_000180 guanylate cyclase 2D,membrane (retina-specific) GUCY2D 16685379 GEFITINIB NM_001945heparin-binding EGF-like growth factor HBEGF 15723263 altered bygefitinib GEFITINIB NM_002038; NM_022872; NM_022873 interferon,alpha-inducible protein 6 IFI6 16685379 GEFITINIB NM_000598;NM_001013398 insulin-like growth factor binding protein 3 IGFBP3 —GEFITINIB NM_000584 interleukin 8 IL8 15723263 altered by gefitinibGEFITINIB NM_001003679; NM_001003680; NM_002303 leptin receptor LEPR16685379 GEFITINIB NM_002745; NM_138957 mitogen-activated protein kinase1 MAPK1 17805209, 17898861 GEFITINIB NM_001040056; NM_001109891;NM_002746 mitogen-activated protein kinase 3 MAPK3 17805209, 17898861GEFITINIB NM_000249 mutL homolog 1, colon cancer, MLH1 16685379nonpolyposis type 2 (E. coli) GEFITINIB NM_003998 nuclear factor ofkappa light polypeptide gene NFKB1 16685379 enhancer in B-cells 1GEFITINIB NM_002523 neuronal pentraxin II NPTX2 16685379 GEFITINIBNM_006177 neural retina leucine zipper NRL 16685379 GEFITINIB NM_003999oncostatin M receptor OSMR 15496427 GEFITINIB NM_003311 pleckstrinhomology-like domain, family A, member 2 PHLDA2 15496427 GEFITINIBNM_000314 phosphatase and tensin homolog PTEN — GEFITINIB NM_001004128;NM_002826 quiescin Q6 sulfhydryl oxidase 1 QSOX1 16685379 altered bygefitinib GEFITINIB NM_016090 RNA binding motif protein 7 RBM7 15496427GEFITINIB NM_002945 replication protein A1, 70 kDa RPA1 16685379GEFITINIB NM_006142 stratifin SFN 16685379 GEFITINIB NM_003036 v-skisarcoma viral oncogene homolog (avian) SKI 16685379 GEFITINIBNM_001099691; NM_003236 transforming growth factor, alpha TGFA 15723263,16230376 resistance GEFITINIB NM_001066 tumor necrosis factor receptorsuperfamily, member 1B TNFRSF1B 16685379 GEFITINIB NM_001071 thymidylatesynthetase TYMS 18347146 IMATINIB NM_000927 ATP-binding cassette,sub-family B (MDR/TAP), ABCB1 15970668 resistance member 1 IMATINIBNM_004827 ATP-binding cassette, sub-family G (WHITE), member 2 ABCG215970668 resistance IMATINIB NM_005157; NM_007313 c-abl oncogene 1,receptor tyrosine kinase ABL1 15329907 target IMATINIB NM_001014431;NM_001014432; NM_005163 v-akt murine thymoma viral oncogene homolog 1AKT1 16740780 activity altered by imatinib IMATINIB NM_001191; NM_138578BCL2-like 1 BCL2L1 16960866 resistance IMATINIB NM_004327; NM_021574breakpoint cluster region BCR 15329907 IMATINIB NM_001012270;NM_001012271; NM_001168 baculoviral IAP repeat-containing 5 BIRC516254145, 16254145, 16166298 resistance IMATINIB NM_001136017;NM_001136125; NM_001136126; cyclin D3 CCND3 15100154 NM_001760 IMATINIBNM_001781 CD69 molecule CD69 15100154 IMATINIB NM_005211 colonystimulating factor 1 receptor CSF1R — target IMATINIB NM_001954;NM_013993; NM_013994 discoidin domain receptor tyrosine kinase 1 DDR1 —target IMATINIB NM_000142; NM_022965 fibroblast growth factor receptor 3FGFR3 14562121 IMATINIB — — FRAP1 16740780 activity altered by imatinibIMATINIB NM_002133 heme oxygenase (decycling) 1 HMOX1 17420286resistance IMATINIB NM_000618; NM_001111283; NM_001111284; insulin-likegrowth factor 1 (somatomedin C) IGF1 16740780 NM_001111285 IMATINIBNM_000417 interleukin 2 receptor, alpha IL2RA 15100154 IMATINIBNM_000222; NM_001093772 v-kit Hardy-Zuckerman 4 feline sarcoma viral KIT17420286 target V560G oncogene homolog D816V IMATINIB NM_001042771;NM_005356 lymphocyte-specific protein tyrosine kinase LCK 15100154target IMATINIB NM_002745; NM_138957 mitogen-activated protein kinase 1MAPK1 15100154 activity altered by imatinib IMATINIB NM_001040056;NM_001109891; NM_002746 mitogen-activated protein kinase 3 MAPK315100154 activity altered by imatinib IMATINIB NM_003998 nuclear factorof kappa light polypeptide gene NFKB1 15100154 activity altered enhancerin B-cells 1 by imatinib IMATINIB NM_001007792; NM_001012331; NM_002529neurotrophic tyrosine kinase, receptor, type 1 NTRK1 — activity alteredby imatinib IMATINIB NM_006206 platelet-derived growth factor receptor,alpha PDGFRA 17614352 target polypeptide IMATINIB NM_002609platelet-derived growth factor receptor, beta PDGFRB — targetpolypeptide IMATINIB NM_000321 retinoblastoma 1 RB1 15100154 IMATINIBNM_001145138; NM_021975 v-rel reticuloendotheliosis viral oncogenehomolog A RELA 15100154 activity altered (avian) by imatinib IMATINIBNM_020630; NM_020975 ret proto-oncogene RET 15709206 IMATINIBNM_001025366; NM_001025367; NM_001025368; vascular endothelial growthfactor A VEGFA 16740780 altered by NM_001025369; NM_001025370; imatinibNM_001033756; NM_003376 IMATINIB NM_000378; NM_024424; NM_024425; Wilmstumor 1 WT1 15329907 resistance NM_024426 LAPATINIB NM_001014431;NM_001014432; NM_005163 v-akt murine thymoma viral oncogene homolog 1AKT1 15665275, 16091755 altered by lapatinib LAPATINIB NM_001012270;NM_001012271; NM_001168 baculoviral IAP repeat-containing 5 BIRC516091755 altered by lapatinib LAPATINIB NM_053056 cyclin D1 CCND115665275 altered by lapatinib LAPATINIB NM_001238; NM_057182 cyclin E1CCNE1 15665275 altered by lapatinib LAPATINIB NM_001798; NM_052827cyclin-dependent kinase 2 CDK2 15665275 altered by lapatinib LAPATINIBNM_004064 cyclin-dependent kinase inhibitor 1B (p27, Kip1) CDKN1B15665275 altered by lapatinib LAPATINIB NM_001963 epidermal growthfactor (beta-urogastrone) EGF — LAPATINIB NM_005228; NM_201282;NM_201283; epidermal growth factor receptor (erythroblastic EGFR15665275 target NM_201284 leukemia viral (v-erb-b) oncogene homolog,avian) LAPATINIB NM_001005862; NM_004448 v-erb-b2 erythroblasticleukemia viral oncogene ERBB2 15665275, 16091755 target homolog 2,neuro/glioblastoma derived oncogene homolog (avian) LAPATINIB NM_001432epiregulin EREG — LAPATINIB NM_000125; NM_001122740; NM_001122741;estrogen receptor 1 ESR1 15665275 NM_001122742 LAPATINIB NM_002745;NM_138957 mitogen-activated protein kinase 1 MAPK1 16091755 altered bylapatinib LAPATINIB NM_001040056; NM_001109891; NM_002746mitogen-activated protein kinase 3 MAPK3 16091755 altered by lapatinibLAPATINIB NM_021960; NM_182763 myeloid cell leukemia sequence 1(BCL2-related) MCL1 — resistance LAPATINIB — — PI3KCA — resistanceLAPATINIB NM_000314 phosphatase and tensin homolog PTEN — sensitivityLESTAURTINIB NM_004119 fms-related tyrosine kinase 3 FLT3 — targetNILOTINIB NM_005157; NM_007313 c-abl oncogene 1, receptor tyrosinekinase ABL1 — target NILOTINIB NM_004327; NM_021574 breakpoint clusterregion BCR — NILOTINIB NM_000222; NM_001093772 v-kit Hardy-Zuckerman 4feline sarcoma viral KIT — target oncogene homolog NILOTINIB NM_006206platelet-derived growth factor receptor, alpha PDGFRA — targetpolypeptide NILOTINIB NM_002609 platelet-derived growth factor receptor,beta PDGFRB — target polypeptide SEMAXANIB NM_002253 kinase insertdomain receptor (a type III receptor KDR — target tyrosine kinase)SORAFENIB NM_001188 BCL2-antagonist/killer 1 BAK1 16007148 death pathwaySORAFENIB NM_004324; NM_138761; NM_138763; BCL2-associated X protein BAX16007148 death pathway NM_138764; NM_138765 SORAFENIB NM_000633;NM_000657 B-cell CLL/lymphoma 2 BCL2 16007148 altered by soraf SORAFENIBNM_001191; NM_138578 BCL2-like 1 BCL2L1 16007148 altered by sorafSORAFENIB NM_006538; NM_138621; NM_207002 BCL2-like 11 (apoptosisfacilitator) BCL2L11 16007148 death pathway SORAFENIB NM_001196;NM_197966; NM_197967 BH3 interacting domain death agonist BID 16007148SORAFENIB NM_004333 v-raf murine sarcoma viral oncogene homolog B1 BRAF— target SORAFENIB NM_004346; NM_032991 caspase 3, apoptosis-relatedcysteine peptidase CASP3 16007148 death pathway SORAFENIB NM_001080124;NM_001080125; NM_001228; caspase 8, apoptosis-related cysteine peptidaseCASP8 16007148 NM_033355; NM_033356; NM_033358 SORAFENIB NM_018947cytochrome c, somatic CYCS 16007148 death pathway SORAFENIB NM_001433endoplasmic reticulum to nucleus signaling 1 ERN1 — resistance SORAFENIBNM_004119 fms-related tyrosine kinase 3 FLT3 — target SORAFENIBNM_002020; NM_182925 fms-related tyrosine kinase 4 FLT4 — targetSORAFENIB NM_002253 kinase insert domain receptor (a type III receptorKDR — target tyrosine kinase) SORAFENIB NM_000222; NM_001093772 v-kitHardy-Zuckerman 4 feline sarcoma viral KIT — target oncogene homologSORAFENIB NM_002745; NM_138957 mitogen-activated protein kinase 1 MAPK1— resistance SORAFENIB NM_001040056; NM_001109891; NM_002746mitogen-activated protein kinase 3 MAPK3 — resistance SORAFENIBNM_021960; NM_182763 myeloid cell leukemia sequence 1 (BCL2-related)MCL1 16007148 altered by soraf SORAFENIB NM_002609 platelet-derivedgrowth factor receptor, beta PDGFRB — target polypeptide SORAFENIBNM_002880 v-raf-1 murine leukemia viral oncogene homolog 1 RAF1 — targetSORAFENIB NM_001167 X-linked inhibitor of apoptosis XIAP 16007148altered by soraf SUNITINIB NM_004333 v-raf murine sarcoma viral oncogenehomolog B1 BRAF — SUNITINIB NM_005211 colony stimulating factor 1receptor CSF1R — target SUNITINIB NM_001160030; NM_001160031; NM_002019fms-related tyrosine kinase 1 (vascular endothelial FLT1 — target growthfactor/vascular permeability factor receptor) SUNITINIB NM_004119fms-related tyrosine kinase 3 FLT3 — target SUNITINIB NM_002020;NM_182925 fms-related tyrosine kinase 4 FLT4 — target SUNITINIBNM_002253 kinase insert domain receptor (a type III receptor KDR —target tyrosine kinase) SUNITINIB NM_000222; NM_001093772 v-kitHardy-Zuckerman 4 feline sarcoma viral KIT — target oncogene homologSUNITINIB NM_006206 platelet-derived growth factor receptor, alphaPDGFRA — target polypeptide SUNITINIB NM_002609 platelet-derived growthfactor receptor, beta PDGFRB — target polypeptide SUNITINIB NM_002880v-raf-1 murine leukemia viral oncogene homolog 1 RAF1 — SUNITINIBNM_020630; NM_020975 ret proto-oncogene RET — target VANDETANIBNM_001963 epidermal growth factor (beta-urogastrone) EGF — VANDETANIBNM_005228; NM_201282; NM_201283; epidermal growth factor receptor(erythroblastic EGFR — target NM_201284 leukemia viral (v-erb-b)oncogene homolog, avian) VANDETANIB NM_001432 epiregulin EREG —VANDETANIB NM_002253 kinase insert domain receptor (a type III receptorKDR — target tyrosine kinase) TEMSIROLIMUS NM_053056 cyclin D1 CCND116954435 resistance? TEMSIROLIMUS NM_004095 eukaryotic translationinitiation factor 4E binding EIF4EBP1 16033649 altered by protein 1temsirolimus TEMSIROLIMUS NM_000125; NM_001122740; NM_001122741;estrogen receptor 1 ESR1 16954435 NM_001122742 TEMSIROLIMUS — — FRAP116033649 target TEMSIROLIMUS NM_000321 retinoblastoma 1 RB1 16954435TEMSIROLIMUS NM_003161 ribosomal protein S6 kinase, 70 kDa, polypeptide1 RPS6KB1 16954435, 16954435, 16033649 altered by temsirolimusEVEROLIMUS NM_001014431; NM_001014432; NM_005163 v-akt murine thymomaviral oncogene homolog 1 AKT1 16033851 altered by everolimus EVEROLIMUSNM_000633; NM_000657 B-cell CLL/lymphoma 2 BCL2 — resistance EVEROLIMUSNM_053056 cyclin D1 CCND1 16033851 altered by everolimus EVEROLIMUSNM_001759 cyclin D2 CCND2 16033851 altered by everolimus EVEROLIMUSNM_001136017; NM_001136125; NM_001136126; cyclin D3 CCND3 16033851altered by NM_001760 everolimus EVEROLIMUS NM_001130678; NM_001130679;NM_001968 eukaryotic translation initiation factor 4E EIF4E 16033851altered by everolimus EVEROLIMUS NM_004095 eukaryotic translationinitiation factor 4E binding EIF4EBP1 16033851 protein 1 EVEROLIMUSNM_004953; NM_182917; NM_198241; eukaryotic translation initiationfactor 4 gamma, 1 EIF4G1 16033851 altered by NM_198242; NM_198244everolimus EVEROLIMUS — — FRAP1 16033851 target EVEROLIMUS NM_000321retinoblastoma 1 RB1 16033851 EVEROLIMUS NM_001010 ribosomal protein S6RPS6 16033851 EVEROLIMUS NM_003161 ribosomal protein S6 kinase, 70 kDa,polypeptide 1 RPS6KB1 16033851 altered by everolimus FLAVOPIRIDOLNM_004323 BCL2-associated athanogene BAG1 15972445 altered byflavopiridol FLAVOPIRIDOL NM_004324; NM_138761; NM_138763;BCL2-associated X protein BAX 12517783, 15634644, 15770523 unrelatedNM_138764; NM_138765 FLAVOPIRIDOL NM_000633; NM_000657 B-cellCLL/lymphoma 2 BCL2 12170773, 12517783, 15770523, unrelated 15972445FLAVOPIRIDOL NM_001191; NM_138578 BCL2-like 1 BCL2L1 12517783, 15634644altered by flavopiridol FLAVOPIRIDOL NM_001196; NM_197966; NM_197967 BH3interacting domain death agonist BID 12170773, 15634644 unrelatedFLAVOPIRIDOL NM_001165; NM_182962 baculoviral IAP repeat-containing 3BIRC3 12517783 altered by flavopiridol FLAVOPIRIDOL NM_001012270;NM_001012271; NM_001168 baculoviral IAP repeat-containing 5 BIRC512517783, 16012789 altered by flavopiridol FLAVOPIRIDOL NM_004346;NM_032991 caspase 3, apoptosis-related cysteine peptidase CASP312170773, 12517783, 15634644, death pathway 15770523, 16012789FLAVOPIRIDOL NM_001080124; NM_001080125; NM_001228; caspase 8,apoptosis-related cysteine peptidase CASP8 15634644, 16012789 unrelatedNM_033355; NM_033356; NM_033358 FLAVOPIRIDOL NM_001229; NM_032996caspase 9, apoptosis-related cysteine peptidase CASP9 12170773, 15634644death pathway FLAVOPIRIDOL NM_031966 cyclin B1 CCNB1 12517783sensitivity FLAVOPIRIDOL NM_053056 cyclin D1 CCND1 12517783, 15634644sensitivity FLAVOPIRIDOL NM_001130829; NM_001786; NM_033379 celldivision cycle 2, G1 to S and G2 to M CDC2 12517783 target FLAVOPIRIDOLNM_001798; NM_052827 cyclin-dependent kinase 2 CDK2 12517783 targetFLAVOPIRIDOL NM_000075 cyclin-dependent kinase 4 CDK4 12517783 targetFLAVOPIRIDOL NM_004935 cyclin-dependent kinase 5 CDK5 — FLAVOPIRIDOLNM_001145306; NM_001259 cyclin-dependent kinase 6 CDK6 — FLAVOPIRIDOLNM_001799 cyclin-dependent kinase 7 CDK7 — FLAVOPIRIDOL NM_001260cyclin-dependent kinase 8 CDK8 — FLAVOPIRIDOL NM_001261 cyclin-dependentkinase 9 CDK9 — target FLAVOPIRIDOL NM_000389; NM_078467cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 15180955,15770523 altered by flavopiridol FLAVOPIRIDOL NM_004064 cyclin-dependentkinase inhibitor 1B (p27, Kip1) CDKN1B 15180955 FLAVOPIRIDOL NM_018947cytochrome c, somatic CYCS 12170773, 12170773, 12517783, death pathway15634644 FLAVOPIRIDOL NM_019887; NM_138929 diablo homolog (Drosophila)DIABLO 12517783, 15634644 death pathway FLAVOPIRIDOL NM_001963 epidermalgrowth factor (beta-urogastrone) EGF — FLAVOPIRIDOL NM_005228;NM_201282; NM_201283; epidermal growth factor receptor (erythroblasticEGFR — NM_201284 leukemia viral (v-erb-b) oncogene homolog, avian)FLAVOPIRIDOL NM_001432 epiregulin EREG — FLAVOPIRIDOL NM_002105 H2Ahistone family, member X H2AFX 15078984 FLAVOPIRIDOL NM_013247;NM_145074 HtrA serine peptidase 2 HTRA2 12517783 death pathwayFLAVOPIRIDOL NM_001315; NM_139012; NM_139013; mitogen-activated proteinkinase 14 MAPK14 15634644 NM_139014 FLAVOPIRIDOL NM_002750; NM_139046;NM_139047; mitogen-activated protein kinase 8 MAPK8 15634644 NM_139049FLAVOPIRIDOL NM_021960; NM_182763 myeloid cell leukemia sequence 1(BCL2-related) MCL1 12517783, 15634644, altered by 15972445, 12517783flavopiridol FLAVOPIRIDOL NM_001618 poly (ADP-ribose) polymerase 1 PARP112170773, 15634644, 15770523, 15972445, 12517783, 12170773, 16012789FLAVOPIRIDOL NM_005609 phosphorylase, glycogen, muscle PYGM —FLAVOPIRIDOL NM_000321 retinoblastoma 1 RB1 15078984, 15180955, 15297405FLAVOPIRIDOL NM_000546; NM_001126112; NM_001126113; tumor protein p53TP53 15180955, 15297405 unrelated NM_001126114; NM_001126115;NM_001126116; NM_001126117 FLAVOPIRIDOL NM_001167 X-linked inhibitor ofapoptosis XIAP 12517783, 15972445, 12517783, altered by 15972445,15385934, 12517783 flavopiridol ROSCOVITINE NM_004324; NM_138761;NM_138763; BCL2-associated X protein BAX 16230394, 16275999 deathpathway NM_138764; NM_138765 ROSCOVITINE NM_001012270; NM_001012271;NM_001168 baculoviral IAP repeat-containing 5 BIRC5 16230394 altered byroscovitine ROSCOVITINE NM_004346; NM_032991 caspase 3,apoptosis-related cysteine peptidase CASP3 16140939 death pathwayROSCOVITINE NM_001229; NM_032996 caspase 9, apoptosis-related cysteinepeptidase CASP9 16140939 death pathway ROSCOVITINE NM_001130829;NM_001786; NM_033379 cell division cycle 2, G1 to S and G2 to M CDC215231455, 15 target ROSCOVITINE NM_001798; NM_052827 cyclin-dependentkinase 2 CDK2 — target ROSCOVITINE NM_000075 cyclin-dependent kinase 4CDK4 15741232 ROSCOVITINE NM_004935 cyclin-dependent kinase 5 CDK515741232 target ROSCOVITINE NM_001145306; NM_001259 cyclin-dependentkinase 6 CDK6 15741232 ROSCOVITINE NM_000389; NM_078467 cyclin-dependentkinase inhibitor 1A (p21, Cip1) CDKN1A 16275999 altered by roscovitineROSCOVITINE NM_018947 cytochrome c, somatic CYCS 16140939, 16275999death pathway ROSCOVITINE NM_019887; NM_138929 diablo homolog(Drosophila) DIABLO 16275999 ROSCOVITINE NM_021960; NM_182763 myeloidcell leukemia sequence 1 (BCL2-related) MCL1 16275999 altered byroscovitine ROSCOVITINE — — PDCD8 16275999 death pathway ROSCOVITINENM_000321 retinoblastoma 1 RB1 14653808, 15231455, 15741232 altered byroscovitine ROSCOVITINE NM_003109; NM_138473 Sp1 transcription factorSP1 14653808 altered by roscovitine ROSCOVITINE NM_000546; NM_001126112;NM_001126113; tumor protein p53 TP53 16003486, 16 sensitivityNM_001126114; NM_001126115; NM_001126116; NM_001126117 ROSCOVITINENM_001167 X-linked inhibitor of apoptosis XIAP 16140939, 16230394,16275999 altered by roscovitine AFLIBERCEPT NM_001025366; NM_001025367;NM_001025368; vascular endothelial growth factor A VEGFA — targetNM_001025369; NM_001025370; NM_001033756; NM_003376 DENILEUKIN NM_000417interleukin 2 receptor, alpha IL2RA — target DIFTITOX DENILEUKINNM_000878 interleukin 2 receptor, beta IL2RB — target DIFTITOXDENILEUKIN NM_000206 interleukin 2 receptor, gamma (severe combinedIL2RG — target DIFTITOX immunodeficiency) ARSENIC NM_000927 ATP-bindingcassette, sub-family B (MDR/TAP), ABCB1 15979894, 15979894, 14642128resistance TRIOXIDE member 1 ARSENIC NM_004827 ATP-binding cassette,sub-family G (WHITE), member 2 ABCG2 17547211 resistance TRIOXIDEARSENIC NM_005157; NM_007313 c-abl oncogene 1, receptor tyrosine kinaseABL1 14633726 TRIOXIDE ARSENIC NM_006111 acetyl-Coenzyme Aacyltransferase 2 ACAA2 15761015 TRIOXIDE ARSENIC NM_001116 adenylatecyclase 9 ADCY9 15761015 TRIOXIDE ARSENIC NM_001134647; NM_198595 actinfilament associated protein 1 AFAP1 15761015 TRIOXIDE ARSENIC NM_005100;NM_144497 A kinase (PRKA) anchor protein 12 AKAP12 17547211 TRIOXIDEARSENIC NM_001628 aldo-keto reductase family 1, member B1 (aldose AKR1B117547211 TRIOXIDE reductase) ARSENIC NM_001014431; NM_001014432;NM_005163 v-akt murine thymoma viral oncogene homolog 1 AKT1 16882451,17077332 TRIOXIDE ARSENIC NM_000688; NM_199166 aminolevulinate, delta-,synthase 1 ALAS1 15725085 TRIOXIDE ARSENIC NM_005589 aldehydedehydrogenase 6 family, member A1 ALDH6A1 17547211 TRIOXIDE ARSENICNM_005165 aldolase C, fructose-bisphosphate ALDOC 15725085 TRIOXIDEARSENIC NM_018466 asparagine-linked glycosylation 13 homolog ALG1315761015 TRIOXIDE (S. cerevisiae) ARSENIC NM_001629 arachidonate5-lipoxygenase-activating protein ALOX5AP 15761015, 15 TRIOXIDE ARSENICNM_001149; NM_020987 ankyrin 3, node of Ranvier (ankyrin G) ANK315761015 TRIOXIDE ARSENIC NM_001083625; NM_015208 ankyrin repeat domain12 ANKRD12 15761015 TRIOXIDE ARSENIC NM_001150 alanyl (membrane)aminopeptidase ANPEP 15949261 TRIOXIDE ARSENIC NM_001002857;NM_001002858; NM_001136015; annexin A2 ANXA2 17547211 TRIOXIDE NM_004039ARSENIC NM_001284 adaptor-related protein complex 3, sigma 1 subunitAP3S1 15761015 TRIOXIDE ARSENIC NM_020980 aquaporin 9 AQP9 15336539,16968895 TRIOXIDE ARSENIC NM_015161 ADP-ribosylation factor-like 6interacting protein 1 ARL6IP1 14703492 TRIOXIDE ARSENIC NM_006407ADP-ribosylation-like factor 6 interacting protein 5 ARL6IP5 16430862,16468075 TRIOXIDE ARSENIC — — ARL7 15725085 TRIOXIDE ARSENIC NM_025139armadillo repeat containing 9 ARMC9 15761015 TRIOXIDE ARSENIC NM_001673;NM_133436; NM_183356 asparagine synthetase ASNS 17547211 TRIOXIDEARSENIC NM_000050; NM_054012 argininosuccinate synthetase 1 ASS115761015, 15 TRIOXIDE ARSENIC NM_001001787; NM_001677 ATPase, Na+/K+transporting, beta 1 polypeptide ATP1B1 15761015 TRIOXIDE ARSENICNM_001001323; NM_001682 ATPase, Ca++ transporting, plasma membrane 1ATP2B1 12852829, 18 TRIOXIDE ARSENIC NM_001001485; NM_001001486;NM_001001487; ATPase, Ca++ transporting, type 2C, member 1 ATP2C1 —TRIOXIDE NM_014382 ARSENIC NM_001001937; NM_004046 ATP synthase, H+transporting, mitochondrial F1 ATP5A1 15949261 TRIOXIDE complex, alphasubunit 1, cardiac muscle ARSENIC — ATP synthase 6; ATPase subunit 6ATP6 14703492, 15949261 TRIOXIDE ARSENIC NM_001105529; NM_006095 ATPase,aminophospholipid transporter (APLT), class ATP8A1 15761015 TRIOXIDE I,type 8A, member 1 ARSENIC NM_001184 ataxia telangiectasia and Rad3related ATR 16891316 TRIOXIDE ARSENIC NM_001185 alpha-2-glycoprotein 1,zinc-binding AZGP1 17547211 TRIOXIDE ARSENIC NM_021813 BTB and CNChomology 1, basic leucine zipper BACH2 15725085 TRIOXIDE transcriptionfactor 2 ARSENIC NM_012342 BMP and activin membrane-bound inhibitorhomolog BAMBI 15725085 TRIOXIDE (Xenopus laevis) ARSENIC NM_004324;NM_138761; NM_138763; BCL2-associated X protein BAX 11135700, 11775218,15622746, 15665116, TRIOXIDE NM_138764; NM_138765 16010437, 16867262,16020671, 16867262, 16882451, 16972261 ARSENIC NM_000633; NM_000657B-cell CLL/lymphoma 2 BCL2 11775218, 12490120, 16105982, TRIOXIDE11780464, (following) 16818652, 11589617, 11135700, 11775218, 12845720,15979894, 16029599, 16007134, 16904648, 11775218, 16010437, 16867262,16818652, 16867262, 16904648, 15622746, 11775218, 16966277 ARSENICNM_001114735; NM_004049 BCL2-related protein A1 BCL2A1 12130515 TRIOXIDEARSENIC NM_001191; NM_138578 BCL2-like 1 BCL2L1 11468182, 15622746,16105982, TRIOXIDE 15665116 ARSENIC NM_017429 beta-carotene15,15′-monooxygenase 1 BCMO1 15761015 TRIOXIDE ARSENIC NM_004327;NM_021574 breakpoint cluster region BCR 14633726 TRIOXIDE ARSENICNM_003766 beclin 1, autophagy related BECN1 16882451 TRIOXIDE ARSENIC —— BHLHB2 15761015 TRIOXIDE ARSENIC NM_001196; NM_197966; NM_197967 BH3interacting domain death agonist BID 15665116, 16972261 TRIOXIDE ARSENICNM_001012270; NM_001012271; NM_001168 baculoviral IAP repeat-containing5 BIRC5 15587394, 16328441 TRIOXIDE ARSENIC NM_000713 biliverdinreductase B (flavin reductase (NADPH)) BLVRB 15725085 TRIOXIDE ARSENICNM_003666 basic leucine zipper nuclear factor 1 BLZF1 15761015 TRIOXIDEARSENIC NM_004052 BCL2/adenovirus E1B 19 kDa interacting protein 3 BNIP315592527 TRIOXIDE ARSENIC NM_004331 BCL2/adenovirus E1B 19 kDainteracting protein 3-like BNIP3L 15592527 TRIOXIDE ARSENIC NM_001725bactericidal/permeability-increasing protein BPI 15761015 TRIOXIDEARSENIC — — BRDG1 15761015 TRIOXIDE ARSENIC NM_017797 BTB (POZ) domaincontaining 2 BTBD2 15725085 TRIOXIDE ARSENIC NM_014962; NM_181443 BTB(POZ) domain containing 3 BTBD3 15725085 TRIOXIDE ARSENIC — — C14ORF10515761015 TRIOXIDE ARSENIC — — C16ORF58 15761015 TRIOXIDE ARSENIC — —C5ORF13 15725085 TRIOXIDE ARSENIC — — C6ORF48 17547211 TRIOXIDE ARSENIC— — C8ORF4 15761015 TRIOXIDE ARSENIC NM_001005505; NM_006030 calciumchannel, voltage-dependent, alpha 2/delta CACNA2D2 15761015 TRIOXIDEsubunit 2 ARSENIC NM_021251; NM_023083; NM_023085; calpain 10 CAPN1015761015 TRIOXIDE NM_023089 ARSENIC NM_004930 capping protein (actinfilament) muscle Z-line, beta CAPZB 12852829 TRIOXIDE ARSENICNM_001014437; NM_001014438; NM_001751; cysteinyl-tRNA synthetase CARS12852829 TRIOXIDE NM_139273 ARSENIC NM_001230; NM_032974; NM_032977caspase 10, apoptosis-related cysteine peptidase CASP10 12388546TRIOXIDE ARSENIC NM_004346; NM_032991 caspase 3, apoptosis-relatedcysteine peptidase CASP3 14668793, 15979894, TRIOXIDE 15979894,15665116, 16951922, 16867262, 16951922 ARSENIC NM_001080124;NM_001080125; NM_001228; caspase 8, apoptosis-related cysteine peptidaseCASP8 16010437, 16972261 TRIOXIDE NM_033355; NM_033356; NM_033358ARSENIC NM_001229; NM_032996 caspase 9, apoptosis-related cysteinepeptidase CASP9 16010437, 17 TRIOXIDE ARSENIC NM_001753 caveolin 1,caveolae protein, 22 kDa CAV1 15725085 TRIOXIDE ARSENIC NM_001233;NM_198212 caveolin 2 CAV2 15725085, 15761015 TRIOXIDE ARSENICNM_001093729; NM_024781 coiled-coil domain containing 102B CCDC102B15761015 TRIOXIDE ARSENIC NM_144718 coiled-coil domain containing 52CCDC52 15761015 TRIOXIDE ARSENIC NM_004167; NM_032964; NM_032965chemokine (C-C motif) ligand 15 CCL15 15761015 TRIOXIDE ARSENICNM_002982 chemokine (C-C motif) ligand 2 CCL2 15761015 TRIOXIDE ARSENICNM_005064; NM_145898 chemokine (C-C motif) ligand 23 CCL23 15761015TRIOXIDE ARSENIC NM_001111045; NM_001111046; NM_001111047; cyclin A1CCNA1 15761015 TRIOXIDE NM_003914 ARSENIC NM_031966 cyclin B1 CCNB112783709 TRIOXIDE ARSENIC NM_004701 cyclin B2 CCNB2 17547211 TRIOXIDEARSENIC NM_053056 cyclin D1 CCND1 — TRIOXIDE ARSENIC NM_001766 CD1dmolecule CD1D 15761015 TRIOXIDE ARSENIC NM_000610; NM_001001389;NM_001001390; CD44 molecule (Indian blood group) CD44 15553829 TRIOXIDENM_001001391; NM_001001392 ARSENIC NM_001803 CD52 molecule CD52 15761015TRIOXIDE ARSENIC NM_001252 CD70 molecule CD70 15761015 TRIOXIDE ARSENICNM_006889; NM_175862 CD86 molecule CD86 15761015 TRIOXIDE ARSENICNM_003607; NM_014826 CDC42 binding protein kinase alpha (DMPK-like)CDC42BPA 15761015 TRIOXIDE ARSENIC NM_024529 cell division cycle 73,Paf1/RNA polymerase II complex CDC73 15761015 TRIOXIDE component,homolog (S. cerevisiae) ARSENIC NM_000389; NM_078467 cyclin-dependentkinase inhibitor 1A (p21, Cip1) CDKN1A 12749819, 15961274 TRIOXIDEARSENIC NM_000077; NM_058195; NM_058197 cyclin-dependent kinaseinhibitor 2A (melanoma, p16, CDKN2A 15191659, 16008847, 16008847,TRIOXIDE inhibits CDK4) 15191659 ARSENIC NM_004936; NM_078487cyclin-dependent kinase inhibitor 2B (p15, inhibits CDKN2B 11877046,12679007, 12679007 TRIOXIDE CDK4) ARSENIC NM_001130851; NM_005192cyclin-dependent kinase inhibitor 3 CDKN3 17547211 TRIOXIDE ARSENICNM_001805 CCAAT/enhancer binding protein (C/EBP), epsilon CEBPE 12130515TRIOXIDE ARSENIC NM_014679 centrosomal protein 57 kDa CEP57 14703492TRIOXIDE ARSENIC NM_001710 complement factor B CFB 17547211 TRIOXIDEARSENIC NM_001127183; NM_001127184; NM_003879 CASP8 and FADD-likeapoptosis regulator CFLAR 16105982, 16105982, 16174796 TRIOXIDE ARSENICNM_001114121; NM_001114122; NM_001274 CHK1 checkpoint homolog (S. pombe)CHEK1 16891316 TRIOXIDE ARSENIC NM_001005735; NM_007194; NM_145862 CHK2checkpoint homolog (S. pombe) CHEK2 16891316 TRIOXIDE ARSENIC NM_001819chromogranin B (secretogranin 1) CHGB 15761015 TRIOXIDE ARSENICNM_001276 chitinase 3-like 1 (cartilage glycoprotein-39) CHI3L1 15761015TRIOXIDE ARSENIC NM_021615 carbohydrate (N-acetylglucosamine 6-O) CHST615761015, 15 TRIOXIDE sulfotransferase 6 ARSENIC NM_014430 celldeath-inducing DFFA-like effector b CIDEB 17547211 TRIOXIDE ARSENICNM_006079 Cbp/p300-interacting transactivator, with Glu/Asp-rich CITED215725085 TRIOXIDE carboxy-terminal domain, 2 ARSENIC NM_006825cytoskeleton-associated protein 4 CKAP4 12852829 TRIOXIDE ARSENICNM_001828 Charcot-Leyden crystal protein CLC 15761015, 15 TRIOXIDEARSENIC NM_022570; NM_197947; NM_197948; C-type lectin domain family 7,member A CLEC7A 15725085 TRIOXIDE NM_197949; NM_197950; NM_197954ARSENIC NM_001130675; NM_004362 calmegin CLGN 17547211 TRIOXIDE ARSENICNM_178868 CKLF-like MARVEL transmembrane domain CMTM8 15761015 TRIOXIDEcontaining 8 ARSENIC NM_014515 CCR4-NOT transcription complex, subunit 2CNOT2 15761015 TRIOXIDE ARSENIC NM_014900 COBL-like 1 COBLL1 15761015TRIOXIDE ARSENIC NM_006438 collectin sub-family member 10 (C-typelectin) COLEC10 15761015 TRIOXIDE ARSENIC NM_006837 COP9 constitutivephotomorphogenic homolog subunit COPS5 17077332 TRIOXIDE 5 (Arabidopsis)ARSENIC NM_001011666; NM_004904; NM_182898; cAMP responsive elementbinding protein 5 CREB5 15761015 TRIOXIDE NM_182899 ARSENIC NM_000756corticotropin releasing hormone CRH 15761015 TRIOXIDE ARSENIC NM_016441cysteine rich transmembrane BMP regulator 1 CRIM1 15761015, 16 TRIOXIDE(chordin-like) ARSENIC NM_000395 colony stimulating factor 2 receptor,beta, low-affinity CSF2RB 15070760 TRIOXIDE (granulocyte-macrophage)ARSENIC NM_001317; NM_022640; NM_022641 chorionic somatomammotropinhormone 1 (placental CSH1 15761015 TRIOXIDE lactogen) ARSENICNM_001077204; NM_024790 centrosome and spindle pole associated protein 1CSPP1 15761015 TRIOXIDE ARSENIC NM_001127656; NM_003476 cysteine andglycine-rich protein 3 (cardiac LIM CSRP3 15725085 TRIOXIDE protein)ARSENIC NM_000099 cystatin C CST3 15725085 TRIOXIDE ARSENIC NM_001903catenin (cadherin-associated protein), alpha 1, 102 kDa CTNNA1 15761015TRIOXIDE ARSENIC NM_004390; NM_148979 cathepsin H CTSH 15761015 TRIOXIDEARSENIC NM_002996 chemokine (C—X3—C motif) ligand 1 CX3CL1 17547211TRIOXIDE ARSENIC NM_000398; NM_001129819; NM_007326 cytochrome b5reductase 3 CYB5R3 15725085 TRIOXIDE ARSENIC NM_000101 cytochrome b-245,alpha polypeptide CYBA 15070760 TRIOXIDE ARSENIC NM_001127383; NM_024843cytochrome b reductase 1 CYBRD1 15761015 TRIOXIDE ARSENIC NM_018947cytochrome c, somatic CYCS 16972261 TRIOXIDE ARSENIC NM_001042355;NM_001042412; NM_015247 cylindromatosis (turban tumor syndrome) CYLD15761015 TRIOXIDE ARSENIC NM_000499 cytochrome P450, family 1, subfamilyA, polypeptide 1 CYP1A1 11678611, 12490585 TRIOXIDE ARSENIC NM_016593cytochrome P450, family 39, subfamily A, polypeptide 1 CYP39A1 15761015TRIOXIDE ARSENIC NM_022820; NM_057095; NM_057096 cytochrome P450, family3, subfamily A, polypeptide CYP3A43 15761015 TRIOXIDE 43 ARSENICNM_018659 cytokine-like 1 CYTL1 15761015, 15761015, 15070760 TRIOXIDEARSENIC NM_001141969; NM_001141970; NM_001350 death-domain associatedprotein DAXX 17081986 TRIOXIDE ARSENIC NM_001005375; NM_020420 deletedin azoospermia 4 DAZ4 15761015 TRIOXIDE ARSENIC NM_014618 deleted inbladder cancer 1 DBC1 15761015 TRIOXIDE ARSENIC NM_004083DNA-damage-inducible transcript 3 DDIT3 11678611, 12749819 TRIOXIDEARSENIC NM_004084 defensin, alpha 1 DEFA1 15761015, 15 TRIOXIDE ARSENICNM_001925 defensin, alpha 4, corticostatin DEFA4 15761015, 15 TRIOXIDEARSENIC NM_012242 dickkopf homolog 1 (Xenopus laevis) DKK1 17547211TRIOXIDE ARSENIC NM_007034 DnaJ (Hsp40) homolog, subfamily B, member 4DNAJB4 15761015 TRIOXIDE ARSENIC NM_015190 DnaJ (Hsp40) homolog,subfamily C, member 9 DNAJC9 15761015 TRIOXIDE ARSENIC NM_001130823;NM_001379 DNA (cytosine-5-)-methyltransferase 1 DNMT1 12679007 TRIOXIDEARSENIC NM_022552; NM_153759; NM_175629; DNA(cytosine-5-)-methyltransferase 3 alpha DNMT3A 12679007 TRIOXIDENM_175630 ARSENIC NM_006892; NM_175848; NM_175849; DNA(cytosine-5-)-methyltransferase 3 beta DNMT3B 12679007 TRIOXIDENM_175850 ARSENIC NM_001394; NM_057158 dual specificity phosphatase 4DUSP4 15725085 TRIOXIDE ARSENIC NM_001376 dynein, cytoplasmic 1, heavychain 1 DYNC1H1 15725085 TRIOXIDE ARSENIC NM_004714; NM_006483;NM_006484 dual-specificity tyrosine-(Y)-phosphorylation regulated DYRK1B15070760 TRIOXIDE kinase 1B ARSENIC — — EBI2 15761015 TRIOXIDE ARSENICNM_005228; NM_201282; NM_201283; epidermal growth factor receptor(erythroblastic EGFR 15961274 TRIOXIDE NM_201284 leukemia viral(v-erb-b) oncogene homolog, avian) ARSENIC NM_001964 early growthresponse 1 EGR1 12749819 TRIOXIDE ARSENIC — — ELA2A 15761015 TRIOXIDEARSENIC — — ENDOGL1 15761015 TRIOXIDE ARSENIC NM_001429 E1A bindingprotein p300 EP300 15031205 TRIOXIDE ARSENIC NM_001135554; NM_001135555;NM_001431 erythrocyte membrane protein band 4.1-like 2 EPB41L2 15761015TRIOXIDE ARSENIC NM_000120; NM_001136018 epoxide hydrolase 1, microsomal(xenobiotic) EPHX1 17547211 TRIOXIDE ARSENIC NM_000502 eosinophilperoxidase EPX 15761015, 15 TRIOXIDE ARSENIC NM_015576ELKS/RAB6-interacting/CAST family member 2 ERC2 15761015 TRIOXIDEARSENIC NM_016570 ERGIC and golgi 2 ERGIC2 — TRIOXIDE ARSENIC NM_000125;NM_001122740; NM_001122741; estrogen receptor 1 ESR1 12014631 TRIOXIDENM_001122742 ARSENIC NM_001040275; NM_001040276; NM_001437 estrogenreceptor 2 (ER beta) ESR2 12014631 TRIOXIDE ARSENIC NM_016337Enah/Vasp-like EVL 15725085 TRIOXIDE ARSENIC NM_001993 coagulationfactor III (thromboplastin, tissue factor) F3 15761015, 16206674TRIOXIDE ARSENIC NM_147189 family with sequence similarity 110, member BFAM110B 15761015 TRIOXIDE ARSENIC NM_017709 family with sequencesimilarity 46, member C FAM46C 15725085 TRIOXIDE ARSENIC NM_000136Fanconi anemia, complementation group C FANCC 15070760 TRIOXIDE ARSENICNM_000043; NM_152871; NM_152872; Fas (TNF receptor superfamily, member6) FAS 15979894, 12478894, TRIOXIDE NM_152873; NM_152874; NM_152875;15979894, 15382040, 11135700, NM_152876; NM_152877 12452020, 16029599,12126518 ARSENIC NM_000639 Fas ligand (TNF superfamily, member 6) FASLG12452020, 12 TRIOXIDE ARSENIC NM_006329 fibulin 5 FBLN5 15761015TRIOXIDE ARSENIC NM_012304 F-box and leucine-rich repeat protein 7 FBXL715725085 TRIOXIDE ARSENIC NM_015850; NM_023105; NM_023106; fibroblastgrowth factor receptor 1 FGFR1 15761015, 17027752 TRIOXIDE NM_023107;NM_023108; NM_023110; NM_023111 ARSENIC NM_000141; NM_001144913;NM_001144914; fibroblast growth factor receptor 2 FGFR2 15761015TRIOXIDE NM_001144915; NM_001144916; NM_001144917; NM_001144918;NM_001144919; NM_022970 ARSENIC NM_001042729; NM_001042747; NM_005248Gardner-Rasheed feline sarcoma viral (v-fgr) FGR 15761015 TRIOXIDEoncogene homolog ARSENIC NM_001024948; NM_017737 formin binding protein1-like FNBP1L 15761015 TRIOXIDE ARSENIC NM_005252 v-fos FBJ murineosteosarcoma viral oncogene FOS 11678611, 11678611, 14682389, TRIOXIDEhomolog 12749819, 14682389 ARSENIC NM_001102371; NM_024955 FAD-dependentoxidoreductase domain containing 2 FOXRED2 15761015 TRIOXIDE ARSENICNM_002031 fyn-related kinase FRK 15761015 TRIOXIDE ARSENIC NM_003088fascin homolog 1, actin-bundling protein FSCN1 15761015, 15 TRIOXIDE(Strongylocentrotus purpuratus) ARSENIC NM_002032 ferritin, heavypolypeptide 1 FTH1 15725085, 15 TRIOXIDE ARSENIC NM_001465; NM_199335FYN binding protein (FYB-120/130) FYB 15761015 TRIOXIDE ARSENICNM_005458 gamma-aminobutyric acid (GABA) B receptor, 2 GABBR2 15761015TRIOXIDE ARSENIC NM_144618 GA binding protein transcription factor, betasubunit 2 GABPB2 12852829 TRIOXIDE ARSENIC NM_001924 growth arrest andDNA-damage-inducible, alpha GADD45A 11678611, 15761015, 11678611TRIOXIDE ARSENIC NM_000157; NM_001005741; NM_001005742; glucosidase,beta; acid (includes glucosylceramidase) GBA 15761015 TRIOXIDENM_001005749; NM_001005750 ARSENIC NM_002061 glutamate-cysteine ligase,modifier subunit GCLM 15725085 TRIOXIDE ARSENIC NM_024711 GTPase, IMAPfamily member 6 GIMAP6 15761015 TRIOXIDE ARSENIC NM_001135213;NM_001135214; NM_014776; G protein-coupled receptor kinase interactingArfGAP 2 GIT2 15761015 TRIOXIDE NM_057169; NM_057170; NM_139201 ARSENICNM_000165 gap junction protein, alpha 1, 43 kDa GJA1 15761015, 15TRIOXIDE ARSENIC NM_000169 galactosidase, alpha GLA 17547211 TRIOXIDEARSENIC NM_001142339; NM_002071; NM_182978 guanine nucleotide bindingprotein (G protein), alpha GNAL 15761015 TRIOXIDE activating activitypolypeptide, olfactory type ARSENIC NM_001039966; NM_001098201;NM_001505 G protein-coupled estrogen receptor 1 GPER 17547211 TRIOXIDEARSENIC NM_005277; NM_201591; NM_201592 glycoprotein M6A GPM6A 15761015TRIOXIDE ARSENIC NM_004778 G protein-coupled receptor 44 GPR44 15761015TRIOXIDE ARSENIC NM_018654 G protein-coupled receptor, family C, group5, GPRC5D 15725085 TRIOXIDE member D ARSENIC NM_000581; NM_201397glutathione peroxidase 1 GPX1 16867262 TRIOXIDE ARSENIC NM_001146320;NM_023927 GRAM domain containing 3 GRAMD3 15070760 TRIOXIDE ARSENICNM_001004056; NM_001004057; NM_182982 G protein-coupled receptor kinase4 GRK4 15761015 TRIOXIDE ARSENIC NM_145740 glutathione S-transferasealpha 1 GSTA1 11678611 TRIOXIDE ARSENIC NM_000852 glutathioneS-transferase pi 1 GSTP1 15231573, 15665116 TRIOXIDE ARSENIC NM_001513;NM_145870; NM_145871 glutathione transferase zeta 1 GSTZ1 15761015TRIOXIDE ARSENIC NM_002105 H2A histone family, member X H2AFX 16891316TRIOXIDE ARSENIC NR_024052; NR_024052; NR_024052; HLA complex group 18HCG18 15761015 TRIOXIDE NR_024052; NR_024052; NR_024052; NR_024052;NR_024052; NR_024052; NR_024052; NR_024052; NR_024052; NR_024053;NR_024053; NR_024053; NR_024053; NR_024053; NR_024053; NR_024053;NR_024053; NR_024053; NR_024053; NR_024053; NR_024053 ARSENIC NM_001525hypocretin (orexin) receptor 1 HCRTR1 15761015 TRIOXIDE ARSENICNM_000601; NM_001010931; NM_001010932; hepatocyte growth factor(hepapoietin A; scatter factor) HGF 15761015 TRIOXIDE NM_001010933;NM_001010934 ARSENIC NM_001530; NM_181054 hypoxia inducible factor 1,alpha subunit (basic helix- HIF1A 12482858, 16330433 TRIOXIDE loop-helixtranscription factor) ARSENIC — — HIG2 15725085 TRIOXIDE ARSENICNM_003521 histone cluster 1, H2bm HIST1H2BM 15761015 TRIOXIDE ARSENICNM_003542 histone cluster 1, H4c HIST1H4C 17547211 TRIOXIDE ARSENICNM_003493 histone cluster 3, H3 HIST3H3 12388546 TRIOXIDE ARSENICNM_000188; NM_033496; NM_033497; hexokinase 1 HK1 15761015 TRIOXIDENM_033498; NM_033500 ARSENIC NM_005514 major histocompatibility complex,class I, B HLA-B 15761015, 16 TRIOXIDE ARSENIC NM_002117 majorhistocompatibility complex, class I, C HLA-C 15761015, 16 TRIOXIDEARSENIC NM_019111 major histocompatibility complex, class II, DR alphaHLA- 15725085 TRIOXIDE DRA ARSENIC NM_001098478; NM_001098479; NM_018950major histocompatibility complex, class I, F HLA-F 15725085 TRIOXIDEARSENIC NM_002127 major histocompatibility complex, class I, G HLA-G15761015, 16 TRIOXIDE ARSENIC NM_002131; NM_145899; NM_145901; highmobility group AT-hook 1 HMGA1 17547211 TRIOXIDE NM_145902; NM_145903;NM_145905 ARSENIC NM_001130688; NM_001130689; NM_002129 high-mobilitygroup box 2 HMGB2 14703492 TRIOXIDE ARSENIC NM_005517 high-mobilitygroup nucleosomal binding domain 2 HMGN2 17547211 TRIOXIDE ARSENICNM_002133 heme oxygenase (decycling) 1 HMOX1 16487037, 17547211,15725085 TRIOXIDE ARSENIC NM_002153 hydroxysteroid (17-beta)dehydrogenase 2 HSD17B2 17547211 TRIOXIDE ARSENIC NM_005526 heat shocktranscription factor 1 HSF1 15978632 TRIOXIDE ARSENIC — — HSP27 15665116TRIOXIDE ARSENIC NM_005345 heat shock 70 kDa protein 1A HSPA1A 12749819TRIOXIDE ARSENIC NM_002154 heat shock 70 kDa protein 4 HSPA4 11678611,11678611, 14682389, TRIOXIDE 15665116, 14682389 ARSENIC NM_005347 heatshock 70 kDa protein 5 (glucose-regulated protein, HSPA5 11678611TRIOXIDE 78 kDa) ARSENIC NM_002155 heat shock 70 kDa protein 6 (HSP70B′)HSPA6 15978632 TRIOXIDE ARSENIC NM_001540 heat shock 27 kDa protein 1HSPB1 15761015, 15 TRIOXIDE ARSENIC NM_001098520; NM_001098521;NM_001098522; HIV-1 Tat interactive protein 2, 30 kDa HTATIP2 15761015TRIOXIDE NM_001098523; NM_006410 ARSENIC NM_002162 intercellularadhesion molecule 3 ICAM3 15761015 TRIOXIDE ARSENIC NM_002165; NM_181353inhibitor of DNA binding 1, dominant negative helix- ID1 15761015TRIOXIDE loop-helix protein ARSENIC NM_002166 inhibitor of DNA binding2, dominant negative helix- ID2 15761015 TRIOXIDE loop-helix proteinARSENIC NM_000202; NM_006123 iduronate 2-sulfatase IDS 15761015 TRIOXIDEARSENIC NM_004907 immediate early response 2 IER2 12749819 TRIOXIDEARSENIC NM_005531 interferon, gamma-inducible protein 16 IFI16 15761015TRIOXIDE ARSENIC NM_022168 interferon induced with helicase C domain 1IFIH1 15761015 TRIOXIDE ARSENIC NM_000605 interferon, alpha 2 IFNA212560223, 17077332 TRIOXIDE ARSENIC NM_000619 interferon, gamma IFNG14668793, 16914093 TRIOXIDE ARSENIC NM_001007245; NM_001550interferon-related developmental regulator 1 IFRD1 17547211 TRIOXIDEARSENIC NM_000597 insulin-like growth factor binding protein 2, 36 kDaIGFBP2 15761015, 15 TRIOXIDE ARSENIC NM_001553 insulin-like growthfactor binding protein 7 IGFBP7 15725085 TRIOXIDE ARSENIC NM_001556inhibitor of kappa light polypeptide gene enhancer in B- IKBKB —TRIOXIDE cells, kinase beta ARSENIC NM_001559 interleukin 12 receptor,beta 2 IL12RB2 15761015 TRIOXIDE ARSENIC NM_006850; NM_181339interleukin 24 IL24 15580305 TRIOXIDE ARSENIC NM_000600 interleukin 6(interferon, beta 2) IL6 12560223 TRIOXIDE ARSENIC NM_001557 interleukin8 receptor, beta IL8RB 15761015 TRIOXIDE ARSENIC NM_005540 inositolpolyphosphate-5-phosphatase, 75 kDa INPP5B 15761015 TRIOXIDE ARSENICNM_002196 insulinoma-associated 1 INSM1 15761015 TRIOXIDE ARSENICNM_001031715; NM_022784 IQ motif containing H IQCH 15761015 TRIOXIDEARSENIC NM_002198 interferon regulatory factor 1 IRF1 14668793, 16914093TRIOXIDE ARSENIC NM_000419 integrin, alpha 2b (platelet glycoprotein IIbof IIb/IIIa ITGA2B 15761015 TRIOXIDE complex, antigen CD41) ARSENICNM_000632; NM_001145808 integrin, alpha M (complement component 3receptor 3 ITGAM 16430862, 16468075 TRIOXIDE subunit) ARSENIC NM_002211;NM_033666; NM_033667; integrin, beta 1 (fibronectin receptor, betapolypeptide, ITGB1 12852829 TRIOXIDE NM_033668; NM_033669; NM_133376antigen CD29 includes MDF2, MSK12) ARSENIC NM_014288 integrin beta 3binding protein (beta3-endonexin) ITGB3BP 17547211 TRIOXIDE ARSENICNM_000889 integrin, beta 7 ITGB7 15761015 TRIOXIDE ARSENIC NM_004867integral membrane protein 2A ITM2A 15725085 TRIOXIDE ARSENIC NM_002228jun oncogene JUN 12749819 TRIOXIDE ARSENIC NM_005354 jun Dproto-oncogene JUND 15761015, 17077332 TRIOXIDE ARSENIC NM_000238;NM_172056; NM_172057 potassium voltage-gated channel, subfamily H (eag-KCNH2 15070760, 15213294 TRIOXIDE related), member 2 ARSENIC NM_138444potassium channel tetramerisation domain containing KCTD12 15761015TRIOXIDE 12 ARSENIC NR_022006; NR_022006; NR_022006; KIAA0087 KIAA008715761015 TRIOXIDE NR_022006; NR_022006; NR_022006; NR_022006; NR_022006ARSENIC NM_020947 KIAA1609 KIAA1609 15761015 TRIOXIDE ARSENIC NM_017596kinesin family member 21B KIF21B 15761015 TRIOXIDE ARSENIC NM_000899;NM_003994 KIT ligand KITLG 15761015 TRIOXIDE ARSENIC NM_003597Kruppel-like factor 11 KLF11 15761015 TRIOXIDE ARSENIC NM_001730Kruppel-like factor 5 (intestinal) KLF5 15761015 TRIOXIDE ARSENICNM_005554 keratin 6A KRT6A 15949261 TRIOXIDE ARSENIC NM_001032998;NM_003937 kynureninase (L-kynurenine hydrolase) KYNU 15761015 TRIOXIDEARSENIC NM_002293 laminin, gamma 1 (formerly LAMB2) LAMC1 12852829TRIOXIDE ARSENIC NM_001014987; NM_001014988; NM_001014989; linker foractivation of T cells LAT 15761015 TRIOXIDE NM_014387 ARSENIC NM_002308;NM_009587 lectin, galactoside-binding, soluble, 9 LGALS9 15761015TRIOXIDE ARSENIC NM_001008530; NM_005606 legumain LGMN 15725085 TRIOXIDEARSENIC NM_005780 lipoma HMGIC fusion partner LHFP 15761015, 15 TRIOXIDEARSENIC NM_014368; NM_199160 LIM homeobox 6 LHX6 15761015 TRIOXIDEARSENIC NM_001013253; NM_001013254; NM_001013255; lymphocyte-specificprotein 1 LSP1 15761015 TRIOXIDE NM_002339 ARSENIC NM_145867 leukotrieneC4 synthase LTC4S 15761015 TRIOXIDE ARSENIC NM_001161572; NM_001161573;NM_001161574; v-maf musculoaponeurotic fibrosarcoma oncogene MAFF16487037 TRIOXIDE NM_012323; NM_152878 homolog F (avian) ARSENICNM_002359; NM_032711 v-maf musculoaponeurotic fibrosarcoma oncogene MAFG16487037 TRIOXIDE homolog G (avian) ARSENIC NM_002360 v-mafmusculoaponeurotic fibrosarcoma oncogene MAFK 16487037 TRIOXIDE homologK (avian) ARSENIC NM_005907 mannosidase, alpha, class 1A, member 1MAN1A1 15761015 TRIOXIDE ARSENIC NM_000240 monoamine oxidase A MAOA15761015 TRIOXIDE ARSENIC NM_002756; NM_145109 mitogen-activated proteinkinase kinase 3 MAP2K3 16818652 TRIOXIDE ARSENIC NM_003010mitogen-activated protein kinase kinase 4 MAP2K4 15978632 TRIOXIDEARSENIC NM_002758 mitogen-activated protein kinase kinase 6 MAP2K616818652 TRIOXIDE ARSENIC NM_003980 microtubule-associated protein 7MAP7 15761015 TRIOXIDE ARSENIC NM_002745; NM_138957 mitogen-activatedprotein kinase 1 MAPK1 15580305, 15961274, 16328441, TRIOXIDE 16328441,15961274, 17050201 ARSENIC NM_001315; NM_139012; NM_139013;mitogen-activated protein kinase 14 MAPK14 16818652, 17 TRIOXIDENM_139014 ARSENIC NM_001040056; NM_001109891; NM_002746mitogen-activated protein kinase 3 MAPK3 15580305, 15961274, 16328441,TRIOXIDE 16328441, 15961274, 17050201 ARSENIC NM_002749; NM_139032;NM_139033; mitogen-activated protein kinase 7 MAPK7 15580305 TRIOXIDENM_139034 ARSENIC NM_002750; NM_139046; NM_139047; mitogen-activatedprotein kinase 8 MAPK8 15580305, 15961274, 16646077, TRIOXIDE NM_13904916818652 ARSENIC NM_001135044; NM_002752; NM_139068; mitogen-activatedprotein kinase 9 MAPK9 15580305, 16818652 TRIOXIDE NM_139069; NM_139070ARSENIC NM_001005415; NM_001005416; NM_016496 membrane-associated ringfinger (C3HC4) 2 MARCH2 15761015 TRIOXIDE ARSENIC — — MASK 17547211TRIOXIDE ARSENIC NM_001112732; NM_024979 MCF.2 cell line derivedtransforming sequence-like MCF2L 12852829 TRIOXIDE ARSENIC NM_004526minichromosome maintenance complex component 2 MCM2 17547211 TRIOXIDEARSENIC NM_002395 malic enzyme 1, NADP(+)-dependent, cytosolic ME115725085 TRIOXIDE ARSENIC NM_032390 MKI67 (FHA domain) interactingnucleolar MKI67IP 14703492 TRIOXIDE phosphoprotein ARSENIC NM_002421matrix metallopeptidase 1 (interstitial collagenase) MMP1 15761015TRIOXIDE ARSENIC NM_001127891; NM_004530 matrix metallopeptidase 2(gelatinase A, 72 kDa MMP2 15553829, 16624393, 16624393 TRIOXIDEgelatinase, 72 kDa type IV collagenase) ARSENIC NM_001032278; NM_024302matrix metallopeptidase 28 MMP28 15761015 TRIOXIDE ARSENIC NM_004994matrix metallopeptidase 9 (gelatinase B, 92 kDa MMP9 15949266, 16624393TRIOXIDE gelatinase, 92 kDa type IV collagenase) ARSENIC NM_005373myeloproliferative leukemia virus oncogene MPL 15761015 TRIOXIDE ARSENICNM_000250 myeloperoxidase MPO 12130515 TRIOXIDE ARSENIC NM_016065mitochondrial ribosomal protein S16 MRPS16 14703492 TRIOXIDE ARSENICNM_005098 musculin (activated B-cell factor-1) MSC 15761015 TRIOXIDEARSENIC NM_012228 methionine sulfoxide reductase B2 MSRB2 15725085TRIOXIDE ARSENIC NM_175617 metallothionein 1E MT1E 15725085 TRIOXIDEARSENIC NM_005950 metallothionein 1G MT1G 15725085 TRIOXIDE ARSENICNM_005951 metallothionein 1H MT1H 15725085 TRIOXIDE ARSENIC NR_001447;NR_001447; NR_001447; metallothionein 1L (gene/pseudogene) MT1L 15725085TRIOXIDE NR_001447; NR_001447; NR_001447 ARSENIC — metallothionein 1pseudogene 2 MT1P2 15725085 TRIOXIDE ARSENIC NM_005952 metallothionein1X MT1X 15725085 TRIOXIDE ARSENIC NM_005953 metallothionein 2A MT2A11678611, 11678611, 15725085, TRIOXIDE 14682389, 14682389 ARSENICNM_004689 metastasis associated 1 MTA1 12478894 TRIOXIDE ARSENICNM_001008528; NM_001008529; NM_198530 matrix-remodelling associated 7MXRA7 17547211 TRIOXIDE ARSENIC NM_001080416; NM_001144755 v-mybmyeloblastosis viral oncogene homolog (avian)- MYBL1 15725085 TRIOXIDElike 1 ARSENIC NM_002467 v-myc myelocytomatosis viral oncogene homologMYC 11714746, 12903512, 12903497, TRIOXIDE (avian) 11775218, 11775218,12903512, 11714746, 15622746, 15761015 ARSENIC NM_005378 v-mycmyelocytomatosis viral related oncogene, MYCN 12478894 TRIOXIDEneuroblastoma derived (avian) ARSENIC NM_001130158; NM_001161819;NM_012223 myosin IB MYO1B 15761015, 15 TRIOXIDE ARSENIC NM_012330 MYSThistone acetyltransferase (monocytic leukemia) 4 MYST4 15761015 TRIOXIDEARSENIC NM_153029 NEDD4 binding protein 1 N4BP1 15761015 TRIOXIDEARSENIC NM_001079691; NM_052818 NEDD4 binding protein 2-like 1 N4BP2L115761015 TRIOXIDE ARSENIC NM_005967 NGFI-A binding protein 2 (EGR1binding protein 2) NAB2 15761015 TRIOXIDE ARSENIC NM_014903 neuronnavigator 3 NAV3 15761015 TRIOXIDE ARSENIC NM_000265 neutrophilcytosolic factor 1 NCF1 15070760, 15761015, 15070760 TRIOXIDE ARSENICNM_000433; NM_001127651 neutrophil cytosolic factor 2 NCF2 15070760TRIOXIDE ARSENIC — NADH dehydrogenase, subunit 4 (complex I) ND414703492 TRIOXIDE ARSENIC NM_006656 sialidase 3 (membrane sialidase)NEU3 15070760 TRIOXIDE ARSENIC NM_003204 nuclear factor(erythroid-derived 2)-like 1 NFE2L1 16487037 TRIOXIDE ARSENIC NM_020529nuclear factor of kappa light polypeptide gene NFKBIA 12560223 TRIOXIDEenhancer in B-cells inhibitor, alpha ARSENIC NM_004556 nuclear factor ofkappa light polypeptide gene NFKBIE 12560223 TRIOXIDE enhancer inB-cells inhibitor, epsilon ARSENIC NM_000269; NM_198175 non-metastaticcells 1, protein (NM23A) expressed in NME1 12452020, 12478894 TRIOXIDEARSENIC NM_002517 neuronal PAS domain protein 1 NPAS1 15761015 TRIOXIDEARSENIC NM_002523 neuronal pentraxin II NPTX2 15761015 TRIOXIDE ARSENICNM_000176; NM_001018074; NM_001018075; nuclear receptor subfamily 3,group C, member 1 NR3C1 17081986 TRIOXIDE NM_001018076; NM_001018077;(glucocorticoid receptor) NM_001020825; NM_001024094 ARSENIC NM_005013nucleobindin 2 NUCB2 17547211 TRIOXIDE ARSENIC NM_024815 nudix(nucleoside diphosphate linked moiety X)-type NUDT18 15761015 TRIOXIDEmotif 18 ARSENIC NM_020401 nucleoporin 107 kDa NUP107 17547211 TRIOXIDEARSENIC NM_015311 obscurin-like 1 OBSL1 15761015 TRIOXIDE ARSENICNM_002552; NM_181741; NM_181742 origin recognition complex, subunit4-like (yeast) ORC4L 15761015 TRIOXIDE ARSENIC NM_001017956;NM_001017957; NM_001017958; osteosarcoma amplified 9, endoplasmicreticulum OS9 17547211 TRIOXIDE NM_006812 associated protein ARSENICNM_000917; NM_001017962; NM_001142595; prolyl 4-hydroxylase, alphapolypeptide I P4HA1 15725085 TRIOXIDE NM_001142596 ARSENIC NM_000437platelet-activating factor acetylhydrolase 2, 40 kDa PAFAH2 15761015TRIOXIDE ARSENIC NM_152911; NM_207127; NM_207128 polyamine oxidase(exo-N4-amino) PAOX 15761015 TRIOXIDE ARSENIC NM_024897; NM_198406progestin and adipoQ receptor family member VI PAQR6 15725085 TRIOXIDEARSENIC NM_001618 poly (ADP-ribose) polymerase 1 PARP1 16328441,16328441, 16646077 TRIOXIDE ARSENIC NM_002583 PRKC, apoptosis, WT1,regulator PAWR 16966277 TRIOXIDE ARSENIC NM_002592; NM_182649proliferating cell nuclear antigen PCNA 12783709, 16029599 TRIOXIDEARSENIC NM_006200 proprotein convertase subtilisin/kexin type 5 PCSK515761015 TRIOXIDE ARSENIC NM_014456; NM_145341 programmed cell death 4(neoplastic transformation PDCD4 17259349 TRIOXIDE inhibitor) ARSENICNM_001111307; NM_001111308; NM_001111309; phosphodiesterase 4A,cAMP-specific PDE4A 15070760 TRIOXIDE NM_006202 (phosphodiesterase E2dunce homolog, Drosophila) ARSENIC NM_001037339; NM_001037340;NM_001037341; phosphodiesterase 4B, cAMP-specific PDE4B 15761015TRIOXIDE NM_002600 (phosphodiesterase E4 dunce homolog, Drosophila)ARSENIC NM_001002810; NM_001002811; NM_001002812; phosphodiesterase 4Dinteracting protein PDE4DIP 15761015 TRIOXIDE NM_014644; NM_022359ARSENIC NM_005451; NM_203352; NM_213636 PDZ and LIM domain 7 (enigma)PDLIM7 15761015 TRIOXIDE ARSENIC NM_002613; NM_031268 3-phosphoinositidedependent protein kinase-1 PDPK1 14633726 TRIOXIDE ARSENIC NM_178140 PDZdomain containing 2 PDZD2 15761015 TRIOXIDE ARSENIC NM_000442platelet/endothelial cell adhesion molecule PECAM1 15761015 TRIOXIDEARSENIC NM_003630 peroxisomal biogenesis factor 3 PEX3 15761015 TRIOXIDEARSENIC NM_002630 progastricsin (pepsinogen C) PGC 17547211 TRIOXIDEARSENIC NM_002632 placental growth factor PGF 17547211 TRIOXIDE ARSENICNM_003311 pleckstrin homology-like domain, family A, member 2 PHLDA215761015 TRIOXIDE ARSENIC NM_032634; NM_152850 phosphatidylinositolglycan anchor biosynthesis, class O PIGO 15761015 TRIOXIDE ARSENIC — —PIK4CA 12852829 TRIOXIDE ARSENIC NM_001018109; NM_003662 pirin(iron-binding nuclear protein) PIR 15761015 TRIOXIDE ARSENIC NM_004571PBX/knotted 1 homeobox 1 PKNOX1 15761015 TRIOXIDE ARSENIC NM_001005376;NM_001005377; NM_002659 plasminogen activator, urokinase receptor PLAUR15761015 TRIOXIDE ARSENIC NM_016274 pleckstrin homology domaincontaining, family O PLEKHO1 15761015 TRIOXIDE member 1 ARSENICNM_005761 plexin C1 PLXNC1 15761015 TRIOXIDE ARSENIC NM_002675;NM_033238; NM_033239; promyelocytic leukemia PML 15748426, 15748426,16891316, TRIOXIDE NM_033240; NM_033244; NM_033246; 16330433, 17081986NM_033247; NM_033249; NM_033250 ARSENIC — — PPGB 15725085 TRIOXIDEARSENIC NM_006347 peptidylprolyl isomerase H (cyclophilin H) PPIH17547211 TRIOXIDE ARSENIC NM_002709; NM_206876 protein phosphatase 1,catalytic subunit, beta isoform PPP1CB 12852829 TRIOXIDE ARSENICNM_006093 proteoglycan 3 PRG3 15761015 TRIOXIDE ARSENIC NM_002738;NM_212535 protein kinase C, beta PRKCB 15725085 TRIOXIDE ARSENICNM_016644 proline rich 16 PRR16 15761015 TRIOXIDE ARSENIC NM_002769protease, serine, 1 (trypsin 1) PRSS1 15761015 TRIOXIDE ARSENICNM_002798 proteasome (prosome, macropain) subunit, beta type, 6 PSMB612852829 TRIOXIDE ARSENIC NM_004159; NM_148919 proteasome (prosome,macropain) subunit, beta type, PSMB8 15725085 TRIOXIDE 8 (largemultifunctional peptidase 7) ARSENIC NM_000959; NM_001039585prostaglandin F receptor (FP) PTGFR 15761015 TRIOXIDE ARSENIC NM_016077peptidyl-tRNA hydrolase 2 PTRH2 14703492 TRIOXIDE ARSENIC NM_004219pituitary tumor-transforming 1 PTTG1 17547211 TRIOXIDE ARSENICNM_001015508; NM_013357 purine-rich element binding protein G PURG15761015 TRIOXIDE ARSENIC NM_012293 peroxidasin homolog (Drosophila)PXDN 15761015 TRIOXIDE ARSENIC NM_004163 RAB27B, member RAS oncogenefamily RAB27B 15761015 TRIOXIDE ARSENIC NM_001126103; NM_001126104;NM_013277 Rac GTPase activating protein 1 RACGAP1 17547211 TRIOXIDEARSENIC NM_001100397; NM_007023 Rap guanine nucleotide exchange factor(GEF) 4 RAPGEF4 15761015 TRIOXIDE ARSENIC NM_000964; NM_001024809;NM_001145301; retinoic acid receptor, alpha RARA 15748426, 16891316,16330433 TRIOXIDE NM_001145302 ARSENIC NM_007211 Ras association(RaIGDS/AF-6) domain family (N- RASSF8 15761015 TRIOXIDE terminal)member 8 ARSENIC NM_002139 RNA binding motif protein, X-linked RBMX12852829 TRIOXIDE ARSENIC NM_001145138; NM_021975 v-relreticuloendotheliosis viral oncogene homolog A RELA 16105982, 16174796,16174796 TRIOXIDE (avian) ARSENIC NM_001042681; NM_001042682; NM_012102arginine-glutamic acid dipeptide (RE) repeats RERE 15761015 TRIOXIDEARSENIC NM_002914; NM_181471 replication factor C (activator 1) 2, 40kDa RFC2 17547211 TRIOXIDE ARSENIC NM_002923 regulator of G-proteinsignaling 2, 24 kDa RGS2 12852829 TRIOXIDE ARSENIC NM_006397ribonuclease H2, subunit A RNASEH2A 17547211 TRIOXIDE ARSENIC NM_014746ring finger protein 144A RNF144A 15761015 TRIOXIDE ARSENIC NM_001134337;NM_001134338; NM_007219 ring finger protein 24 RNF24 15761015 TRIOXIDEARSENIC NM_005977; NM_183043; NM_183044 ring finger protein (C3H2C3type) 6 RNF6 15761015 TRIOXIDE ARSENIC NM_002941; NM_133631 roundabout,axon guidance receptor, homolog 1 ROBO1 15725085 TRIOXIDE (Drosophila)ARSENIC NM_000985; NM_001035006 ribosomal protein L17 RPL17 12852829TRIOXIDE ARSENIC NM_000980 ribosomal protein L18a RPL18A 15725085TRIOXIDE ARSENIC NM_000978 ribosomal protein L23 RPL23 14703492 TRIOXIDEARSENIC NM_000971 ribosomal protein L7 RPL7 12852829 TRIOXIDE ARSENICNM_001019; NM_001030009 ribosomal protein S15a RPS15A 14703492 TRIOXIDEARSENIC NM_003161 ribosomal protein S6 kinase, 70 kDa, polypeptide 1RPS6KB1 14633726 TRIOXIDE ARSENIC NM_001042576; NM_004587 ribosomebinding protein 1 homolog 180 kDa (dog) RRBP1 15761015 TRIOXIDE ARSENICNM_015659 ribosomal L1 domain containing 1 RSL1D1 15761015 TRIOXIDEARSENIC NM_001005861; NM_002958 RYK receptor-like tyrosine kinase RYK15761015 TRIOXIDE ARSENIC NM_002966 S100 calcium binding protein A10S100A10 15949261 TRIOXIDE ARSENIC NM_002964 S100 calcium binding proteinA8 S100A8 15761015, 15 TRIOXIDE ARSENIC NM_002965 S100 calcium bindingprotein A9 S100A9 15761015 TRIOXIDE ARSENIC NM_015265 SATB homeobox 2SATB2 15761015 TRIOXIDE ARSENIC NM_138967 secretory carrier membraneprotein 5 SCAMP5 15761015 TRIOXIDE ARSENIC NM_002411 secretoglobin,family 2A, member 2 SCGB2A2 15761015 TRIOXIDE ARSENIC NM_021626 serinecarboxypeptidase 1 SCPEP1 15725085 TRIOXIDE ARSENIC NM_021920 secretinSCT 15761015 TRIOXIDE ARSENIC NM_002998 syndecan 2 SDC2 15761015,12852829, 15725085 TRIOXIDE ARSENIC NM_002999 syndecan 4 SDC4 15761015TRIOXIDE ARSENIC NM_003005 selectin P (granule membrane protein 140 kDa,antigen SELP 16206674 TRIOXIDE CD62) ARSENIC NM_030666 serpin peptidaseinhibitor, clade B (ovalbumin), SERPINB1 15761015 TRIOXIDE member 1ARSENIC NM_014755 SERTA domain containing 2 SERTAD2 15725085 TRIOXIDEARSENIC NM_001039465; NM_006925 splicing factor, arginine/serine-rich 5SFRS5 14703492 TRIOXIDE ARSENIC NM_003026 SH3-domain GRB2-like 2 SH3GL215761015 TRIOXIDE ARSENIC NM_001245; NM_198845; NM_198846 sialic acidbinding Ig-like lectin 6 SIGLEC6 15761015 TRIOXIDE ARSENIC NM_007163solute carrier family 14 (urea transporter), member 2 SLC14A2 15761015TRIOXIDE ARSENIC NM_005073 solute carrier family 15 (oligopeptidetransporter), SLC15A1 15761015 TRIOXIDE member 1 ARSENIC NM_004171solute carrier family 1 (glial high affinity glutamate SLC1A2 17547211TRIOXIDE transporter), member 2 ARSENIC NM_002555; NM_183233 solutecarrier family 22, member 18 SLC22A18 15725085 TRIOXIDE ARSENICNM_006516 solute carrier family 2 (facilitated glucose transporter),SLC2A1 17064664 TRIOXIDE member 1 ARSENIC NM_080546 solute carrierfamily 44, member 1 SLC44A1 15761015 TRIOXIDE ARSENIC NM_017842 solutecarrier family 48 (heme transporter), member 1 SLC48A1 15761015, 16TRIOXIDE ARSENIC NM_178498 solute carrier family 5 (sodium/glucosecotransporter), SLC5A12 15761015 TRIOXIDE member 12 ARSENIC NM_004211solute carrier family 6 (neurotransmitter transporter, SLC6A5 15761015TRIOXIDE glycine), member 5 ARSENIC NM_001145044; NM_013272 solutecarrier organic anion transporter family, member SLCO3A1 15761015TRIOXIDE 3A1 ARSENIC NM_001003688; NM_005900 SMAD family member 1 SMAD115761015 TRIOXIDE ARSENIC NM_001002800; NM_005496 structural maintenanceof chromosomes 4 SMC4 17547211 TRIOXIDE ARSENIC NM_000454 superoxidedismutase 1, soluble SOD1 16867262 TRIOXIDE ARSENIC NM_018419 SRY (sexdetermining region Y)-box 18 SOX18 15761015 TRIOXIDE ARSENIC NM_007017;NM_178424 SRY (sex determining region Y)-box 30 SOX30 15761015 TRIOXIDEARSENIC NM_003107 SRY (sex determining region Y)-box 4 SOX4 15725085TRIOXIDE ARSENIC NM_003109; NM_138473 Sp1 transcription factor SP111714746, 15761015 TRIOXIDE ARSENIC NM_001130438; NM_003127 spectrin,alpha, non-erythrocytic 1 (alpha-fodrin) SPTAN1 12852829 TRIOXIDEARSENIC NM_175039; NM_175040 ST6(alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl- ST6GALNAC4 17547211TRIOXIDE 1,3)-N-acetylgalactosaminide alpha-2,6- sialyltransferase 4ARSENIC NM_015136 stabilin 1 STAB1 15761015 TRIOXIDE ARSENIC NM_007315;NM_139266 signal transducer and activator of transcription 1, STAT114668793, 16914093 TRIOXIDE 91 kDa ARSENIC NM_001009181; NM_003154statherin STATH 15761015 TRIOXIDE ARSENIC NM_001128204; NM_001128205;NM_001128206; sulfatase 1 SULF1 15725085 TRIOXIDE NM_015170 ARSENICNM_015551 sushi domain containing 5 SUSD5 15761015 TRIOXIDE ARSENICNM_001135774; NM_003490; NM_133633 synapsin III SYN3 15761015 TRIOXIDEARSENIC NM_003898 synaptojanin 2 SYNJ2 12852829 TRIOXIDE ARSENICNM_001083962; NM_003199 transcription factor 4 TCF4 15761015 TRIOXIDEARSENIC NR_001566; NR_001566; NR_001566; telomerase RNA component TERC11714746 TRIOXIDE NR_001566; NR_001566; NR_001566 ARSENIC NM_003218;NM_017489 telomeric repeat binding factor (NIMA-interacting) 1 TERF116129045 TRIOXIDE ARSENIC NM_005652 telomeric repeat binding factor 2TERF2 16129045 TRIOXIDE ARSENIC NM_198253; NM_198255 telomerase reversetranscriptase TERT 11714746, 16966277, 15761015, TRIOXIDE 15761015,16129045, 11714746, 16966277, 16285558, 15996315 ARSENIC NM_003222transcription factor AP-2 gamma (activating enhancer TFAP2C 15761015TRIOXIDE binding protein 2 gamma) ARSENIC NM_003225 trefoil factor 1TFF1 12014631 TRIOXIDE ARSENIC NM_001024847; NM_003242 transforminggrowth factor, beta receptor II (70/80 kDa) TGFBR2 12852829 TRIOXIDEARSENIC NM_003254 TIMP metallopeptidase inhibitor 1 TIMP1 16624393TRIOXIDE ARSENIC NM_003255 TIMP metallopeptidase inhibitor 2 TIMP216624393 TRIOXIDE ARSENIC NM_015444 transmembrane protein 158 TMEM15815761015 TRIOXIDE ARSENIC NM_000594 tumor necrosis factor (TNFsuperfamily, member 2) TNF 12560223 TRIOXIDE ARSENIC NM_006290 tumornecrosis factor, alpha-induced protein 3 TNFAIP3 17547211 TRIOXIDEARSENIC NM_001077654; NM_014350 tumor necrosis factor, alpha-inducedprotein 8 TNFAIP8 17547211 TRIOXIDE ARSENIC NM_001066 tumor necrosisfactor receptor superfamily, member 1B TNFRSF1B 15761015 TRIOXIDEARSENIC NM_001039664; NM_003790; NM_148965; tumor necrosis factorreceptor superfamily, member 25 TNFRSF25 15761015 TRIOXIDE NM_148966;NM_148967; NM_148970 ARSENIC NM_001561 tumor necrosis factor receptorsuperfamily, member 9 TNFRSF9 16010437 TRIOXIDE ARSENIC NM_003808;NM_172087; NM_172088 tumor necrosis factor (ligand) superfamily, member13 TNFSF13 15761015 TRIOXIDE ARSENIC NM_001244 tumor necrosis factor(ligand) superfamily, member 8 TNFSF8 15761015 TRIOXIDE ARSENICNM_001067 topoisomerase (DNA) II alpha 170 kDa TOP2A 16884364 TRIOXIDEARSENIC NM_000546; NM_001126112; NM_001126113; tumor protein p53 TP5311714746, 14682389, 11714746, TRIOXIDE NM_001126114; NM_001126115;15622746, 11775218, 15979894, NM_001126116; NM_001126117 12490120,16467208 ARSENIC NM_022112 tumor protein p53 regulated apoptosisinducing protein 1 TP53AIP1 15031205, 16467208 TRIOXIDE ARSENICNM_001076787; NM_006034 tumor protein p53 inducible protein 11 TP53I1112883691, 15225615, 15761015 TRIOXIDE ARSENIC NM_001126240;NM_001126241; NM_001126242; tumor protein p73 TP73 15031205, 16467208TRIOXIDE NM_005427 ARSENIC NM_003295 tumor protein,translationally-controlled 1 TPT1 15949261 TRIOXIDE ARSENIC NM_013293transformer 2 alpha homolog (Drosophila) TRA2A 15761015 TRIOXIDE ARSENICNM_147200; NM_147686 TRAF3 interacting protein 2 TRAF3IP2 15761015TRIOXIDE ARSENIC NM_006470 tripartite motif-containing 16 TRIM1615725085 TRIOXIDE ARSENIC NM_004237 thyroid hormone receptor interactor13 TRIP13 17547211 TRIOXIDE ARSENIC NM_001136035; NM_001142554;NM_017722 TRM1 tRNA methyltransferase 1 homolog TRMT1 15725085 TRIOXIDE(S. cerevisiae) ARSENIC NM_001015881; NM_004089; NM_198057 TSC22 domainfamily, member 3 TSC22D3 17081986 TRIOXIDE ARSENIC NM_017931tetratricopeptide repeat domain 38 TTC38 15761015 TRIOXIDE ARSENICNM_006472 thioredoxin interacting protein TXNIP 15725085 TRIOXIDEARSENIC NM_001071 thymidylate synthetase TYMS 17547211 TRIOXIDE ARSENICNM_007019; NM_181799; NM_181800; ubiquitin-conjugating enzyme E2C UBE2C17547211 TRIOXIDE NM_181801; NM_181802; NM_181803 ARSENIC NM_003338ubiquitin-conjugating enzyme E2D 1 (UBC4/5 UBE2D1 15761015 TRIOXIDEhomolog, yeast) ARSENIC NM_004181 ubiquitin carboxyl-terminal esteraseL1 (ubiquitin UCHL1 15725085 TRIOXIDE thiolesterase) ARSENIC NM_003355uncoupling protein 2 (mitochondrial, proton carrier) UCP2 15761015TRIOXIDE ARSENIC NM_001025366; NM_001025367; NM_001025368; vascularendothelial growth factor A VEGFA 12482858, 15949266, 16928304 TRIOXIDENM_001025369; NM_001025370; NM_001033756; NM_003376 ARSENIC NM_004666vanin 1 VNN1 15761015 TRIOXIDE ARSENIC NM_018256 WD repeat domain 12WDR12 15725085 TRIOXIDE ARSENIC NM_025222 WD repeat domain 82 WDR8215761015 TRIOXIDE ARSENIC NM_018639 WD repeat and SOCS box-containing 2WSB2 15725085 TRIOXIDE ARSENIC NM_000378; NM_024424; NM_024425; Wilmstumor 1 WT1 16966277 TRIOXIDE NM_024426 ARSENIC NM_001167 X-linkedinhibitor of apoptosis XIAP 16105982, 16 TRIOXIDE ARSENIC NM_001469X-ray repair complementing defective repair in Chinese XRCC6 15761015TRIOXIDE hamster cells 6 ARSENIC NM_003407 zinc finger protein 36, C3Htype, homolog (mouse) ZFP36 12749819 TRIOXIDE ARSENIC NM_004926 zincfinger protein 36, C3H type-like 1 ZFP36L1 15725085 TRIOXIDE ARSENICNM_003453; NM_197968 zinc finger, MYM-type 2 ZMYM2 17027752 TRIOXIDEARSENIC NM_018102; NM_199441 zinc finger protein 334 ZNF334 15761015TRIOXIDE ARSENIC NM_001007094; NM_003421 zinc finger protein 37A ZNF37A15761015 TRIOXIDE ARSENIC NM_001077349; NM_033196 zinc finger protein682 ZNF682 15761015 TRIOXIDE ARSENIC NM_001142305; NM_016643 zinc fingerprotein 771 ZNF771 15761015 TRIOXIDE ARSENIC NM_001005413; NM_007057;NM_032997 ZW10 interactor ZWINT 17547211 TRIOXIDE BORTEZOMIBNM_001014431; NM_001014432; NM_005163 v-akt murine thymoma viraloncogene homolog 1 AKT1 15781649 unrelated BORTEZOMIB NM_001160;NM_013229; NM_181861; apoptotic peptidase activating factor 1 APAF116024631 death pathway NM_181868; NM_181869 BORTEZOMIB NM_001188BCL2-antagonist/killer 1 BAK1 16024631 death pathway BORTEZOMIBNM_004324; NM_138761; NM_138763; BCL2-associated X protein BAX 16024631death pathway NM_138764; NM_138765 BORTEZOMIB NM_000633; NM_000657B-cell CLL/lymphoma 2 BCL2 15781649, 16022909, 16024631 altered bybortezomib BORTEZOMIB NM_001191; NM_138578 BCL2-like 1 BCL2L1 12893773,15543232, 15781649, altered by 16024631 bortezomib BORTEZOMIB NM_006538;NM_138621; NM_207002 BCL2-like 11 (apoptosis facilitator) BCL2L1116024631 death pathway BORTEZOMIB NM_001196; NM_197966; NM_197967 BH3interacting domain death agonist BID 12893773 death pathway BORTEZOMIBNM_001166 baculoviral IAP repeat-containing 2 BIRC2 12893773, 15543232,15781649, altered by 16024631 bortezomib BORTEZOMIB NM_001165; NM_182962baculoviral IAP repeat-containing 3 BIRC3 12893773, 16024631 altered bybortezomib BORTEZOMIB NM_001012270; NM_001012271; NM_001168 baculoviralIAP repeat-containing 5 BIRC5 16373703 BORTEZOMIB NM_001216 carbonicanhydrase IX CA9 16061869 altered by bortezomib BORTEZOMIB NM_004346;NM_032991 caspase 3, apoptosis-related cysteine peptidase CASP312893773, 15735676, 16024631, death pathway 16675587, 17121930BORTEZOMIB NM_001227; NM_033338; NM_033339; caspase 7, apoptosis-relatedcysteine peptidase CASP7 16024631 death pathway NM_033340 BORTEZOMIBNM_001080124; NM_001080125; NM_001228; caspase 8, apoptosis-relatedcysteine peptidase CASP8 12893773, 15735676, 16024631 death pathwayNM_033355; NM_033356; NM_033358 BORTEZOMIB NM_001229; NM_032996 caspase9, apoptosis-related cysteine peptidase CASP9 12893773, 15735676,16024631 death pathway BORTEZOMIB NM_053056 cyclin D1 CCND1 12893773,15781649 sensitivity BORTEZOMIB NM_000389; NM_078467 cyclin-dependentkinase inhibitor 1A (p21, Cip1) CDKN1A 12893773, 15543232 BORTEZOMIBNM_004064 cyclin-dependent kinase inhibitor 1B (p27, Kip1) CDKN1B15543232 BORTEZOMIB NM_001127183; NM_001127184; NM_003879 CASP8 andFADD-like apoptosis regulator CFLAR 12893773, 16024631 altered bybortezomib BORTEZOMIB NM_018947 cytochrome c, somatic CYCS 12893773,16024631 death pathway BORTEZOMIB NM_000761 cytochrome P450, family 1,subfamily A, polypeptide 2 CYP1A2 15764713 drug metabolism BORTEZOMIBNM_000769 cytochrome P450, family 2, subfamily C, polypeptide CYP2C1915764713 drug 19 metabolism BORTEZOMIB NM_000771 cytochrome P450, family2, subfamily C, polypeptide 9 CYP2C9 15764713 drug metabolism BORTEZOMIBNM_000106; NM_001025161 cytochrome P450, family 2, subfamily D,polypeptide 6 CYP2D6 15764713 drug metabolism BORTEZOMIB NM_017460cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A4 15764713drug metabolism BORTEZOMIB NM_004083 DNA-damage-inducible transcript 3DDIT3 16024631 altered by bortezomib BORTEZOMIB NM_004401; NM_213566 DNAfragmentation factor, 45 kDa, alpha polypeptide DFFA 15735676 BORTEZOMIBNM_019887; NM_138929 diablo homolog (Drosophila) DIABLO 12893773,16024631 death pathway BORTEZOMIB NM_001530; NM_181054 hypoxia induciblefactor 1, alpha subunit (basic helix- HIF1A 16061869 altered byloop-helix transcription factor) bortezomib BORTEZOMIB — — HSP27 —resistance BORTEZOMIB NM_005347 heat shock 70 kDa protein 5(glucose-regulated protein, HSPA5 16024631 altered by 78 kDa) bortezomibBORTEZOMIB NM_013247; NM_145074 HtrA serine peptidase 2 HTRA2 16024631death pathway BORTEZOMIB NM_002228 jun oncogene JUN 15735676 altered bybortezomib BORTEZOMIB NM_002755 mitogen-activated protein kinase kinase1 MAP2K1 12893773 BORTEZOMIB NM_003010 mitogen-activated protein kinasekinase 4 MAP2K4 15735676 BORTEZOMIB NM_002745; NM_138957mitogen-activated protein kinase 1 MAPK1 12893773 altered by bortezomibBORTEZOMIB NM_001315; NM_139012; NM_139013; mitogen-activated proteinkinase 14 MAPK14 12893773 altered by NM_139014 bortezomib BORTEZOMIBNM_001040056; NM_001109891; NM_002746 mitogen-activated protein kinase 3MAPK3 12893773 altered by bortezomib BORTEZOMIB NM_002750; NM_139046;NM_139047; mitogen-activated protein kinase 8 MAPK8 12893773 altered byNM_139049 bortezomib BORTEZOMIB NM_021960; NM_182763 myeloid cellleukemia sequence 1 (BCL2-related) MCL1 12893773 resistance BORTEZOMIBNM_003998 nuclear factor of kappa light polypeptide gene NFKB1 12893773,16230421, 17164350 resistance enhancer in B-cells 1 BORTEZOMIB NM_020529nuclear factor of kappa light polypeptide gene NFKBIA 15543232 alteredby enhancer in B-cells inhibitor, alpha bortezomib BORTEZOMIBNM_001001716; NM_002503 nuclear factor of kappa light polypeptide geneNFKBIB 15543232 altered by enhancer in B-cells inhibitor, betabortezomib BORTEZOMIB NM_004556 nuclear factor of kappa lightpolypeptide gene NFKBIE 15543232 enhancer in B-cells inhibitor, epsilonBORTEZOMIB NM_001618 poly (ADP-ribose) polymerase 1 PARP1 12893773,15735676 altered by bortezomib BORTEZOMIB — — PDCD8 12893773, 16024631BORTEZOMIB NM_021127 phorbol-12-myristate-13-acetate-induced protein 1PMAIP1 16024631 death pathway BORTEZOMIB NM_002793 proteasome (prosome,macropain) subunit, beta type, 1 PSMB1 — target resistance BORTEZOMIBNM_002794 proteasome (prosome, macropain) subunit, beta type, 2 PSMB2 —target resistance BORTEZOMIB NM_001130725; NM_001144932; NM_002797proteasome (prosome, macropain) subunit, beta type, 5 PSMB5 — targetresistance BORTEZOMIB NM_002807 proteasome (prosome, macropain) 26Ssubunit, non- PSMD1 — target ? ATPase, 1 BORTEZOMIB NM_002808 proteasome(prosome, macropain) 26S subunit, non- PSMD2 — target ? ATPase, 2BORTEZOMIB NM_002880 v-raf-1 murine leukemia viral oncogene homolog 1RAF1 12893773 altered by bortezomib BORTEZOMIB NM_000321 retinoblastoma1 RB1 12893773 BORTEZOMIB NM_001145138; NM_021975 v-relreticuloendotheliosis viral oncogene homolog A RELA 12893773, 16061869,16230421, resistance (avian) 17164350 BORTEZOMIB NM_006142 stratifin SFN16373703 BORTEZOMIB NM_003150; NM_139276; NM_213662 signal transducerand activator of transcription 3 STAT3 17164350 altered by (acute-phaseresponse factor) bortezomib BORTEZOMIB NM_000594 tumor necrosis factor(TNF superfamily, member 2) TNF 16230421 BORTEZOMIB NM_000546;NM_001126112; NM_001126113; tumor protein p53 TP53 15543232, 16061869,16373703 unrelated NM_001126114; NM_001126115; NM_001126116;NM_001126117 BORTEZOMIB NM_021138 TNF receptor-associated factor 2 TRAF216024631 BORTEZOMIB NM_001167 X-linked inhibitor of apoptosis XIAP12893773, 15543232, 16024631 altered by bortezomib CELECOXIBNM_001105515; NM_005845 ATP-binding cassette, sub-family C (CFTR/MRP),ABCC4 18690847 member 4 CELECOXIB NM_001023587; NM_005688 ATP-bindingcassette, sub-family C (CFTR/MRP), ABCC5 18690847 member 5 CELECOXIBNM_001014431; NM_001014432; NM_005163 v-akt murine thymoma viraloncogene homolog 1 AKT1 14654083, 16123214, 17270149 altered bycelecoxib CELECOXIB NM_004324; NM_138761; NM_138763; BCL2-associated Xprotein BAX 14654083 NM_138764; NM_138765 CELECOXIB NM_000633; NM_000657B-cell CLL/lymphoma 2 BCL2 14654083 CELECOXIB NM_001191; NM_138578BCL2-like 1 BCL2L1 14654083 CELECOXIB NM_001012270; NM_001012271;NM_001168 baculoviral IAP repeat-containing 5 BIRC5 16004971, 16123214,17270149, altered by 16707021, 17270149 celecoxib CELECOXIB NM_004346;NM_032991 caspase 3, apoptosis-related cysteine peptidase CASP3 16123214death pathway CELECOXIB NM_053056 cyclin D1 CCND1 15489888, 17270149altered by celecoxib CELECOXIB NM_001127183; NM_001127184; NM_003879CASP8 and FADD-like apoptosis regulator CFLAR — resistance CELECOXIBNM_001278 conserved helix-loop-helix ubiquitous kinase CHUK 15489888CELECOXIB NM_000103; NM_031226 cytochrome P450, family 19, subfamily A,polypeptide 1 CYP19A1 15964185 altered by celecoxib CELECOXIB NM_001927desmin DES 18089846 CELECOXIB NM_004864 growth differentiation factor 15GDF15 18089846 CELECOXIB NM_000852 glutathione S-transferase pi 1 GSTP118089846 CELECOXIB NM_000576 interleukin 1, beta IL1B 16357062 alteredby celecoxib CELECOXIB NM_000600 interleukin 6 (interferon, beta 2) IL616702388 altered by celecoxib CELECOXIB NM_002755 mitogen-activatedprotein kinase kinase 1 MAP2K1 16123214 CELECOXIB NM_030662mitogen-activated protein kinase kinase 2 MAP2K2 16123214 CELECOXIBNM_021960; NM_182763 myeloid cell leukemia sequence 1 (BCL2-related)MCL1 14654083 CELECOXIB NM_002417 antigen identified by monoclonalantibody Ki-67 MKI67 16507397 CELECOXIB NM_003998 nuclear factor ofkappa light polypeptide gene NFKB1 15489888 enhancer in B-cells 1CELECOXIB NM_020529 nuclear factor of kappa light polypeptide geneNFKBIA 15489888 enhancer in B-cells inhibitor, alpha CELECOXIB NM_002507nerve growth factor receptor (TNFR superfamily, NGFR 17447067 member 16)CELECOXIB NM_001159995; NM_001159996; NM_001159999; neuregulin 1 NRG116357062 altered by NM_001160001; NM_001160008; celecoxib NM_004495;NM_013956; NM_013957; NM_013958; NM_013959; NM_013960; NM_013961;NM_013962; NM_013964 CELECOXIB NM_001618 poly (ADP-ribose) polymerase 1PARP1 16123214 altered by celecoxib CELECOXIB NM_002613; NM_0312683-phosphoinositide dependent protein kinase-1 PDPK1 — target CELECOXIBNM_000963 prostaglandin-endoperoxide synthase 2 (prostaglandin PTGS215489888, 16004971, 16507397, target G/H synthase and cyclooxygenase)18089846 CELECOXIB NM_001145138; NM_021975 v-rel reticuloendotheliosisviral oncogene homolog A RELA 15489888, 16685529, 17097285 altered by(avian) celecoxib CELECOXIB NM_000351 steroid sulfatase (microsomal),isozyme S STS 16178010 CELECOXIB NM_003167 sulfotransferase family,cytosolic, 2A, SULT2A1 15483193, 17239972 altered bydehydroepiandrosterone (DHEA)-preferring, member 1 celecoxib CELECOXIBNM_000594 tumor necrosis factor (TNF superfamily, member 2) TNF15489888, 16702388 CELECOXIB NM_000546; NM_001126112; NM_001126113;tumor protein p53 TP53 16507397 NM_001126114; NM_001126115;NM_001126116; NM_001126117 COLCHICINE NM_000927 ATP-binding cassette,sub-family B (MDR/TAP), ABCB1 15342794, 15725475, 16007523 resistancemember 1 COLCHICINE NM_004996; NM_019862; NM_019898; ATP-bindingcassette, sub-family C (CFTR/MRP), ABCC1 12067707 resistance NM_019899;NM_019900 member 1 COLCHICINE NM_000611; NM_001127223; NM_001127225;CD59 molecule, complement regulatory protein CD59 17045307 NM_001127226;NM_001127227; NM_203329; NM_203330; NM_203331 COLCHICINE NM_001025076;NM_001025077; NM_001083591; CUG triplet repeat, RNA binding protein 2CUGBP2 11478917 NM_006561 COLCHICINE NM_017460 cytochrome P450, family3, subfamily A, polypeptide 4 CYP3A4 16007523, 16 drug metabolismCOLCHICINE NM_001556 inhibitor of kappa light polypeptide gene enhancerin B- IKBKB 17029595 cells, kinase beta COLCHICINE NM_002228 junoncogene JUN 12221076 death pathway/ survival COLCHICINE NM_002750;NM_139046; NM_139047; mitogen-activated protein kinase 8 MAPK8 12221076death pathway/ NM_139049 survival COLCHICINE NM_001135044; NM_002752;NM_139068; mitogen-activated protein kinase 9 MAPK9 12221076 deathpathway/ NM_139069; NM_139070 survival COLCHICINE NM_000243Mediterranean fever MEFV — COLCHICINE NM_001136022; NM_004554 nuclearfactor of activated T-cells, cytoplasmic, NFATC4 17044076calcineurin-dependent 4 COLCHICINE NM_003998 nuclear factor of kappalight polypeptide gene NFKB1 15744361 enhancer in B-cells 1 COLCHICINENM_020529 nuclear factor of kappa light polypeptide gene NFKBIA 17029595enhancer in B-cells inhibitor, alpha COLCHICINE NM_000176; NM_001018074;NM_001018075; nuclear receptor subfamily 3, group C, member 1 NR3C115744361 NM_001018076; NM_001018077; (glucocorticoid receptor)NM_001020825; NM_001024094 COLCHICINE NM_004103; NM_173174; NM_173175;PTK2B protein tyrosine kinase 2 beta PTK2B 11478917 NM_173176 COLCHICINENM_006788 ralA binding protein 1 RALBP1 15386349 unrelated COLCHICINENM_001145138; NM_021975 v-rel reticuloendotheliosis viral oncogenehomolog A RELA 15744361 (avian) COLCHICINE NM_000353 tyrosineaminotransferase TAT 15744361 altered by colchicine COLCHICINENM_000546; NM_001126112; NM_001126113; tumor protein p53 TP53 12221076cell death NM_001126114; NM_001126115; NM_001126116; NM_001126117COLCHICINE NM_030773 tubulin, beta 1 TUBB1 — target COLCHICINE NM_001069tubulin, beta 2A TUBB2A — target OBLIMERSEN NM_000633; NM_000657 B-cellCLL/lymphoma 2 BCL2 11095261, 15867202 target OBLIMERSEN NM_004346;NM_032991 caspase 3, apoptosis-related cysteine peptidase CASP3 16675587OBLIMERSEN — — IGH-6 15867202 TEGAFUR NM_001785 cytidine deaminase CDA18537153 TEGAFUR NM_000762 cytochrome P450, family 2, subfamily A,polypeptide 6 CYP2A6 11376561, 12172220, 11376561, target 15980104TEGAFUR NM_000110 dihydropyrimidine dehydrogenase DPYD 18537153TIPIFARNIB NM_000927 ATP-binding cassette, sub-family B (MDR/TAP), ABCB115122075 resistance member 1 TIPIFARNIB NM_017460 cytochrome P450,family 3, subfamily A, polypeptide 4 CYP3A4 15122075 TIPIFARNIBNM_000777 cytochrome P450, family 3, subfamily A, polypeptide 5 CYP3A515122075 TIPIFARNIB NM_000463 UDP glucuronosyltransferase 1 family,polypeptide A1 UGT1A1 15122075 VORINOSTAT NM_001014431; NM_001014432;NM_005163 v-akt murine thymoma viral oncogene homolog 1 AKT1 15781658,16144943 VORINOSTAT NM_001188 BCL2-antagonist/killer 1 BAK1 15781658,16144943 death pathway VORINOSTAT NM_004324; NM_138761; NM_138763;BCL2-associated X protein BAX 15781658, 15897598 death pathwayNM_138764; NM_138765 VORINOSTAT NM_000633; NM_000657 B-cell CLL/lymphoma2 BCL2 15897598, 16144943, 15897598 resistance VORINOSTAT NM_001114735;NM_004049 BCL2-related protein A1 BCL2A1 15897598 resistance VORINOSTATNM_001191; NM_138578 BCL2-like 1 BCL2L1 12893773, 16144943, 15897598resistance VORINOSTAT NM_006538; NM_138621; NM_207002 BCL2-like 11(apoptosis facilitator) BCL2L11 16144943 death pathway VORINOSTATNM_001196; NM_197966; NM_197967 BH3 interacting domain death agonist BID12893773, 17410615, death pathway 17410615, 15897598 VORINOSTATNM_001166 baculoviral IAP repeat-containing 2 BIRC2 12893773, 16377638VORINOSTAT NM_001165; NM_182962 baculoviral IAP repeat-containing 3BIRC3 12893773, 15897598, 16377638 altered by vorinostat VORINOSTATNM_001012270; NM_001012271; NM_001168 baculoviral IAP repeat-containing5 BIRC5 16144943, 17410615, 17410615, altered by 18156316 vorinostatVORINOSTAT NM_032982; NM_032983 caspase 2, apoptosis-related cysteinepeptidase CASP2 15897598 death pathway VORINOSTAT NM_004346; NM_032991caspase 3, apoptosis-related cysteine peptidase CASP3 12893773,15781658, 15897598, death pathway 17410615 VORINOSTAT NM_001227;NM_033338; NM_033339; caspase 7, apoptosis-related cysteine peptidaseCASP7 15897598 death pathway NM_033340 VORINOSTAT NM_001080124;NM_001080125; NM_001228; caspase 8, apoptosis-related cysteine peptidaseCASP8 12893773, 15781658, 15897598, death pathway NM_033355; NM_033356;NM_033358 17410615 VORINOSTAT NM_001229; NM_032996 caspase 9,apoptosis-related cysteine peptidase CASP9 12893773, 15897598 deathpathway VORINOSTAT NM_053056 cyclin D1 CCND1 12893773, 17431121,12893773 altered by vorinostat VORINOSTAT NM_000389; NM_078467cyclin-dependent kinase inhibitor 1A (p21, Cip1) CDKN1A 12893773,altered by 16144943, 17431121, 15897598, vorinostat 12893773, 14707268,17431121 VORINOSTAT NM_004064 cyclin-dependent kinase inhibitor 1B (p27,Kip1) CDKN1B 16144943, 17431121, 17431121 altered by vorinostatVORINOSTAT NM_001127183; NM_001127184; NM_003879 CASP8 and FADD-likeapoptosis regulator CFLAR 12893773, 15897598 resistance VORINOSTATNM_018947 cytochrome c, somatic CYCS 12893773, 15781658 death pathwayVORINOSTAT NM_000499 cytochrome P450, family 1, subfamily A, polypeptide1 CYP1A1 15713371 altered by vorinostat VORINOSTAT NM_000104 cytochromeP450, family 1, subfamily B, polypeptide 1 CYP1B1 15713371 altered byvorinostat VORINOSTAT NM_019887; NM_138929 diablo homolog (Drosophila)DIABLO 12893773 death pathway VORINOSTAT NM_001005862; NM_004448v-erb-b2 erythroblastic leukemia viral oncogene ERBB2 16144943 alteredby homolog 2, neuro/glioblastoma derived oncogene vorinostat homolog(avian) VORINOSTAT NM_004964 histone deacetylase 1 HDAC1 15930892 targetVORINOSTAT NM_001527 histone deacetylase 2 HDAC2 — target VORINOSTATNM_003883 histone deacetylase 3 HDAC3 15930892 target VORINOSTATNM_006044 histone deacetylase 6 HDAC6 15930892 target VORINOSTATNM_018486 histone deacetylase 8 HDAC8 — target VORINOSTAT NM_003493histone cluster 3, H3 HIST3H3 17431121 altered by vorinostat VORINOSTATNM_013247; NM_145074 HtrA serine peptidase 2 HTRA2 16026644 deathpathway VORINOSTAT NM_002755 mitogen-activated protein kinase kinase 1MAP2K1 12893773, 15781658 VORINOSTAT NM_002745; NM_138957mitogen-activated protein kinase 1 MAPK1 12893773, 15781658 VORINOSTATNM_001315; NM_139012; NM_139013; mitogen-activated protein kinase 14MAPK14 12893773 altered by NM_139014 vorinostat VORINOSTAT NM_001040056;NM_001109891; NM_002746 mitogen-activated protein kinase 3 MAPK312893773, 15781658 VORINOSTAT NM_002750; NM_139046; NM_139047;mitogen-activated protein kinase 8 MAPK8 12893773, 15781658, 15964800altered by NM_139049 vorinostat VORINOSTAT NM_003998 nuclear factor ofkappa light polypeptide gene NFKB1 12893773 altered by enhancer inB-cells 1 vorinostat VORINOSTAT NM_001618 poly (ADP-ribose) polymerase 1PARP1 12893773, 16377638, altered by 17431121, 15897598 vorinostatVORINOSTAT — — PDCD8 12893773, 15781658, 16026644 death pathwayVORINOSTAT NM_002880 v-raf-1 murine leukemia viral oncogene homolog 1RAF1 12893773, 16144943, 12893773 altered by vorinostat VORINOSTATNM_000965; NM_016152 retinoic acid receptor, beta RARB 16832676VORINOSTAT NM_000321 retinoblastoma 1 RB1 12893773, 14707268, 15897598altered by vorinostat VORINOSTAT NM_001145138; NM_021975 v-relreticuloendotheliosis viral oncogene homolog A RELA 12893773, 15964800altered by (avian) vorinostat VORINOSTAT NM_000594 tumor necrosis factor(TNF superfamily, member 2) TNF 16377638 VORINOSTAT NM_003810 tumornecrosis factor (ligand) superfamily, member 10 TNFSF10 17410615VORINOSTAT NM_001167 X-linked inhibitor of apoptosis XIAP 12893773,15964800, altered by 16144943, 17410615, 17410615 vorinostat

TABLE 2 Found Targets List (with fold- Avg Abs (FC) Chemical TargetGenes Target Genes List Found Targets changes) Avg Abs (FC) UP-REG ScoreNucleotides Nucleotides >> Antimetabolites Nucleotides >>Antimetabolites >> Folic acid METHOTREXATE 35 ABCB1 ABCC1 ABCC2 19 ABCC1(7.70) ABCC2 (4.39, 7.36 6.93 197 (Abitrexate, Antifolan, Arbitrexate,ABCC4 ABCG2 ALB ALPI (10 + 9) 5.45) ABCC4 (2.34) ATIC Emtexate, Folex,Ledertrexate, ATIC CD4 CD68 CD8A (54.3%) (3.75) NAT1 (2.39) PARP1Metatrexan, Methotrate, Mexate, CYP3A4 DHFR DKK1 (2.68) PRC1 (3.44) TYMSRheumatrex, Trexall) GSTM1 ICAM1 IL8 MMP3 (3.69) UBE2C (9.47) WNT5A(28.92) MTHFR MTR NAT1 ODC1 ABCB1 (−3.59) CD68 (−3.38) PARP1 PRC1 RB1SELE SLC19A1 CYP3A4 (−7.84) DKK1 (−16.44) SLC46A1 TAGLN TIMP1 TYMS ICAM1(−8.24) IL8 (−16.97) UBE2C VDR WISP1 WNT5A SLC19A1 (−3.24) TIMP1 (−4.76)VDR (−6.07) PEMETREXED 8 DHFR FPGS GART GGH RBM17 4 GART (2.18) TYMS(3.69) 3.50 2.94 73 (Alimta) SLC19A1 TYMP TYMS (2 + 2) SLC19A1 (−3.24)TYMP (−3.83, −5.95) (50.0%) Nucleotides >> Antimetabolites >> PurineFLUDARABINE 25 ADA AKT1 ARNT BCL2 6 CCNA2 (5.27) CCNE1 (5.62) 3.56 3.8862 (Fludara, Fludura) CCNA2 CCND1 CCNE1 (4 + 2) HIST3H3 (2.04) VEGFACDKN1B CYCS DIABLO (24.0%) (2.60) CCND1 (−2.52) MCL1 (−3.34) ERK HIF1AHIST3H3 HIST4H4 MAP2K1 MAP2K2 MAPK1 MAPK3 MCL1 PDCD8 POLA1 RRM1 STAT1VEGFA XIAP Nucleotides >> Antimetabolites >> Pyrimidine FLUOROURACIL 132ABCB1 ABCC1 ABCG2 64 ABCC1 (7.70) ADSS (3.13, 7.06 5.18 137 (5 FU,Fluorouracil, ACADL ADSS AIFM1 (35 + 29) 3.02) BECN1 (2.18) CA12Adrucil, Arumel, Carac, AMFR AMT ANGPTL2 (48.5%) (21.62, 17.07, 11.24,25.25) Carzonal, Effluderm, AREG ATP5O BARX2 CASP2 (2.27) CASP3 (2.14)Efudex, Efudix, Efurix, BAX BBS4 BCL2 BDH1 CASP8 (8.85, 2.67) CCNE2 FU,Fluoroblastin, BECN1 BIRC5 BNIP3 (3.25) CCNF (2.52) CDCA8 Fluoroplex,Fluracil, BNIP3L BOLL BTG3 BUB3 (2.55) CTNND2 (3.12, 2.44) Fluracilum,Fluri, Fluril, C13ORF34 CA12 CASP2 CTTN (2.13) DTYMK (2.69, Fluro,Uracil, Ftoruracil, CASP3 CASP7 CASP8 2.60) E2F3 (2.71) EML2 Kecimeton,Phthoruracil, CASP9 CCND3 CCNE2 (4.55) FEN1 (2.79, 2.41) Phtoruracil,Queroplex, CCNF CCNG2 CDCA8 FOXO3 (2.21) GOLGA8A Timazin, URF, Ulup)CDKN1A CDKN1C CIDEB (8.56) GSTP1 (3.00) KPNA2 CKS2 CTNND2 CTTN (2.49)LTB4DH (18.28) CYR61 DPYD DRD5 MED13L (6.09) MELK (6.04) DTYMK E2F3 EGFRMKI67 (5.91) NDUFA10 EIF2B2 EIF3S3 EML2 (2.42) NKAIN1 (22.33) ERBB2ERBB4 ERCC1 PARP1 (2.68) PCDHA5 ERCC2 ERP29 F3 F8 (2.75) PRC1 (3.44)RAD23B FANCG FAS FEN1 FGF7 (2.57, 2.55, 4.15) RNF34 FOXO3 GADD45A GAMT(2.18, 2.49, 2.45) RRM2 GFRA1 GOLGA8A GSTP1 (3.30, 3.47) TYMS (3.69)GSTT1 HINT1 HIST1H1D UBE2C (9.47) ZNF552 (8.76, HNRPC IGFBP4 IL8RA 2.45)IRAK1 JMJD2B KIAA1467 ABCB1 (−3.59) ACADL (−19.18) KIF3A KPNA2 KRAS AMFR(−5.37) LGALS8 LMNB1 LTB4DH ANGPTL2 (−2.89, −3.89) M6PR MALT1 MAPK13AREG (−119.30) BTG3 (−7.01) MAPT MED13L MELK CDKN1A (−7.85, −4.44) METRNMKI67 MYC CDKN1C (−7.69) CYR61 (−3.69, NDUFA10 NKAIN1 −2.81, −3.06) DPYD(−2.82, NUCKS1 PARP1 PCDHA5 −4.07, −4.30) EGFR (−12.64) PDAP1 PGR PPP3CAERBB4 (−3.94, −3.33) PRC1 PRNP PSCD3 F3 (−3.63) F8 (−3.51, −2.90) PSG9PSRC1 RAD23B FAS (−5.93) FGF7 (−2.01, −3.09, RAMP1 RNF34 RPL3 −3.61)GAMT (−3.39, −2.43) RRM2 RTKN SCUBE2 GFRA1 (−5.66) IGFBP4 SERPINE2 SFNSNAPC1 (−2.66) IL8RA (−5.26) TERF2 THNSL2 TMSB4X LGALS8 (−2.28) PGR(−11.29) TMSL8 TNFRSF10B TP53 PPP3CA (−2.42) PRNP (−3.95) TYMP TYMSUBE2C TMSB4X (−2.05) UPP1 UPRT UXT TMSL8 (−11.70) TNFRSF10B WBSCR1 XAF1ZNF32 (−2.25) TYMP (−3.83, −5.95) ZNF552 ZNF582 ZRSR2 UPP1 (−3.24,−2.71, −2.28) CAPECITABINE 5 CES1 CES2 CES3 DPYD TYMS 4 CES1 (13.90)CES3 (10.19) 7.88 9.26 555 (Xeloda) (3 + 1) TYMS (3.69) (80.0%) DPYD(−2.82, −4.07, −4.30) GEMCITABINE 12 BAX BCL2 CASP3 CDKN1A 4 CASP3(2.14) PARP1 (2.68) 3.66 2.84 70 (DDFC, DFDC, GEO, CMPK PARP1 PDPK1RBM17 RRM1 (3 + 1) TYMS (3.69) Gemcin, Gemcitabina, SLC29A1 TP53 TYMS(33.3%) CDKN1A (−7.85, −4.44) Gemcitabine, HCl, Gemcitabinehydrochloride, Gemcitabinum, Gemtro, Gemzar) DNA DNA >> Alkylatingagents DNA >> Alkylating agents >> Nitrogen mustards CYCLOPHOSPHAMIDE 56ABCB1 ABCC1 ABCG2 29 ABCC1 (7.70) BECN1 (2.18) 6.89 7.19 218 (ASTA, AstaB 518, CP, AMFR BAG1 BBS4 BCL2 (17 + 12) CA12 (21.62, 17.07, 11.24, CPA,CTX, CY, Clafen, BECN1 BTG3 BUB3 CA12 (51.8%) 25.25) CASP3 (2.14)Claphene, CASP3 CASP9 CDKN1B CTNND2 (3.12, 2.44) Cyclophosphamid,CTNNBIP1 CTNND2 CYP2B6 (10.92, 3.17) E2F3 Cyclophosphamide CYP2B6 E2F3EGFR (2.71) GSTA1 (16.89) ILF3 Monohydrate, EIF1AX EIF4EBP1 ERBB2 (3.78)MED13L (6.09) MELK Cyclophosphamide ERBB4 ESR1 ESR2 (6.04) MKI67 (5.91)NKAIN1 Sterile, GAMT GFRA1 GSTA1 (22.33) RRM2 (3.30, 3.47)Cyclophosphamidum, GTF3C1 IGFBP4 ILF3 ST14 (2.22) STK39 (6.44,Cyclophosphan, IRS1 JMJD2B KIAA1467 6.78) ZNF552 (8.76, 2.45)Cyclophosphane, KIF3A MAPK14 MAPT ABCB1 (−3.59) AMFR (−5.37)Cyclophosphoramide, MED13L MELK METRN BTG3 (−7.01) CTNNBIP1 (−7.17)Cyclostin, MGMT MKI67 NAIP EGFR (−12.64) ERBB4 Cyklofosfamid, NKAIN1 PGRPLOD1 (−3.94, −3.33) GAMT (−3.39, −2.43) Cytophosphan, PLOD3 RAMP1 RRM2GFRA1 (−5.66) IGFBP4 Cytoxan, Cytoxan, SCUBE2 SRM ST14 (−2.66) IRS1(−13.62) PGR (−11.29) Lyoph, STK39 THNSL2 TP53 PLOD1 (−2.05)EndoxanEndoxan, R, ZNF552 Endoxan-Asta, Endoxana, Endoxanal, Endoxane,Enduxan, Genoxal, Hexadrin Lyophilized, Cytoxan, Mitoxan, Neosar,Procytox, Rcra, Waste, Number, U058, Revimmune, Semdoxan, Sendoxan,Senduxan, Zyklophosphamid) IFOSFAMIDE 10 BCL2 CASP9 CYP2A6 5 CYP2B6(10.92, 3.17) 11.00 4.08 122 (Cyfos, Holoxan, 1000, CYP2B6 CYP3A4 CYP3A5(3 + 2) DNMT1 (2.20) GSTP1 (3.00) IFEX, Ifex/Mesnex Kit, DNMT1 GSTM1GSTP1 (50.0%) CYP3A4 (−7.84) CYP3A5 (−34.94) Ifosfamide/Mesna Kit, GSTT1Isoendoxan, Mitoxana, Naxamide) MELPHALAN 9 ABCC1 BIRC5 CASP2 5 ABCC1(7.70) CASP2 (2.27) 6.40 6.40 355 (Alkeran, L-PAM, L- CASP3 CDA GSTA1(5 + 0) CASP3 (2.14) GSTA1 (16.89) Phenylalanine mustard, GSTP1 MGMTMGST2 (55.6%) GSTP1 (3.00) L-Sarcolysin, L- Sarcolysine, L- Sarkolysin,Levofalan, Melfalan, Mephalan, Phenylalanine mustard, Phenylalaninenitrogen mustard, Sarcolysine, Sarkolysin) DNA >> Alkylating agents >>Nitrosoureas CARMUSTINE 230 ABCB1 ABCC1 ACTC1 106 ABCC1 (7.70) AGT(3.57) 5.24 4.73 102 (Becenun, Bi CNU, ACTG2 ACTN1 ADAM15 (50 + 56) AKT2(2.40, 3.07, 2.01) BiCNU, Carmubris, ADAMTS4 ADCYAP1 (46.1%) ALAD (4.21)AMH (2.39) Gliadel, Gliadel Wafer, ADRA1B AGT AGTRL1 AQP8 (3.03) B4GALT5(2.55, Nitrumon) AKT2 ALAD ALOX15B 2.84) BAIAP3 (2.18) BECN1 AMH APC2AQP8 (2.18) BICD1 (13.67) BLK ARGBP2 ARPC2 ARTN (3.63) CDC25C (8.00)CDK8 ASMTL ATP1A3 ATP4B (2.39) CEACAM3 (2.96, 2.75) ATP5D ATP6V0C ATXN2LCHEK1 (4.69) CKM (20.86) AVPR1A B4GALT5 CLTCL1 (5.12) CRABP1 BAIAP2BAIAP3 BCL10 (3.09) CYP19A1 (2.64) BCL2 BCL2L1 BECN1 DHX16 (2.71) DVL1(2.75, BICD1 BLK BMP7 BRF1 2.21) EIF2B1 (2.16) EPHX1 CA6 CALB2 CCL2CD151 (4.56) EZH2 (4.80) FNTA CD68 CD79A CD80 (3.94) FTH1 (2.42, 2.32,CDC25C CDK8 CDKN1A 2.35) FTL (3.51, 4.41, 3.40) CDX4 CEACAM3 CEBPB GCM1(2.70) GOLGA2 (2.44, CHEK1 CHRM4 CHRNB3 2.57) GPR37 (2.96) GRB7 CHRNGCKM CLTCL1 (2.78) GSR (10.75, 10.84) CNTNAP1 COL9A1 GSTA1 (16.89) GSTP1(3.00) COX6A2 CRABP1 CRAT HNF1A (3.45) INPPL1 (2.26) CRYBB1 CST5 CTF1KCNH2 (4.05) MAP4K2 CTNNAL1 CYP19A1 (2.72) MAPK10 (3.15) DHX16 DNASE1L2DVL1 MAT1A (6.12) MDK (17.02) ECM2 EEF1G EIF2B1 MED1 (2.44) NPAS1 (4.81)EIF6 EPHX1 ESRRA PRC1 (3.44) PTPN3 (2.46, EZH2 FBN1 FKBP1A 2.03) RAD51(4.60) FNTA FOXJ1 FTH1 FTL SLCO1A2 (2.31) SMPD2 FYN GABRA2 GABRA6 (2.55)SNCG (2.23) UGT8 GAMT GAST GCM1 GDI1 (5.58, 9.40) GDI2 GFAP GHSR ABCB1(−3.59) ACTG2 (−9.33) GNRHR GOLGA2 ACTN1 (−2.46, −2.62) GOLGA4 GP1BBGPR25 ADAMTS4 (−3.13, −5.12) GPR32 GPR37 GPR65 ADRA1B (−7.78) ALOX15B(−17.05) GRB7 GRN GSR GSTA1 ATP1A3 (−5.85) GSTM1 GSTM3 GSTP1 BAIAP2(−4.34, −2.72, −3.14) GTF2F1 H2AFX HADHSC BCL10 (−2.16, −3.00) BMP7(−16.37, HAGH HCFC1 HMGN2 −4.33) BRF1 (−3.38) HNF1A HOXA4 ICAM5 CALB2(−5.76) CCL2 (−8.86) IDS IER3 IKBKG INPPL1 CD151 (−2.41) CD68 (−3.38)INSIG1 INSL3 IRS1 ISLR CDKN1A (−7.85, −4.44) ITGA3 ITIH1 KCNH2 COX6A2(−2.12) CRAT (−3.15) KIF5A KRT17 KRT31 CST5 (−2.40) CTNNAL1 LAD1 LAIR1LAMB3 (−5.85) FBN1 (−2.95) FKBP1A LMX1B LOXL1 LRCH4 (−5.05) FOXJ1(−5.38, −2.05) LRMP MAD1L1 MAP4K2 FYN (−2.59) GAMT (−3.39, −2.43) MAPK10MAT1A MDK GDI2 (−2.36) GPR65 (−2.59) MED1 MGAT3 MGMT GSTM3 (−3.01) HOXA4MSR1 MUC2 MVD (−8.73) IER3 (−4.31) IRS1 (−13.62) MYBPH MYD88 MYOD1 KRT17(−5.21) LAIR1 MYOG NDUFC1 NKX2-2 (−2.82) LAMB3 (−23.74) NPAS1 NPBWR2NRTN LOXL1 (−2.57) MAD1L1 (−2.73) OMP PAEP PAX8 PBX2 MGAT3 (−12.97) MSR1PCBD1 PCDHGC3 (−2.93, −2.73) MYBPH (−4.47) PCOLCE PCYT1A MYD88 (−2.51)NRTN (−7.31) PFKFB2 PFKM PFN1 PAX8 (−5.65) PCOLCE (−3.31) PIK3R3 PMS2L11PZP (−2.82) RCN1 (−2.52, POLR2E PPM1G PRC1 −2.24) RNASE4 (−2.13) PRLPRM2 PSCD1 PTPN3 SGCA (−17.29) SLC16A2 (−6.80) PZP RAD23A RAD51 SNRPB2(−2.25) RAD9 RCN1 RGR RIT2 SOCS1 (−5.85, −5.20) SPEG RNASE4 SEPT5 SFPQ(−5.28) ST8SIA1 (−6.37) SGCA SHMT2 SHOX TCF21 (−20.30) TSPAN4 (−3.44,SIAT1 SLC10A1 SLC16A2 −3.61) WIPF1 (−2.18, −3.58) SLC30A3 SLC6A2 ZYX(−3.12) SLCO1A2 SMARCD1 SMPD2 SNAPC1 SNAPC3 SNCG SNRPB2 SOCS1 SPEGSPRR2B SRP14 SRY ST8SIA1 STAM STS STX1B STXBP2 TAC1 TCF21 TEGT TLE3TNFRSF11B TP53 TRAF1 TSPAN4 TUBB TUBG1 UGT8 UPF1 VGF WIPF1 YWHAH ZBTB17ZYX FOTEMUSTINE 2 MGMT TXNRD1 1 TXNRD1 (12.56) 12.56 12.56 627(Muphoran) (1 + 0) (50.0%) DNA >> Alkylating agents >> PlatinumCARBOPLATIN 11 ALB BAX BCL2 BCL2L12 4 BCL2L12 (4.27) CASP3 3.76 3.03 82(Paraplatin, Paraplatin-AQ) BIRC2 CASP3 CASP9 (3 + 1) (2.14) PARP1(2.68) DCT FAS PARP1 RBM17 (36.4%) FAS (−5.93) CISPLATIN 111 A2M ABCB1ABCC1 54 ABCC1 (7.70) ABCC2 (4.39, 5.10 4.46 108 (Abiplatin,Biocisplatinum, Briplatin, ABCC2 ABCC5 AKT1 (27 + 27) 5.45) ABCC5 (4.30,6.53) Carboquone, Cis Pt II, Cismaplat, AKT2 AKT3 ALB APEX1 (48.6%) AKT2(2.40, 3.07, 2.01) Cisplatine, Cisplatyl, Citoplationo, AXL BAX BCL2BCL2L1 BCL2L12 (4.27) CASP2 Lederplatin, Neoplatin, Plastin, Platamine,BCL2L12 BIRC2 BIRC3 (2.27) CASP3 (2.14) CASP8 Platiblastin, Platidiam,Platinex, Platinol, BIRC5 CASP2 CASP3 (8.85, 2.67) CREBBP (2.11,Platinol-AQ, Platinoxan, Randa) CASP8 CASP9 CAT 2.52) ETV4 (2.09) GSTP1CDKN1A CFLAR CLU (3.00) HSPE1 (5.96) KRT4 CNTF CREBBP CYCS (8.00) LASS4(5.10) MCM2 CYP3A4 DIABLO DPYD (3.39) MED1 (2.44) NCOA3 EDN2 EGFR EP300(3.29, 4.36, 3.16) NR1I2 ERBB2 ERCC1 ERCC2 (3.23) PARP1 (2.68) PMAIP1ETV4 FADD FANCG FAS (12.40) PTK2 (2.54) FASLG FGFR3 FOSL1 SLC31A1 (2.02,2.41) GDF15 GSTM1 GSTM3 SPINT2 (6.04) TF (9.84, GSTP1 GSTT1 GUK1 8.91)TXN (4.58, 5.09) TYMS HIF1A HSPE1 HTRA2 (3.69) VEGFA (2.60) IFITM1IGFBP3 IL4R A2M (−4.77) ABCB1 (−3.59) ITGA9 ITGB4 JUN KRT19 AKT3 (−3.90,−3.96) BIRC3 (−2.84) KRT4 LASS4 MCM2 CAT (−3.31) CDKN1A (−7.85, MED1MGMT MMP10 −4.44) CYP3A4 (−7.84) MMP15 MMP16 MRPS27 DPYD (−2.82, −4.07,−4.30) MT1A MT2A MT3 MVP EDN2 (−3.91) EGFR (−12.64) NAIP NCOA3 NOTCH4FAS (−5.93) FGFR3 (−8.75) NR1I2 NTHL1 PARP1 GSTM3 (−3.01) IL4R (−4.02)PCNA PDIA3 PFDN5 ITGA9 (−2.21) JUN (−2.62) PGK1 PMAIP1 PRNP MMP10(−2.05) MT1A (−7.47) PTEN PTGS2 PTK2 RB1 MT2A (−8.59, −9.15) MVP (−2.25)RHOC RPL36 RPS5 NOTCH4 (−2.63, −3.15) RUNX3 SFN SLC31A1 PFDN5 (−2.17)PRNP (−3.95) SOCS1 SPINT2 TF TP53 PTEN (−2.30, −2.56) PTGS2 (−36.04,TP73 TRAM1 TRAP1 −32.79) SOCS1 (−5.85, TUBA1A TXN TYMS −5.20) TRAM1(−3.53) VEGFA XIAP XPA XRCC1 ZFP36L1 OXALIPLATIN 17 BCL2 BCL2L1 BIRC5 8CCNA2 (5.27) CCNB1 (3.17) 5.20 3.95 139 (DACPLAT, Eloxatin, Elplat,CCNA2 CCNB1 CCNE1 (6 + 2) CCNE1 (5.62) CDC2 (2.92) Foloxatine,Transplatin) CDC2 CDK2 CDKN1B (47.1%) GSTP1 (3.00) TYMS (3.69) EGFRERCC1 ERCC2 EGFR (−12.64) IL8RA (−5.26) GSTP1 IL8RA MYC RB1 TYMS DNA >>Alkylating agents >> Alkyl sulfonates BUSULFAN 5 GSTA1 GSTM1 GSTP1 2GSTA1 (16.89) GSTP1 (3.00) 9.95 9.95 397 (Busulfex, Citosulfan,Leucosulfan, MGMT MGST2 (2 + 0) Mablin, Mielevcin, Mielosan, Mielucin,(40.0%) Milecitan, Mileran, Misulban, Mitosan, Mitostan, Myeleukon,Myeloleukon, Myelosan, Mylecytan, Myleran, Myleran Tablets) DNA >>Alkylating agents >> Hydrazines PROCARBAZINE 1 MGMT — — — — — (Matulane,Nathulane, Natulan, Natulan hydrochloride, Natulanar, Natunalar) DNA >>Alkylating agents >> Triazenes DACARBAZINE 22 APEX1 BIRC5 CASP3 9 CASP3(2.14) CASP8 (8.85, 7.30 7.13 162 (Deticene) CASP8 CD38 CD69 (5 + 4)2.67) MAP3K1 (2.06, 2.62) CYP1A1 CYP1A2 EPO (40.9%) SLC2A1 (22.83) VEGFAIFNA1 IFNA2 IL8 IRF1 (2.60) MAP3K1 MAPK1 MAPK3 IL8 (−16.97) IRF1 (−2.23)MCL1 MGMT POLA2 MCL1 (−3.34) TNFSF10 (−7.51) SLC2A1 TNFSF10 VEGFATEMOZOLOMIDE 10 AGT DCT MGMT MPG 3 AGT (3.57) PARP1 (2.68) 6.21 6.21 186(Temodal, Temodar) PARP1 PMAIP1 POLB (3 + 0) PMAIP1 (12.40) POLI POLLTP53 (30.0%) DNA >> Alkylating agents >> Aziridines THIOTEPA 5 GSTA1GSTA2 GSTM1 3 GSTA1 (16.89) GSTA2 11.90 11.90 713 (Thioplex, Thiotepa)GSTP1 MGMT (3 + 0) (15.07, 16.53) GSTP1 (3.00) (60.0%) DNA >> Alkylatingagents >> Other ECTEINASCIDIN 743 4 CCNA2 CCNB1 CCNB2 4 CCNA2 (5.27)CCNB1 (3.17) 3.77 3.77 376 (Trabectedin, ET-743, E2F1 (4 + 0) CCNB2(4.19) E2F1 (2.45) Yondelis) (100.0%) DNA >> Spindle poisons/Mitoticinhibitors DNA >> Spindle poisons/Mitotic inhibitors >> TaxanesDOCETAXEL 33 ABCB1 ABCC1 ABCC2 15 ABCC1 (7.70) ABCC2 (4.39, 8.72 3.67 77(Taxotere) BCL2 BCL2L1 BIRC5 (7 + 8) 5.45) CASP3 (2.14) CASP3 CFLARCYP19A1 (45.5%) CYP19A1 (2.64) GSTP1 CYP1B1 CYP3A4 ERBB2 (3.00) PARP1(2.68) VEGFA GSTP1 HIF1A HRAS IL6 (2.60) MAPK1 MAPK3 MDM2 ABCB1 (−3.59)CYP1B1 (−3.87) PAR1 PARP1 PGR POR CYP3A4 (−7.84) HRAS PTGS2 RAF1 RB1SKP2 (−2.10) IL6 (−39.79) PGR (−11.29) TNF TNFRSF10B TP53 PTGS2 (−36.04,−32.79) TUBB TUBB1 VEGFA TNFRSF10B (−2.25) PACLITAXEL 129 ABCB1 ABCC1ABCC2 65 ABCC1 (7.70) ABCC2 (4.39, 6.54 6.14 147 (Epitaxol, LipoPac,AIFM1 AKR1C2 AKT1 (31 + 34) 5.45) AKT2 (2.40, 3.07, 2.01) Onxol,Paxceed, AKT2 AKT3 AMFR APAF1 (50.4%) ASPM (5.55, 8.12) AURKA Paxene,Taxol, Taxol A, ARR3 ASPM AURKA BAD (4.00) BECN1 (2.18) CA12 VascularWrap, Xorane) BAX BBS4 BCL2 BCL2L1 (21.62, 17.07, 11.24, 25.25) BECN1BID BIRC2 BIRC3 CASP3 (2.14) CASP8 (8.85, BIRC5 BMP7 BTG3 2.67) CCNB1(3.17) CTNND2 C7ORF23 CA12 CALCA (3.12, 2.44) CYP19A1 (2.64) CASP3 CASP7CASP8 E2F3 (2.71) FTH1 (2.42, CASP9 CAV1 CCNB1 2.32, 2.35) FTL (3.51,4.41, CCND1 CD46 CD47 3.40) GSTP1 (3.00) MED1 CDKN1A CFLAR CLU (2.44)MED13L (6.09) MELK CTCF CTNND2 CTSL1 (6.04) NAT1 (2.39) NCOA3 CXCR4CXCR6 CXCR7 (3.29, 4.36, 3.16) NKAIN1 CYCS CYP19A1 CYP2C8 (22.33) NR1I2(3.23) PARP1 CYP3A4 DIABLO E2F3 (2.68) PRC1 (3.44) RRM2 EGFR ERBB4 FASFASLG (3.30, 3.47) S100P (41.69) FDPS FTH1 FTL FURIN TOP2A (5.88) TYMS(3.69) FXYD3 GADD45A GAMT VEGFA (2.60) ZNF552 (8.76, GFRA1 GSTM1 GSTM52.45) GSTP1 GSTT1 HIF1A ABCB1 (−3.59) AKT3 (−3.90, −3.96) ICAM1 IFI30IGFBP4 AMFR (−5.37) BIRC3 (−2.84) ITGB5 JMJD2B JUN BMP7 (−16.37, −4.33)KIAA1467 KIF3A KRT13 BTG3 (−7.01) CAV1 (−22.26, −24.68) MAPK1 MAPK14MAPK3 CCND1 (−2.52) CD47 MAPK8 MAPK9 MAPT (−6.41, −16.99) CDKN1A (−7.85,MCL1 MDM2 MED1 −4.44) CXCR4 (−2.72) MED13L MELK METRN CXCR6 (−2.50)CYP3A4 (−7.84) MMP9 MT1E MT2A MYC EGFR (−12.64) ERBB4 NAT1 NCOA3 NFKB1(−3.94, −3.33) FAS (−5.93) NFKBIA NKAIN1 NR1I2 FURIN (−2.72) FXYD3(−2.65) PARP1 PDPK1 PMP22 GAMT (−3.39, −2.43) GFRA1 POR PRC1 PTEN PTGS2(−5.66) GSTM5 (−3.70, −6.54) RAMP1 RB1 RBL2 RELA ICAM1 (−8.24) IGFBP4(−2.66) RFX5 RPL23A RPLP1 JUN (−2.62) MAPK8 (−2.06) RRM2 RTKN S100P MCL1(−3.34) MMP9 (−10.90) SCUBE2 TFF1 THNSL2 MT1E (−15.67) MT2A TNFRSF10BTOP2A TP53 (−8.59, −9.15) NFKBIA (−4.00) TUBB TUBB1 TYMS PMP22 (−6.22)PTEN (−2.30, −2.56) VEGFA XIAP ZNF552 PTGS2 (−36.04, −32.79) TNFRSF10B(−2.25) DNA >> Spindle poisons/Mitotic inhibitors >> Vinca AlkaloidsVINBLASTINE 13 ABCB1 ABCC1 ABCC2 9 ABCC1 (7.70) ABCC2 (4.39, 3.57 4.40135 (Nincaluicolflastine, Rozevin, CASP2 IKBKB JUN (4 + 5) 5.45) CASP2(2.27) IKBKB Velban, Velbe Vinblastin, Vinblastina, MAPK8 MAPK9 NFATC4(69.2%) (2.08, 2.59, 3.48) Vinblastine Sulfate, Vinblastinum, NFKBIATNFRSF10B ABCB1 (−3.59) JUN (−2.62) Vincaleucoblastin,Vincaleucoblastine, TP53 TUBB2A MAPK8 (−2.06) NFKBIA (−4.00)Vincaleukoblastine, Vincoblastine) TNFRSF10B (−2.25) VINCRISTINE 70ABCB1 ABCC1 ABCC2 31 ABCC1 (7.70) ABCC2 (4.39, 6.79 6.69 152 (Marqibo,Onco TCS, Oncovin, Vincasar, AKT1 APAF1 APOA1 (16 + 15) 5.45) ASPM(5.55, 8.12) Vincasar PFS, Vincrex, Vincristine ASPM AURKA BAD BAX(44.3%) AURKA (4.00) CASP2 (2.27) Sulfate PFS, Vinkristin) BCL2 CASP1CASP10 CASP3 (2.14) CASP8 (8.85, CASP2 CASP3 CASP4 2.67) CES1 (13.90)E2F1 CASP5 CASP6 CASP7 (2.45) GULP1 (21.16, 15.15) CASP8 CASP9 CATMAP3K7 (3.78) PRC1 (3.44) CEBPB CES1 CFTR CYC1 RARB (2.96) SLC2A1(22.83) E2F1 EGFR FADD FAIM2 TYMS (3.69) XBP1 (2.26) GAPDH GSTM1 GULP1ABCB1 (−3.59) CASP1 (−4.93) HRAS IAPP IGF1 IGF1R CASP4 (−2.29, −2.55)IL6 LMNA LMNB1 CASP5 (−2.47) CAT (−3.31) MAP2K4 MAP3K7 MAPK1 EGFR(−12.64) HRAS (−2.10) MDM2 MEF2A MGMT IGF1 (−5.82, −4.31, −5.16, −5.25)MYC NFKB1 P11 PCAF IL6 (−39.79) LMNA (−2.45) PRC1 PRNP PTK2B PCAF(−4.52, −6.85) PTPN13 RARB RBM17 PRNP (−3.95) PTPN13 (−3.49) RELA ROS1RUNX3 ROS1 (−5.49) VDR (−6.07) SLC2A1 SOS1 STAT1 STAT2 STAT3 TNF TP53TUBB2A TYMS VDR XBP1 VINFLUNINE 1 TUBB1 — — — — — VINDESINE 1 TUBB1 — —— — — (DAVA, Eldesine, Eldisine) VINORELBINE 3 RBM17 SLC29A1 TUBB2A — —— — — (Navelbine, Navelbine Base) DNA >> Spindle poisons/Mitoticinhibitors >> Other EPOTHILONES 17 BAX BCL2 BCL2L1 BIRC3 3 BIRC3 (−2.84)MCL1 (−3.34) 3.66 0.00 0 MCL1 TUBA1 TUBA2 (0 + 3) TUBB4 (−4.81) TUBA3TUBA6 TUBA8 (17.6%) TUBB1 TUBB2A TUBB2C TUBB3 TUBB4 TUBB4Q XIAP DNA >>Cytotoxic/Antitumor antibiotics DNA >> Cytotoxic/Antitumorantibiotics >> Anthracyclines DOXORUBICIN 444 ABCB1 ABCB1A ABCB4 198ABCC1 (7.70) ABCC3 (8.66) 5.97 5.64 123 (ADM, Adriablastin, ABCB5 ABCC1ABCC3 (97 + 101) AKR1C3 (3.54) AKT2 (2.40, Adriamycin, Adriamycin ABCG2ADAM19 (44.6%) 3.07, 2.01) ATM (2.79) PFS, Adriamycin RDF, ADAMTS5 AHCYAIFM1 BCL2L11 (3.13) BCL2L12 Adriamycin AKR1A1 AKR1C2 AKR1C3 (4.27)BECN1 (2.18) BIK Semiquinone, AKT1 AKT2 AKT3 ALB (3.06) BUB1B (12.77)CA12 Adriblastin, Adriblastina, AMFR ANGPT1 AP4E1 (21.62, 17.07, 11.24,25.25) Caelyx, DM2, Doxil, APAF1 API5 APOA1 APP CABC1 (3.10) CASP2(2.27) Doxo, Myocet, RDF ARHGEF1 ARHGEF17 CASP3 (2.14) CASP8 (8.85,Rubex, Resmycin, ARL6IP5 ATF4 ATM 2.67) CBR1 (6.01) CCNA2 Rubex)ATP6V0E1 AZGP1 (5.27) CCNB1 (3.17) CCNE1 B4GALT1 BACH1 BAD (5.62) CDC2(2.92) CDC25C BAG1 BAK1 BAX BBS12 (8.00) CDKN2A (18.18, 9.22) BBS4 BCL2BCL2A1 CENPA (3.86) CES1 (13.90) BCL2L1 BCL2L11 CHEK1 (4.69) CHEK2(2.55) BCL2L12 BECN1 BID BIK CLIP1 (2.08) CPT1A (2.21) BIRC2 BIRC3 BIRC5CREBBP (2.11, 2.52) BIRC6 BIRC7 BIRC8 CTNND2 (3.12, 2.44) BTG1 BTG2 BTG3BUB1B CYP2B6 (10.92, 3.17) DEK BUB3 C21ORF87 (2.71) DNMT1 (2.20) DTYMKC5ORF13 C7ORF23 CA12 (2.69, 2.60) E2F1 (2.45) CABC1 CALD1 CAPN6 E2F3(2.71) EGF (16.93) CASP1 CASP10 CASP2 EHMT2 (4.08, 2.31, 2.75) CASP3CASP4 CASP5 ERBB3 (2.54, 3.81, 4.45) CASP6 CASP7 CASP8 ETV6 (2.09) FOXO3(2.21) CASP9 CBR1 CCL2 FTL (3.51, 4.41, 3.40) G6PD CCNA2 CCNB1 CCND1(5.12) GSTA1 (16.89) GSTP1 CCND2 CCNE1 CD44 (3.00) GULP1 (21.16, 15.15)CDC2 CDC25C CDK10 HCRTR1 (2.33) HDAC1 CDK2 CDKN1A CDKN1B (6.44) HFE(3.86, 3.08) CDKN2A CEBPB CENPA HSAJ2425 (2.32) HSPA9 CES1 CFLAR CFTR(2.34) HSPB1 (4.23, 3.70, CHEK1 CHEK2 CHUK 3.27) HSPD1 (3.65, 5.01) CISHCLDN1 CLIP1 IKBKB (2.08, 2.59, 3.48) ILF3 CLPTM1 CLU COL18A1 (3.78)KCNH2 (4.05) KRT18 COX2 CPT1A CREBBP (3.49, 2.64, 3.00, 2.48) LY75CRISP2 CRYAA CRYAB (4.92) MAD2L1 (3.87) CSPG4 CTGF CTNNBIP1 MAP3K7(3.78) MDK (17.02) CTNND2 CTSB CTSD MED13L (6.09) MELK (6.04) CTSG CXCL6CYC1 MLL (2.05, 2.04) MME (3.38, CYCS CYP1A1 CYP27B1 4.93) MRPS18A(2.34) CYP2B6 DDEF1 DDIT3 NKAIN1 (22.33) NOLC1 DEK DGKI DHPS DIABLO(2.54, 2.56) OXTR (4.19) DKK2 DNAJA1 DNMT1 PARP1 (2.68) PDCD5 (3.33)DPP4 DSPP DTYMK E2F1 PMAIP1 (12.40) PRKDC E2F3 ECHS1 ECOP EDN1 (2.47,2.93) PROC (27.80) EFNB3 EGF EGFR EGR1 PSMB7 (2.15) PTK2 (2.54) EHMT2EIF1AX EIF2A PTPRH (42.24) RAD51 (4.60) EIF4EBP1 EP300 EPHA2 RARB (2.96)RHCG (3.15) ERAP1 ERBB2 ERBB3 RRM2 (3.30, 3.47) SMAD3 ERBB4 ESR1 ESR2ETV6 (4.63, 3.78) SOD1 (2.68, F3 F7 FADD FAIM2 FAS 2.37) SSH3 (3.00,3.18) ST14 FASLG FCGR3A FDFT1 (2.22) STK39 (6.44, 6.78) FHL2 FKBP5 FKBP8FN1 TCF3 (4.52, 3.83) TERT FOLR1 FOS FOXJ1 (3.67) TNFRSF25 (7.01) FOXO1FOXO3 FSHB FTL TOP2A (5.88) TRIM28 (2.33) FTMT FUT4 G6PD TUBA4A (2.16)TYMS (3.69) GADD45G GAMT GAPDH UQCRH (3.18, 3.28) VEGFA GATA1 GDF15GFI1B (2.60) ZMYM2 (3.03, 4.70) GFRA1 GLO1 GNRHR ZNF552 (8.76, 2.45) GP9GPX1 GSK3B GSTA1 ABCB1 (−3.59) ADAMTS5 (−3.42) GSTA4 GSTP1 GTF3C1 AKT3(−3.90, −3.96) GULP1 H2AFX HBG2 AMFR (−5.37) ANGPT1 (−13.77, HCRTR1HDAC1 HFE −19.66) APP (−3.45) HGF HIF1A HIST1H2BC ARL6IP5 (−3.81, −3.50)HLA-DQB1 HLA-DRB4 ATP6V0E1 (−4.06) BCL2A1 (−18.59, HMP19 HNRNPM HRAS−2.78) BIRC3 (−2.84) HS3ST1 HSAJ2425 BTG2 (−3.68) BTG3 (−7.01) HSP90AA1HSPA4 HSPA5 CAPN6 (−3.15) CASP1 (−4.93) HSPA8 HSPA9 HSPB1 CASP4 (−2.29,−2.55) HSPD1 HTRA1 HUWE1 CASP5 (−2.47) CCL2 (−8.86) IAPP IFNA1 IGF1IGF1R CCND1 (−2.52) CCND2 (−7.50, IGFBP4 IKBKB IKBKG IL6 −3.63, −13.98)CD44 (−5.46) IL8 ILF3 IRS1 JAG2 CDKN1A (−7.85, −4.44) JMJD2B JUN KCNH2CISH (−6.49, −6.90) CRISP2 KCNJ13 KCNJ16 KDSR (−3.03) CRYAB (−3.91)KHSRP KIAA1467 KIF3A CSPG4 (−4.23) CTGF (−2.88) KLF2 KRT18 LGALS3CTNNBIP1 (−7.17) CTSB (−2.39) LIG4 LIMA1 LMNA LMNB1 CTSD (−2.66) CTSG(−8.64) LY75 MAD2L1 MAP2K1 CXCL6 (−7.14) DKK2 (−2.84, MAP2K2 MAP2K3−19.13) DPP4 (−21.02) MAP2K4 MAP2K6 EDN1 (−4.13) EFNB3 (−4.49) MAP3K7MAP3K8 MAPK1 EGFR (−12.64) EGR1 (−6.04) MAPK14 MAPK3 MAPK8 ERBB4 (−3.94,−3.33) F3 (−3.63) MAPK9 MAPT MCL1 FAS (−5.93) FCGR3A (−2.85) MDH2 MDKMDM2 FN1 (−3.36, −3.49, −4.91) MED13L MEF2A MELK FOXJ1 (−5.38, −2.05)METAP2 METRN MFGE8 FOXO1 (−2.47, −3.13) GAMT MGMT MLL MLLT3 MME (−3.39,−2.43) GFRA1 (−5.66) MMP1 MMP2 MRPS18A GP9 (−2.54) HGF (−2.73, −6.54)MSH6 MT1G MT1L MT2A HLA-DQB1 (−3.19, −3.83) MTR MTSS1 MVP MYC HLA-DRB4(−4.14) NAIP NBN NDUFB7 HRAS (−2.10) HSPA5 (−2.00) NFKB1 NFKB2 NFKBIAIGF1 (−5.82, −4.31, −5.16, −5.25) NID1 NKAIN1 NMBR IGFBP4 (−2.66) IL6(−39.79) NOLC1 NOS2 NR4A1 IL8 (−16.97) IRS1 (−13.62) OR12D2 OR2F1 OXTRJUN (−2.62) KCNJ16 (−14.12) P11 P2RX2 P2RY6 KDSR (−2.45) KLF2 (−3.43,PARP1 PAX6 PCAF PCNA −2.31) LMNA (−2.45) PDCD5 PDPK1 PITX1 MAP2K3(−3.18, −3.56) PLAU PLOD1 PLOD3 MAP2K6 (−4.53) MAPK8 (−2.06) PMAIP1POLD4 POMT2 MCL1 (−3.34) MMP1 (−58.24) POR PPARD PPT2 MMP2 (−4.48) MT1G(−11.42, PRKACA PRKCA PRKCD −6.38) MT1L (−11.08) PRKDC PRL PRNP PROCMT2A (−8.59, −9.15) MTSS1 PROCR PSMA1 PSMA2 (−2.60) MVP (−2.25) NFKBIAPSMA3 PSMA4 PSMA5 (−4.00) NR4A1 (−5.37) PCAF PSMA6 PSMA7 PSMB2 (−4.52,−6.85) PLOD1 (−2.05) PSMB3 PSMB7 PTEN PRKCA (−3.26) PRNP (−3.95) PTGS2PTK2 PTK2B PROCR (−2.63) PTEN (−2.30, PTPN13 PTPRH RAD51 −2.56) PTGS2(−36.04, −32.79) RALBP1 RAMP1 RARB PTPN13 (−3.49) RELB RB1 RBL1 RBL2RBM17 (−2.34) ROS1 (−5.49) RBPMS REL RELA RELB SERPINE1 (−2.71) RGS13RHCG ROS1 SLC22A16 (−13.33) SLIT3 (−4.84) RRM2 RUNX1 RUNX3 SMAD2 (−2.15,−3.51) SAT SCNN1G SCUBE2 SMAD7 (−2.99) TGM2 (−6.85, SEC22B SERPINE1−4.62) THBD (−5.54) THBS1 SERPINH1 SKP2 (−2.30, −3.06) TMSB4X (−2.05)SLC22A16 SLC22A5 TNFRSF10B (−2.25) SLC29A1 SLC38A2 TNFSF10 (−7.51)TRIM34 (−3.03) SLC5A5 SLC9A1 SLIT3 TUBB4 (−4.81) UPP1 (−3.24, SMAD2SMAD3 SMAD4 −2.71, −2.28) VDR (−6.07) SMAD7 SMC1A SOD1 ZFP36L2 (−2.99)SOD2 SOS1 SP1 SPARC SPHK2 SRM SSH3 ST14 STAT1 STAT2 STAT3 STK39 STMN1STX3 TAGLN TCF3 TERT TFF1 TGFB1 TGM2 THBD THBS1 THNSL2 TIA1 TLX3 TMSB4XTNF TNFRSF10A TNFRSF10B TNFRSF1A TNFRSF1B TNFRSF25 TNFSF10 TOMM20 TOP2ATOP2B TP53 TP73 TRAP1 TRIM23 TRIM28 TRIM34 TRP53 TTPA TUBA4A TUBB TUBB4TYMS UGCG UGT2B4 UPP1 UQCRH VDR VEGFA XIAP ZFP36L2 ZMYM2 ZNF22 ZNF552EPIRUBICIN 7 ABCB1 ABCC1 ABCG2 4 ABCC1 (7.70) CASP3 (2.14) 4.83 5.24 224(Ellence, Epi-Dx, Epiadriamycin, BIRC5 CASP3 CHD1 (3 + 1) TOP2A (5.88)Epidoxorubicin, Epirubicina, Epirubicine, TOP2A (57.1%) ABCB1 (−3.59)Epirubicinum, IMI 28, Pharmorubicin Pfs, Pidorubicina, Pidorubicine,Pidorubicinum, Ridorubicin) DNA >> Cytotoxic/Antitumor antibiotics >>Anthracenediones MITOXANTRONE 25 ABCB1 ABCG2 AMOTL1 11 CASP2 (2.27)ELAVL4 (8.24, 5.46 5.64 135 (Mitox, Novantron, BIRC2 CASC3 CASP2 (6 + 5)12.95) RARB (2.96) SYTL2 Novantrone) ELAVL4 ELOVL5 (44.0%) (10.42, 7.94)TMEM99 (2.94) EPB41L2 FAM130A1 IRX1 TOP2A (5.88) LAMA2 LEMD2 MAFF ABCB1(−3.59) AMOTL1 (−9.67, MDM2 PACRGL RARB −12.72) IRX1 (−2.23) RASA1 RBM17RRAGD LAMA2 (−5.62) MAFF (−3.57) SFRP4 SYTL2 TMEM99 TOP2A XIAP DNA >>Cytotoxic/Antitumor antibiotics >> Streptomyces BLEOMYCIN 7 BIRC2 BLMHCAT LIG1 4 LIG1 (3.03) LIG3 (2.27) 3.53 2.65 75 (Bleo, Bleonexane) LIG3SOCS1 XRCC1 (2 + 2) CAT (−3.31) SOCS1 (−5.85, −5.20) (57.1%) MITOMYCIN25 ALDH3A1 APP ATF4 13 ALDH3A1 (12.05) BMP4 5.50 6.14 196 (Ametycin,Ametycine, BMP4 CCNB1 CD59 (8 + 5) (3.33) CCNB1 (3.17) GSTP1 Mit-C,Mito-C, Mitocin- EGR1 EPHA2 GSTP1 (52.0%) (3.00) LIG1 (3.03) NFYA C,Mitomycin C, HLA-C LIG1 MAPRE1 (2.84) NQO1 (18.75) RFC4 Mitomycin-C,MGMT MMP14 NFYA (2.95) Mitomycinum, NQO1 POR PRNP RB1 APP (−3.45) CD59(−8.71, −4.89, Mitomycinum C, RBBP7 RFC4 RPS3A −4.77, −7.00) EGR1(−6.04) Mitomycyna C, RUNX3 SUB1 TP53 PRNP (−3.95) RPS3A (−2.73,Mitozytrex, Muamycin, −2.31, −2.81, −2.51, −2.45, −2.68) Mutamycin,Mytomycin, Mytozytrex) DNA >> Cytotoxic/Antitumor antibiotics >> OtherHYDROXYUREA 21 BAX C13ORF34 CASP3 13 CASP3 (2.14) CCNA2 (5.27) 4.64 4.27162 (Biosupressin, Droxia, CCNA2 CCNB1 CCND1 (8 + 5) CCNB1 (3.17) CCNE1(5.62) Hidrix, Hydrea, Hydreia, CCND2 CCND3 CCNE1 (61.9%) CDCA8 (2.55)KPNA2 (2.49) Hydura, Hydurea, CCNG1 CDCA8 CDKN1A PRC1 (3.44) UBE2C(9.47) Litaler, Litalir, Onco- CKS2 EDN3 FAS KPNA2 CCND1 (−2.52) CCND2(−7.50, Carbide, Oxyurea, PRC1 PSRC1 RRM1 TP53 −3.63, −13.98) CCNG1(−3.23) Ureaphil) UBE2C CDKN1A (−7.85, −4.44) FAS (−5.93) DNA >>Topoisomerase inhibitors DNA >> Topoisomerase inhibitors >> CamptothecaCAMPTOTHECIN 47 ABCB1 AGRN ALB ANXA4 20 CASP2 (2.27) CASP3 (2.14) 4.282.70 46 BAX BCL2 BIRC5 CAB39 (8 + 12) CCNB1 (3.17) CEACAM1 CASP2 CASP3CCNB1 (42.6%) (2.43, 2.23) GSTP1 (3.00) CDK2 CDKN1A CEACAM1 PARP1 (2.68)PRC1 (3.44) CEBPZ CTSB EI24 VEGFA (2.60) EPM2AIP1 FDXR GSTP1 ABCB1(−3.59) CDKN1A (−7.85, HNRNPC IL1B IL8 JUN −4.44) CTSB (−2.39) MAP2K3MAP3K5 MAPK9 IL1B (−12.47) IL8 (−16.97) MDM2 NCK2 PARP1 PLK3 JUN (−2.62)MAP2K3 (−3.18, −3.56) PPP1R1B PRC1 RB1 PLK3 (−2.94) PPP1R1B RBL1 RBL2SDC1 TAP1 (−5.77) SDC1 (−2.52) THBS1 TAX1BP3 THBS1 TNFSF9 (−2.30, −3.06)TNFSF9 (−2.43) TOP1 TP53 TP53I3 TP53TG1 VEGFA XIAP TOPOTECAN 7 ABCG2ARNT H2AFX 1 VEGFA (2.60) 2.60 2.60 37 (Hycamptamine, HIF1A TOP1 TOP1MT(1 + 0) Hycamptin, Hycamtin) VEGFA (14.3%) IRINOTECAN 204 ABCB1 ABCC1ABCC2 104 ABCC1 (7.70) ABCC2 (4.39, 7.59 6.54 169 (CP0, Camptosar, ABCC4ABCG2 ADD3 (53 + 51) 5.45) ABCC4 (2.34) AURKB IRINOTECAN, CPT-11) AKAP10ALAS2 ALDH1A1 (51.0%) (2.61) BCL9 (5.39) BUB1 ANGPTL2 ANXA6 APC (2.75)CCNA2 (5.27) CCNB2 ARAF AREG ARHGAP5 (4.19) CCNF (2.52) CCR6 ARID4A ATF3ATG10 (2.28) CDC2 (2.92) CDKN3 ATP5O AURKB BCL7A (5.50) CENPF (7.39,8.14) BCL9 BIRC5 BMP8A CES1 (13.90) CES3 (10.19) BOLL BUB1 CASP4 CREBBP(2.11, 2.52) CCNA2 CCNB2 CCNF CYP2B6 (10.92, 3.17) CCR1 CCR6 CD70 CD80CYP2C9 (3.97) CYP2D6 CDC2 CDC25B CDC2L5 (3.52, 3.15) DENND4A (2.86,CDK5R2 CDKN1A CDKN3 2.30) DYRK2 (3.69, 2.90, CENPE CENPF CES1 2.19,2.26) EML2 (4.55) CES2 CES3 CHD1 ETV6 (2.09) GATA3 (6.10) COL6A1 COMMD6GOLGA8A (8.56) MAD2L1 CREBBP CYP1A2 (3.87) MCM4 (4.63) MX2 CYP2A6 CYP2B6(2.64) NEK2 (23.93, 26.08) CYP2C19 CYP2C8 PLEKHH3 (2.59) PLK1 (2.97,CYP2C9 CYP2D6 CYP2E1 2.70) PMAIP1 (12.40) CYP3A4 CYP3A5 PROM1 (4.29)PTGES (9.53) DCLRE1A DDB2 DEFA1 RAC3 (2.23) RAD23B (2.57, DENND4A DMWDDNMT2 2.55, 4.15) RBBP5 (2.08, DPYD DRD5 DRG1 2.99) RFC3 (4.94, 4.23)SPIB DUSP2 DYRK1A DYRK2 (4.00) STK38 (4.45, 4.62) EBI2 EGFR EGR1 EML2STK4 (2.65) TAF2 (2.17, EP300 ERBB4 ETS2 ETV6 2.48) TBCC (2.21, 2.21) F8FANCG FASLG FGF2 TOB1 (2.20) TOP2A (5.88) FN1 FOS FOSB GATA3 TPX2 (5.74)TTK (20.36) GDF15 GOLGA8A TYMS (3.69) UBE2C (9.47) GPR109B GPX3 H2AFXUGT1A6 (35.81, 53.16) HBEGF HIST1H2AC UGT1A8 (30.25) YES1 (2.33) HMMRHRG HSPA4L ID2 ZFX (2.61) IGF1 IL1B IL8 ITGAV ABCB1 (−3.59) ALAS2(−5.81, ITGAX ITGB3BP JUN −8.89) ANGPTL2 (−2.89, −3.89) KLF9 KRT5 LGALS8LTF ANXA6 (−3.31) AREG (−119.30) MAD2L1 MAL MALL CASP4 (−2.29, −2.55)MAP3K5 MCF2L MCM4 CCR1 (−2.53, −4.69) CDKN1A MDM2 MEF2B MGMT (−7.85,−4.44) COL6A1 (−3.54) MMP9 MPO MSH2 CYP3A4 (−7.84) CYP3A5 (−34.94) MTHFSMX2 NCK1 DPYD (−2.82, 4.07, −4.30) NCOA1 NEK2 NID1 OSMR EBI2 (−5.77)EGFR (−12.64) PCDHGC3 PDE4B EGR1 (−6.04) ERBB4 PLEKHH3 PLK1 PLK2 (−3.94,−3.33) ETS2 (−3.94 −5.62, PLK3 PMAIP1 POR −5.40) F8 (−3.51, −2.90)PPP3CB PRKCA PRKCB FGF2 (−9.80) FN1 (−3.36, −3.49, PRKCD PRKCI PROM1−4.91) GPX3 (−4.85) PSG9 PTGES PTPN13 HBEGF (−5.28, −5.37) PTPN22 PTPRDPTPRN HSPA4L (−2.34) ID2 (−2.96, −3.38) RAC3 RAD23B RB1 IGF1 (−5.82,−4.31, −5.16, RBBP5 RBL1 RELA RFC3 −5.25) IL1B (−12.47) IL8 RGS1 RUNX1SDC4 (−16.97) ITGAX (−2.53, −2.13) SERPINE2 SESN2 SFN ITGB3BP (−2.46)JUN (−2.62) SGK SLC16A4 SLC9A3R2 KLF9 (4.25) KRT5 (−12.89) SNAG1 SPIBSTK38 STK4 LGALS8 (−2.28) LTF (−20.86) SULT1A4 TAF2 TBCC MAL (−7.99)MALL (−2.75, −2.73) TGFA THY1 TMEM41B MMP9 (−10.90) OSMR TMSB4X TNFAIP6TOB1 (−5.11, −3.52) PDE4B (−5.96) TOB2 TOP1 TOP1MT PLK3 (−2.94) PPP3CB(−2.30) TOP2A TOPORS TP53 PRKCA (−3.26) PTPN13 (−3.49) TPX2 TRADD TRAF1TTK PTPRD (−6.35) SESN2 TYMP TYMS UBE2C (−2.98) SLC16A4 (−7.88) UCHL5UGT1A1 UGT1A10 TMEM41B (−2.16) TMSB4X (−2.05) UGT1A6 UGT1A7 TNFAIP6(−22.06) UGT1A8 UGT1A9 XRCC4 TYMP (−3.83, −5.95) ZFP36L2 (−2.99) YES1ZFP36L2 ZFX ZNF32 ZNF582 ZRSR2 DNA >> Topoisomerase inhibitors >>Podophyllum ETOPOSIDE 102 ABCB1 ABCC1 ABCC2 53 ABCC1 (7.70) ABCC2 (4.39,8.65 6.31 167 (Eposin, Etopophos, Lastet, Toposar, ABCC3 AGRN AKT1 (27 +26) 5.45) ABCC3 (8.66) Vepesid, Vepesid J, Zuyeyidal) ALDH3A1 ANXA4 AREG(52.0%) ALDH3A1 (12.05) BIK (3.06) ATF4 BAK1 BCL2 BCL2L1 BRCA1 (3.05)CASP2 (2.27) BCL2L2 BIK BIRC2 BIRC3 CASP3 (2.14) CCNA2 (5.27) BIRC5BRCA1 BTC CEACAM1 (2.43, 2.23) CAB39 CALCA CASP2 CYP2B6 (10.92, 3.17)CASP3 CASP7 CASP9 CYP2C9 (3.97) EGF (16.93) CCNA2 CD44 CDK2 ERBB3 (2.54,3.81, 4.45) CDKN1A CDKN1B ETV6 (2.09) FOXO3 (2.21) CEACAM1 CEBPZ CFLARGSTP1 (3.00) PARP1 (2.68) CYP27B1 CYP2A6 PRC1 (3.44) RAD52 (7.35) CYP2B6CYP2C8 CYP2C9 RAD54L (8.38) TOP2A (5.88) CYP3A4 CYP3A5 DDIT3 TYMS (3.69)UBE2C (9.47) EGF EGFR EI24 UGT1A8 (30.25) WRN (3.29) EPM2AIP1 ERBB2ERBB3 XRCC2 (5.72) ERBB4 EREG ETV6 FDXR ABCB1 (−3.59) AREG (−119.30)FOXO1 FOXO3 GSTM1 BIRC3 (−2.84) BTC (−3.47, GSTP1 HBEGF HSPA5 −22.42)CD44 (−5.46) MAP2K3 MAP2K7 CDKN1A (−7.85, −4.44) MAP3K5 MCL1 MDM2 CYP3A4(−7.84) CYP3A5 (−34.94) NCK2 NFKBIA PARP1 EGFR (−12.64) ERBB4 PLK3 PRC1PRNP PTEN (−3.94, −3.33) EREG (−25.83) RAD52 RAD54L RBM17 FOXO1 (−2.47,−3.13) HBEGF RUNX1 RUNX3 SDC1 (−5.28, −5.37) HSPA5 (−2.00) TAP1 TAX1BP3TGFA MAP2K3 (−3.18, −3.56) MCL1 TMSB4X TNFRSF10A (−3.34) NFKBIA (−4.00)PLK3 TNFRSF10B TNFSF10 (−2.94) PRNP (−3.95) PTEN (−2.30, TNFSF9 TOP2ATOP2B −2.56) SDC1 (−2.52) TP53 TP53I3 TP53TG1 TMSB4X (−2.05) TNFRSF10BTP73 TYMS UBE2C (−2.25) TNFSF10 (−7.51) UGT1A1 UGT1A3 TNFSF9 (−2.43) VDR(−6.07) UGT1A8 VDR WRN XAF1 XIAP XRCC2 XRCC3 XRCC4 DNA >> Other DNA >>Other >> All BEXAROTENE 68 ADD3 ADRB2 AKR1C1 39 AKR1C1 (31.20, 14.60,8.93 12.16 214 (Targret, Targretin, Targretin-gel, AKR1C3 AMOTL2 (12 +27) 19.24, 4.57) AKR1C3 (3.54) Targretyn, Targrexin) ARL6IP5 ASNS BNIP2(57.4%) CYP26A1 (99.46) KRT15 C10ORF10 C10ORF116 (2.99) PER2 (3.13) PNO1CEBPG COX2 CTH CTSH (3.43) RARB (2.96) RXRB CYCS CYP26A1 CYR61 (2.45)SLC7A1 (3.17) DDIT4 DHRS3 DKK1 SLC7A5 (2.98) UAP1 (2.13) DUSP1 DUSP5EGR3 XBP1 (2.26) EIF1 EPHA2 GARS ADRB2 (−10.39) AMOTL2 (−2.31) GPM6BHERPUD1 ID1 ARL6IP5 (−3.81, −3.50) IER2 IGFBP6 IL15 ITGB6 ASNS (−3.65)CTH (−4.18) ITM2A ITPR1 KLF10 CTSH (−3.47) CYR61 (−3.69, −2.81, KRT15KRT17 LOXL2 −3.06) DDIT4 (−2.17) MAF MAFF MLLT11 DKK1 (−16.44) DUSP1(−5.64) MMP1 MTHFD2 ODC1 GPM6B (−11.99) ID1 (−2.07) PER2 PLAT PLAURIGFBP6 (−3.88) IL15 (−2.46) PLOD2 PNO1 PNRC1 ITGB6 (−21.40) ITM2A(−3.63) RARB RB1 RXRB S100A9 ITPR1 (−2.44) KLF10 (−2.47) SCD SFRS2 SIAH2KRT17 (−5.21) MAF (−2.53, −3.02) SLC7A1 SLC7A5 SMAD5 MAFF (−3.57) MMP1(−58.24) SPARC TGM2 TM4SF1 PLAUR (−5.48) PLOD2 TSC22D3 UAP1 VAMP8(−2.46) S100A9 (−2.26) SCD XBP1 (−8.09, −15.46, −10.15) TGM2 (−6.85,−4.62) Cellular Cellular >> CI monoclonal antibodies Cellular >> CImonoclonal antibodies >> Receptor tyrosine kinase CETUXIMAB 1 EGFR 1EGFR (−12.64) 12.64 0.00 0 (Erbitux) (0 + 1) (100.0%) TRASTUZUMAB 2 EGFRERBB2 1 EGFR (−12.64) 12.64 0.00 0 (Herceptin) (0 + 1) (50.0%)Cellular >> CI monoclonal antibodies >> Anti-CD20 RITUXIMAB 1 MS4A1 1MS4A1 (7.61) 7.61 7.61 761 (Rituxan) (1 + 0) (100.0%) TOSITUMOMAB 1MS4A1 1 MS4A1 (7.61) 7.61 7.61 761 (Bexxar) (1 + 0) (100.0%) Cellular >>CI monoclonal antibodies >> Other ALEMTUZUMAB 1 CD52 1 CD52 (−5.80) 5.800.00 0 (Campath, (0 + 1) MabCampath) (100.0%) BEVACIZUMAB 1 VEGFA 1VEGFA (2.60) 2.60 2.60 259 (Avastin) (1 + 0) (100.0%) EDRECOLOMAB 1TACSTD1 — — — — — (Panorex) GEMTUZUMAB 1 CD33 1 CD33 (−3.02, −3.56) 3.290.00 0 (Mylotarg) (0 + 1) (100.0%) Cellular >> Tyrosine kinaseinhibitors Cellular >> Tyrosine kinase inhibitors >> All AXITINIB 6 FLT1FLT4 KDR KIT 5 FLT1 (−2.68) FLT4 (−2.80) 10.12 0.00 0 PDGFRA PDGFRB (0 +5) KDR (−2.85, −2.51) KIT (−38.04) (83.3%) PDGFRA (−4.21, −4.58)BOSUTINIB 3 ABL1 BCR SRC 3 ABL1 (3.58) SRC (2.09) 2.69 2.84 189 (2 + 1)BCR (−2.40) (100.0%) CEDIRANIB 2 FLT1 FLT4 2 FLT1 (−2.68) FLT4 (−2.80)2.74 0.00 0 (Recentin) (0 + 2) (100.0%) DASATINIB 11 ABL1 ABL2 BCR EPHA26 ABL1 (3.58) SRC (2.09) 8.51 2.67 72 (Sprycel) FYN KIT LCK PDGFRB (3 +3) YES1 (2.33) SRC STAT5B YES1 (54.5%) BCR (−2.40) FYN (−2.59) KIT(−38.04) ERLOTINIB 1 EGFR 1 EGFR (−12.64) 12.64 0.00 0 (Tarceva) (0 + 1)(100.0%) GEFITINIB 48 ABCG2 ADORA1 AREG 22 CYP2C9 (3.97) CYP2D6 13.206.42 66 (Iressa, Irressat, Tarceva) AVEN CGRRF1 (5 + 17) (3.52, 3.15)EGF (16.93) COL4A3BP CORO1C (45.8%) GCLC (7.00, 3.83) NRL CYP1A2 CYP2C19(2.45) CYP2C9 CYP2D6 CYP2F1 ADORA1 (−2.74) AREG (−119.30) CYP3A4 CYP3A5DUSP3 COL4A3BP (−2.58) DUSP9 EGF EGFR EPOR CORO1C (−3.41, −5.23) EPS15ERBB2 ESR1 CYP2F1 (−2.63) CYP3A4 (−7.84) FGF6 GADD45A CYP3A5 (−34.94)EGFR GADD45G GARS GCLC (−12.64) HBEGF (−5.28, −5.37) GNB2 GUCY2D HBEGFIFI6 (−7.89) IL8 (−16.97) IFI6 IL8 LEPR MAPK1 LEPR (−22.59, −4.51) NPTX2MAPK3 MLH1 NFKB1 (−11.45) OSMR (−5.11, −3.52) NPTX2 NRL OSMR PHLDA2(−3.07) QSOX1 (−4.99) PHLDA2 QSOX1 RBM7 SKI (−4.75, −2.71, −3.52) RPA1SFN SKI TGFA TNFRSF1B IMATINIB 29 ABCB1 ABCG2 ABL1 11 ABL1 (3.58) DDR1(3.07, 7.04 3.06 31 (Gleevec, Glivec) AKT1 BCL2L1 BCR BIRC5 (3 + 8)2.69, 3.21) VEGFA (2.60) CCND3 CD69 CSF1R (37.9%) ABCB1 (−3.59) BCR(−2.40) DDR1 FGFR3 FRAP1 FGFR3 (−8.75) IGF1 (−5.82, −4.31, HMOX1 IGF1IL2RA KIT −5.16, −5.25) IL2RA(−2.77, LCK MAPK1 MAPK3 −4.16) KIT (−38.04)NFKB1 NTRK1 PDGFRA PDGFRA (−4.21, −4.58) WT1 PDGFRB RB1 RELA RET (−2.49)VEGFA WT1 LAPATINIB 11 AKT1 BIRC5 CCND1 3 CCNE1 (5.62) 6.93 5.62 51(Tycerb, Tykerb) CCNE1 CDK2 CDKN1B (1 + 2) CCND1 (−2.52) EGFR (−12.64)EGFR ERBB2 ESR1 (27.3%) MAPK1 MAPK3 LESTAURTINIB 1 FLT3 1 FLT3 (−8.47)8.47 0.00 0 (0 + 1) (100.0%) NILOTINIB 5 ABL1 BCR KIT PDGFRA 4 ABL1(3.58) 12.11 3.58 71 (Ketek) PDGFRB (1 + 3) BCR (−2.40) KIT (−38.04)(80.0%) PDGFRA (−4.21, −4.58) SEMAXANIB 1 KDR 1 KDR (−2.85, −2.51) 2.680.00 0 (0 + 1) (100.0%) SORAFENIB 18 BAK1 BAX BCL2 BCL2L1 9 BCL2L11(3.13) BRAF (2.27) 7.63 3.32 73 (Nexavar) BCL2L11 BID BRAF (4 + 5) CASP3(2.14) CASP8 (8.85, CASP3 CASP8 CYCS (50.0%) 2.67) FLT3 FLT4 KDR KITMCL1 FLT3 (−8.47) FLT4 (−2.80) PDGFRB RAF1 XIAP KDR (−2.85, −2.51) KIT(−38.04) MCL1 (−3.34) SUNITINIB 11 BRAF CSF1R FLT1 FLT3 7 BRAF (2.27)8.76 2.27 20 (SU-11248, Sutent) FLT4 KDR KIT PDGFRA (1 + 6) FLT1 (−2.68)FLT3 (−8.47) PDGFRB RAF1 RET (63.6%) FLT4 (−2.80) KDR (−2.85, −2.51) KIT(−38.04) PDGFRA (−4.21, −4.58) VANDETANIB 2 EGFR KDR 2 EGFR (−12.64) KDR(−2.85, −2.51) 7.66 0.00 0 (Zactima) (0 + 2) (100.0%) Cellular >> mTORinhibitors Cellular >> mTOR inhibitors >> All TEMSIROLIMUS 6 CCND1EIF4EBP1 ESR1 2 RPS6KB1 (2.20, 2.29) 2.38 2.25 37 (Torisel) FRAP1 RB1RPS6KB1 (1 + 1) CCND1 (−2.52) (33.3%) EVEROLIMUS 11 AKT1 CCND1 CCND2 3RPS6KB1 (2.20, 2.29) 4.38 2.25 20 (Certican) CCND3 EIF4E EIF4EBP1 (1 +2) CCND1 (−2.52) CCND2 (−7.50, EIF4G1 FRAP1 RB1 RPS6 (27.3%) −3.63,−13.98) RPS6KB1 Cellular >> Cyclin-dependant kinase inhibitorsCellular >> Cyclin-dependant kinase inhibitors >> All FLAVOPIRIDOL 35BAG1 BAX BCL2 BCL2L1 13 CASP3 (2.14) CASP8 (8.85, 3.91 3.04 60(HMR-1275, Alvocidib) BID BIRC3 BIRC5 CASP3 (7 + 6) 2.67) CCNB1 (3.17)CDC2 CASP8 CASP9 CCNB1 (37.1%) (2.92) CDK6 (2.18, 2.25) CCND1 CDC2 CDK2CDK8 (2.39) PARP1 (2.68) CDK4 CDK5 CDK6 CDK7 BIRC3 (−2.84) CCND1 (−2.52)CDK8 CDK9 CDKN1A CDKN1A (−7.85, −4.44) EGFR CDKN1B CYCS DIABLO (−12.64)MAPK8 (−2.06) EGFR H2AFX HTRA2 MCL1 (−3.34) MAPK14 MAPK8 MCL1 PARP1 PYGMRB1 TP53 XIAP ROSCOVITINE 17 BAX BIRC5 CASP3 5 CASP3 (2.14) CDC2 (2.92)3.35 2.43 42 (Seliciclib) CASP9 CDC2 CDK4 CDK5 (3 + 2) CDK6 (2.18, 2.25)CDK6 CDKN1A CYCS (29.4%) CDKN1A (−7.85, −4.44) MCL1 DIABLO MCL1 PDCD8(−3.34) RB1 SP1 TP53 XIAP Cellular >> Other Cellular >> Other >> AllAFLIBERCEPT 1 VEGFA 1 VEGFA (2.60) 2.60 2.60 259 (VEGF Trap) (1 + 0)(100.0%) DENILEUKIN 3 IL2RA IL2RB IL2RG 1 IL2RA (−2.77, −4.16) 3.47 0.000 DIFTITOX (0 + 1) (Ontak) (33.3%) Other/Ungrouped Other/Ungrouped >>Other Other/Ungrouped >> Other >> Other ARSENIC TRIOXIDE 496 ABCB1 ABCG2ABL1 246 ABL1 (3.58) AKAP12 (4.65, 6.01 5.42 99 (Arsenite, Arsenolite,ACAA2 ADCY9 AFAP1 (91 + 154 + 1) 2.82) AKR1B1 (18.32) Arsodent,Claudelite, AKAP12 AKR1B1 AKT1 (49.6%) ATP8A1 (3.45) ATR (2.33)Claudetite, Trisenox) ALAS1 ALDH6A1 ALDOC BACH2 (2.04) BAMBI (2.21)ALG13 ALOX5AP ANK3 BECN1 (2.18) BLVRB (2.08) ANKRD12 ANPEP ANXA2 BLZF1(2.70) CAPN10 (2.13, AP3S1 AQP9 ARL6IP1 7.15, 2.57) CASP3 (2.14) ARL6IP5ARL7 ARMC9 CASP8 (8.85, 2.67) CCNB1 ASNS ASS1 ATP1B1 (3.17) CCNB2 (4.19)ATP2B1 ATP2C1 ATP5A1 CDC42BPA (2.48) CDKN2A ATP6 ATP8A1 ATR (18.18,9.22) CDKN3 (5.50) AZGP1 BACH2 BAMBI CHEK1 (4.69) CHEK2 (2.55) BAX BCL2BCL2A1 CHGB (3.36, 6.71) CLGN BCL2L1 BCMO1 BCR (3.78) CMTM8 (3.87) DNMT1BECN1 BHLHB2 BID (2.20) DNMT3B (4.55) BIRC5 BLVRB BLZF1 DUSP4 (2.60)EPHX1 (4.56) BNIP3 BNIP3L BPI ERC2 (7.66, 17.63) FGFR1 BRDG1 BTBD2 BTBD3(6.81, 6.75, 7.28, 9.06, 5.07, C14ORF105 C16ORF58 6.12) FOXRED2 (2.33)FRK C5ORF13 C6ORF48 (20.73) FTH1 (2.42, 2.32, C8ORF4 CACNA2D2 2.35)GABPB2 (3.34, 5.13) CAPN10 CAPZB CARS GCLM (38.53) GSTA1 CASP10 CASP3CASP8 (16.89) GSTP1 (3.00) HCG18 CASP9 CAV1 CAV2 (2.45, 2.85, 2.24)HCRTR1 CCDC102B CCDC52 (2.33) HIG2 (9.01) HIST3H3 CCL15 CCL2 CCL23(2.04) HMGA1 (2.56, 6.05) CCNA1 CCNB1 CCNB2 HSPA1A (4.07, 2.39) HSPB1CCND1 CD1D CD44 CD52 (4.23, 3.70, 3.27) IFRD1 CD70 CD86 CDC42BPA (6.54,6.75) IGFBP2 (2.42) CDC73 CDKN1A CDKN2A IKBKB (2.08, 2.59, 3.48) CDKN2BCDKN3 CEBPE IQCH (2.10) KCNH2 (4.05) CEP57 CFB CFLAR KLF5 (2.46) KYNU(2.22, CHEK1 CHEK2 CHGB 2.53) LAT (2.44) MAFG CHI3L1 CHST6 CIDEB (3.54,5.15) MAP7 (4.36, CITED2 CKAP4 CLC 4.74) MCM2 (3.39) ME1 CLEC7A CLGNCMTM8 (8.79, 22.62, 9.07) NPAS1 CNOT2 COBLL1 (4.81) NUP107 (2.16) ORC4LCOLEC10 COPS5 CREB5 (2.05) PAQR6 (2.43) PARP1 CRH CRIM1 CSF2RB (2.68)PAWR (2.19) PIR CSH1 CSPP1 CSRP3 (2.63) PTRH2 (2.31) RNF24 CST3 CTNNA1CTSH (2.24) RPL23 (5.58) CX3CL1 CYB5R3 CYBA RPS6KB1 (2.20, 2.29) CYBRD1CYCS CYLD RSL1D1 (2.55) SCPEP1 CYP1A1 CYP39A1 (2.35) SLC2A1 (22.83)CYP3A43 CYTL1 DAXX SLC44A1 (2.84) SLC5A12 DAZ4 DBC1 DDIT3 DEFA1 (6.44,4.94) SMC4 (2.40) DEFA4 DKK1 DNAJB4 SOD1 (2.68, 2.37) SOX4 DNAJC9 DNMT1DNMT3A (2.17) SYNJ2 (4.91, 9.38) DNMT3B DUSP4 TERT (3.67) TFAP2C (3.61)DYNC1H1 DYRK1B EBI2 TNFRSF25 (7.01) TOP2A EGFR EGR1 ELA2A (5.88) TP53I11(2.08, 2.00) ENDOGL1 EP300 TRIP13 (8.20) TRMT1 (2.04) EPB41L2 EPHX1 EPXTYMS (3.69) UBE2C (9.47) ERC2 ERGIC2 ESR1 UCHL1 (26.51) VEGFA ESR2 EVLF3 FAM110B (2.60) WDR12 (4.78) ZMYM2 FAM46C FANCC FAS (3.03, 4.70)ZNF334 (12.87) FASLG FBLN5 FBXL7 ZNF682 (3.69, 7.03) ZWINT FGFR1 FGFR2FGR (6.72) FNBP1L FOS FOXRED2 ABCB1 (−3.59) ACAA2 (−2.69) FRK FSCN1 FTH1FYB ADCY9 (−2.46) GABBR2 GABPB2 ALDH6A1 (−2.90) ALDOC (−4.73) GADD45AGBA GCLM ALOX5AP (−5.07, −7.13) GIMAP6 GIT2 GJA1 GLA ANK3 (−9.06, −7.92,−7.43) GNAL GPM6A GPR30 ANPEP (−5.41) AQP9 (−13.82) GPR44 GPRC5D GPX1ARL6IP5 (−3.81, −3.50) GRAMD3 GRK4 GSTA1 ARMC9 (−5.30, −5.49) ASNS GSTP1GSTZ1 H2AFX (−3.65) ASS1 (−2.76) BCL2A1 HCG18 HCRTR1 HGF (−18.59, −2.78)BCR (−2.40) HIF1A HIG2 HIST1H2BM BHLHB2 (−2.28) BTBD3 (−2.40, HIST1H4CHIST3H3 HK1 −2.31) CACNA2D2 (−17.47) HLA-B HLA-C HLA-DRA CAV1 (−22.26,−24.68) HLA-F HLA-G HMGA1 CAV2 (−14.35, −7.56) HMGB2 HMGN2 HMOX1CCDC102B (−2.74, −2.50) HSD17B2 HSF1 HSP27 CCL15 (−4.50) CCL2 (−8.86)HSPA1A HSPA4 HSPA5 CCL23 (−15.78, −18.04) HSPA6 HSPB1 HTATIP2 CCND1(−2.52) CD44 (−5.46) ICAM3 ID1 ID2 IDS IER2 CD52 (−5.80) CD86 (−5.13,−2.01) IFI16 IFIH1 IFNA2 IFNG CDKN1A (−7.85, −4.44) IFRD1 IGFBP2 IGFBP7CFB (−9.87) CHI3L1 (−3.97, −12.11) IKBKB IL12RB2 IL24 IL6 CHST6 (−15.14)IL8RB INPP5B INSM1 CITED2 (−2.04) CKAP4 (−3.35) IQCH IRF1 ITGA2B CLEC7A(−2.69, −3.19) ITGAM ITGB1 ITGB3BP COBLL1 (−3.44) CREB5 (−9.32, ITGB7ITM2A JUN JUND −11.86) CSF2RB (−2.47) KCNH2 KCTD12 CST3 (−2.29) CTSH(−3.47) KIAA0087 KIAA1609 CX3CL1 (−3.73, −9.86, −4.60) KIF21B KITLGKLF11 CYB5R3 (−2.89, −2.40, −2.01) KLF5 KRT6A KYNU CYBRD1 (−2.20) CYTL1(−6.17) LAMC1 LAT LGALS9 DBC1 (−3.01) DKK1 (−16.44) LGMN LHFP LHX6 LSP1EBI2 (−5.77) EGFR (−12.64) LTC4S MAFF MAFG EGR1 (−6.04) ELA2A MAFKMAN1A1 MAOA (−4.13) EVL (−2.26) F3 (−3.63) MAP2K3 MAP2K4 FAM110B (−3.73)FAM46C (−2.08) MAP2K6 MAP7 MAPK1 FAS (−5.93) FBLN5 (−2.08) MAPK14 MAPK3MAPK7 FBXL7 (−4.06) FGFR2 MAPK8 MAPK9 MARCH2 (−31.03, −2.09, −16.52) FGR(−6.72, MASK MCF2L MCM2 ME1 −9.45, −8.54) FYB (−2.23) MKI67IP MMP1 MMP2GIMAP6 (−2.66) GJA1 MMP28 MMP9 MPL MPO (−9.56) GPM6A (−34.94) MRPS16 MSCMSRB2 GRAMD3 (−2.12) HGF (−2.73, MT1E MT1G MT1H MT1L −6.54) HLA-DRA(−4.55) MT1X MT2A MTA1 HSD17B2 (−17.74) HSPA5 (−2.00) MXRA7 MYBL1 MYCHSPA6 (−4.66) ID1 (−2.07) MYCN MYO1B MYST4 ID2 (−2.96, −3.38) IFI16N4BP1 N4BP2L1 NAB2 (−3.75, −3.71) IL6 (−39.79) NAV3 NCF1 NCF2 ND4 IL8RB(−3.46) IRF1 (−2.23) NEU3 NFE2L1 NFKBIA ITGAM (−3.25) ITGB3BP (−2.46)NFKBIE NME1 NPAS1 ITM2A (−3.63) JUN (−2.62) NPTX2 NR3C1 NUCB2 KCTD12(−4.62) KITLG NUDT18 NUP107 OBSL1 (−2.48, −3.23, −6.48) KRT6A (−11.07)ORC4L OS9 P4HA1 LGALS9 (−2.05) P53AIP1 PAFAH2 PAOX LGMN (−2.41) LHFP(−3.42) PAQR6 PARP1 PAWR LSP1 (−2.10) LTC4S (−2.70) PCNA PCSK5 PDCD4MAFF (−3.57) MAN1A1 (−2.01) PDE4A PDE4B PDE4DIP MAOA (−3.11) MAP2K3PDLIM7 PDPK1 PDZD2 (−3.18, −3.56) MAP2K6 (−4.53) PECAM1 PEX3 PGC PGFMAPK8 (−2.06) MARCH2 (−3.34, PHLDA2 PIGO PIK4CA −3.08) MMP1 (−58.24) PIRPKNOX1 PLAUR MMP2 (−4.48) MMP28 (−8.08, PLEKHO1 PLXNC1 PML −14.29) MMP9(−10.90) MT1E PPGB PPIH PPP1CB (−15.67) MT1G (−11.42, −6.38) PRG3 PRKCBPRR16 MT1H (−8.15, −8.00) MT1L (−11.08) PRSS1 PSMB6 PSMB8 MT1X (−8.45,−9.49) PTGFR PTRH2 PTTG1 MT2A (−8.59, −9.15) MXRA7 PURG PXDN RAB27B(−2.88, 4.06, −3.93, −3.20) RACGAP1 RAPGEF4 MYO1B (−3.04, −2.30, −2.61)RARA RASSF8 RBMX NAV3 (−6.48, −8.99) NCF1 (−3.16, RELA RERE RFC2 RGS2−3.30) NCF2 (−3.56) RNASEH2A RNF144A NFKBIA (−4.00) NPTX2 (−11.45) RNF24RNF6 ROBO1 NUCB2 (−3.02, −3.50) RPL17 RPL18A RPL23 NUDT18 (−4.22) OBSL1(−5.40, RPL7 RPS15A RPS6KB1 −4.33) P4HA1 (−2.49) RRBP1 RSL1D1 RYK PDE4B(−5.96) PDE4DIP (−6.65, S100A10 S100A8 S100A9 −2.11, −2.32, −2.90) SATB2SCAMP5 PDLIM7 (−2.16) PDZD2 (−33.94) SCGB2A2 SCPEP1 SCT PECAM1 (−4.62)PGC SDC2 SDC4 SELP (−3.76, −25.02) PGF (−2.56) SERPINB1 SERTAD2 PHLDA2(−3.07) PLAUR (−5.48) SFRS5 SH3GL2 SIGLEC6 PLEKHO1 (−2.69) PML SLC14A2SLC15A1 (−2.88, −3.32, −3.67, −3.53) SLC1A2 SLC22A18 PPP1CB (−5.15,−2.92) SLC2A1 SLC44A1 PRR16 (−16.52) PTGFR (−7.80) SLC5A12 SLC6A5 PXDN(−3.39, −3.20) SLCO3A1 SMAD1 SMC4 RASSF8 (−5.90, −17.88, −2.19, SOD1SOX18 SOX30 −10.81) RGS2 (−9.73) SOX4 SP1 SPTAN1 RNF144A (−2.56) RPL17(−3.08, ST6GALNAC4 STAB1 −2.59, −2.80) RPL7 (−2.15, STAT1 STATH SULF1−2.41) S100A8 (−10.28) SUSD5 SYN3 SYNJ2 S100A9 (−2.26) SDC2 (−3.99) TCF4TERC TERF1 SELP (−4.50) SERPINB1 (−2.41) TERF2 TERT TFAP2C SH3GL2(−5.52) TFF1 TGFBR2 TIMP1 SMAD1 (−3.04) SUSD5 (−2.47) TIMP2 TMEM158 TNFTCF4 (−3.68, −2.69) TNFAIP3 TNFAIP8 TGFBR2 (−3.67, −4.16) TIMP1 TNFRSF1BTNFRSF25 (−4.76) TIMP2 (−3.34) TNFRSF9 TNFSF13 TNFAIP3 (−3.78, −3.05)TNFSF8 TOP2A TP53 TNFAIP8 (−3.52) TNFSF13 (−4.94) TP53I11 TP73 TPT1 TPT1(−2.57, −2.61, −2.20) TRA2A TRAF3IP2 TRIM16 UBE2D1 (−2.48) VNN1 TRIP13TRMT1 TSC22D3 (−2.97, −2.90) WT1 (−2.49) TTC38 TXNIP TYMS DNMT3A (2.41,−2.89) UBE2C UBE2D1 UCHL1 UCP2 VEGFA VNN1 WDR12 WDR82 WSB2 WT1 XIAPXRCC6 ZFP36 ZFP36L1 ZMYM2 ZNF334 ZNF37A ZNF682 ZNF771 ZWINT BORTEZOMIB61 AKT1 APAF1 BAK1 BAX 18 BCL2L11 (3.13) CASP3 3.99 4.28 63 (Velcade)BCL2 BCL2L1 BCL2L11 (9 + 9) (2.14) CASP8 (8.85, 2.67) BID BIRC2 BIRC3BIRC5 (29.5%) CYP2C9 (3.97) CYP2D6 CA9 CASP3 CASP7 (3.52, 3.15) NFKBIB(2.90, CASP8 CASP9 CCND1 2.95, 2.86) PARP1 (2.68) CDKN1A CDKN1B CFLARPMAIP1 (12.40) PSMB5 CYCS CYP1A2 CYP2C19 (2.22) CYP2C9 CYP2D6 CYP3A4BIRC3 (−2.84) CCND1 (−2.52) DDIT3 DFFA DIABLO CDKN1A (−7.85, −4.44)HIF1A HSPA5 HTRA2 JUN CYP3A4 (−7.84) HSPA5 (−2.00) MAP2K1 MAP2K4 MAPK1JUN (−2.62) MAPK8 (−2.06) MAPK14 MAPK3 MAPK8 MCL1 (−3.34) NFKBIA MCL1NFKB1 NFKBIA (−4.00) NFKBIB NFKBIE PARP1 PDCD8 PMAIP1 PSMB1 PSMB2 PSMB5PSMD1 PSMD2 RAF1 RB1 RELA SFN STAT3 TNF TP53 TRAF2 XIAP CELECOXIB 17AKT1 BIRC5 CASP3 8 CASP3 (2.14) CYP19A1 12.38 2.46 57 (Celebra,Celebrex) CCND1 CYP19A1 ILB IL6 (4 + 4) (2.64) NRG1 (2.37) PARP1 MAP2K1MAP2K2 NRG1 (47.1%) (2.68) PARP1 PDPK1 PTGS2 CCND1 (−2.52) IL1B (−12.47)RELA STS SULT2A1 TNF IL6 (−39.79) PTGS2 (−36.04, −32.79) COLCHICINE 21ABCB1 ABCC1 CD59 9 ABCC1 (7.70) IKBKB (2.08, 4.96 5.21 49(Col-probenecid, Colbenemid, CUGBP2 CYP3A4 IKBKB (2 + 7) 2.59, 3.48)Condylon, Proben-C) JUN MAPK8 MAPK9 (42.9%) ABCB1 (−3.59) CD59 (−8.71,−4.89, MEFV NFATC4 NFKB1 −4.77, −7.00) CUGBP2 NFKBIA NR3C1 PTK2B (−7.53,−8.05) CYP3A4 (−7.84) RALBP1 RELA TAT TP53 JUN (−2.62) MAPK8 (−2.06)TUBB1 TUBB2A NFKBIA (−4.00) OBLIMERSEN 2 BCL2 IGH-6 — — — — —(Genasense, Augmerosen) TEGAFUR 1 CYP2A6 — — — — — (UFT) TIPIFARNIB 4ABCB1 CYP3A4 CYP3A5 3 ABCB1 (−3.59) CYP3A4 (−7.84) 15.46 0.00 0(Zarnestra) UGT1A1 (0 + 3) CYP3A5 (−34.94) (75.0%) VORINOSTAT 47 AKT1BAK1 BAX BCL2 17 BCL2L11 (3.13) CASP2 4.07 3.36 71 (Zolinza) BCL2A1BCL2L1 BCL2L11 (10 + 7) (2.27) CASP3 (2.14) CASP8 BID BIRC2 BIRC3 BIRC5(36.2%) (8.85, 2.67) HDAC1 (6.44) CASP2 CASP3 CASP7 HDAC2 (4.18) HDAC6(2.00) CASP8 CASP9 CCND1 HIST3H3 (2.04) PARP1 CDKN1A CDKN1B CFLAR (2.68)RARB (2.96) CYCS CYP1A1 CYP1B1 BCL2A1 (−18.59, −2.78) DIABLO ERBB2 HDAC1BIRC3 (−2.84) CCND1 (−2.52) HDAC2 HDAC3 HDAC6 CDKN1A (−7.85, −4.44)HDAC8 HIST3H3 HTRA2 CYP1B1 (−3.87) MAPK8 (−2.06) MAP2K1 MAPK1 MAPK14TNFSF10 (−7.51) MAPK3 MAPK8 NFKB1 PARP1 PDCD8 RAF1 RARB RB1 RELA TNFTNFSF10 XIAP

What is claimed:
 1. A method for treating a patient having cancer, themethod comprising: a) characterizing molecular anomalies of a cancersample from the patient in comparison to a normal sample from the samepatient which is a normal histological counterpart of the cancer sample,said molecular anomalies characterization comprising determining genesdifferentially expressed in the cancer sample in comparison to thenormal sample by oligonucleotide array and optionally determining thegain or loss of gene copy number in the cancer sample in comparison tothe normal sample by Comparative Genomic Hybridization and determiningderegulated genes in the cancer sample based on the genes differentiallyexpressed and optionally the gain or loss of gene copy number; b)providing a drug database comprising target genes associated with aplurality of drugs disclosed in Table 1; c) determining a score for eachdrug of said plurality of drugs comprising calculating, for each drug ofthe plurality of drugs, a percentage of deregulated genes in the cancersample from the patient as characterized in step (a) that are targetgenes for each drug of the plurality of drugs as provided in step (b)and determining the score for each drug of the plurality of drugs basedon the percentage of deregulated genes among the target genes in thecancer sample from the patient, wherein a higher score is predictive ofa higher relative efficacy of the drug for treating the cancer in thepatient and wherein the step of characterizing molecular anomalies ofthe cancer sample comprises determining a fold change for thedifferentially expressed genes and optionally for the gain or loss ofgene copy number; and d) selecting a drug with a high score for treatingthe patient, wherein the score (W) for a given drug is determined by oneof the following algorithms: $\begin{matrix}{{W = {P\frac{\left( {\sum_{C}F_{c > 2}} \right)}{n_{C}F_{c > 2}}}};} & (i)\end{matrix}$ wherein: W is the score for the given drug; P is thepercentage of target genes for the given drug which are deregulated inthe cancer of the patient; Σ is sum; F_(c>2) is the Fold Change of eachderegulated target gene for the given drug with a Fold Change higherthan 2; and n_(C)F_(c>2) refers to the number of target genes for thegiven drug with a Fold Change higher than 2; $\begin{matrix}{{W = {P\left( {{\frac{\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{\left( {\sum_{Cm}F_{Cm}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}};} & ({ii})\end{matrix}$ wherein: W is the score for the given drug; P is thepercentage of target genes for the given drug which are deregulated inthe cancer of the patient; Σ is sum; CM refers to major target genes forthe given drug; Cm refers to minor target genes for the given drug; CRrefers to resistance genes for the given drug; n₁CM, n₂Cm and n₃CR arerespectively the number of deregulated target genes with a definedthreshold for major target genes, minor target genes and resistancegenes; F_(CM), F_(Cm) and F_(CR) are the Fold Change of each gene higherthan the defined threshold for major target genes, minor target genesand resistance genes, respectively; q₁, q₂ and q₃ are multiplicationcoefficients for major target genes, minor target genes and resistancegenes, respectively; and z₁, z₂ and z₃ are multiplication coefficientsassociated with the presence of a mutation in a major target gene, aminor target gene and a resistance gene, respectively; $\begin{matrix}{{W = {{\frac{P_{CM}\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{P_{Cm}\left( {\sum_{Cm}F_{Cm}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{P_{CR}\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}}};} & ({iii})\end{matrix}$ wherein: W is the score for the given drug; Σ is sum; CMrefers to major target genes for the given drug; Cm refers to minortarget genes for the given drug; CR refers to resistance genes for thegiven drug; n₁CM, n₂Cm and n₃CR are respectively the number ofderegulated target genes with a defined threshold for major targetgenes, minor target genes and resistance genes; F_(CM), F_(Cm) andF_(CR) are the Fold Change of each gene higher than the definedthreshold for major target genes, minor target genes and resistancegenes, respectively; q₁, q₂ and q₃ are multiplication coefficients formajor target genes, minor target genes and resistance genes,respectively; z₁, z₂ and z₃ are multiplication coefficients associatedwith the presence of a mutation in a major target gene, a minor targetgene and a resistance gene, respectively; and P_(CM), P_(Cm) and P_(CR)are the percentage of target genes for the given drug which arederegulated in the cancer of the patient for major target genes, minortarget genes and resistance genes, respectively; $\begin{matrix}{{W = {P\left( {{\frac{\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{\left( {\sum_{Cm}{F_{Cm} \times {Int}_{Cm}}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}}{or}{{W = {{\frac{P_{CM}\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} + {\frac{P_{Cm}\left( {\sum_{Cm}{F_{Cm} \times {Int}_{Cm}}} \right)}{n_{2}{Cm}}q_{2}z_{2}} - {\frac{P_{CR}\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}}};}} & ({iv})\end{matrix}$ wherein: W is the score for the given drug; P is thepercentage of target genes for the given drug which are deregulated inthe cancer of the patient; Σ is sum; CM refers to major target genes forthe given drug; Cm refers to minor target genes for the given drug; CRrefers to resistance genes for the given drug; n₁CM, n₂Cm and n₃CR arerespectively the number of deregulated target genes with a definedthreshold for major target genes, minor target genes and resistancegenes; F_(CM), F_(Cm) and F_(CR) are the Fold Change of each gene higherthan the defined threshold for major target genes, minor target genesand resistance genes, respectively; q₁, q₂ and q₃ are multiplicationcoefficients for major target genes, minor target genes and resistancegenes, respectively; z₁, z₂ and z₃ are multiplication coefficientsassociated with the presence of a mutation in a major target gene, aminor target gene and a resistance gene, respectively; P_(CM), P_(Cm)and P_(CR) are the percentage of target genes for the given drug whichare deregulated in the cancer of the patient for major target genes,minor target genes and resistance genes, respectively; and Int_(CM),Int_(Cm) and Int_(CR) are the intensity for major target genes, minortarget genes and resistance genes, respectively; or $\begin{matrix}{{W = {P\left( {{\frac{\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}}{or}{W = {{\frac{P_{CM}\left( {\sum_{CM}F_{CM}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{P_{CR}\left( {\sum_{CR}F_{CR}} \right)}{n_{3}{CR}}q_{3}z_{3}}}}{or}{W = {P\left( {{\frac{\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}} \right)}}{or}{{W = {{\frac{P_{CM}\left( {\sum_{CM}{F_{CM} \times {Int}_{CM}}} \right)}{n_{1}{CM}}q_{1}z_{1}} - {\frac{P_{CR}\left( {\sum_{CR}{F_{CR} \times {Int}_{CR}}} \right)}{n_{3}{CR}}q_{3}z_{3}}}};}} & (v)\end{matrix}$ wherein: W is the score for the given drug; P is thepercentage of target genes for the given drug which are deregulated inthe cancer of the patient; Σ is sum; CM refers to major target genes forthe given drug; CR refers to resistance genes for the given drug; n₁CMand n₃CR are respectively the number of deregulated target genes with adefined threshold for major target genes and resistance genes; F_(CM)and F_(CR) are the Fold Change of each gene higher than the definedthreshold for major target genes and resistance genes, respectively; q₁and q₃ are multiplication coefficients for major target genes andresistance genes, respectively; z₁ and z₃ are multiplicationcoefficients associated with the presence of a mutation in a majortarget gene and a resistance gene, respectively; P_(CM), and P_(CR) arethe percentage of genes for the given drug which are deregulated in thecancer of the patient for major target genes and resistance genes,respectively; and Int_(CM) and Int_(CR) are the intensity for majortarget genes and resistance genes, respectively.
 2. The method accordingto claim 1, wherein the target genes for each drug are classified in thedatabase into: major target genes (CM) which have been demonstrated tohave a clear cause and effect link with the drug's mechanism of action;minor target genes (Cm), the level of regulation of which is modified inthe presence of the drug, without a direct link with the drug'smechanism of action; and resistance genes (CR) which induce a directresistance to the drug or are associated with a major toxicity.
 3. Themethod according to claim 1, wherein F_(c>2) is the Fold Change of eachover-expressed target gene for the given drug with a Fold Change higherthan 2 and n_(C)F_(c>2) is either the number of target genes for thegiven drug with a Fold Change higher than 2, or the number ofover-expressed target genes for the given drug with a Fold Change higherthan
 2. 4. The method according to claim 1, wherein for algorithm (ii)F_(CM), F_(Cm) and F_(CR) are the Fold Change of each over-expressedtarget gene for the given drug with the defined threshold and whereinn₁CM, n₂Cm and n₃CR are either the number of target genes for the givendrug with the defined threshold or the number of over-expressed targetgenes for the given drug with the defined threshold.
 5. The methodaccording to claim 1, wherein for algorithm (iii) F_(CM), F_(Cm) andF_(CR) are the Fold Change of each over-expressed target gene for thegiven drug with the defined threshold and wherein n₁CM, n₂Cm and n₃CRare either the number of target genes for the given drug with thedefined threshold or the number of over-expressed target genes for thegiven drug with the defined threshold.
 6. The method according to claim1, wherein for algorithm (iv) F_(CM), F_(Cm) and F_(CR) are the FoldChange of each over-expressed target gene for the given drug with thedefined threshold and wherein n₁CM, n₂Cm and n₃CR are either the numberof target genes for the given drug with the defined threshold or thenumber of over-expressed target genes for the given drug with thedefined threshold.
 7. The method according to claim 1, wherein foralgorithm (v) F_(CM) and F_(CR) are the Fold Change of eachover-expressed target gene for the given drug with the defined thresholdand wherein n₁CM and n₃CR are either the number of target genes for thegiven drug with the defined threshold or the number of over-expressedtarget genes for the given drug with the defined threshold.
 8. Themethod according to claim 4, wherein the defined threshold is a FoldChange of at least
 2. 9. The method according to claim 5, wherein thedefined threshold is a Fold Change of at least
 2. 10. The methodaccording to claim 6, wherein the defined threshold is a Fold Change ofat least
 2. 11. The method according to claim 7, wherein the definedthreshold is a Fold Change of at least
 2. 12. The method according toclaim 1, wherein for algorithm (ii) the multiplication coefficients forthe target genes are between 10 and 1,000 for major target genes (q₁),between 0.1 and 10 for minor target genes (q₂) and between 10 to 1,000for resistance genes (q₃).
 13. The method according to claim 1, whereinfor algorithm (iii) the multiplication coefficients associated with amutation z₁, z₂ and z₃ are 1 when no mutation exists and, depending onthe functional impact of the mutation, are between 10 and 1,000.
 14. Themethod according to claim 1, wherein said plurality of drugs areAxitinib, Capecitabine, Trastuzumab, Erlotinib, Gefitinib, Lapatinib,Bevacizumab, Imatinib, Temsirolimus, Dasatinib, Sorafenib, Nilotinib,Bosutinib, Sunitinib, Cetuximab, Vinorelbine, Dacarbazine, Docetaxel,Paclitaxel, Pemetrexed, Gemcitabine, Irinotecan and Topotecan.
 15. Themethod according to claim 1, wherein the molecular anomalies of saidcancer sample are determined by northern analysis, mRNA microarrays,cDNA microarrays or RT-PCR.
 16. The method according to claim 1, whereinsaid cancer is leukemia, lymphoma, bladder cancer, breast cancer,stomach cancer, thyroid cancer, prostate cancer, testis cancer, livercancer, pancreatic cancer, bone cancer, kidney cancer, endometrialcancer, melanoma, lung cancer, gastric cancer, colorectal cancer, heador neck cancer, brain cancer, neuroblastoma, or ovarian cancer.
 17. Themethod according to claim 1, said method further comprising treatingsaid patient with the drug selected by one of said algorithms.